"Rank","NCT Number","Title","Recruitment","Study Results","Conditions","Interventions","Sponsor/Collaborators","Gender","Age Groups","Phases","Enrollment","Funded Bys","Study Types","Study Designs","Other IDs","First Received","Start Date","Completion Date","Last Updated","Last Verified","Results First Received","Acronym","Primary Completion Date","Outcome Measures","URL"
1,"NCT01163240","Epidemiological Study in Children and Adolescents With Chronic Hepatitis B","Completed","No Results Available","Liver Diseases|Hepatitis, Chronic|Hepatitis, Viral, Human|Hepatitis|Virus Diseases|Digestive System Diseases|Hepatitis B, Chronic|Hepatitis B|DNA Virus Infections","","Novartis Pharmaceuticals|Novartis","Both","Child|Adult","","1640","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CLDT600A2414","July 14, 2010","June 2009","null","September 26, 2011","September 2011","No Study Results Posted","EPIC B","September 2011","Obtain epidemiological data in children and adolescents with chronic hepatitis B that will assist the feasibility and design of studies for the Novartis telbivudine clinical pediatric development program","https://ClinicalTrials.gov/show/NCT01163240"
2,"NCT00023309","Lamivudine and Adefovir to Treat Chronic Hepatitis B","Completed","Has Results","HBV (Hepatitis B Virus)|Hepatitis B|Hepatitis","Drug: Lamivudine and adefovir|Drug: Adefovir alone","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","41","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","010246|01-DK-0246","September 3, 2001","August 2001","August 2013","July 18, 2014","July 2014","July 7, 2011","null","April 2010","Maintained Combined Response (Virological, Biochemical and Histological Response).|HBeAg Loss at Week 196|Virological Response|Biological Response|Histological Response","https://ClinicalTrials.gov/show/NCT00023309"
3,"NCT01988753","Non-invasive Biomarkers of Fibrosis in Pediatric Viral Hepatitis","Recruiting","No Results Available","Viral Hepatitis|Liver Fibrosis|Liver Disease|Hepatitis B|Hepatitis C","","Baylor College of Medicine","Both","Child","","45","Other","Observational","Time Perspective: Prospective","H-30472","November 14, 2013","October 2013","February 2017","March 23, 2015","March 2015","No Study Results Posted","null","December 2015","Non-invasive shearwave elastography (SWE) for detecting fibrosis in children with hepatitis|Serum Biomarker analysis","https://ClinicalTrials.gov/show/NCT01988753"
4,"NCT00160940","Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis","Recruiting","No Results Available","Hepatitis C|Hepatitis B|Autoimmune Hepatitis|Liver Cirrhosis, Biliary|Cholangitis, Sclerosing","","University Health Network, Toronto","Both","Adult|Senior","","200","Other","Observational","Observational Model: Defined Population|Time Perspective: Cross-Sectional|Time Perspective: Prospective","02-0019-C","September 8, 2005","February 2002","null","November 29, 2005","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00160940"
5,"NCT01464827","ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients","Completed","Has Results","Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1","Drug: ABT-450|Drug: ABT-333|Drug: ABT-267|Drug: Ribavirin|Drug: Ritonavir","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior","Phase 2","580","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M11-652|2010-022455-31","September 28, 2011","October 2011","September 2013","April 2, 2015","April 2015","December 23, 2014","null","March 2013","Number of Participants With Adverse Events (AEs)|Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose for 8 Weeks Versus 12 Weeks of Treatment With 3 DAAs and Ribavirin|Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment of Different Durations With 3 Direct-acting Antiviral Agents (DAAs) and Ribavirin|Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 2 DAAs and Ribavirin Versus 3 DAAs and Ribavirin|Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 3 DAAs With Versus Without Ribavirin|Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose in Treatment-na√Øve Versus Null-responders","https://ClinicalTrials.gov/show/NCT01464827"
6,"NCT00755950","Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis","Terminated","No Results Available","Acute Hepatitis A|Acute Hepatitis B|Acute Hepatitis C|Acute Hepatitis E|Acute EBV Hepatitis|Acute CMV Hepatitis","Dietary Supplement: Silymarin|Dietary Supplement: Silymarin|Other: Lactose monohydrate","University of Maryland|MADAUS GmbH|The Egyptian Company for Blood Transfusion Services (EgyBlood)|Tanta Fever Hospital|Banha Fever Hospital|Alexandria University","Both","Adult|Senior","Phase 2|Phase 3","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","HP-00042363|LE13K0.48","September 17, 2008","October 2008","December 2015","March 2, 2015","March 2015","No Study Results Posted","null","November 2011","Incidence, severity and duration of Adverse Events|Normalization of total (<1.0 mg/dl) and direct bilirubin (<0.3 mg/dl)|Normalization of ALT, AST, CRP and ESR|Symptom resolution & return to normal physical activity|In AVH patients with specific etiologies resolution of clinical signs and symptoms|Persistence of acute HCV with progression to chronicity","https://ClinicalTrials.gov/show/NCT00755950"
7,"NCT02476617","Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults","Recruiting","No Results Available","Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1a","Drug: ombitasvir/ABT-450/ritonavir|Drug: dasabuvir|Drug: ribavirin","AbbVie","Both","Adult|Senior","Phase 3","40","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-243","June 17, 2015","June 2015","November 2016","October 16, 2015","October 2015","No Study Results Posted","null","February 2016","Change in interferon-stimulated gene (ISG) expression in peripheral blood mononucleated cells (PBMCs)","https://ClinicalTrials.gov/show/NCT02476617"
8,"NCT02493855","Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults","Recruiting","No Results Available","Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1a","Drug: ombitasvir/ABT-450/ritonavir|Drug: dasabuvir|Drug: ribavirin","AbbVie","Both","Adult|Senior","Phase 2","60","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-242|2014-001478-32","July 2, 2015","June 2015","December 2016","October 16, 2015","October 2015","No Study Results Posted","null","January 2016","Slope of the second phase decline in plasma HCV RNA levels during treatment","https://ClinicalTrials.gov/show/NCT02493855"
9,"NCT01609933","A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study","Active, not recruiting","No Results Available","Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1","Drug: ABT-450/r|Drug: ABT-267|Drug: pegylated interferon alpha-2a (pegIFN)|Drug: Ribavirin (RBV)","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior","Phase 2","93","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M13-101|2011-005393-32","May 30, 2012","December 2012","May 2017","October 10, 2015","October 2015","No Study Results Posted","null","September 2016","Percentage of subjects achieving 12-week sustained virologic response following treatment with 2 direct acting anti-virals and peginterferon alpha-2a and ribavirin in Hepatitis C infected adults.|Percentage of subjects achieving 24-week sustained virologic response following treatment with 2 direct acting anti-viral and peginterferon alpha-2a and ribavirin in Hepatitis C infected adults.|Percentage of subjects with extended rapid virologic response (Hepatitis C ribonucleic acid less than lower limit of quantitation at Weeks 4 through 12 of therapy with ABT 450/r plus ABT-267 plus peginterferon alpha-2a plus ribavirin)|Number and percentage of subjects having treatment-emergent adverse events.","https://ClinicalTrials.gov/show/NCT01609933"
10,"NCT01888900","New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C","Recruiting","No Results Available","Cirrhosis|Chronic Hepatitis C|Hepatitis C|Hepatitis C, Chronic","Drug: Asunaprevir and Daclatsvir|Drug: Asunaprevir, daclatsvir, peginterferon, ribavirin","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Bristol-Myers Squibb|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","70","NIH|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","130150|13-DK-0150","June 26, 2013","May 2013","April 2016","June 4, 2015","February 2015","No Study Results Posted","null","April 2016","Changes in interferon stimulated genes during therapy with asunaprevir and dacalatsvir|Safety and efficacy of asunaprevir and dacalatsvir","https://ClinicalTrials.gov/show/NCT01888900"
11,"NCT00001457","Lamivudine for Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B|Chronic Hepatitis D|Glomerulonephritis|Polyarteritis Nodosa","Drug: Lamivudine","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Child|Adult|Senior","Phase 2","60","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","950199|95-DK-0199","November 3, 1999","September 1995","September 2005","March 3, 2008","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001457"
12,"NCT02103439","An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients","Active, not recruiting","Has Results","Hepatitis|Hepatitis C|Hepatitis C/ Human Immunodeficiency Virus Coinfection","Drug: Algeron|Drug: PegIntron","Biocad","Both","Adult|Senior","Phase 3","140","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","BCD-016-4","April 1, 2014","September 2013","December 2015","July 22, 2015","July 2015","May 21, 2015","null","July 2014","Early Virological Response|Early Virological Response in Patients With Different Hepatitis C Virus Genotypes|Rapid Virological Response|Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes|Viral Breakthrough|Biochemical Response","https://ClinicalTrials.gov/show/NCT02103439"
13,"NCT00946010","Investigation of Hepatitis B and Hepatitis C in Taiwan","Completed","No Results Available","Hepatitis B|Hepatitis C","Biological: blood sampling and abdominal sonography","National Taiwan University Hospital","Both","Adult|Senior","","6228","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","200801059R","April 1, 2008","April 2008","January 2011","January 20, 2011","January 2011","No Study Results Posted","null","August 2010","genotype and DNA level or RNA level of HBV and HCV virus","https://ClinicalTrials.gov/show/NCT00946010"
14,"NCT02108444","Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients","Completed","No Results Available","Hepatitis|Hepatitis B|Lymphoma|Hematologic Diseases","","Peking University","Both","Adult|Senior","Phase 4","107","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","PKU 2013-Autonomous-9","March 30, 2014","January 2007","March 2014","July 22, 2014","July 2014","No Study Results Posted","null","December 2013","the incidence of hepatitis B virus delayed reactivation|the incidence of hepatitis B virus related hepatitis flare|Number of patients that achieve a tumor response|overall survival rate","https://ClinicalTrials.gov/show/NCT02108444"
15,"NCT02123212","Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C","Completed","No Results Available","Hepatitis C|Chronic Hepatitis C","Other: Mailer|Other: In-person recruitment|Other: EHR Alert","National Opinion Research Center|NORC at the University of Chicago|University of Alabama at Birmingham|Henry Ford Health System|Icahn School of Medicine at Mount Sinai|Centers for Disease Control and Prevention","Both","Adult|Senior","","29607","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Screening|Masking: Open Label","527-11 SC|6960","April 22, 2014","February 2013","March 2014","March 25, 2015","March 2015","No Study Results Posted","Best-C","March 2014","Positive Hepatitis C Test|Tested for Hepatitis C","https://ClinicalTrials.gov/show/NCT02123212"
16,"NCT00439959","Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults","Terminated","No Results Available","Hepatitis C, Chronic|Hepatitis C","Drug: GSK625433/placebo","GlaxoSmithKline","Both","Adult","Phase 1","48","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Double-Blind","HSP108233","February 22, 2007","October 2006","March 2007","May 31, 2012","March 2011","No Study Results Posted","null","March 2007","Safety parameters: adverse events; telemetry; clinical laboratory values, vital signs, and ECGs. Plasma levels of GSK625433. Change in HCV viral load. Taken throughout the study|Plasma levels of GSK625433. Metabolic analysis of CYP substrates to estimate enzyme activity. Resistance analysis for subjects with HCV infection. Taken throughout the study","https://ClinicalTrials.gov/show/NCT00439959"
17,"NCT01995071","A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)","Completed","No Results Available","Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis","Drug: ABT-493|Drug: ABT-530|Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin (RBV)","AbbVie","Both","Adult|Senior","Phase 2","89","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M13-595","November 21, 2013","November 2013","June 2015","June 25, 2015","June 2015","No Study Results Posted","null","June 2015","Maximal decrease in log10 hepatitis C virus ribonucleic acid levels from baseline|The percentage of subjects with sustained virologic response 12 weeks post-treatment|The percentage of subjects with on-treatment virologic failure during the treatment period|The percentage of subjects with post-treatment relapse","https://ClinicalTrials.gov/show/NCT01995071"
18,"NCT00782301","Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients","Withdrawn","No Results Available","Hepatitis B|Human Immunodeficiency Virus|Hepatitis C, Chronic","Drug: maraviroc|Drug: etravirine","ViiV Healthcare|Pfizer","Both","Child|Adult|Senior","Phase 4","0","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","A4001080","October 29, 2008","March 2009","February 2010","January 18, 2012","January 2012","No Study Results Posted","null","February 2010","Percentage of subjects with Grade 3 and Grade 4 ALT test abnormalities associated with a change from baseline ALT ‚â•100 IU/L through Week 48.|Percentage of HCV treated subjects with Grade 3 and Grade 4 ALT test abnormalities associated with a change from baseline ALT ‚â•100 IU/L through 96.|Time to development of Grade 3 and Grade 4 ALT test abnormalities associated with a change from baseline ALT ‚â•100 IU/L.|Percentage of subjects with Hy's law abnormalities through Week 48.|Percentage of HCV treated subjects with Hy's law abnormalities through Week 96.|Change from baseline in mean Hepatitis C viral load through Week 48|Undetectable HCV viral load 24 weeks after stopping HCV treatment.|Percentage of subjects with HIV-1 RNA levels <48 copies/mL at Week 48.|Change from baseline in CD4+ cell count at Week 48.|Change from baseline in mean hepatitis B DNA through Week 48","https://ClinicalTrials.gov/show/NCT00782301"
19,"NCT00289731","Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc","Completed","No Results Available","Hepatitis B|Hepatitis A","Biological: TWINRIX‚Ñ¢|Biological: Engerix‚Ñ¢-B|Biological: HAVRIX‚Ñ¢|Biological: HB VAX PRO‚Ñ¢|Biological: Vaqta‚Ñ¢","GlaxoSmithKline","Both","Adult|Senior","Phase 4","577","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","100382|100383|100384|100385","February 9, 2006","November 2003","May 2007","October 27, 2011","October 2011","No Study Results Posted","null","May 2007","Anti- HAV and anti-HBs- concentrations|Anti-HAV, and anti-HBs antibody concentrations.|Occurrence, intensity and relationship to vaccination of all serious adverse events (SAEs).|Occurrence, intensity and relationship to vaccination of SAEs with causal relationship to vaccination or referring to hepatitis A or B infection.","https://ClinicalTrials.gov/show/NCT00289731"
20,"NCT02243293","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection","Recruiting","No Results Available","Chronic Hepatitis C|Hepatitis C Virus","Drug: ABT-493|Drug: ABT-530|Drug: Ribavirin (RBV)","AbbVie","Both","Adult|Senior","Phase 2","350","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-868|2014-002927-90","September 4, 2014","January 2014","February 2016","July 29, 2015","July 2015","No Study Results Posted","null","February 2016","Percentage of subjects who achieve 12-week sustained virologic response (SVR12) in each treatment arm|Percentage of subjects who achieve 4-week sustained virologic response (SVR4) in each treatment arm|Percentage of subjects with virologic failure during treatment|Percentage of subjects with Post-Treatment relapse","https://ClinicalTrials.gov/show/NCT02243293"
21,"NCT02442284","A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection","Recruiting","No Results Available","Chronic Hepatitis C|Cirrhosis|Hepatitis C Virus","Drug: Ombitasvir|Drug: Paritaprevir|Drug: Ritonavir|Drug: Dasabuvir|Drug: Ribavirin","AbbVie","Both","Adult|Senior","Phase 3","100","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-251","May 11, 2015","May 2015","October 2016","October 9, 2015","October 2015","No Study Results Posted","null","July 2016","Percentage of participants with Sustained Virologic Response 12 weeks post-treatment|Percentage of participants with virologic failure during treatment|Percentage of participants with virologic relapse post-treatment|Percentage of participants with Sustained Virologic Response 12 weeks post-treatment among participants with ongoing psychiatric disorders","https://ClinicalTrials.gov/show/NCT02442284"
22,"NCT02219503","A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis","Completed","No Results Available","Chronic Hepatitis C Infection|Compensated Cirrhosis|Hepatitis C Virus","Drug: ombitasvir/ABT-450/ritonavir|Drug: dasabuvir","AbbVie","Both","Adult|Senior","Phase 3","60","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-490|2014-001953-18","August 15, 2014","September 2014","September 2015","October 9, 2015","October 2015","No Study Results Posted","TURQUOISE-III","June 2015","Percentage of participants with Sustained Virologic Response 12 weeks post-treatment|Percentage of participants with on-treatment virologic failure|Percentage of participants with post-treatment relapse","https://ClinicalTrials.gov/show/NCT02219503"
23,"NCT00289718","Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule","Completed","Has Results","Hepatitis B|Hepatitis A","Biological: Twinrix‚Ñ¢ adult","GlaxoSmithKline","Both","Adult|Senior","Phase 3","51","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","100556 (Y11)|100557 (Y12)|100558 (Y13)|100559 (Y14)|100560 (Y15)","February 9, 2006","November 2004","January 2009","November 6, 2014","November 2014","January 11, 2010","null","January 2009","Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration|Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration|Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration|Number of Subjects Reporting Serious Adverse Events (SAE) Assessed by the Investigators as Related to Vaccination or to Study Procedures or Lack of Efficacy|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Number of Subjects Reporting Serious Adverse Events (SAE)","https://ClinicalTrials.gov/show/NCT00289718"
24,"NCT02068222","A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection","Completed","No Results Available","Chronic Hepatitis C|Hepatitis C Virus","Drug: ABT-450/r|Drug: ABT-530|Drug: Ribavirin (RBV)","AbbVie","Both","Adult|Senior","Phase 2","12","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-213","February 19, 2014","April 2014","March 2015","March 13, 2015","March 2015","No Study Results Posted","null","March 2015","The percentage of subjects who achieve 12-week sustained virologic response (SVR12) in each treatment arm|The percentage of subjects who achieve 24-week sustained virologic response (SVR24) in each treatment arm|The percentage of subjects with virologic failure during treatment|The percentage of subjects with Post-Treatment relapse","https://ClinicalTrials.gov/show/NCT02068222"
25,"NCT02120274","Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C","Active, not recruiting","No Results Available","RNA Virus Infections|Flaviviridae Infections|Hepatitis C|Hepatitis C, Chronic","Drug: Vitamin D|Drug: Vitamin B 12","Federal University of S√£o Paulo","Both","Adult|Senior","Phase 4","85","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","DB12SHCV|U1111-1155-6986","April 18, 2014","March 2014","January 2016","August 11, 2015","August 2015","No Study Results Posted","null","January 2016","SVR12|RVR, EVR, EOT","https://ClinicalTrials.gov/show/NCT02120274"
26,"NCT02219477","A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis","Active, not recruiting","No Results Available","Chronic Hepatitis C|Decompensated Cirrhosis|Hepatitis C Virus","Drug: ABT-450/ritonavir/ABT-267|Drug: ABT-333|Drug: Ribavirin","AbbVie","Both","Adult|Senior","Phase 3","60","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-227|2014-001477-13","August 15, 2014","November 2014","February 2017","October 16, 2015","October 2015","No Study Results Posted","TURQUOISE-CPB","June 2016","Percentage of participants with Sustained Virologic Response 12 weeks post-treatment|Percentage of participants with virologic failure during treatment|Percentage of participants with virologic relapse post-treatment|Percentage of participants with improvement in laboratory parameters associated with hepatic function|Percentage of Genotype 4 participants with Sustained Virologic Response 12 weeks post-treatment","https://ClinicalTrials.gov/show/NCT02219477"
27,"NCT00686790","Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)","Completed","Has Results","Hepatitis D, Chronic|Hepatitis B, Chronic","Biological: Peginterferon alfa-2b (PegIntron, SCH 54031)","Merck Sharp & Dohme Corp.","Both","Adult","Phase 3","68","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","P04603","May 27, 2008","December 2005","May 2009","September 24, 2015","September 2015","December 21, 2010","null","May 2009","Number of Participants With a Virological Response|Number of Participants With a Biochemical Response|Number of Participants With a Combined Response|Number of Participants With Hepatitis B Virus (HBV) Replication Response (HBV Response)|Number of Participants With a Liver Histology Response","https://ClinicalTrials.gov/show/NCT00686790"
28,"NCT01908660","Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","Recruiting","No Results Available","Human Immunodeficiency Virus|Hepatitis B, Chronic|Hepatitis C, Chronic","Drug: antiretroviral drugs","Valme University Hospital|Hospital Universitario Virgen de la Victoria|Hospital Universitario Reina Sofia|Hospital Torrec√°rdenas|Hospital de la L√≠nea de la Concepci√≥n|Hospital Poniente|Hospital Universitario Virgen Macarena|Complejo Hospitalario de Especialidades Juan Ram√≥n Jimenez","Both","Adult|Senior","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SEG-HEP-2007","June 28, 2013","January 2007","October 2015","December 11, 2014","May 2014","No Study Results Posted","null","September 2015","Incidence of grade 3 or 4 transaminase elevations|Incidence of grade 3 or 4 bilirubin elevations|Percentage of patients with undetectable HIV RNA at the end of follow-up|CD4 cell count at the end of follow-up","https://ClinicalTrials.gov/show/NCT01908660"
29,"NCT00289744","Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule","Completed","Has Results","Hepatitis B|Hepatitis A","Biological: TWINRIX‚Ñ¢ ADULT|Biological: Engerix TM","GlaxoSmithKline","Both","Child","Phase 3","171","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","100561 (Y6)|100562 (Year 7)|100563 (Year 8)|100564 (Year 9)|100565 (Year 10)","February 9, 2006","February 2004","April 2009","October 2, 2014","October 2011","April 8, 2010","null","April 2009","Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration|Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration|Number of Subjects With Immune Response to the Additional Dose of Engerix‚Ñ¢-B|Number of Subjects Reporting Serious Adverse Events (SAEs) Assessed by the Investigator as Causally Related to Primary Vaccination, Study Procedures or Lack of Vaccine Efficacy|Number of Subjects Reporting Solicited Local and General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events|Number of Subjects Reporting Serious Adverse Events (SAEs)","https://ClinicalTrials.gov/show/NCT00289744"
30,"NCT00117533","Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta","Recruiting","No Results Available","Chronic Hepatitis B|Chronic Hepatitis D","Drug: pegylated IFN alfa-2b plus ribavirin","National Taiwan University Hospital|National Health Research Institutes, Taiwan|National Science Council, Taiwan","Both","Adult|Senior","Phase 4","20","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","930904","June 30, 2005","September 2005","June 2007","May 24, 2006","September 2005","No Study Results Posted","null","null","the efficacy of 24-week pegylated IFN alfa-2b plus RBV for SVR of HDV in patients with dual chronic hepatitis D and B|the efficacy of pegylated IFN alfa-2b plus RBV in patients with dual chronic hepatitis D and B on: The biochemical response rate|The degree of histologic change","https://ClinicalTrials.gov/show/NCT00117533"
31,"NCT00230854","Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin","Completed","No Results Available","Chronic Hepatitis C|Hepatitis, Viral, Human","Drug: EMZ702","Transition Therapeutics","Both","Adult","Phase 1","28","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","IET-202","September 29, 2005","August 2005","July 2007","June 4, 2013","June 2013","No Study Results Posted","null","null","To evaluate the safety and tolerability of repeated intravenous infusions of EMZ702 in combination with pegylated interferon and ribavirin in patients with chronic hepatitis C genotype 1|To evaluate the viral response and pharmacokinetic profile of repeated intravenous infusions of EMZ702 in combination with pegylated interferon and ribavirin in patients with chronic hepatitis C genotype 1","https://ClinicalTrials.gov/show/NCT00230854"
32,"NCT02582632","A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Na√Øve Hepatitis C Virus Genotype 1b-Infected Adults","Not yet recruiting","No Results Available","Hepatitis C Infection|Hepatitis C Virus","Drug: Ombitasvir/Paritaprevir/Ritonavir|Drug: dasabuvir","AbbVie","Both","Adult|Senior","Phase 3","160","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M15-684|2015-003370-33","October 20, 2015","November 2015","February 2017","October 20, 2015","October 2015","No Study Results Posted","null","November 2016","Percentage of participants who achieve sustained virologic response 12 weeks post-treatment (SVR12)|Percentage of participants with virologic failure during treatment|Percentage of participants with post-treatment relapse|Percentage of female participants who achieve sustained virologic response 12 (SVR12) weeks post-treatment|Percentage of participants with low baseline viral load who achieve sustained virologic response 12 (SVR12) weeks post-treatment","https://ClinicalTrials.gov/show/NCT02582632"
33,"NCT02135666","Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix¬Æ (SB208127) in Study HAB-084 (208127/084)","Not yet recruiting","No Results Available","Hepatitis B|Hepatitis A","Procedure: Blood sampling","GlaxoSmithKline","Both","Adult","Phase 4","180","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","117307|2013-004586-13","May 8, 2014","May 2015","October 2019","December 22, 2014","December 2014","No Study Results Posted","null","October 2019","Immunogenicity with respect to components of the study vaccine in terms of antibody titres|Occurrence of Serious adverse events (SAEs)","https://ClinicalTrials.gov/show/NCT02135666"
34,"NCT00496158","Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus","Terminated","No Results Available","Chronic Hepatitis|Hepatitis B","Drug: Clevudine|Drug: Adefovir","Pharmasset","Both","Child|Adult|Senior","Phase 3","null","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment|Masking: Double-Blind","CI-PSI-5268-06-306","July 2, 2007","August 2007","null","April 23, 2009","April 2009","No Study Results Posted","QUASH2","null","","https://ClinicalTrials.gov/show/NCT00496158"
35,"NCT00635310","Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With Vasopressin","Recruiting","No Results Available","Chronic Hepatitis C|Chronic Hepatitis B|Biopsy|Hemodialysis","Procedure: Percutaneous liver biopsy|Procedure: Percutaneous liver biopsy","National Taiwan University Hospital|National Science Council, Taiwan","Both","Child|Adult|Senior","","3520","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label","940211","March 5, 2008","January 2005","July 2013","December 19, 2012","December 2012","No Study Results Posted","null","June 2013","Biopsy-related serious hemorrhage rate by intention-to-treat (ITT) analysis|Biopsy-related serious hemorrhage rate by per-protocol (PP) analysis","https://ClinicalTrials.gov/show/NCT00635310"
36,"NCT00289770","Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults","Completed","Has Results","Hepatitis B|Hepatitis A","Biological: Twinrix‚Ñ¢","GlaxoSmithKline","Both","Adult|Senior","Phase 3","50","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","100551 (EXT Y11)|100552 (EXT Y12)|100553 (EXT Y13)|100554 (EXT Y14)|100555 (EXT Y15)","February 9, 2006","November 2004","December 2009","June 26, 2014","November 2011","November 30, 2010","null","December 2009","Number of Subjects With Anti-hepatitis A (Anti-HAV) Antibody Concentrations Equal to or Above Cut-off Value|Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above Cut-off Values|Anti-HAV and Anti-HBs Antibody Concentrations|Anti-HBs Antibody Concentrations|Number of Subjects, Receiving an Additional Vaccination of Engerix, With an Anamnestic Response|Number of Subjects With Solicited Local and General Symptoms Assessed|Number of Subjects With Unsolicited Symptoms|Number of Subjects With Serious Adverse Events (SAEs)|Number of Subjects With Serious Adverse Events (SAEs) Determined by the Investigator to Have a Causal Relationship to Primary Vaccination or Due to Lack of Vaccine Efficacy","https://ClinicalTrials.gov/show/NCT00289770"
37,"NCT01939197","A Two Part, Open-label Study to Evaluate the Safety and Effectiveness of ABT-450/r/ABT-267 or ABT-450/r/ABT-267 and ABT-333 Given With or Without a Drug Called Ribavirin in People With Both Hepatitis C Virus Genotype 1 or 4 Infection and Human Immunodeficiency Virus, Type 1 Infection","Recruiting","No Results Available","Hepatitis C Virus Infection|Human Immunodeficiency Virus Infection|Chronic Hepatitis C|Compensated Cirrhosis and Non-cirrhotics","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin (RBV)","AbbVie","Both","Adult|Senior","Phase 3","320","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-004|2012-005143-24","September 6, 2013","August 2013","September 2016","October 3, 2015","October 2015","No Study Results Posted","TURQUOISE-I","July 2016","Percentage of subjects in genotype 1 Analysis Group 1 in Part 2 achieving sustained virologic response 12 weeks post-treatment (SVR12) compared to the historical SVR12 rate for sofosbuvir plus ribavirin as reported in the PHOTON-1 study|The percentage of subjects in genotype 1 Analysis Group 2 of Part 2 achieving sustained virologic response 12 weeks post-treatment (SVR12) compared to the historical rate for sofosbuvir plus ribavirin|The percentage of Part 1a subjects achieving sustained virologic response 12 weeks post-treatment (SVR12) in the 24-week treatment group compared to the 12-week treatment group using Fisher's exact test|The percentage of subjects of Part 1b subjects achieving sustained virologic response 12 weeks post-treatment (SVR12) in the darunavir once-daily arm compared to the darunavir twice-daily arm using Fisher's exact test|The percentage of Part 1b subjects achieving sustained virologic response 12 weeks post-treatment (SVR12)|The percentage of Part 2 GT 1b cirrhotic subjects achieving sustained virologic response 12 weeks post-treatment (SVR12) in Arm F (without ribavirin) compared to Arm G (with ribavirin) using Fisher's exact test|The percentage of genotype 4 subjects in Part 2 achieving sustained virologic response 12 weeks post-treatment (SVR12) by arm and overall|Percentage of subjects with on treatment Hepatitis C Virus virologic failure during the Treatment Period for each arm in Part 1, set of all subjects in Part 1b, the genotype 1 Analysis Group 1 and 2 in Part 2, the GT4 Analysis Group by arm and overall|The percentage of subjects with Hepatitis C Virus post-treatment relapse (analyses performed as described for secondary endpoint 7).|Percentage of subjects with plasma HIV-1 RNA suppression at end of treatment and 12 weeks post-treatment (analyses performed as described for secondary endpoint 7) and comparison of the darunavir once-daily and twice-daily arms in Part 1b","https://ClinicalTrials.gov/show/NCT01939197"
38,"NCT00814606","A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C","Withdrawn","No Results Available","Hepatitis C|Hepatitis C Virus","Drug: Fluvastatin|Drug: Peginterferon alfa2a|Drug: ribavirin","University of Chicago","Both","Adult","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","16336A","December 23, 2008","February 2010","October 2010","June 28, 2013","June 2013","No Study Results Posted","null","October 2010","Efficacy of adding fluvastatin to pegylated interferon alfa-2a and ribavirin in patients infected with genotype 1 HCV who are previous partial responders to standard treatment.|Safety of adding fluvastatin to pegylated interferon alfa-2a and ribavirin in patients infected with genotype 1 HCV who are previous partial responders to standard treatment.","https://ClinicalTrials.gov/show/NCT00814606"
39,"NCT00188240","Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy","Recruiting","No Results Available","Hepatitis C|Hepatitis B","Drug: Pegasys; Copegus.","University Health Network, Toronto","Both","Adult|Senior","","200","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","03-0510-AE 04-0292-A","September 9, 2005","August 2003","null","November 28, 2005","September 2005","No Study Results Posted","null","null","Phase I - To evaluate the prevalence of insulin resistance in patients with hepatitis C without cirrhosis and compare it to that observed in patients with hepatitis B also without cirrhosis.|Phase II - Interventional phase - To evaluate the effect of anti-viral therapy on insulin resistance, determined by the OGTT method, in patients with hepatitis C found to have insulin resistance pre-treatment.|- To evaluate the safety, efficacy and tolerability of Pegasys (peginterferon alfa-2a) given in combination with Copegus (ribavirin) given for 24 weeks or 48 weeks in treatment na√Øve patients with chronic hepatitis C (CHC).","https://ClinicalTrials.gov/show/NCT00188240"
40,"NCT00088504","Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C","Completed","No Results Available","Hepatitis C|Hepatitis","Drug: Merimepodib|Drug: PEG-Interferon-alpha 2a (Pegasys¬Æ)|Drug: Ribavirin (Copegus¬Æ)","Vertex Pharmaceuticals Incorporated","Both","Adult|Senior","Phase 2","315","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","VX03-497-205","July 27, 2004","July 2004","October 2006","December 17, 2007","December 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00088504"
41,"NCT01740089","Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C","Completed","Has Results","Hepatitis|Hepatitis C","Drug: Algeron|Drug: PegIntron|Drug: Ribavirin","Biocad","Both","Adult|Senior","Phase 2|Phase 3","150","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","PEG-IFN–∞-2","November 30, 2012","November 2011","December 2013","July 22, 2015","July 2015","March 1, 2015","null","July 2012","Number of Randomized Patients Achieving Early Virologic Response (EVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) or ‚â• 2log10 Decrease of Viral Load After 12 Weeks of Study Treatment.|Number of Randomized Patients Achieving Rapid Virologic Response (RVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) After 4 Weeks of Treatment.|Number of Randomized Patients Achieving Sustained Virologic Response (SVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) 24 Weeks After Last Dose of Study Treatment.|Number of Patients Who Have Undetectable HCV RNA (< 15 IU/ml) at the End of Treatment.","https://ClinicalTrials.gov/show/NCT01740089"
42,"NCT01821794","Tenofovir DF With or Without Peginterferon for Chronic Hepatitis B","Recruiting","No Results Available","Chronic Hepatitis B e Antigen Negative|Chronic Hepatitis B e Antigen Positive","Drug: Peginterferon and Tenofovir","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 3","31","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","130091|13-DK-0091","March 15, 2013","March 2013","December 2021","April 30, 2015","April 2015","No Study Results Posted","null","May 2020","HBsAg loss at the end of 48-weeks post-treatment follow-up (week 240)|ALT normalization|Cumulative HBsAg loss|HBsAg seroconversion|HBeAg loss|ALT corresponding to approx 1.25XULN|HBV DNA & lt; 1000 IU/mL|HBV DNA & lt; 20 IU/m|Absence antiviral drug-resistance HBV mu|Sustained HBV DNA less than 1000 IU/mL|Rate treatment discontinuation due to AE|Rates of AE and SAE|HBV DNA & lt; 1000IU/mL & amp; ALT approx 1.25XULN|Rate of treatment failure","https://ClinicalTrials.gov/show/NCT01821794"
43,"NCT01953458","Therapeutic Option for Hepatitis B and C: a French Cohort","Recruiting","No Results Available","Viral Hepatitis B|Viral Hepatitis C","","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb|Gilead Sciences|Janssen-Cilag Ltd.|Merck Sharp & Dohme Corp.|Roche Pharma AG","Both","Adult|Senior","","25000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ANRS CO22 HEPATHER|2011-A01438-33","September 19, 2013","August 2012","August 2022","September 5, 2014","June 2014","No Study Results Posted","HEPATHER","June 2016","There is no specific primary outcome measure but we indicated below (see Description) a list of potential outcome measures according to the objectives.","https://ClinicalTrials.gov/show/NCT01953458"
44,"NCT00815464","A Single-Arm Study Evaluating the Efficacy of Liquid Acupuncture Therapeutics in Chronic Hepatitis B","Not yet recruiting","No Results Available","Hepatitis B, Chronic|Liver Diseases|Virus Diseases|Hepatitis|Diffuse Hepatic Disease","Device: Liquid Acupuncture (Herb Acupoint Injection)","Yu Medical Garden","Both","Adult","","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","YMG-PR-001","December 29, 2008","March 2009","March 2010","December 29, 2008","December 2008","No Study Results Posted","CHB","September 2009","Permanent Efficacy response after whole treatment circle close(about 24-48 weeks): 1„ÄÅHBeAg loss(if HBeAg positive) 2„ÄÅHBV DNA non-detectability (PCR <500 copies/ml) 3„ÄÅLiver function normal(If Liver function off normal)|HBsAg titer will decrease continually up to loss after cessation of the treatment.","https://ClinicalTrials.gov/show/NCT00815464"
45,"NCT01889433","An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C","Recruiting","No Results Available","Hepatitis|Hepatitis C","Drug: Algeron|Drug: Pegasys","Biocad","Both","Adult|Senior","Phase 3","500","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","BCD-016-3","June 26, 2013","November 2013","November 2016","July 17, 2015","July 2015","No Study Results Posted","null","November 2016","EVR|RVR|SVR (24)|EOT|Biochemical Response|Histological Response","https://ClinicalTrials.gov/show/NCT01889433"
46,"NCT01772121","Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India","Completed","No Results Available","Hepatitis B|Hepatitis C","","Gilead Sciences","Both","Adult|Senior","","1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GX-US-174-0196","January 17, 2013","May 2012","October 2012","July 7, 2015","July 2015","No Study Results Posted","null","October 2012","Variation in the IL28B rs12979860 SNP|Prevelance of HBV and HCV genotypes|Characterize the SNPs present in innate immune factors toll-like receptor 7 (TLR7)","https://ClinicalTrials.gov/show/NCT01772121"
47,"NCT01413360","The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients","Recruiting","No Results Available","Chronic Hepatitis|Chronic Hepatitis C|Chronic Alcoholic Hepatitis","Drug: High dose vitamin C","Seoul National University Hospital","Both","Adult|Senior","Phase 4","30","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","VitC","August 9, 2011","August 2011","December 2014","November 26, 2014","November 2014","No Study Results Posted","null","December 2014","The change of serum alanine aminotransferase level|The change of serum interleukin 22 level","https://ClinicalTrials.gov/show/NCT01413360"
48,"NCT02250807","Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection","Active, not recruiting","No Results Available","Chronic Hepatitis C|Genotype 4 Chronic Hepatitis C","Drug: Simeprevir|Drug: Sofosbuvir","Janssen R&D Ireland","Both","Adult|Senior","Phase 3","40","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CR105429|TMC435HPC3021|2014-003446-27","September 24, 2014","January 2015","January 2016","September 25, 2015","September 2015","No Study Results Posted","null","November 2015","Percentage of Subjects With Sustained Virologic Response (SVR 12) at Week 12 After End of Treatment (EOT)|Percentage of Subjects With Sustained Virologic Response at Week 4 (SVR 4) and 24 (SVR 24) After EOT|Percentage of Subjects With On-treatment Virologic Response of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)|Percentage of Subjects With on-treatment failure along with Viral Breakthrough|Percentage of Subjects With Viral Relapse","https://ClinicalTrials.gov/show/NCT02250807"
49,"NCT00524576","Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix‚Ñ¢-B Vaccine","Completed","Has Results","Hepatitis B|Hepatitis B Vaccine","Biological: Engerix‚Ñ¢-B","GlaxoSmithKline","Both","Child|Adult","Phase 4","144","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","108988","August 31, 2007","November 2007","May 2008","March 17, 2011","March 2011","May 14, 2009","null","May 2008","Number of Participants With Immunological Response to Challenge Dose in Terms of Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration|Number of Participants With Anti-HBs Antibody Concentrations Above the Cut-off Value|Concentration of Anti-HBs Antibodies|Number of Participants Reporting Solicited Local Symptoms|Number of Participants Reporting Solicited General Symptoms|Number of Participants Reporting Unsolicited Adverse Events (AE)|Number of Participants Reporting Serious Adverse Events (SAE)","https://ClinicalTrials.gov/show/NCT00524576"
50,"NCT02011763","Safety of Two Doses of Avaxim¬Æ 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents","Completed","No Results Available","Hepatitis A|Hepatitis A Virus","Biological: Avaxim 80U Pediatric: Inactivated Hepatitis A Virus","Sanofi Pasteur, a Sanofi Company|Sanofi","Both","Child","Phase 4","355","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","HAF87|U1111-1127-7652","December 10, 2013","December 2013","August 2015","September 29, 2015","September 2015","No Study Results Posted","null","September 2014","Number of participants reporting solicited injection site and systemic events and unsolicited adverse events following vaccination with Avaxim¬Æ 80U Pediatric (Inactivated Hepatitis A vaccine).","https://ClinicalTrials.gov/show/NCT02011763"
51,"NCT00188201","Neurocognitive Functioning in Patients With Hepatitis C Pre- and Post-Treatment With Antiviral Medication","Recruiting","No Results Available","Hepatitis C|Hepatitis B","","University Health Network, Toronto","Both","Adult","","150","Other","Observational","Observational Model: Defined Population|Time Perspective: Longitudinal|Time Perspective: Prospective","01-0827-E|EOP-48307","September 9, 2005","January 2002","null","November 28, 2005","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00188201"
52,"NCT01195181","Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.","Completed","No Results Available","Hepatitis C Virus|Chronic Liver Disease|Viral Hepatitis|Therapeutic Uses|Antiviral Agents","Drug: peginterferon plus ribavirin","Azienda Ospedaliera di Padova|Regione Veneto|University of Padua","Both","Adult","Phase 4","506","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HEPCOVE protocol|DRG N.2920/2002","August 31, 2010","September 2005","August 2010","September 3, 2010","September 2010","No Study Results Posted","null","December 2009","Evaluation of real dose drugs intake in relation to sustained virological response (SVR).|Description of the profile of the virus decay during antiviral therapy in relation to virological response.","https://ClinicalTrials.gov/show/NCT01195181"
53,"NCT00347009","Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis","Completed","Has Results","Hepatitis B, Chronic|Cirrhosis|Fibrosis|Chronic Hepatitis B","Drug: adefovir dipivoxil","GlaxoSmithKline","Both","Adult|Senior","Phase 4","155","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ADF104070","June 30, 2006","May 2005","September 2009","May 31, 2012","March 2011","September 20, 2010","null","September 2009","Number of Participants With Histologic Improvement at Month 36 (Intent-to-Treat Population)|Number of Participants With Histologic Improvement at Month 36 (Per Protocol Population)|Number of Participants With a Reduction From Baseline in the Child-Pugh Score by 2 Points or More at Months 12, 24, and 36|Number of Participants With a Reduction From Screening of at Least 2 Points in the Knodell Necroinflammation Score at Month 36|Change From Baseline in Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level at Months 12, 24, and 36|Number of Participants Achieving Virological Response (HBV DNA Level <= 10^3 Copies/ml) at Months 12, 24, and 36|Number of Participants Achieving Virological Response (HBV DNA Level <= 10^4 Copies/ml) at Months 12, 24, and 36|Number of Participants With Undetectable HBV DNA at Months 12, 24, and 36|Number of Participants With Virological Breakthrough at Months 12, 24, and 36|Number of Participants With Alanine Aminotransferase (ALT) Normalization at Months 12, 24, and 36|Number of Participants Who Were Hepatitis B Envelope Antigen (HBeAg) Positive at Baseline and Developed Undetectable Levels of HBeAg at Months 12, 24, and 36|Number of Participants Who Were HBeAg Positive at Baseline, With HBeAg Seroconversion at Months 12, 24, and 36|Number of Participants Who Were Hepatitis B Surface Antigen (HBsAg) Positive at Baseline and Developed Undetectable Levels of HBsAg at Months 12, 24, and 36|Number of Participants Who Were HBsAg Positive at Baseline, With HBsAg Seroconversion at Months 12, 24, and 36","https://ClinicalTrials.gov/show/NCT00347009"
54,"NCT00496002","Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus","Terminated","No Results Available","Chronic Hepatitis|Hepatitis B","Drug: Clevudine|Drug: Adefovir","Pharmasset","Both","Child|Adult|Senior","Phase 3","null","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment|Masking: Double-Blind","CI-PSI-5268-06-305","July 2, 2007","August 2007","null","April 23, 2009","April 2009","No Study Results Posted","QUASH 1","null","","https://ClinicalTrials.gov/show/NCT00496002"
55,"NCT00412529","Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B","Completed","Has Results","Hepatitis B|Chronic Hepatitis B","Drug: Entecavir|Drug: Telbivudine","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 3","44","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CLDT600A2407","December 15, 2006","December 2006","null","February 23, 2015","February 2015","December 2, 2010","null","February 2008","Change in Mean Hepatitis B Virus (HBV) DNA Levels|Change in Mean HBV DNA Level|The Area Under the Curve (AUC) of HBV DNA Change.|Change in Alanine Aminotransferase (ALT) Levels|Characterization of Very Early Viral Kinetics: Estimation of Viral Clearance|Characterization of Very Early Viral Kinetics: Estimation of the Rate of Infected Cell Loss|Characterization of Very Early Viral Kinetics: Estimation of the Efficiency Factor of Blocking Virus Production|Number of Patients Who Are Polymerase Chain Reaction (PCR) Negative","https://ClinicalTrials.gov/show/NCT00412529"
56,"NCT02593162","A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection","Recruiting","No Results Available","Hepatitis C Viral Infection|Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 4","Drug: Faldaprevir|Drug: TD-6450|Drug: Ribavirin","Trek Therapeutics, PBC","Both","Adult|Senior","Phase 2","24","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","TRK-450-0201","October 29, 2015","October 2015","July 2016","October 29, 2015","October 2015","No Study Results Posted","null","July 2016","Percentage of subjects achieving 12-week sustained virologic response following treatment with 2 direct acting anti-virals and ribavirin in Genotype 4 Hepatitis C infected adults|Percentage of subjects with virologic response at Week 12 (HCV RNA less than lower limit of quantitation at end of therapy with Faldaprevir plus TD-6450 plus ribavirin)|Percentage of subjects with virologic response 2, 4 and 8 weeks after treatment completion (HCV RNA less than lower limit of quantitation at 2, 4 and 8 weeks after end of therapy with Faldaprevir plus TD-6450 plus ribavirin)","https://ClinicalTrials.gov/show/NCT02593162"
57,"NCT00403585","Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814","Completed","Has Results","Hepatitis B, Chronic|Chronic Hepatitis B","Drug: adefovir dipivoxil 10mg","GlaxoSmithKline","Both","Adult|Senior","Phase 4","80","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ADF108005|update with ADF103814","November 23, 2006","July 2006","April 2008","November 24, 2010","November 2010","April 24, 2009","null","April 2008","Hepatitis B Virus (HBV) DNA (log10 Copies/mL) Change From Baseline at Week 156 of Adefovir Therapy|Number of Participants Achieving ALT Normalization at Week 104 & 156|Number of Participants Achieving Virological Response at Week 104 & 156|HBV DNA Levels at Each Collection Time Point From Baseline Through Week 156|Number of Participants With HBeAg Loss, HBeAg Seroconversion, HBsAg Loss and HBsAg Seroconversion at Week 104 & 156|Safety Assessment: Number of Participants With a Serious Adverse Event and an Adverse Event","https://ClinicalTrials.gov/show/NCT00403585"
58,"NCT00154869","Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C","Recruiting","No Results Available","Hepatitis B, Chronic|Hepatitis C, Chronic","Drug: Peginterferon Alfa-2a plus Ribavirin","National Taiwan University Hospital|Hoffmann-La Roche","Both","Adult|Senior","Phase 3","320","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","921003|ML17862","September 8, 2005","June 2004","August 2007","August 10, 2007","August 2005","No Study Results Posted","null","null","To demonstrate the efficacy of peginterferon alfa-2a (PEG-IFN alfa-2a) (Pegasys¬Æ) plus ribavirin (RBV) for sustained virological response (SVR) in HBV-coinfected versus monoinfected chronic hepatitis C (CHC) patients|To demonstrate the efficacy of peginterferon alfa-2a (PEG-IFN alfa-2a) (Pegasys¬Æ) plus ribavirin (RBV) on the reduction of HCV viremia after 24 and 48 weeks of treatment (depending on genotype) in coinfected versus monoinfected CHC patients|To demonstrate the efficacy of PEG-IFN alfa-2a plus RBV in dual chronic hepatitis C and B on:|1) the biochemical response rate|2) the score of histologic change|3) serum HBV DNA disappearance|4) HBsAg disappearance|5) combined response of HBV DNA disappearance and normalization of ALT|6) end of treatment virological response|To assess the influence of serum HBV load on the clearance of serum HCV RNA, the loss of serum HBV DNA, and normalization of serum ALT|To assess the influence of HBV genotype on the clearance of serum HCV RNA, the loss of serum HBV DNA, and normalization of serum ALT|To assess the safety profile of the PEG-IFN alfa-2a plus RBV combination therapy in dual chronic hepatitis C and B","https://ClinicalTrials.gov/show/NCT00154869"
59,"NCT00603252","Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults","Completed","No Results Available","Hepatitis B|Hepatitis A","Biological: Twinrix|Biological: Engerix-B|Biological: Havrix|Biological: HBVAXPRO|Biological: Vaqta","GlaxoSmithKline","Both","Adult|Senior","Phase 4","213","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","111149","January 16, 2008","January 2008","June 2008","May 22, 2014","May 2014","No Study Results Posted","null","May 2008","Anti-HAV immune response to the challenge dose|Anti-HBs antibody response to the challenge dose|Percentage of subjects with anti-HAV antibody titres ‚â• 15 mIU/ml and GMTs calculated on seropositive subjects|Percentage of subjects with anti-HBs antibody titres ‚â• 3.3 mIU/ml, ‚â• 10 mIU/ml, ‚â• 100 mIU/ml and anti-HBs GMTs calculated on seropositive subjects|Occurrence and intensity of solicited local symptoms|Occurrence, intensity and relationship of solicited general symptoms|Occurrence, intensity and relationship to vaccination of unsolicited symptoms reported|Occurrence of all serious adverse events (SAEs) reported","https://ClinicalTrials.gov/show/NCT00603252"
60,"NCT01306071","Observational Study of Persons With Hepatitis B Virus Infection in North America","Recruiting","No Results Available","Chronic Hepatitis B e Antigen Positive|Chronic Hepatitis B e Antigen Negative","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","","200","NIH","Observational","Time Perspective: Prospective","110108|11-DK-0108","February 26, 2011","February 2011","null","June 10, 2015","June 2015","No Study Results Posted","null","null","To describe participants with hepatitis","https://ClinicalTrials.gov/show/NCT01306071"
61,"NCT01581554","Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B","Recruiting","No Results Available","Chronic Hepatitis B e Antigen Positive|Chronic Hepatitis B e Antigen Negative","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","","50","NIH","Observational","Time Perspective: Prospective","110151|11-DK-0151","April 19, 2012","April 2011","null","June 5, 2015","May 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01581554"
62,"NCT00823342","ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, na√Øve to Anti-VHB Therapy","Terminated","No Results Available","HBe Negative Chronic Hepatitis B|Hepatitis B Viral Infection","Drug: CLEVUDINE + TENOFOVIR PLACEBO|Drug: CLEVUDINE IN ASSOCIATION TENOFOVIR|Drug: TENOFOVIR + CLEVUDINE PLACEBO","French National Agency for Research on AIDS and Viral Hepatitis|Gilead Sciences|Pharmasset","Both","Adult|Senior","Phase 3","150","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","2008-000733-21|ANRS HB 05","January 14, 2009","December 2008","September 2011","May 7, 2009","May 2009","No Study Results Posted","null","March 2011","Compare the long term efficacy of new anti-HBV strategies of CLV monotherapy VS TDF monotherapy VS the combination of CLV + TDF for 96 weeks in HBeAg negative patients with CHB, na√Øve to anti-HBV-therapy, at 24 weeks post-treatment|Compare the safety profile of CLV + TDF compared to that of CLV and TDF in HBeAg negative patients with CHB, na√Øve to anti-HBV-therapy. - To compare perceived toxicity as expressed by the nature and the number of self-reported side effects, percept","https://ClinicalTrials.gov/show/NCT00823342"
63,"NCT02366286","Identification of Chronic Hepatitis B Infections Among Somali Immigrants in Minnesota Through Community-wide Screening","Recruiting","No Results Available","Hepatitis B|Hepatitis C|Carcinoma, Hepatocellular","","Mayo Clinic|Gargar Urgent Care & Clinic|Axis Medical Center","Both","Adult|Senior","","1000","Other","Observational","Time Perspective: Prospective","09-001670|IN-US-174-0230","October 8, 2014","November 2010","December 2016","February 11, 2015","February 2015","No Study Results Posted","null","December 2016","Number of subjects who test positive for markers of Hepatitis B Virus infection (HBsAg, HBcAb, HBsAb)|Number of subjects who test positive for markers of Hepatitis C Virus infection (anti-HCV infection)|Rate of HBV vaccination in subjects with negative HBV serology|Incidence of HCC over the period of the study","https://ClinicalTrials.gov/show/NCT02366286"
64,"NCT01306617","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Na√Øve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","Completed","Has Results","Chronic Hepatitis C Infection|Hepatitis C|Hepatitis C Virus","Drug: ABT-450|Drug: ABT-333|Drug: ribavirin|Drug: ritonavir","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M12-746","February 28, 2011","February 2011","October 2012","December 29, 2014","December 2014","December 29, 2014","null","November 2011","Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Detection (LLOD) From Week 4 Through Week 12|Percentage of Participants With HCV RNA < 1000 International Units Per Milliliter (IU/mL)|Percentage of Participants With HCV RNA Below the Lower Limit of Quantitation (LLOQ; <25 IU/mL) at Week 4|Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment|Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-Treatment|Time to Failure to Suppress or Rebound During Treatment|Time to Virologic Relapse Post-treatment|Resistance-Associated Variants and Phenotypic Resistance|Pharmacokinetics (C Trough) of ABT 450 in HCV Infected Participants|Pharmacokinetics (C Trough) of ABT-333 in HCV Infected Participants|Pharmacokinetics (C Trough) of Ritonavir in HCV Infected Participants|Pharmacokinetics (C Trough) of Ribavirin in HCV Infected Participants","https://ClinicalTrials.gov/show/NCT01306617"
65,"NCT02511431","Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir","Recruiting","No Results Available","Hepatitis D","Drug: Lonafarnib|Drug: Ritonavir|Other: Placebo","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","21","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","150170|15-DK-0170","July 29, 2015","July 2015","December 2030","August 11, 2015","July 2015","No Study Results Posted","null","January 2017","Primary Therapeutic Endpoint: Decline of HDV RNA Quantitative Measurements of & gt; 2 logs from baseline at 12 and 24 weeks of therapy with lonafarnib and ritonavir.|The ability to tolerate lonafarnib and ritonavir at the prescribed dose for 12 and 24 weeks of therapy.|Sustained undetectable HDV RNA in serum at weeks 12 and 24 of post-treatment follow-up.|Comparison of HDV RNA decline between 12 and 24 weeks of therapy at differing doses.|Comparison of ALT changes between different doses of lonafarnib|Loss of HBsAg from the serum at the end of therapy, at week 12 of post-therapy follow-up and at week 24 of post-therapy follow-up.|Changes in symptom scale measurements and quality of life before, during and after therapy.|Seroconversion of HBsAg at the end of therapy, at week 12 of post- therapy follow up and at week 24 of post-therapy follow-up.|Changes in the fecal microbiome before and after treatment|Comparison of fecal microbiome analysis between different groups|Undetectable HDV RNA in serum by quantitative measurements at the end of therapy.|Comparison of serologic HDV RNA decline between different doses of lonafarnib","https://ClinicalTrials.gov/show/NCT02511431"
66,"NCT02148562","Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity","Enrolling by invitation","No Results Available","Hepatitis B|Hepatitis B, Chronic|End Stage Liver Disease|Carcinoma, Hepatocellular","","Universitaire Ziekenhuizen Leuven|Fund for Scientific Research, Flanders, Belgium","Both","Child|Adult|Senior","","274","Other","Observational","Time Perspective: Prospective","S56121|12G1714N","April 4, 2014","April 2014","December 2017","May 22, 2014","May 2014","No Study Results Posted","null","December 2017","genetic variants of Hepatitis B|genetic variation in host-specific immune markers","https://ClinicalTrials.gov/show/NCT02148562"
67,"NCT00725842","Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)","Terminated","Has Results","Hepatitis C|Hepatitis C, Chronic","Biological: Peg-IFN alfa-2b|Drug: Ribavirin","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","97","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P05484","July 28, 2008","January 2009","June 2011","September 18, 2015","September 2015","June 13, 2012","RE-CHUT","June 2011","Number of Participants With Positive Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) at 24 Weeks Off-treatment|Number of Participants With Rapid Virologic Response (RVR), Early Virologic Response (EVR), or Slow Response Who Relapsed After Treatment|Assessment of Pre-treatment Risk Factors of Relapse in Participants With Sustained Virologic Response|Number of Participants With Positive HCV-RNA at 72 Weeks Off-treatment","https://ClinicalTrials.gov/show/NCT00725842"
68,"NCT00704717","Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)","Completed","Has Results","Hepatitis C, Chronic|Hepatitis C","Biological: PegIntron (peginterferon alfa-2b; SCH 54031) pen|Drug: Rebetol (ribavirin; SCH 18908)","Merck Sharp & Dohme Corp.","Both","Child|Adult|Senior","","185","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P04301","June 23, 2008","September 2005","December 2007","April 8, 2015","April 2015","February 11, 2009","null","December 2007","Satisfaction of Patients Receiving PegIntron Pen Plus Rebetol Therapy, Assessed by a Survey.","https://ClinicalTrials.gov/show/NCT00704717"
69,"NCT00705107","Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-na√Øve Adult Patients With Hepatitis C in Romania (Study P04247)","Terminated","Has Results","Hepatitis C, Chronic|Hepatitis C","Biological: PegIntron pen (peginterferon alfa-2b; SCH 54031)|Drug: Rebetol (ribavirin; SCH 18908)","Merck Sharp & Dohme Corp.","Both","Child|Adult|Senior","","267","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P04247","June 23, 2008","November 2004","November 2007","June 3, 2015","June 2015","February 11, 2009","null","November 2007","Number of Subjects Who Completed Treatment.|Average Length of Treatment.","https://ClinicalTrials.gov/show/NCT00705107"
70,"NCT00512941","Laboratory Profile of Hepatitis B and C in Users of a Reference Service","Completed","No Results Available","Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted|Hepatitis B, Chronic","","UPECLIN HC FM Botucatu Unesp","Both","Adult|Senior","","531","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","upeclin/HC/FMB-Unesp-15","August 6, 2007","June 2007","August 2007","September 4, 2008","September 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00512941"
71,"NCT00867243","Prediction of Hepatitis C Recurrence in Liver Transplant Recipients","Terminated","No Results Available","Complication of Transplanted Liver|Hepatitis C, Chronic","","Northwestern University|Northwestern Memorial Hospital","Both","Adult|Senior","","24","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STU12442 1963-002","March 19, 2009","October 2005","May 2011","June 10, 2013","June 2013","No Study Results Posted","null","May 2010","To assess whether in-vitro donor-specific immune reactivity patterns are indicative of rate of HCV recurrence|To compare in-vitro donor-specific immune reactivity patterns and rejection episodes in liver transplant recipients|To establish immune monitoring protocol for HCV+ liver transplant recipients that will aid in tailoring immunosuppression protocols for these patients and in devising strategies to treat patients with recurrent hepatitis C post-liver transplantation.","https://ClinicalTrials.gov/show/NCT00867243"
72,"NCT01366638","A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection","Completed","Has Results","Hepatitis C, Chronic","Drug: TMC435|Drug: Peginterferon alfa-2b (pegIFN alfa-2b)|Drug: Ribavirin (RBV)","Janssen Pharmaceutical K.K.","Both","Adult|Senior","Phase 3","79","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CR017935|TMC435HPC3010","June 2, 2011","May 2011","November 2012","April 10, 2014","April 2014","October 17, 2013","null","November 2012","The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)|The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)|The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment|The Number of Participants With Viral Breakthrough|The Number of Participants Demonstrating Viral Relapse|The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at the End of Treatment (EOT)|The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up|The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2b (PegIFNŒ±-2b) and Ribavirin (RBV) at Week 24|The Area Under the Plasma Concentration-Time Curve (From 0 to 24 Hours) (AUC24h)|Plasma Concentrations of TMC435","https://ClinicalTrials.gov/show/NCT01366638"
73,"NCT00230503","Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B","Completed","No Results Available","Hepatitis B, Chronic","Drug: pradefovir mesylate|Drug: adefovir dipivoxyl","Valeant Pharmaceuticals International, Inc.","Both","Adult","Phase 2","220","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","RNA200103-201","September 28, 2005","June 2004","December 2006","June 21, 2012","June 2012","No Study Results Posted","null","December 2006","- Safety: Clinical examinations of laboratory tests|- Efficacy: Change in viral load over time|- Efficacy: Proportion of patients with undetectable viral load","https://ClinicalTrials.gov/show/NCT00230503"
74,"NCT01292239","A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients","Completed","Has Results","Hepatitis C, Chronic","Drug: Placebo|Drug: TMC435|Drug: Peginterferon alfa-2a (pegIFN alfa-2a)|Drug: Ribavirin (RBV)","Janssen Pharmaceutical K.K.","Both","Adult|Senior","Phase 3","183","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","CR017686|TMC435HPC3003","February 1, 2011","February 2011","October 2012","December 16, 2013","December 2013","October 15, 2013","null","October 2012","The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)|The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the Last Dose of Treatment (SVR24)|The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up|The Percentage of Participants With Undetectable Plasma Levels of Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)|The Number of Participants With Viral Breakthrough|The Number of Participants Demonstrating Viral Relapse|The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)|The Percentage of Participants in the TMC435 Treatment Group Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2a (PegIFN Alpha-2a) and Ribavirin (RBV) at Week 24|Plasma Concentrations of TMC435|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435","https://ClinicalTrials.gov/show/NCT01292239"
75,"NCT00948220","Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic|Liver Diseases|Virus Diseases","Drug: peginterferon alfa-2a and ribavirin","University of Ulm|Hoffmann-La Roche","Male","Adult","Phase 4","26","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label","OSTEO","July 24, 2009","July 2003","March 2008","June 6, 2011","May 2011","No Study Results Posted","null","January 2007","Change of the bone mineral density of the lumbar spine and right hip measured by DEXA in patients with chronic hepatitis C with or without antiviral combination treatment with peginterferon and ribavirin|Change in markers of bone formation and resorption over time during antiviral therapy and after cessation of therapy.","https://ClinicalTrials.gov/show/NCT00948220"
76,"NCT01288209","A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy","Completed","Has Results","Hepatitis C, Chronic","Drug: TMC435|Drug: Peginterferon alfa-2a (PegIFNŒ±-2a )|Drug: Ribavirin (RBV)","Janssen Pharmaceutical K.K.","Both","Adult|Senior","Phase 3","106","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CR017689|TMC435HPC3004","February 1, 2011","February 2011","September 2012","December 18, 2013","December 2013","October 15, 2013","null","September 2012","The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)|The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the End of Treatment (EOT) and 24 Weeks After the Last Dose of Treatment (SVR24)|The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up|The Percentage of Participants With Undetectable Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)|The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels During Treatment for Participants Who Did Not Achieve Undetectable Plasma HCV RNA Levels at Week 12|The Number of Participants With Viral Breakthrough During the Study|The Number of Participants Demonstrating Viral Relapse During the Study|The Number Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)|The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2a (PegIFNŒ±-2a) and Ribavirin (RBV) at Week 24|Plasma Concentrations of TMC435|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435","https://ClinicalTrials.gov/show/NCT01288209"
77,"NCT00841477","An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users","Completed","No Results Available","Hepatitis B Infection|Hepatitis C Infection|HIV Infection","Biological: hepatitis B vaccine 3 dose schedule (0,1,2 month)|Behavioral: HBV Vaccination Self-Efficacy Intervention","National Institute on Drug Abuse (NIDA)","Both","Adult|Senior","Phase 3","1260","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor)","DESPR DA017505","February 10, 2009","January 2004","December 2009","April 13, 2015","April 2015","No Study Results Posted","null","June 2007","compliance (adherence) for 3 doses hepatitis vaccination|incidence of HIV and HCV infection and change of risk behaviors|immunological response","https://ClinicalTrials.gov/show/NCT00841477"
78,"NCT01745822","Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand","Active, not recruiting","No Results Available","Hepatitis B Chronic Infection|Pregnancy","Drug: tenofovir disoproxil fumarate|Drug: placebo","Institut de Recherche pour le Developpement|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Centers for Disease Control and Prevention|Gilead Sciences","Female","Adult|Senior","Phase 3","328","Other|NIH|U.S. Fed|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","U01HD071889","December 6, 2012","January 2013","October 2017","October 19, 2015","October 2015","No Study Results Posted","iTAP","December 2016","Infant's Hepatitis B infection status at 6 months of age|Adverse events|Flares after study treatment interruption|Infant's HBV infection status|Infant growth related outcomes, including weight, height and HC Z-scores","https://ClinicalTrials.gov/show/NCT01745822"
79,"NCT00473993","Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland","Completed","No Results Available","Hepatitis C, Chronic|Substance Abuse Treatment Centers|Opioid-Related Disorders","","Seidenberg, Arztpraxis A., M.D.|University of Zurich","Both","Child|Adult|Senior","","null","Other","Observational","Time Perspective: Retrospective","HepCOP Zurich","May 15, 2007","July 2007","December 2007","February 13, 2009","May 2007","No Study Results Posted","HepCOP","null","","https://ClinicalTrials.gov/show/NCT00473993"
80,"NCT01448915","Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)","Recruiting","No Results Available","HIV Infection|Hepatitis C","Behavioral: Contigent voucher incentive (CVI)","Johns Hopkins University|National Institute on Drug Abuse (NIDA)","Both","Adult|Senior","Phase 4","800","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","NA00029706|R01DA016065","September 27, 2011","September 2009","July 2013","October 6, 2011","October 2011","No Study Results Posted","null","July 2013","Hepatitis C Treatment Eligibility|Liver Disease Staging|Hepatitis C Treatment Incentives|Liver stiffness|Body mass index|Serum markers","https://ClinicalTrials.gov/show/NCT01448915"
81,"NCT00838071","Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation","Completed","No Results Available","Hepatitis B, Chronic","Drug: Specific intravenous anti-hepatitis B immunoglobulin","Instituto Grifols, S.A.|Grifols Biologicals Inc.","Both","Adult|Senior","Phase 3","20","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","IG301","February 5, 2009","October 2003","August 2004","February 5, 2009","February 2009","No Study Results Posted","null","July 2004","To determine if after 4 months of continuous monthly administration of HB-IVIG Grifols, the anti-hepatitis B antibodies contained in the product reach levels considered as protective, and to assess if these levels are kept constant during 2 more months.|To determine the in vivo recovery of 6 consecutive doses of HB-IVIG Grifols and demonstrate that it remains constant for each dose.|To determine various pharmacokinetic parameters after 6 administrations of HB-IVIG Grifols|To determine the incidence of recurrences during the treatment|To evaluate tolerance to the administration of HB-IVIG Grifols|To confirm the viral safety of the product supervising viral markers","https://ClinicalTrials.gov/show/NCT00838071"
82,"NCT00055445","IdB 1016 Treatment for Hepatitis C Disease","Completed","No Results Available","Hepatitis C, Chronic","Drug: IdB 1016","National Center for Complementary and Integrative Health (NCCIH)","Both","Adult","Phase 1|Phase 2","45","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","R21 AT000992-01A1|IdB-1016-UW-001","March 3, 2003","November 2003","April 2006","August 17, 2006","July 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00055445"
83,"NCT00659256","Hepatitis C Treatment and Atherosclerosis","Completed","No Results Available","Chronic Hepatitis C|Atherosclerosis","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","","70","NIH","Observational","","080106|08-DK-0106","April 15, 2008","April 2008","March 2015","March 25, 2015","March 2015","No Study Results Posted","null","null","Intima-media thickness|Coronary calcium score, Framingham score","https://ClinicalTrials.gov/show/NCT00659256"
84,"NCT00110799","SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic|Hepatitis C|Thrombocytopenia","Drug: SB497115|Other: Placebo","GlaxoSmithKline","Both","Adult|Senior","Phase 2","75","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","TPL102357","May 13, 2005","April 2005","November 2006","May 31, 2012","March 2011","No Study Results Posted","null","October 2006","Treatment response, assessed by the proportion of subjects with a shift from baseline platelet count (20, 000 to <70,000¬µL) to =100,000/¬µL after 4 weeks of study treatment.|Mean increase in platelet counts and markers of thrombopoiesis. Safety and tolerability, population PK, pharmacodynamics. Effect of antiviral outcome measures during and after therapy.","https://ClinicalTrials.gov/show/NCT00110799"
85,"NCT00039962","Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin","Completed","No Results Available","Hepatitis C|Hepatitis C, Chronic","Drug: thymalfasin (thymosin alpha 1)|Drug: PEGinterferon alfa-2a","SciClone Pharmaceuticals","Both","Adult|Senior","Phase 3","500","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","Ta1-CHC-2K0804","June 17, 2002","May 2002","null","January 8, 2008","January 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00039962"
86,"NCT00516321","Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease","Completed","Has Results","Hepatitis C, Chronic","Drug: eltrombopag|Drug: placebo","GlaxoSmithKline","Both","Adult|Senior","Phase 3","687","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","TPL103922","August 13, 2007","October 2007","May 2011","October 10, 2013","August 2012","March 22, 2012","null","April 2011","Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase|Number of Participants Whose Platelet Count Increased From a Baseline Count of <75 Gi/L to a Count Greater Than or Equal to (>=) 90 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase|Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase|Median Platelet Count at the Indicated Time Points During the OL Phase|Median Platelet Count at the Indicated Time Points During the DB Phase|Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy During the DB Phase|Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase|Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase|Number of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase|Number of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase|Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase|Number of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase|Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase|Number of Participants (Par.) Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3) During the DB Phase|Number of Par. With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS) During the DB Phase|Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS During the DB Phase|Number of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication During the DB Phase|Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase|Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase|Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During the DB Phase|Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase|Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase|Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase","https://ClinicalTrials.gov/show/NCT00516321"
87,"NCT00529568","Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease","Completed","Has Results","Hepatitis C, Chronic","Drug: eltrombopag|Drug: placebo","GlaxoSmithKline","Both","Adult|Senior","Phase 3","759","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","TPL108390","September 12, 2007","October 2007","August 2011","October 10, 2013","March 2013","April 19, 2012","null","August 2011","Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase|Number of Participants Whose Platelet Count Increased From a Baseline Count of <75 Gi/L to a Count Greater Than or Equal to (>=) 100 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase|Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase|Median Platelet Count at the Indicated Time Points During the OL Phase|Median Platelet Count at the Indicated Time Points During the DB Phase|Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy|Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase|Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase|Number of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase|Number of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase|Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase|Number of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase|Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase|Number of Participants Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3)|Number of Participants With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS)|Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS|Number of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication|Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase|Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase|Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During the DB Phase|Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase|Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase|Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase","https://ClinicalTrials.gov/show/NCT00529568"
88,"NCT00040027","Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin","Completed","No Results Available","Hepatitis C|Hepatitis C, Chronic","Drug: thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a|Drug: placebo + PEGinterferon alfa-2a","SciClone Pharmaceuticals","Both","Adult|Senior","Phase 3","500","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","Ta1-CHC-2K0803a","June 18, 2002","April 2002","null","January 8, 2008","January 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00040027"
89,"NCT01290731","A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy","Completed","Has Results","Hepatitis C, Chronic","Drug: TMC435|Drug: Pegylated interferon (pegIFN alpha-2a)|Drug: Ribavirin (RBV)","Janssen Pharmaceutical K.K.","Both","Adult|Senior","Phase 3","49","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CR017698|TMC435HPC3008","February 3, 2011","January 2011","August 2012","December 16, 2013","December 2013","October 17, 2013","null","August 2012","The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)|The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)|The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up|The Percentage of Participants With Undetectable Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)|The Number of Participants With Viral Breakthrough|The Number of Participants Demonstrating Viral Relapse|Plasma Concentrations of TMC435|Area Under the Plasma Concentration-time Curve From 0 to 24 Hrs (AUC24h) for TMC435|The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)","https://ClinicalTrials.gov/show/NCT01290731"
90,"NCT00023322","Pegylated Interferon to Treat Chronic Hepatitis D","Completed","Has Results","Hepatitis D","Drug: Peginterferon Alpha-2a","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","13","NIH","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","010247|01-DK-0247","September 3, 2001","August 2001","October 2012","July 9, 2013","July 2013","April 15, 2013","null","May 2012","Histological Response at 3 Years|Histological Response at 5 Years","https://ClinicalTrials.gov/show/NCT00023322"
91,"NCT00727311","Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)","Completed","Has Results","Hepatitis C, Chronic|Hepatitis C","Biological: PegIntron (peginterferon alfa-2b; SCH 54031) injector|Drug: Rebetol (ribavirin; SCH 18908)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","2302","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P04538","July 30, 2008","August 2005","June 2009","October 8, 2015","October 2015","December 22, 2010","null","June 2009","Number of Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative Participants at End of Therapy (EoT)|Number of Participants With Early Virologic Response (EVR)|Number of Participants With Sustained Virologic Response (SVR)|Number of HCV-RNA Negative Participants at Follow-up","https://ClinicalTrials.gov/show/NCT00727311"
92,"NCT00076336","Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis","Completed","Has Results","Hepatitis|Hepatitis B, Chronic|Cirrhosis","Drug: Telbivudine|Drug: Lamivudine|Drug: Placebo","Novartis Pharmaceuticals|Novartis","Both","Child|Adult|Senior","Phase 3","232","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","CLDT600A2301","January 20, 2004","December 2003","null","August 4, 2011","August 2011","January 3, 2011","null","December 2009","Number of Participants With Clinical Response|Time to Initial Clinical Response|Duration of Initial Clinical Response|Number of Participants With Improvement, Stabilization, and Worsening in Child-Turcotte-Pugh (CTP) Score at Week 52 and Week 104|Number of Participants With Improvement, Stabilization, and Worsening in a Modified (3-component) CTP Score","https://ClinicalTrials.gov/show/NCT00076336"
93,"NCT00725205","Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)","Completed","Has Results","Hepatitis C, Chronic|Hepatitis C","Biological: PegIntron (Peginterferon alfa-2b)|Drug: Rebetol (Ribavirin)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","294","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P04690","July 25, 2008","March 2006","October 2010","October 7, 2015","October 2015","October 10, 2011","null","October 2010","Number of Participants Who Are Triple-80 Compliant|Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up|Number Of Participants Self-Administering Pegylated Interferon Alfa-2b","https://ClinicalTrials.gov/show/NCT00725205"
94,"NCT00996476","A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients","Completed","Has Results","Hepatitis C, Chronic","Drug: TMC435|Drug: PegIFNŒ±-2a|Drug: RBV","Janssen Pharmaceutical K.K.","Both","Adult|Senior","Phase 2","92","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CR016402|TMC435-TiDP16-C215","October 15, 2009","July 2009","January 2011","March 21, 2014","March 2014","October 17, 2013","DRAGON","January 2011","Change in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels From Baseline to Week 4|The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels During the Study|The Percentage of Participants With a Decrease of Greater Than or Equal to 2 log10 IU/mL From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Through the Post-treatment Follow-up Period|The Percentage of Participants With Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Undetectable or Below the Limit of Quantification (<1.2 log10 IU/mL Detectable) During Treatment and During Post Treatment Follow-up|The Number of Participants With Viral Breakthrough|The Percentage of Participants With Viral Relapse|Actual Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values up to Week 24 in the Post-treatment Follow-up Period|The Number of Participants With Alanine Aminotransaminase (ALT) Values Within the Normal Range at the End-of-treatment (EOT)|The Percentage of Participants With Sustained Virologic Response (SVR)|Predose Plasma Concentrations (C0h) of TMC435 (Sparse Blood Sampling)|Predose Plasma Concentrations (C0h) of TMC435 (Intensive Blood Sampling)|The Area Under the Plasma Concentration-time Curve From the Time of Administration up to 24 Hours After Dosing (AUC24) for TMC435|Time to Reach the Maximum Plasma Concentration (Tmax) of TMC435|The Number of Participants Who Met Virologic Stopping/Continuation Rules and Completed All Study Medications","https://ClinicalTrials.gov/show/NCT00996476"
95,"NCT00727077","Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)","Terminated","No Results Available","Hepatitis C, Chronic|Hepatitis C","Biological: IntronA (interferon alfa-2b; SCH 30500)|Drug: Rebetol (ribavirin; SCH 18908)","Merck Sharp & Dohme Corp.","Both","Child","","3","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P04397","July 30, 2008","June 2006","June 2007","April 7, 2015","April 2015","No Study Results Posted","null","June 2007","Incidence of serious adverse events|Sustained virologic response (defined as undetectable viral load at 24 weeks post-treatment)","https://ClinicalTrials.gov/show/NCT00727077"
96,"NCT00787371","Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)","Completed","No Results Available","Hepatitis C, Chronic|Hepatitis C","Biological: PegIntron (peginterferon alfa-2b)|Biological: PegIntron (peginterferon alfa-2b)|Biological: PegIntron (peginterferon alfa-2b)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 2","69","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P04508|JPC-04-356-20","November 6, 2008","June 2005","July 2006","April 9, 2015","April 2015","No Study Results Posted","null","July 2006","Percentage of patients who achieve normalization of ALT in each treatment group|Safety: adverse events, adverse reactions, laboratory test result (hematology, blood biochemistry and thyroid function test)","https://ClinicalTrials.gov/show/NCT00787371"
97,"NCT02190305","Rapid Diagnostics for HIV and Hepatitis","Recruiting","No Results Available","HIV Infections|Hepatitis B Infections|Hepatitis C Infections","Device: Multiplo HBc/HIV/HCV and Reveal HBsAg","MedMira Laboratories Inc.","Both","Child|Adult|Senior","","4000","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label","MCP002","July 9, 2014","May 2014","August 2015","April 23, 2015","April 2015","No Study Results Posted","null","August 2015","Clinical performance of Reveal HBsAg and Multiplo HBc/HIV/HCV","https://ClinicalTrials.gov/show/NCT02190305"
98,"NCT00736242","Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)","Completed","Has Results","Chronic Hepatitis C|Hepatitis C|HIV Infections","Biological: PEG-IFN alfa-2b|Drug: RBV","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","232","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P04584","July 30, 2008","December 2005","December 2011","February 2, 2015","February 2015","December 21, 2012","null","December 2011","Number of Participants With Sustained Virologic Response (SVR)|Number of Participants With Rapid Virologic Response (RVR)|Number of Participants With Early Virologic Response (EVR)|Participant Study Status at End of Follow-up (EOF)|Number of Participants With Hepatitis C Virus (HCV)-RNA Negativity During PEG-IFN Alfa-2b/RBV Treatment|Number of Participants With Human Immunodeficiency Virus (HIV)-RNA Negativity During PEG-IFN Alfa-2b/RBV Treatment|Median Cluster of Differentiation 4 (CD4) Cell Count During PEG-IFN Alfa-2b/RBV Treatment|Number of Participants With A Serious Adverse Event (SAE) During PEG-IFN Alfa-2b/RBV Treatment","https://ClinicalTrials.gov/show/NCT00736242"
99,"NCT00120354","Long-Term Lamivudine Therapy for Chronic Hepatitis B","Completed","No Results Available","Hepatitis B, Chronic","Procedure: Blood Testing|Procedure: Percutaneous Liver Biopsy|Procedure: Lamivudine Therapy","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 4","50","NIH","Interventional","Primary Purpose: Treatment","050195|05-DK-0195","July 15, 2005","July 2005","March 2007","September 26, 2015","March 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00120354"
100,"NCT00723632","Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)","Completed","Has Results","Hepatitis C, Chronic|Hepatitis C","Biological: peginterferon alfa-2b|Drug: ribavirin","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","901","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P04588","July 25, 2008","September 2005","December 2010","October 1, 2015","October 2015","November 11, 2011","null","December 2010","Average Cost Per Participant With Sustained Virologic Response (SVR) Stratified by Weight Category|Average Cost Per Participant With SVR Stratified by Ribavirin Dosage|Average Cost Per Participant With SVR Stratified by Prior Treatment Status","https://ClinicalTrials.gov/show/NCT00723632"
101,"NCT00039871","PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)","Completed","Has Results","Hepatitis|Hepatitis C, Chronic|Fibrosis|Liver Cirrhosis","Biological: PegIntron (peginterferon alfa-2b; SCH 54031)|Drug: REBETOL (ribavirin; SCH 18908)","Merck Sharp & Dohme Corp.","Both","Adult","Phase 3","2333","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","P02370","June 13, 2002","May 2002","September 2007","March 26, 2015","March 2015","September 29, 2008","null","September 2007","Sustained Virologic Response (SVR) Rate|Sustained Virologic Response (SVR) for Participants With Undetectable HCV-RNA at Treatment Week 12|Sustained Virologic Response (SVR) for Participants With Detectable But ‚â•2 Log Drop in HCV-RNA at Treatment Week 12","https://ClinicalTrials.gov/show/NCT00039871"
102,"NCT01350648","Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection","Recruiting","No Results Available","Hepatitis|HIV|Liver Cancer","","National Institutes of Health Clinical Center (CC)|Washington D.C. Veterans Affairs Medical Center","Both","Adult|Senior","","2000","NIH|U.S. Fed","Observational","Time Perspective: Prospective","110152|11-CC-0152","May 7, 2011","May 2011","null","October 6, 2015","September 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01350648"
103,"NCT00724295","Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)","Completed","No Results Available","Hepatitis C, Chronic|Hepatitis C","Drug: peginterferon alfa-2b|Drug: ribavirin","Merck Sharp & Dohme Corp.","Both","Child|Adult|Senior","","1077","Industry","Observational","Time Perspective: Prospective","P04505","July 25, 2008","April 2005","December 2008","February 3, 2015","February 2015","No Study Results Posted","null","December 2008","Overall incidence of adverse events and adverse drug reactions.|Assessment of trends of adverse drug reactions by patient factors and concomitant medications. Incidence of adverse events (AEs) in the elderly vs younger patients; rates of hematologic AEs; dose reduction and discontinuation rates.|Sustained virologic response rate and improvement of ALT (alanine transaminase).","https://ClinicalTrials.gov/show/NCT00724295"
104,"NCT02584543","A Phase ‚Ö£ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)","Not yet recruiting","No Results Available","Hepatitis E|Hepatitis B","Biological: HEV vaccine|Biological: HBV vaccine","Xiamen Innovax Biotech Co., Ltd","Both","Adult|Senior","Phase 4","600","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","PRO-HE-007","October 21, 2015","October 2015","August 2016","October 21, 2015","October 2015","No Study Results Posted","null","June 2016","Adverse reactions/events|Immunogenicity","https://ClinicalTrials.gov/show/NCT02584543"
105,"NCT02402699","Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan","Recruiting","No Results Available","Advanced Melanoma|Hepatitis B|Hepatitis C","","Bristol-Myers Squibb","Both","Adult|Senior","","25","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CA184-414","March 16, 2015","May 2015","September 2020","August 19, 2015","August 2015","No Study Results Posted","Yervoy RMP","September 2020","Identify and describe observed adverse events (AEs) based on liver function abnormalities and changes in hepatitis viral load","https://ClinicalTrials.gov/show/NCT02402699"
106,"NCT02056054","De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation","Recruiting","No Results Available","De Novo Autoimmune Hepatitis","Other: Pediatric transplant subject with d-AIH|Other: Pediatric transplant subject with acute rejection|Other: Pediatric transplant subject with chronic rejection|Other: Adult non-transplant patients with auto-immune hepatitis|Other: Adult non-transplant subjects with chronic hepatitis C virus|Other: Pediatric control subjects|Other: Adult transplanted subjects with de novo autoimmune hepatitis","Yale University","Both","Child|Adult|Senior","","180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1302011561","January 28, 2014","March 2013","March 2016","January 20, 2015","February 2014","No Study Results Posted","null","March 2016","Liver Allograft Loss|Need for Transplantation","https://ClinicalTrials.gov/show/NCT02056054"
107,"NCT00056862","Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3","Completed","Has Results","Hepatitis C","Drug: Peginterferon alfa-2a|Drug: Peginterferon alfa-2a|Drug: Ribavirin","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 4","58","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","030136|03-DK-0136","March 25, 2003","March 2003","June 2010","November 13, 2013","November 2013","November 12, 2010","null","January 2010","Virological Response (Intention to Treat)|Virological Response Category (Per Protocol)|First Phase Decline in Logarithm of HCV RNA Level|Slope of Second Phase Decline in HCV Levels|Time to Negativity","https://ClinicalTrials.gov/show/NCT00056862"
108,"NCT00125762","FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy","Recruiting","No Results Available","Cirrhosis|Hepatitis B|Hepatitis C","Device: FibroScan","Afdhal, Nezam, M.D.|Echosens|Beth Israel Deaconess Medical Center","Both","Adult|Senior","Phase 3","300","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label","2004p-000251","August 1, 2005","March 2005","null","August 12, 2005","July 2005","No Study Results Posted","null","null","To diagnose cirrhosis in patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV)|To determine correlation of FibroScan measurement with Metavir fibrosis scores by differentiating no/mild (F0/F1) from severe fibrosis (F2 - F4)","https://ClinicalTrials.gov/show/NCT00125762"
109,"NCT00028275","Gamma Interferon Therapy for Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: Gamma Interferon 1b","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Child|Adult|Senior","Phase 2","20","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","020072|02-DK-0072","December 18, 2001","December 2001","November 2003","March 3, 2008","November 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00028275"
110,"NCT01182311","Duration of Long-term Immunity After Hepatitis B Virus Immunization","Completed","No Results Available","Hepatitis B","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","","205","NIH","Observational","Time Perspective: Prospective","100187|10-DK-0187","August 13, 2010","August 2010","null","April 8, 2015","March 2015","No Study Results Posted","null","null","To measure anti-HBs titers and immune response in HIV positive and negative adults who were vaccinated more than 10 years ago and to compare them to individuals who spontaneously recovered from acute hepatitis B more than 10 years ago|To assess the clinical, serological and immunological response to a booster dose of hepatitis B vaccine in those individuals who did not maintain the immune response to the primary vaccination.","https://ClinicalTrials.gov/show/NCT01182311"
111,"NCT00767936","Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocelluar Carcinoma","Terminated","No Results Available","Liver Cancer|Hepatitis B|Hepatitis C|Hepatobiliary Cancers Liver|Hepatobiliary Cancers","","Stanford University","Male","Adult|Senior","","135","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HEP0013|98795|SU-05222008-1183","October 3, 2008","March 2008","September 2013","October 9, 2013","October 2013","No Study Results Posted","null","March 2013","identify mutations in the hepatitis B virus genome that predisposes these high risk individuals to the development of liver cancer","https://ClinicalTrials.gov/show/NCT00767936"
112,"NCT00608894","LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis","Completed","No Results Available","Autoimmune Hepatitis","Drug: LCP-Tacro (tacrolimus)|Drug: Azathioprine","Veloxis Pharmaceuticals","Both","Adult|Senior","Phase 2","60","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","LCP-Tacro Study 2016","January 23, 2008","December 2007","July 2009","December 18, 2014","October 2009","No Study Results Posted","null","February 2009","Percent of patients that achieve biochemical remission of (AIH) at Month 6 during treatment with LCP-Tacro + prednisone or azathioprine + prednisone. Biochemical remission is defined as ALT, total bilirubin and gamma globulin within normal limits.|Percent of patients who achieve biochemical remission by Month 3 during treatment with LCP-Tacro + prednisone or azathioprine + prednisone.|Percents of patients in each treatment group classified as either in remission, having an incomplete response, a treatment failure, or a case of relapse. Each patient will be classified as being one of the four states at Month 6.","https://ClinicalTrials.gov/show/NCT00608894"
113,"NCT01495585","Lonafarnib for Chronic Hepatitis D","Completed","No Results Available","Hepatitis D","Drug: Lonafarnib","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","14","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","120046|12-DK-0046","December 16, 2011","December 2011","April 2015","May 2, 2015","April 2015","No Study Results Posted","null","April 2015","The primary endpoint of therapy will be an improvement in quantitative serum HDV RNA levels after 28 days of lonafarnib therapy.|Several secondary endpoints will be measured, including side effects, ALT levels, and symptoms.","https://ClinicalTrials.gov/show/NCT01495585"
114,"NCT01590641","A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B","Completed","No Results Available","Hepatitis B|HBV","Drug: Single Ascending Dose (SAD) Cohorts GS-9620|Drug: Multiple Ascending Dose (MAD) Cohorts","Gilead Sciences","Both","Adult","Phase 1","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","GS-US-283-0106","April 30, 2012","April 2012","October 2013","November 13, 2013","November 2013","No Study Results Posted","null","September 2013","Assessment of adverse events in single and multiple oral doses of GS-9620|Assessment of plasma drug concentrations of GS-9620 using non-compartmental methods|Measurement of pharmacodynamic markers (cytokines and interferon-stimulated genes [ISGs])|Reduction of hepatitis B (HBV) viral load from baseline","https://ClinicalTrials.gov/show/NCT01590641"
115,"NCT00001854","Long-Term Therapy With Ribavirin for Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: Ribavirin","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 4","50","NIH","Interventional","Primary Purpose: Treatment","990042|99-DK-0042","November 3, 1999","February 1999","January 2008","September 26, 2015","January 2008","No Study Results Posted","null","October 2007","","https://ClinicalTrials.gov/show/NCT00001854"
116,"NCT00100659","PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C","Completed","Has Results","Chronic Hepatitis C","Drug: Pegylated Interferon/ribavirin","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Roche Pharma AG","Both","Child|Adult","Phase 3","114","NIH|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","67767 (completed)","January 4, 2005","December 2004","February 2010","July 10, 2013","July 2013","May 10, 2013","null","August 2008","Sustained Viral Response (SVR)|Vital Signs Events.|Laboratory Assessments|Adverse Events","https://ClinicalTrials.gov/show/NCT00100659"
117,"NCT01442311","Directly Observed Hepatitis C Treatment in Methadone Clinics","Completed","No Results Available","Hepatitis C|Medication Adherence","Other: enhanced DOT (both pegylated interferon alfa-2a and ribavirin)|Other: standard DOT (PEG-DOT control arm)","Albert Einstein College of Medicine of Yeshiva University|National Institute on Drug Abuse (NIDA)","Both","Adult|Senior","","80","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","2006-224|K23DA022454-01A1","September 27, 2011","October 2007","March 2013","June 25, 2015","June 2015","No Study Results Posted","null","March 2013","Adherence|sustained viral response (SVR)|end of treatment response (ETR)|treatment completion","https://ClinicalTrials.gov/show/NCT01442311"
118,"NCT00998621","ADHEPTA Study: Adherence Questionnaire in Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic|HIV Infection","Other: Adherence questionnaire","Fundacion IMIM","Both","Adult|Senior","","1120","Other","Observational","Time Perspective: Prospective","ADH-HEPC-2009-01","October 19, 2009","October 2009","January 2013","October 14, 2015","October 2009","No Study Results Posted","ADHEPTA","September 2010","Main objective of the study is the development and validation of a Questionnaire measuring treatment adherence in patients with HCV infection.|Adherence will be measured according to 80/80/80 rule.|Establish a relationship between adherence, virological response (VR) and Sustained virological response (SVR).","https://ClinicalTrials.gov/show/NCT00998621"
119,"NCT01590654","A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection","Completed","No Results Available","Hepatitis B","Drug: Single Ascending Dose (SAD) Cohorts GS-9620|Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620","Gilead Sciences","Both","Adult","Phase 1","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","GS-US-283-0102","April 30, 2012","April 2012","December 2013","December 18, 2013","December 2013","No Study Results Posted","null","November 2013","Assessment of adverse events in single and multiple oral doses of GS-9620|Assessment of plasma drug concentrations of GS-9620 using non-compartmental methods|Measurement of pharmacodynamic markers (cytokines and interferon-stimulated genes [ISGs])|Reduction of hepatitis B (HBV) viral load from baseline","https://ClinicalTrials.gov/show/NCT01590654"
120,"NCT01842451","A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C|CHC|HCV|Hepatitis C","Drug: VX-135|Drug: Daclatasvir","Vertex Pharmaceuticals Incorporated","Both","Adult","Phase 2","23","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","VX13-135-105","April 24, 2013","June 2013","May 2014","May 1, 2015","April 2014","No Study Results Posted","null","May 2014","The safety and tolerability as assessed by adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), echocardiograms, and laboratory assessments|The proportion of subjects who have a sustained virologic response (SVR; i.e., HCV RNA concentration below the lower limit of quantitation [<LLOQ; <25 IU/mL]) at 4 weeks after the last planned dose of treatment (SVR4)|The proportion of subjects who have an SVR at 12 weeks after the last planned dose of treatment (SVR12)|The proportion of subjects who have an SVR at 44 weeks after the last planned dose of treatment (SVR24)|The proportion of subjects who have virologic relapse|The proportion of subjects who have virologic breakthrough|The amino acid sequence of the nonstructural NS5A and NS5B proteins in subjects who have treatment failure|The proportion of subjects who achieve SVR12 by HCV genotype 1 subtype (1a versus non-1a)|The proportion of subjects who achieve SVR12 by IL-28B genotype (CC versus non-CC)","https://ClinicalTrials.gov/show/NCT01842451"
121,"NCT00286663","Autoimmune Hepatitis Study","Terminated","No Results Available","Hepatitis, Autoimmune","","University of Rochester|National Institutes of Health (NIH)","Both","Adult|Senior","Phase 1","100","Other|NIH","Observational","Time Perspective: Prospective","RSRB 12494","February 1, 2006","January 2006","June 2008","July 8, 2008","July 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00286663"
122,"NCT01259453","Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules","Completed","No Results Available","Hepatitis B","Biological: Vaccination to prevent hepatitis B virus infection","Yale University|DePaul University|Hispanic Health Council|Case Western Reserve University|National Institute on Drug Abuse (NIDA)","Both","Adult|Senior","Phase 4","595","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","0005011791|5R01DA014502","December 10, 2010","May 2003","August 2006","December 13, 2010","December 2010","No Study Results Posted","HVS","August 2006","Vaccine Efficacy|Vaccine completion rate|Association of exchange status with completion","https://ClinicalTrials.gov/show/NCT01259453"
123,"NCT01353989","Hepatitis A Vaccination in the Elderly","Recruiting","No Results Available","Hepatitis A","","Rijnstate Hospital","Both","Adult|Senior","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Hepatitis A vaccination","June 21, 2010","July 2010","May 2012","June 3, 2011","June 2011","No Study Results Posted","null","November 2011","How fast do patients> 60 year reach protective anti-HAV levels after vaccination?","https://ClinicalTrials.gov/show/NCT01353989"
124,"NCT00028093","Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease","Completed","Has Results","Chronic Hepatitis C","Drug: Peginterferon alfa-2a with Ribavirin|Drug: Peginterferon alfa-2a","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 4","50","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","020065|02-DK-0065","December 11, 2001","December 2001","June 2010","September 4, 2013","May 2013","May 26, 2011","null","June 2010","Change in Hepatitis C Virus RNA Levels During Phase I","https://ClinicalTrials.gov/show/NCT00028093"
125,"NCT01062659","Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients","Withdrawn","No Results Available","Hepatitis C, Chronic|Liver Diseases|Virus Diseases","","University of Ulm","Both","Adult","","0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TCell","February 3, 2010","February 2010","March 2013","March 31, 2014","March 2014","No Study Results Posted","null","December 2012","","https://ClinicalTrials.gov/show/NCT01062659"
126,"NCT00265642","Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic","Drug: Irbesartan|Drug: placebo","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Sanofi","Both","Adult|Senior","Phase 3","166","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","2005-006027-37|ANRS HC 19 Fibrosar","December 14, 2005","October 2006","November 2013","February 6, 2014","July 2012","No Study Results Posted","Fibrosar","April 2013","Assessment of liver fibrosis changes by measurement of area of porto-septal fibrosis (morphometry)at M24|Assessment of liver fibrosis changes at M24 by non-invasive tests ((blood test mainly and also elastometry)","https://ClinicalTrials.gov/show/NCT00265642"
127,"NCT00175435","Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator","Completed","No Results Available","Hepatitis B","Biological: Resiquimod gel|Biological: Resiquimod gel|Biological: Resiquimod gel","University of British Columbia","Both","Adult","Phase 1|Phase 2","39","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator)","C05-0027","September 11, 2005","August 2005","April 2007","October 29, 2010","October 2010","No Study Results Posted","null","April 2007","A single application of an immune modulating gel will enhance the protective response against hepatitis B disease when vaccination is given at the same time as gel as evidenced by increased HB antibody and T-cell response.|Minimal adverse effects to gel application as noted by laboratory assessment of liver enzyme and complete blood count (CBC) and physical assessment of the site/surrounding area and solicited local and general post vaccine events.","https://ClinicalTrials.gov/show/NCT00175435"
128,"NCT00724230","Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-na√Øve Subjects With Low Viral Load (Study P04841)(COMPLETED)","Completed","No Results Available","Hepatitis C, Chronic|Hepatitis C","Drug: PegIntron (peginterferon alfa-2b; SCH 54031)|Drug: Rebetol (ribavirin; SCH 18908)","Merck Sharp & Dohme Corp.","Both","Child|Adult|Senior","","505","Industry","Observational","Time Perspective: Prospective","P04841","July 25, 2008","February 2006","December 2008","February 2, 2015","February 2015","No Study Results Posted","null","December 2008","Overall incidence of adverse events and adverse drug reactions.|Assessment of trends of adverse drug reactions by patient factors and concomitant medications; Incidence, severity, and outcome of adverse events (AEs) between the elderly vs younger patients|Sustained virologic response rate by HCV genotype, baseline viral load, and patient demographic characteristics|Rate of ALT normalization at end of treatment period and at 24 weeks post completing therapy.","https://ClinicalTrials.gov/show/NCT00724230"
129,"NCT00845676","Treatment of Acute Hepatitis C Virus in HIV Co-Infection","Completed","Has Results","Hepatitis C|Human Immunodeficiency Virus|HIV Infections","Drug: Pegylated interferon alfa-2a + Ribavirin","University of California, San Francisco|California HIV/AIDS Research Program","Both","Adult|Senior","Phase 4","21","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CHRP ID06-SF-218","February 17, 2009","March 2008","December 2013","April 10, 2014","April 2014","August 13, 2013","null","December 2010","Sustained Virologic Response (SVR)|Safety and Tolerability of Treatment|Association of SVR With Entry HCV RNA, Entry ALT, Entry CD4, and IL28B Genotype","https://ClinicalTrials.gov/show/NCT00845676"
130,"NCT00001729","Combination Drug Therapy for Patients With Hepatitis C","Completed","No Results Available","Chronic Hepatitis C|Fibrosis|Hemolytic Anemia","Drug: Ribavirin","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Child|Adult|Senior","Phase 3","120","NIH","Interventional","Endpoint Classification: Efficacy Study|Primary Purpose: Treatment","980003|98-DK-0003","November 3, 1999","October 1997","September 2002","March 3, 2008","September 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001729"
131,"NCT01760148","Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)","Recruiting","No Results Available","Hepatitis C, Chronic|Liver Diseases|Interferon Deficiency","Drug: interferon alpha 2b","Junqi Niu|Chinese Academy of Sciences|First Hospital of Jilin University","Both","Child|Adult|Senior","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2012ZX10002007|2009ZX10004-105-jida02|2008ZX10002-014-jida02","September 8, 2012","July 2012","March 2014","January 1, 2013","January 2013","No Study Results Posted","sIFN-pred2","February 2014","Absolute Blood HCV RNA Copies at designed time points|IL-28B polymorphism|HCV genotype|Alanine Aminotransferase (ALT) and Aspartate transaminase (AST)|Fibrosis stage|Regular blood test|Electrocardiography|Alcohol ,smoking condition|Drug abuse history","https://ClinicalTrials.gov/show/NCT01760148"
132,"NCT00059397","Hepatitis C: Grading and Staging by MR","Completed","No Results Available","Hepatitis","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","Adult|Senior","","80","NIH","Observational","Time Perspective: Prospective","R03 (DK62765) (completed 2007)","April 24, 2003","April 2003","null","March 17, 2010","March 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00059397"
133,"NCT01685203","A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection","Completed","Has Results","Hepatitis C, Chronic","Drug: ABT-450/r|Drug: ABT-267|Drug: Ribavirin (RBV)","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior","Phase 2","316","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M13-393|2011-005762-38","September 12, 2012","August 2012","February 2015","August 3, 2015","August 2015","June 9, 2015","PEARL-I","June 2014","Percentage of Participants in Each Treatment Group With Sustained Virologic Response 12 Weeks Post-treatment|Percentage of Participants in Each Treatment Group With Sustained Virologic Response 24 Weeks Post-treatment|Percentage of Participants in Each Treatment Group With On-treatment Virologic Failure.|Percentage of Participants in Each Treatment Group With Post-treatment Virologic Relapse.|Percentage of Participants in Each Treatment Group With Treatment-emergent Adverse Events","https://ClinicalTrials.gov/show/NCT01685203"
134,"NCT00142740","Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025","Completed","No Results Available","HIV Infection|Hepatitis B","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","Both","Child|Adult","Phase 4","337","NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","ATN 052","August 31, 2005","October 2005","June 2008","February 12, 2015","December 2014","No Study Results Posted","null","June 2008","To confirm the correlation of HLA-DRB1 and HLA-DQB1 alleles and haplotypes with HBV antibody concentrations and antibody decay kinetics in vaccinated adolescents.|To determine if other genetic variations (768 single nucleotide polymorphisms (SNP) in about 50 genes) in the immune response pathways can confer additional effects on immune responses to hepatitis B vaccination.|To compare the strength of genetic and non-genetic associations with specific antibody responses following HBV vaccination.|To explore similarities and differences in genetic associations between HIV-positive and HIV-negative cohorts.","https://ClinicalTrials.gov/show/NCT00142740"
135,"NCT02445703","Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine","Completed","No Results Available","Hepatitis A|Hepatitis B","Biological: Inactivated Hepatitis A vaccine (HAV)|Biological: Combined hepatitis A and hepatitis B vaccine (HABV)","Sinovac Biotech Co., Ltd","Both","Child","Phase 4","301","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator)","PRO-HAB-4005","May 13, 2015","May 2014","null","May 13, 2015","May 2015","No Study Results Posted","null","January 2015","The Post-immunization Seropositivity Rates (SPR) to Hepatitis A|The Post-immunization Geometric Mean Concentration (GMC) of Hepatitis A Antibody (anti-HAV)|The Post-immunization GMC of Hepatitis B Surface Antibody (HBsAb)|The Post-immunization SPR to Hepatitis B|Occurrence of Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT02445703"
136,"NCT02098616","Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus","Recruiting","No Results Available","Hepatitis C","Drug: DCV/ASV/BMS-791325|Drug: DCV/ASV/BMS-791325 + RBV","Timothy Morgan, MD|VA Long Beach Healthcare System|National Cancer Institute (NCI)|Bristol-Myers Squibb|Southern California Institute for Research and Education","Both","Adult|Senior","","60","Other|U.S. Fed|NIH|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","IRB #1285|AI443-128","March 25, 2014","July 2014","null","July 10, 2014","July 2014","No Study Results Posted","RHACE 1","April 2015","Sustained Virologic Response|Safety|Sustained virologic response|Post treatment virologic response|On treatment virologic response|Virologic failure|Day 2 positive predictive value|Interferon lambda genotype and virologic response","https://ClinicalTrials.gov/show/NCT02098616"
137,"NCT00120796","Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)","Terminated","No Results Available","Hepatitis B","Drug: Lamivudine|Biological: Recombinant hepatitis B surface antigen","French National Agency for Research on AIDS and Viral Hepatitis|GlaxoSmithKline","Both","Adult|Senior","Phase 3","210","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ANRS 12100 HEPADAK-2","July 12, 2005","August 2005","July 2008","March 28, 2008","March 2008","No Study Results Posted","null","July 2008","undetectability of HBV DNA blood level|HBV DNA blood levels|Transaminases blood level|Lamivudine treatment compliance|Feasibility of the vaccine injections schedule|Safety|AgHBe seroconversion (in positive patients)|AgHBs negativation","https://ClinicalTrials.gov/show/NCT00120796"
138,"NCT01899092","Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C","Recruiting","No Results Available","Hepatitis C","Drug: TT-034","Tacere Therapeutics, Inc.","Both","Adult","Phase 1|Phase 2","14","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","B2801001","July 8, 2013","January 2014","December 2016","October 14, 2015","October 2015","No Study Results Posted","null","October 2016","The primary objective is to assess the safety and tolerability of single escalating doses of TT-034 administered IV as a single infusion to subjects with CHC.|To assess the activity of TT-034 on the viral load of subjects with CHC receiving single escalating doses of TT-034","https://ClinicalTrials.gov/show/NCT01899092"
139,"NCT02185794","Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C Virus Infection","Drug: GS-9857|Drug: Placebo to match GS-9857|Drug: SOF/GS-5816","Gilead Sciences","Both","Adult","Phase 1","100","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","GS-US-338-1121","July 7, 2014","June 2014","September 2015","October 8, 2015","October 2015","No Study Results Posted","null","December 2014","Incidence of adverse events, laboratory abnormalities, 12-lead electrocardiogram abnormalities and interval measurements, and vital sign measurements|Change from baseline in plasma HCV RNA (log10 IU/mL)|Categorical change from baseline in HCV RNA (< 1, ‚â• 1 to <2, ‚â• 2 to <3, or ‚â• 3 log10 IU/mL reductions)","https://ClinicalTrials.gov/show/NCT02185794"
140,"NCT00671671","Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.","Completed","Has Results","Hepatitis, Chronic|Hepatitis C Virus","Drug: Small Molecule Agent (PF-868554)|Drug: Small Molecule Agent (PF-868554)","Pfizer","Both","Adult","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","A8121006","April 25, 2008","April 2008","December 2008","November 25, 2013","November 2013","November 25, 2013","null","December 2008","Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 11 (Cohort A): Full Analysis Set|Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 11 (Cohort A): Modified Analysis Set|Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 4 (Cohort B): Full Analysis Set|Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 4 (Cohort B): Modified Analysis Set|Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Nadir: Full Analysis Set|Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Nadir: Modified Analysis Set|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ‚àû)]|Plasma Concentration at The End of Dosing Interval (Ctau)|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Plasma Decay Half-Life (t1/2)","https://ClinicalTrials.gov/show/NCT00671671"
141,"NCT01369199","Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B","Active, not recruiting","No Results Available","Hepatitis B","Drug: Entecavir and peginterferon","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pittsburgh","Both","Adult|Senior","Phase 3","40","NIH|Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","DK082864 HBRN IT Adult Trial","June 6, 2011","May 2012","May 2016","October 28, 2015","October 2015","No Study Results Posted","HBRN","May 2015","Safety: Number, type and rate of adverse events/serious adverse events through treatment and end of follow-up 48 weeks after stopping treatment. Efficacy: HBeAg loss (lack of detectable HBeAg) AND HBV DNA ‚â§1,000 IU/mL 48 weeks after stopping treatment.|HBeAg loss|HBeAg seroconversion|Time to HBsAg loss|ALT <45 IU/L for men, <30 IU/L for women (approximately 1.5 ULN)|ALT normalization (men <30 IU/L, women <20 IU/L)|HBV DNA ‚â§1000 IU/mL|HBV DNA <20 IU/mL (LLOQ of COBAS Ampliprep/COBAS TaqMan HBV v2.0 test)","https://ClinicalTrials.gov/show/NCT01369199"
142,"NCT01336010","Treatment of Recently Acquired Hepatitis C Virus Infection","Completed","No Results Available","Acute Hepatitis C","Drug: Peginterferon alfa-2a|Drug: Ribavirin","Kirby Institute","Both","Child|Adult|Senior","Phase 4","82","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","5 R01 DA15999-07","April 13, 2011","August 2011","June 2015","August 31, 2015","August 2015","No Study Results Posted","ATAHC-II","June 2015","Evaluate the safety and efficacy of response-guided pegylated interferon and ribavirin for the treatment of recent HCV infection. Response-guided means the duration of treatment will be determined by the subject's early response to treatment.","https://ClinicalTrials.gov/show/NCT01336010"
143,"NCT01636778","Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients","Completed","Has Results","Hepatitis C, Chronic","Drug: SB-497115-GR","GlaxoSmithKline","Both","Adult|Senior","Phase 2","45","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","116101","July 5, 2012","July 2012","November 2014","September 10, 2015","July 2015","January 22, 2015","null","May 2014","Number of Participants Whose Platelet Count Increased From a Baseline Count of < 80 Gi/L to a Count >=100 Gi/L During Part 1|Number of Participants Whose Platelet Counts Maintained at >=50 Gi/L During Part 2|Median Platelet Count at the Indicated Time Points in Part 1|Time in Weeks to Achieve Platelet Count >= 100 Gi/L|Median Platelet Count at the Indicated Time Points in Part 2|Median Platelet Count at the Indicated Time Points During Follow-up Period After Part 2|Minimum Platelet Count on Antiviral Therapy|Dose of Eltrombopag That Enabled Initiation of Antiviral Therapy|Number of Antiviral Therapy Dose Reductions in Part 2|Number of Participants With the Indicated Levels of Peg-IFN Alpha-2a Therapy Dose Reductions in Part 2|Number of Participants With the Indicated Levels of Peg-IFN Alpha-2b Therapy Dose Reductions in Part 2|Number of Participants With the Indicated Levels of RBV Therapy Dose Reductions in Part 2|Time to First Dose Reduction of Antiviral Therapy in Part 2|Number of Participants Who Discontinued Antiviral Therapy in Part 2|Number of Participants Who Discontinued Peg-IFN Alpha-2a Therapy in Part 2|Number of Participants Who Discontinued Peg-IFN Alpha-2b Therapy in Part 2|Number of Participants Achieving Adherence to Antiviral Therapy in Part 2|Number of Participants Achieving Adherence to Peg-IFN Alpha 2a Antiviral Therapy in Part 2|Number of Participants Achieving Adherence to Peg-IFN Alpha-2b Antiviral Therapy in Part 2|Number of Participants With Sustained Virologic Response (SVR) in Part 2|Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) in Part 2|Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) in Part 2|Number of Participants With End of Treatment Response (ETR) for Undetectable HCV RNA at the End of Peg-IFN/RBV Treatment in Part 2|Mean Serum HCV RNA at the Indicated Time Points In Part 2|Mean Serum HCV RNA at the Indicated Time Points During Follow-up Period After Part 2|Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part1|Number of Participants With Any AE and Any SAE in Part 2|Number of Participants With Any AE and Any SAE During Follow-up Period After Part 2|Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 1 With Follow-up Period|Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 2|Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During Follow-up Period After Part 2|Mean Change From Baseline in Heart Rate at the Indicated Time Points in Part 1 With Follow-up Period|Mean Change From Antiviral Baseline in Heart Rate at the Indicated Time Points in Part 2|Mean Heart Rate at the Indicated Time Points During Follow-up Period After Part 2|Mean Change From Baseline in Weight at the Indicated Time Points in Part 1 With Follow-up Period|Mean Change From Baseline in Weight at the Indicated Time Points in Part 2|Mean Weight at the Indicated Time Points During Follow-up Period After Part 2|Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 1 With Follow-up Period|Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 2|Mean Body Temperature at the Indicated Time Points During Follow-up Period After Part 2|Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points in Part 1 With Follow-up Periodc|Mean Change From Baseline in BMI at the Indicated Time Points in Part 2|Mean BMI at the Indicated Time Points During Follow-up Period After Part 2|Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per Division of Acquired Immunodeficiency Syndrome (DAIDS) in Part 1|Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS in Part 2|Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS During Follow-up Period After Part 2|Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 1|Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 2|Number of Participants With the Indicated Shifts From BL in Severity Grades for Hematology Parameters Per DAIDS During Follow-up Period After Part 2|Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part1 With Follow Up Period|Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part 2|Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points During Follow-up Period After Part 2|Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points|Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) During Follow-up After Part 2|Number of Participants With Abdominal Ultrasound With Doppler at the Indicated Time Points|Number of Participants With Abdominal Ultrasound With Doppler During Follow-up Period After Part 2|Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler in the Study|Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler During Follow-up Period After Part 2","https://ClinicalTrials.gov/show/NCT01636778"
144,"NCT00368225","Transplant-Related Accelerated Progression of Hepatitis C","Completed","No Results Available","Hepatitis C|Cirrhosis","","National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","","100","NIH","Observational","Time Perspective: Prospective","060193|06-CC-0193","August 23, 2006","June 2006","January 2009","September 26, 2015","January 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00368225"
145,"NCT01591668","A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: Single Ascending Dose Cohorts GS-9620|Drug: Multiple Ascending Dose Cohorts GS-9620","Gilead Sciences","Both","Adult","Phase 1","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","GS-US-243-0102","March 23, 2012","March 2012","December 2012","August 12, 2013","August 2013","No Study Results Posted","null","December 2012","Incidence of adverse events in single and multiple doses of GS-9620|Assessment of plasma drug concentrations of GS-9620 using non-compartmental methods|Measurement of pharmacodynamic markers (cytokines and interferon-stimulated genes [ISGs])|Reduction of hepatitis C (HCV) RNA viral load from baseline","https://ClinicalTrials.gov/show/NCT01591668"
146,"NCT00122616","Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C","Completed","No Results Available","HIV Infections|Hepatitis C, Chronic","Biological: Peginterferon alpha-2a (Pegasys¬Æ)|Drug: Ribavirin|Drug: HIV antiretroviral therapy|Drug: HIV antiretroviral therapy","French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche","Both","Adult|Senior","Phase 3","52","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ANRSHC12 FIBROSTOP","July 19, 2005","November 2003","March 2009","February 21, 2012","February 2012","No Study Results Posted","null","March 2009","Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir).|Distribution of the change of fibrosis Metavir score in each group|Distribution of fibrosis score from Chevallier classification|Plasmatic fibrosis markers dosages|Viral load quantification for HIV and HCV|Number and percentage of CD4/CD8 cell count throughout the study|Number and percentage of patient had more thand 200 copies/ml throughout the study|Occurrence of hepatic complication related to HCV|Survival throughout the study|Quality of life questionnaire|Fibrotest (plasmatic fibrosis marker)|Histological improvement according to the total interferon dose received","https://ClinicalTrials.gov/show/NCT00122616"
147,"NCT01140997","Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: Ypeginterferon alfa-2b|Drug: Peginterferon alfa-2a","Xiamen Amoytop Biotech Co., Ltd.|Peking University People's Hospital","Both","Adult","Phase 2","211","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","TB1006IFN","June 8, 2010","July 2010","March 2012","January 31, 2013","June 2010","No Study Results Posted","PEGIFN","January 2011","Efficacy","https://ClinicalTrials.gov/show/NCT01140997"
148,"NCT01474811","HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network","Recruiting","No Results Available","Hepatitis C","","University of North Carolina, Chapel Hill|University of Florida","Both","Adult|Senior","","4500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HCV-TARGET Study","November 10, 2011","November 2011","December 2016","June 10, 2015","June 2015","No Study Results Posted","null","December 2016","Sustained virological response (SVR)|Treatment persistence|Virological breakthrough|Management of adverse events","https://ClinicalTrials.gov/show/NCT01474811"
149,"NCT00029107","Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis","Completed","Has Results","Hepatitis C|Vasculitis","Drug: Rituximab","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","47","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","020096|02-I-0096","January 5, 2002","December 2001","May 2011","April 10, 2012","April 2012","October 26, 2011","null","May 2011","Percent of Patients in Remission","https://ClinicalTrials.gov/show/NCT00029107"
150,"NCT00640588","Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine","Completed","No Results Available","Hepatitis B, Chronic","Drug: Telbivudine|Drug: oral adefovir","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 3","30","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label","CLDT600AES01","March 17, 2008","March 2008","December 2009","May 7, 2012","May 2012","No Study Results Posted","EBEREST","December 2009","HBV viral load will be measured by HBV DNA quantification in plasma (log opies/mL) at baseline, 2, 4, 8, 12, 16, 20 and 24 weeks|Liver function assessed at baseline, 2, 4, 8, 12, 16, 20 and 24 weeks HBV genotype measured at baseline","https://ClinicalTrials.gov/show/NCT00640588"
151,"NCT00237484","Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","Completed","No Results Available","Hepatitis C, Chronic","Drug: Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin|Drug: Combination of (a) pegylated interferon alfa-2b and (b) ribavirin","Merck Sharp & Dohme Corp.","Both","Adult","Phase 3","89","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P04257","October 10, 2005","July 2005","June 2011","October 1, 2015","October 2015","No Study Results Posted","Pegade","June 2011","Proportion of subjects who have achieved sustained virological response (SVR) in the infliximab (induction dose) plus PEGETRON and the PEGETRON groups at 24 weeks post treatment end|Early virological response (EVR)|Safety parameters","https://ClinicalTrials.gov/show/NCT00237484"
152,"NCT00702663","Seroprevalence of Hepatitis B Infection and Effect of Booster Response Amongst Taiwanese Young Adults","Recruiting","No Results Available","Hepatitis B","","Far Eastern Memorial Hospital","Both","Adult","","1800","Other","Observational","Time Perspective: Cross-Sectional","96035","June 18, 2008","October 2007","October 2008","June 19, 2008","June 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00702663"
153,"NCT00389298","A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.","Completed","No Results Available","Hepatitis C, Chronic","Drug: VCH-759 (BCH-27759)","Vertex Pharmaceuticals Incorporated|ViroChem Pharma","Male","Adult","Phase 1|Phase 2","36","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","VCH759-201","October 16, 2006","October 2006","June 2007","September 23, 2009","September 2009","No Study Results Posted","null","null","Change in baseline HCV plasma RNA (i.e., viral load) at Day 11.|The change in plasma HCV RNA (i.e., viral load) over the treatment period (Days 1 to 10 will also be assessed.","https://ClinicalTrials.gov/show/NCT00389298"
154,"NCT01994486","Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1","Completed","Has Results","Hepatitis C, Chronic","Drug: Telaprevir and Sofosbuvir","University of Florida|Vertex Pharmaceuticals Incorporated","Both","Adult|Senior","Phase 2","20","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","20132125","November 12, 2013","December 2013","September 2014","February 20, 2015","February 2015","February 20, 2015","STEADFAST","April 2014","Frequency of Adverse Events Leading to Discontinuation of Both Telaprevir and Sofosbuvir Among Subjects Treated With Telaprevir and Sofosbuvir|Safety of Telaprevir and Sofosbuvir When Dosed in Combination for 12 Weeks|Characterize Steady State of Sofosbuvir Active SOF Metabolite, GS-331007|Proportion of Subjects Who Achieve Undetectable Hepatitis C Virus RNA at 12 Weeks After Completing Study Drug Regimen|Proportion of Subjects With Viral Relapse","https://ClinicalTrials.gov/show/NCT01994486"
155,"NCT01727934","Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C","Active, not recruiting","No Results Available","Hepatitis C","Drug: Miravirsen sodium","Santaris Pharma A/S","Both","Adult|Senior","Phase 2","10","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","SPC3649-207","November 12, 2012","November 2012","April 2014","January 3, 2014","January 2014","No Study Results Posted","null","January 2014","The proportion of subjects with sustained virological response 24 weeks after the end of therapy.|The proportion of subjects with a sustained virological response 12 and 48 weeks after the end of therapy.|The proportion of subjects with undetectable HCV RNA levels at the end of treatment.|Change in HCV RNA levels from baseline throughout the study.|The proportion of subjects who experience virological failure throughout the study.|Safety will be assessed by evaluation of adverse events, physical examinations, vital signs, 12-lead ECGs, and laboratory assessments (clinical chemistry, hematology, urinalysis).","https://ClinicalTrials.gov/show/NCT01727934"
156,"NCT01314261","Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","Completed","Has Results","Chronic Hepatitis C|Hepatitis C Virus (HCV) Infection","Drug: ABT-267|Drug: Pegylated interferon (pegIFN)|Drug: Ribavirin (RBV)|Other: Placebo for ABT-267","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult","Phase 2","37","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","M12-114","March 11, 2011","March 2011","February 2013","January 21, 2015","January 2015","December 29, 2014","null","January 2012","Percentage of Participants With 4-week Rapid Virologic Response (RVR)|Maximum Plasma Concentration (Cmax) of ABT-267|Time to Maximum Plasma Concentration (Tmax) of ABT-267|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-267|Plasma Concentrations of Ribavirin (RBV)|Serum Concentrations of Pegylated Interferon (pegIFN)|Percentage of Participants With Partial Early Virologic Response (pEVR)|Percentage of Participants With Complete Early Virologic Response (cEVR)|Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-pegylated Interferon/Ribavirin (pegIFN/RBV) Dosing|Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-pegylated Interferon/Ribavirin (pegIFN/RBV) Dosing|Median Time to Suppression of Hepatitis C Virus Ribonucleic Acid (HCV RNA)|Percentage of Participants With Extended Rapid Virologic Response (eRVR)","https://ClinicalTrials.gov/show/NCT01314261"
157,"NCT01716585","A Study to Evaluate Chronic Hepatitis C Infection","Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT/450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin|Drug: Placebo for ABT-450/r/ABT-267|Drug: Placebo for ABT- 333|Drug: Placebo for ribavirin","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior","Phase 3","636","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","M11-646|2012-002019-25","October 18, 2012","November 2012","October 2014","December 23, 2014","December 2014","December 23, 2014","null","October 2013","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period|Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm|Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm","https://ClinicalTrials.gov/show/NCT01716585"
158,"NCT00561015","A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection","Completed","Has Results","Hepatitis C, Chronic","Drug: Telaprevir|Drug: Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)|Drug: Placebo","Tibotec BVBA","Both","Adult","Phase 2","52","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","CR013513|VX-950-TiDP24-C209","November 19, 2007","December 2007","May 2009","June 7, 2013","June 2013","March 8, 2013","null","June 2008","Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Day 15|Maximum Plasma Concentration (Cmax) for Telaprevir on Day 1|Time to Reach Maximum Plasma Concentration (Tmax) for Telaprevir on Day 1|Area Under Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) for Telaprevir on Day 1|Area Under Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) for Telaprevir on Day 15|Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Week 24 and Week 26|Maximum Plasma Concentration (Cmax) for Telaprevir on Day 15|Minimum Plasma Concentration (Cmin) for Telaprevir on Day 15|Percentage of Participants Achieving Virological Response (HCV RNA Level < 10 IU/ml)|Median Time to Virological Response (HCV RNA Level < 10 IU/ml)|Percentage of Participants With Viral Breakthrough|Percentage of Participants Who Demonstrated Virological Relapse|Percentage of Participants Who Achieved Sustained Virological Response (SVR)","https://ClinicalTrials.gov/show/NCT00561015"
159,"NCT00782158","Hepatitis B and HIV Co-Infection in Patients in Uganda","Completed","No Results Available","Hepatitis B|HIV Infections","","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","","11000","NIH","Observational","","999909016|09-I-N016","October 29, 2008","October 2008","null","April 9, 2015","March 2015","No Study Results Posted","null","null","Liver fibrosis and hepatoxicity","https://ClinicalTrials.gov/show/NCT00782158"
160,"NCT00426712","Safety of HEPLISAV‚Ñ¢ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients","Completed","No Results Available","Hepatitis B","Biological: 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen|Biological: Hepatitis B Vaccine (Recombinant)","Dynavax Technologies Corporation","Both","Adult|Senior","Phase 1","42","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor)","DV2-HBV-09","January 23, 2007","January 2006","March 2008","August 19, 2015","August 2015","No Study Results Posted","null","March 2008","Occurrence of adverse events and local and systemic reaction rates|Portion of subjects who have a seroprotective immune response (anti-HBsAg antibody ‚â• 10 mIU/mL)","https://ClinicalTrials.gov/show/NCT00426712"
161,"NCT02465203","3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study","Completed","No Results Available","Hepatitis C, Chronic","Drug: Previous treatment in DEB025 study","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 3","105","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label","CDEB025A2313|2011-006132-24","March 17, 2015","September 2012","January 2014","June 3, 2015","June 2015","No Study Results Posted","null","January 2014","HCV RNA sequencing|Safety parameters as measured by HCV RNA Sequencing|Safety parameters as measured by FibroScan/Fibrotest and Lab Parameters (e.g. ALT, AST, GGT)|Safety parameters as measured by Liver Ultrasound and Lab Parameters (e.g. alpha-fetoprotein)|Safety parameters as measured by AEs/SAEs and Lab Parameters (e.g. TGs, bilirubin, platelets)","https://ClinicalTrials.gov/show/NCT02465203"
162,"NCT00106964","Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth","Completed","Has Results","HIV Infection|Hepatitis B","Biological: Engerix-B 20 mcg|Biological: Engerix-B 40 mcg|Biological: Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","Both","Child|Adult","Phase 4","371","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","ATN 024","April 1, 2005","January 2004","June 2009","February 12, 2015","December 2014","October 26, 2012","null","January 2008","Sero-response to Hepatitis B Surface Antigen|Safety of 3 Hepatitis B Vaccine Regimens in HIV+ Youth - ADVERSE EVENTS BY INTERVENTION ARM ON STUDY - POSSIBLY OR PROBABLY RELATED|Safety of 3 Hepatitis B Vaccine Regimens in HIV+ Youth - ADVERSE EVENTS BY INTERVENTION ARM ON STUDY - DEFINITELY RELATED|Safety of 3 Hepatitis B Vaccine Regimens in HIV+ Youth - ABNORMAL LABORATORY VALUES GRADE 2 OR ABOVE BY INTERVENTION ARM ON STUDY|Response Rates in HIV+ Youth Within Each Study Arm by Study Duration|Sero-Response to Hepatitis B Surface Antigen; Predictor: STUDY ARM","https://ClinicalTrials.gov/show/NCT00106964"
163,"NCT01341275","Adolescents' Response to Hepatitis B Vaccine Booster Dose","Recruiting","No Results Available","Hepatitis B","Biological: hepatitis B vaccine|Biological: hepatitis B vaccine","Baylor College of Medicine|Centers for Disease Control and Prevention","Both","Child|Adult","Phase 4","400","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","H-26257","April 22, 2011","April 2010","November 2011","April 22, 2011","April 2011","No Study Results Posted","REACH","November 2011","anti-HBSAg titers","https://ClinicalTrials.gov/show/NCT01341275"
164,"NCT01900886","Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C","Active, not recruiting","No Results Available","Hepatitis C, Chronic|Personality Disorders in Prison","Other: Peginterferon alfa-2a|Drug: Ribavirin","Grupo de Enfermedades Infecciosas de la Sociedad Espa√±ola de Sanidad Penitenciaria","Both","Adult","","263","Other","Observational","Time Perspective: Prospective","GEI-HCC-2010-01","July 8, 2013","December 2010","December 2013","July 12, 2013","December 2010","No Study Results Posted","Perseo","June 2013","Sustained Viral Response (SVR)","https://ClinicalTrials.gov/show/NCT01900886"
165,"NCT02031133","Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C","Active, not recruiting","No Results Available","Hepatitis C","Drug: Miravirsen","Santaris Pharma A/S","Both","Adult|Senior","Phase 2","10","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","SPC3649-207E","January 7, 2014","January 2014","January 2017","November 17, 2014","November 2014","No Study Results Posted","null","January 2017","Safety and tolerability will be assessed by evaluation of liver ultrasound, physical examinations, vital signs, and routine laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis).|Change in HCV RNA level from baseline through end of study.","https://ClinicalTrials.gov/show/NCT02031133"
166,"NCT01500772","Alisporivir With pegIFN/RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C","Terminated","No Results Available","Hepatitis C","Drug: Alisporivir","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 3","6","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CDEB025A2306|2011-004653-31","December 23, 2011","February 2012","null","May 4, 2012","May 2012","No Study Results Posted","null","February 2014","SVR12|SVR24|SVR12LOD|Overall safety profile","https://ClinicalTrials.gov/show/NCT01500772"
167,"NCT01522625","Tenofovir in Chronic Hepatitis B With Mild ALT Elevation","Recruiting","No Results Available","Chronic Hepatitis B","Drug: tenofovir disoproxil fumarate 300mg per day|Drug: Placebo","E-DA Hospital|Gilead Sciences|Taipei Institute of Pathology, Taiwan","Both","Adult|Senior","Phase 4","160","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver)","EMRP36100N","January 27, 2012","January 2012","December 2018","January 29, 2015","January 2015","No Study Results Posted","null","January 2018","Severity of hepatic necroinflammation and fibrosis|Undetectable hepatitis B viral DNA|Normalization of serum alanine aminotransferase|Serum level of HBsAg|Serious adverse reaction","https://ClinicalTrials.gov/show/NCT01522625"
168,"NCT02265237","A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)","Recruiting","No Results Available","Hepatitis C Virus","Drug: ombitasvir/ABT-450/ritonavir|Drug: Ribavirin","AbbVie","Both","Adult|Senior","Phase 3","190","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M11-665|2014-001496-31","October 10, 2014","October 2014","February 2017","October 10, 2015","October 2015","No Study Results Posted","null","September 2016","Percentage of subjects with sustained virologic response 12 (SVR12) weeks post treatment|Percentage of subjects with treatment-emergent adverse events|Percentage of subjects with SVR12 in subjects receiving 12 weeks of treatment compared to subjects receiving 16 weeks of treatment.|Percentage of subjects with on-treatment virologic failure|Percentage of subjects with post-treatment relapse|Percentage of subjects with SVR12 in subjects receiving 16 weeks of treatment compared to subjects receiving 24 weeks of treatment.","https://ClinicalTrials.gov/show/NCT02265237"
169,"NCT01771653","Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection","Completed","No Results Available","Hepatitis C Infection","","Southern Illinois University","Both","Adult","","37","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KOI-SIUSOM-12-002","January 16, 2013","September 2011","July 2015","August 5, 2015","August 2015","No Study Results Posted","null","July 2015","Virologic Response|Adverse events|Effect of baseline variables on treatment outcome","https://ClinicalTrials.gov/show/NCT01771653"
170,"NCT00221624","Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients","Completed","No Results Available","HCV Infection|Hepatitis C, Chronic","Drug: Peginterferon alfa-2a|Drug: ribavirin|Drug: amantadine","University Hospital, Bordeaux|Hoffmann-La Roche","Both","Adult|Senior","Phase 3","131","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","7929-01|2000-030","September 13, 2005","November 2001","April 2004","June 12, 2007","June 2007","No Study Results Posted","PEGARI","null","sustained virological response, defined as an undetectable HCV RNA level 24 weeks after the end of anti HCV treatment (i.e. overall 72 weeks after randomization)|ALT < upper limit of normal values,|histological response according to METAVIR score|adverse effects|quality of life assessed","https://ClinicalTrials.gov/show/NCT00221624"
171,"NCT00637663","Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA","Completed","No Results Available","Hepatitis B, Chronic","Drug: Entecavir|Drug: Lamivudine","Pusan National University Hospital|Yonsei University","Both","Adult|Senior","Phase 4","72","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","0740-67-5","March 4, 2008","February 2008","November 2010","March 4, 2015","March 2015","No Study Results Posted","null","November 2010","Percentage number of patients with HBV DNA < 60 IU/mL (Undetectable serum HBV DNA by PCR method) while on randomized therapy|Percentage number of patients who achieved ALT normalization, HBeAg loss, HBe seroconversion, HBsAg loss and HBs seroconversion|Cumulative discontinuation rates due to lamivudine or entecavir resistance mutations and clinical breakthrough, Safety assessment","https://ClinicalTrials.gov/show/NCT00637663"
172,"NCT00124215","Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection","Completed","No Results Available","Hepatitis C","Biological: GI-5005","GlobeImmune","Both","Adult|Senior","Phase 1","48","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","GI-5005-01","July 25, 2005","June 2005","February 2010","May 3, 2010","May 2010","No Study Results Posted","null","June 2007","Safety and tolerability","https://ClinicalTrials.gov/show/NCT00124215"
173,"NCT00287469","A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal.","Completed","No Results Available","Hepatitis","Biological: Hepatitis E vaccine, recombinant (Sar 56 kDa)","U.S. Army Office of the Surgeon General|GlaxoSmithKline|National Institute of Allergy and Infectious Diseases (NIAID)|Walter Reed Army Institute of Research (WRAIR)","Both","Adult|Senior","Phase 2","2000","U.S. Fed|Industry|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Double-Blind","WRAIR 749|HSRRB A-9117.1|GSK 304558/003 (HEV-003)","February 2, 2006","February 2000","January 2004","June 1, 2015","June 2015","No Study Results Posted","null","null","definite hepatitis E disease with onset at least two weeks after vaccine/placebo dose 3.|definite and probable hepatitis E disease with onset at least two weeks post vaccine/placebo dose 3|definite hepatitis E disease with onset at least two weeks post vaccine/placebo dose and before two weeks after vaccine/placebo dose 3.|hepatitis E disease severity.|vaccine safety|level of total immunoglobulin to HEV capsid","https://ClinicalTrials.gov/show/NCT00287469"
174,"NCT01717560","Hepatitis C Treatment in Underserved Populations","Enrolling by invitation","No Results Available","Chronic Hepatitis C|Illicit Drug Use","Other: Collaborative, multidisciplinary, integrated care","Brian Edlin|Weill Medical College of Cornell University|State University of New York - Downstate Medical Center","Both","Adult|Senior","","30","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","0308006281","April 29, 2008","February 2005","December 2020","October 25, 2012","October 2012","No Study Results Posted","null","December 2012","Sustained virologic response, defined as an undetectable serum HCV RNA level 24 weeks after completion of antiviral therapy.|completion of medical and psychiatric evaluation for antiviral therapy|initiation of antiviral therapy|adherence to antiviral therapy|completion of antiviral therapy|levels of alcohol and illicit drug use|entry into treatment for substance use|entry into treatment for another unaddressed medical or psychiatric condition|neuropsychiatric side effects, including depression and hostility/irritability|treatment-limiting systemic, hematologic, or other side effects|other adverse events or adverse effects|reinfection","https://ClinicalTrials.gov/show/NCT01717560"
175,"NCT00876148","Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting","Completed","No Results Available","Hepatitis B Virus|Allograft|Hematological Malignancies","","Azienda Ospedaliera San Giovanni Battista","Both","Adult|Senior","","null","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","LAM Allo SCT","April 3, 2009","null","null","April 3, 2009","April 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00876148"
176,"NCT01356160","GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus","Completed","No Results Available","Hepatitis C, Chronic","Drug: GS-5885|Drug: GS-9451|Biological: peginterferon alfa-2a|Drug: ribavirin tablet|Drug: GS-9451 Placebo","Gilead Sciences","Both","Adult|Senior","Phase 2","351","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","GS-US-256-0148","May 2, 2011","July 2011","June 2013","January 2, 2014","January 2014","No Study Results Posted","null","June 2013","To evaluate the antiviral efficacy of response guided therapy.|To evaluate the safety and tolerability of each regimen.|To characterize viral dynamics of GS-5885 and GS-9451 when administered with PEG and RBV.|To characterize the viral resistance to GS-5885 and GS-9451 when administered in combination with PEG and RBV.|To characterize steady state pharmacokinetics of GS-5885 and GS-9451 when administered with PEG and RBV.","https://ClinicalTrials.gov/show/NCT01356160"
177,"NCT01435226","GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection","Completed","No Results Available","Hepatitis C, Chronic","Drug: GS-5885|Drug: GS-9451|Drug: tegobuvir|Drug: placebo to match tegobuvir|Drug: placebo to match RBV|Drug: Ribavirin","Gilead Sciences","Both","Adult|Senior","Phase 2","170","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","GS-US-248-0131","September 13, 2011","September 2011","July 2013","November 22, 2013","November 2013","No Study Results Posted","null","January 2013","Safety and Tolerability|Antiviral Activity|Viral Dynamics|Composite (or Profile) of Pharmacokinetics Composite (or Profile) of Pharmacokinetics|Antiviral Efficacy","https://ClinicalTrials.gov/show/NCT01435226"
178,"NCT02349048","Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection","Recruiting","No Results Available","Hepatitis C Virus","Drug: Simeprevir 150 mg|Drug: Daclatasvir 60 mg|Drug: Sofosbuvir 400 mg","Janssen Research & Development, LLC","Both","Adult|Senior","Phase 2","90","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CR105963|TMC435HPC2013","January 22, 2015","January 2015","May 2016","October 7, 2015","October 2015","No Study Results Posted","ACCORDION-1","December 2015","Percentage of Participants With Sustained Virologic Response at 12 Weeks After end of Study Drug Treatment (SVR12)|Percentage of Participants With On-treatment Virologic Response|Percentage of Participants With Sustained Virologic Response at 4 Weeks (SVR4) and 24 Weeks (SVR24) After end of Study Drug Treatment|Percentage of Participants With On-treatment Failure|Percentage of Participants With Viral Relapse|Change from Baseline in HCV Nonstructural Protein 3/4A (NS3/4A), NS5A and NS5B Sequence in Participants not Achieving SVR|Percentage of Participants With or Without an NS3 Q80K Polymorphism at Baseline Achieving SVR","https://ClinicalTrials.gov/show/NCT02349048"
179,"NCT01980745","CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS","Active, not recruiting","No Results Available","Hepatitis, Autoimmune","Drug: Chloroquine diphosphate 250mg|Drug: Placebo","University of Sao Paulo General Hospital","Both","Adult|Senior","Phase 4","62","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","CAPPesq 0697/07|0697/07","September 24, 2013","February 2002","November 2014","November 4, 2013","September 2013","No Study Results Posted","null","November 2013","Recurrence of autoimune hepatitis after treatment withdrawal in patients maintained only with chloroquine|Side effects of chloroquine","https://ClinicalTrials.gov/show/NCT01980745"
180,"NCT01715415","A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults","Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin|Drug: Placebo for ABT-450/r/ABT-267|Drug: Placebo for ABT-333|Drug: Placebo for ribavirin","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior","Phase 3","394","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","M13-098|2012-002035-29","October 25, 2012","November 2012","October 2014","December 23, 2014","December 2014","December 23, 2014","null","November 2013","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period|Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm|Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm","https://ClinicalTrials.gov/show/NCT01715415"
181,"NCT00561353","A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection","Completed","Has Results","Hepatitis C, Chronic","Drug: TMC435|Drug: Placebo|Drug: Peginterferon (PegIFNŒ±-2a)|Drug: Ribavirin","Tibotec Pharmaceuticals, Ireland","Both","Adult|Senior","Phase 2","121","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","CR012607|TMC435350-TiDP16-C201","November 19, 2007","January 2008","May 2010","May 14, 2014","May 2014","December 18, 2013","null","December 2008","Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Na√Øve HCV-Infected Participants (Cohort 1 and 2, Panel A)|Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Na√Øve HCV-Infected Participants (Cohort 1 and 2, Panel B)|Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)|Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Na√Øve HCV-Infected Participants (Cohort 1 and 2, Panel A)|Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Na√Øve HCV-Infected Participants (Cohort 1 and 2, Panel B)|Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)|Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A)|Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B)|Virologic Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)|Virologic Response Parameters in Treatment-Na√Øve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)|Virologic Response Parameters Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)|Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Na√Øve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A)|Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Na√Øve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B)|Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)|Viral Breakthrough in Treatment-Na√Øve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1, Panel A and B)|Viral Breakthrough in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)|Viral Relapse in Treatment-Na√Øve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)|Viral Relapse in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)|Sustained Virologic Response (SVR) in Treatment-Na√Øve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)|Sustained Virologic Response (SVR) in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)|Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Na√Øve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)|Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)|Predose Plasma Concentration (C0h) of TMC435 in Treatment-Na√Øve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)|Predose Plasma Concentration (C0h) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)|Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Na√Øve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)|Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)|Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Na√Øve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)|Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Na√Øve Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)","https://ClinicalTrials.gov/show/NCT00561353"
182,"NCT01263600","Hepatitis B Research Network Pediatric Cohort Study (HBRN)","Recruiting","No Results Available","Hepatitis B","","University of Pittsburgh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","Child","","500","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","DK082864Pediatric|U01DK082864","December 14, 2010","December 2010","December 2017","March 4, 2015","March 2015","No Study Results Posted","null","December 2016","Antigen loss: e and s|Hepatitis exacerbation marked by alanine aminotransferase (ALT) Flare|Cirrhosis|Hepatic Decompensation|Hepatocellular carcinoma (HCC)|Death|Liver transplantation|Reaching 18 years of Age","https://ClinicalTrials.gov/show/NCT01263600"
183,"NCT01833533","A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection","Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin|Drug: Placebo for Ribavirin","AbbVie","Both","Adult|Senior","Phase 3","305","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","M14-002|2012-005522-29","February 27, 2013","March 2013","September 2014","September 4, 2015","September 2015","December 23, 2014","PEARL-IV","December 2013","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses|Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment|Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Secondary Analyses|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants With Virologic Relapse After Treatment","https://ClinicalTrials.gov/show/NCT01833533"
184,"NCT01767116","A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection","Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin|Drug: Placebo for ribavirin","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior","Phase 3","419","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","M13-961|2012-003687-52","November 30, 2012","December 2012","August 2014","August 19, 2015","August 2015","December 23, 2014","PEARL-III","December 2013","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analyses of Each Treatment Arm Compared to Historical Rate|Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analysis of ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV Compared With ABT-450/r/ABT-267 and ABT-333, Plus RBV|Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment|Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Superiority Analyses of Each Treatment Arm Compared to Historical Rate|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants With Virologic Relapse After Treatment","https://ClinicalTrials.gov/show/NCT01767116"
185,"NCT00148837","Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis","Active, not recruiting","No Results Available","Hepatitis C, Chronic|Fibrosis","Drug: Peg-interferon alpha 2b (drug)|Drug: Ribavirin (drug)|Drug: Prazosin (drug)","French National Agency for Research on AIDS and Viral Hepatitis","Both","Adult|Senior","Phase 2","112","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","2004-001326-24|ANRSHC17 Prazor","September 7, 2005","September 2004","null","February 6, 2008","February 2008","No Study Results Posted","null","null","Proportion of patients presenting a decrease of fibrosis as measured on the liver biopsy and considered as clinically interesting (decrease of fibrosis pre- and post-therapeutic (W96) measures of at least 10 percent)|Metavir scoring system; immunostaining of alpha-smooth muscle actin; indirect markers of fibrosis (Fibrotest) at W96|Sustained virological response: undetectable HCV RNA at W96|Sustained biochemical response: ALT level at W96","https://ClinicalTrials.gov/show/NCT00148837"
186,"NCT00219999","Hepatitis C Virus and the Humoral Immune System","Completed","No Results Available","Hepatitis C Virus","","Rockefeller University|National Institute of Allergy and Infectious Diseases (NIAID)|New York Presbyterian Hospital","Both","Child|Adult|Senior","","161","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","LDU-0437|R01AI60561","September 19, 2005","September 2001","May 2013","August 6, 2013","August 2013","No Study Results Posted","null","May 2013","Define the relationships between HCV infection, B cell phenotype, and B cell function","https://ClinicalTrials.gov/show/NCT00219999"
187,"NCT02216422","A Study to Evaluate Chronic Hepatitis C Infection in Cirrhotic Adults With Genotype 1b Infection","Active, not recruiting","No Results Available","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin (RBV)","AbbVie","Both","Adult|Senior","Phase 3","36","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-252","August 12, 2014","September 2014","December 2015","October 3, 2015","October 2015","No Study Results Posted","Turquoise-IV","December 2015","Percentage of subjects with sustained virologic response 12 weeks post-treatment|Percentage of subjects with virologic failure during treatment|Percentage of subjects with virologic relapse after treatment","https://ClinicalTrials.gov/show/NCT02216422"
188,"NCT00445419","Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides","Completed","No Results Available","Chronic Hepatitis C","Biological: PEV2A PEV2B","Pevion Biotech Ltd","Both","Adult","Phase 1","30","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind","PHEPC001|2006DR1345","March 8, 2007","December 2006","June 2008","February 5, 2010","February 2010","No Study Results Posted","null","null","Incidence of adverse events|Specific cellular immune response by Elispot and FACS|Specific proliferative response|Humoral immunity","https://ClinicalTrials.gov/show/NCT00445419"
189,"NCT00166296","Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients","Completed","Has Results","Major Depressive Disorder.|Hepatitis C, Chronic","Drug: Escitalopram|Drug: Placebo","Germans Trias i Pujol Hospital|Hoffmann-La Roche|H. Lundbeck A/S","Both","Adult","Phase 2","133","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","PSQHEPGTP1|EudraCT number: 2004-002982-19","September 9, 2005","March 2005","October 2007","March 4, 2011","March 2011","February 8, 2011","null","October 2007","Number of Participants Who Developed a Major Depressive Episode According to Diagnostic & Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Criteria During the First 12 Weeks of Antiviral Treatment.|Number of Participants With Sustained Hepatitis C Viral Response (Negativization of Serum Hepatitis C Virus Ribonucleic Acid).|Total Score in the Montgomery-Asberg Depression Rating Scale|Total Score in the Depression Subscale of the Hospital Anxiety and Depression Scale.","https://ClinicalTrials.gov/show/NCT00166296"
190,"NCT00703118","A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","Completed","Has Results","Hepatitis C, Chronic","Drug: Telaprevir|Drug: Peg-IFN-alfa-2a|Drug: Ribavirin|Drug: Placebo","Tibotec BVBA|Tibotec Pharmaceutical Limited","Both","Adult|Senior","Phase 3","663","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","CR014842|VX-950-TIDP24-C216","June 19, 2008","October 2008","July 2010","December 5, 2013","December 2013","July 18, 2011","null","July 2010","Number of Participants With Sustained Virologic Response (SVR) 24 Weeks After the Last Planned Dose of Study Medication - SVR24 Planned|Number of Participants Acheiving Rapid Virologic Response (RVR) at Week 4|Number of Participants Acheiving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 48 (End of Treatment)|Number of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Medication - SVR12 Planned|Number of Participants Who Meet the Telaprevir Stopping Rule at Week 4, Week 6, or Week 8|Number of Participants Who Have Viral Relapse During Entire Follow-up Period (up to Week 72)|Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4|Number of Participants Acheiving Extended Rapid Virologic Response at Week 4 and Week 12","https://ClinicalTrials.gov/show/NCT00703118"
191,"NCT01782495","A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients","Recruiting","No Results Available","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: ribavirin (RBV)","AbbVie","Both","Adult|Senior","Phase 2","195","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M12-999|2012-004792-39","January 22, 2013","February 2013","July 2017","October 16, 2015","October 2015","No Study Results Posted","CORAL-I","December 2015","Percentage of subjects with sustained virologic response 12 weeks post-treatment|Percentage of subjects with sustained virologic response 24 weeks post treatment|Percentage of subjects with virologic failure during treatment|Percentage of subjects with post-treatment relapse","https://ClinicalTrials.gov/show/NCT01782495"
192,"NCT00973219","Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load","Active, not recruiting","No Results Available","Chronic Hepatitis B","Drug: Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Both","Adult|Senior","","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","TTM16002|EudraCT number: 2009-013117-94|ABR number: 28338","September 8, 2009","September 2009","November 2018","January 19, 2015","January 2015","No Study Results Posted","LVL","April 2015","The primary objective is to demonstrate the efficacy of combination therapy (Peg-IFN and adefovir or Peg-IFN and tenofovir) for inducing loss of HBsAg compared to no-treatment in HBeAg negative chronic hepatitis B patients with low viral load.|The secondary objectives are to evaluate: a. the rate of HBsAg loss and anti-HBs seroconversion, b. To establish predictive markers at baseline and during the first 12 weeks of treatment for response of primary and secondary endpoints.","https://ClinicalTrials.gov/show/NCT00973219"
193,"NCT00475176","S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C","Completed","Has Results","Chronic Hepatitis C","Drug: Peginterferon alfa-2a|Drug: Ribavirin|Drug: S-adenosyl methionine for Chronic Liver Disease","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","24","NIH","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","070143|07-DK-0143","May 17, 2007","May 2007","May 2011","May 31, 2013","May 2013","May 1, 2012","null","May 2011","Improvement in Viral Kinetics During the First 2 Weeks of Therapy|2-log Decline in HCV RNA by Week 12 (Early Virological Response) and Sustained Eradication of HCV RNA (Sustained Virological Response).","https://ClinicalTrials.gov/show/NCT00475176"
194,"NCT01725529","An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients","Completed","Has Results","Hepatitis C, Chronic","Drug: TMC435|Drug: Peginterferon-alpha (PegIFNŒ±-2a)|Drug: Ribavirin (RBV)|Drug: Placebo","Janssen R&D Ireland","Both","Adult|Senior","Phase 3","457","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","CR017962|TMC435HPC3005","November 9, 2012","November 2012","November 2014","July 15, 2015","July 2015","July 15, 2015","null","August 2014","Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)|Percentage of Participants With Sustained Virologic Response 24 Weeks After End of Study Drug Treatment (SVR24)|Percentage of Participants With Sustained Virologic Response at Week 72 (SVRW72)|Percentage of Participants With On-treatment Failure|Percentage of Participants With Viral Breakthrough|Percentage of Participants With Viral Relapse|Percentage of Participants With On-treatment Normalization of Alanine Aminotransferase Level","https://ClinicalTrials.gov/show/NCT01725529"
195,"NCT00051077","Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)","Withdrawn","No Results Available","HIV Infections|Hepatitis B|Hepatitis C","Drug: Adefovir dipivoxil|Drug: Peginterferon-alfa-2A|Drug: Ribavirin|Procedure: Liver Biopsy","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult","Phase 2","0","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Double-Blind","A5149|10953|ACTG A5149","January 3, 2003","null","null","May 16, 2012","May 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00051077"
196,"NCT02275221","Immune Response in Patients With Hepatitis B and C Infection","Recruiting","No Results Available","Hepatitis B|Hepatitis C","","Basildon and Thurrock University Hospitals NHS Foundation Trust|Foundation for Liver Research","Both","Adult|Senior","","150","Other","Observational","Time Perspective: Prospective","B664","October 20, 2014","August 2013","July 2016","July 8, 2015","July 2015","No Study Results Posted","null","July 2016","To investigate whether changes in immune cell response for in-patients with Hepatitis B or C can be used to develop better treatment regimes|Changes in immune cell reaction as determined by cytokine expression for patients with Hepatitis B during their inpatient stay|Changes in immune cell reaction as determined by cytokine expression for patients with Hepatitis C during their inpatient stay|Changes in immune cell reaction as determined by t-cell populations for patients with Hepatitis B during their inpatient stay|Changes in immune cell reaction as determined by t-cell populations for patients with Hepatitis C during their inpatient stay","https://ClinicalTrials.gov/show/NCT02275221"
197,"NCT00704405","Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)","Completed","Has Results","Hepatitis C, Chronic","Drug: Vaniprevir|Drug: Pegylated Interferon (Peg-IFN)|Drug: Ribavirin (RBV)|Drug: Placebo (PBO)","Merck Sharp & Dohme Corp.","Both","Adult","Phase 2","285","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","7009-009|2007_659","June 23, 2008","March 2009","September 2012","September 1, 2015","September 2015","September 26, 2014","null","March 2012","Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 600 mg b.i.d.|Number of Participants Experiencing an Adverse Event (AE)|Number of Participants Discontinuing From Study Treatment Due to AEs|Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 300 mg b.i.d.|Percentage of Participants Achieving cEVR|Percentage of Participants Achieving SVR24 After 24 Weeks of Vaniprevir 600 mg b.i.d.","https://ClinicalTrials.gov/show/NCT00704405"
198,"NCT01274013","Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers","Active, not recruiting","No Results Available","Chronic Hepatitis C","","Avera McKennan Hospital & University Health Center","Both","Adult","","100","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","ARI-1280-HEPC","January 7, 2011","October 2009","January 2016","July 20, 2015","July 2015","No Study Results Posted","null","December 2015","The Vitamin D levels of the 100 subjects will be statistically analyzed as the primary variable and correlated with the rest of the variables via ANOVA and meta-analysis","https://ClinicalTrials.gov/show/NCT01274013"
199,"NCT01001754","Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection","Active, not recruiting","No Results Available","Hepatitis C, Chronic","Drug: PEG-rIL-29|Drug: Peginterferon alfa-2a|Drug: Ribavirin","ZymoGenetics|Bristol-Myers Squibb","Both","Adult|Senior","Phase 2","600","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","526H04|2009-011786-80","October 23, 2009","May 2010","May 2012","December 2, 2011","December 2011","No Study Results Posted","EMERGE","November 2010","HCV RNA|Incidence and severity of adverse events|Incidence and severity of adverse events and laboratory abnormalities|PD biomarkers|Quality of life assessments|Serum drug concentration profile","https://ClinicalTrials.gov/show/NCT01001754"
200,"NCT01143896","Hepatitis C Translating Initiatives for Depression Into Effective Solutions","Active, not recruiting","No Results Available","Hepatitis C|Depression","Other: Depression collaborative care model","VA Office of Research and Development","Both","Adult|Senior","","309","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Open Label","SDP 10-044|10-05","June 11, 2010","February 2012","September 2016","May 8, 2015","May 2015","No Study Results Posted","HEPTIDES","September 2014","Initiation of hepatitis C antiviral treatment and depression severity|Quality of hepatitis C care|Medication adherence|Quality of depression care","https://ClinicalTrials.gov/show/NCT01143896"
201,"NCT01743521","DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)","Active, not recruiting","No Results Available","Early Chronic Hepatitis C","Drug: TPV/PEG-IFN/RBV","Kirby Institute|Janssen-Cilag Ltd.","Both","Adult","Phase 4","20","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","VHCRP1102|VX-950HCP4010","November 28, 2012","January 2013","February 2016","August 31, 2015","August 2015","No Study Results Posted","DARE-C","June 2015","SVR12|SVR24|Undetectable HCV RNA (ETR)|Undetectable HCV RNA (weeks 1,2,3,4,5,6,8)|gene IL28B polymorphism|Baseline resistance-associated variants|Resistance-associated variants|Indicators of toxicity (ALT, HB, Neutrophils, Platelets)|Plasma ribavirin levels and haemoglobin|CD4 and HIV RNA","https://ClinicalTrials.gov/show/NCT01743521"
202,"NCT01732081","""Real-life"" Cohort of Patients With Chronic Hepatitis B Virus Infection","Recruiting","No Results Available","Hepatitis B","","University Hospital, Strasbourg, France","Both","Child|Adult|Senior","","3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","5452","November 16, 2012","January 2011","January 2021","November 16, 2012","November 2012","No Study Results Posted","null","January 2021","to determine factors associated with the outcome of chronic HBV infection","https://ClinicalTrials.gov/show/NCT01732081"
203,"NCT02050646","The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis","Recruiting","No Results Available","Autoimmune Hepatitis","Other: Low Salt Diet|Other: Liberal salt diet","Yale University","Both","Child|Adult","","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Basic Science|Masking: Double Blind (Caregiver, Investigator)","1303011696|YSOM Pediatrics Department","November 4, 2013","April 2013","April 2016","January 20, 2015","January 2014","No Study Results Posted","null","April 2016","Change from baseline in production of pathogenic TH17 cells.|Change from baseline in regulatory T cell function.","https://ClinicalTrials.gov/show/NCT02050646"
204,"NCT01159925","Surveillance Study to Determine the Trends in Acute Hepatitis A Among Panamanian Children","Completed","No Results Available","Acute Hepatitis A|Hepatitis","Procedure: Serum sample","GlaxoSmithKline","Both","Child","","42","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","112158","July 8, 2010","July 2009","December 2011","November 21, 2012","November 2012","No Study Results Posted","null","December 2011","Occurrence of confirmed acute hepatitis A cases identified in the selected sentinel hospitals during the study period by age group, area of residence and year of surveillance|Occurrence of possible and probable cases of acute hepatitis A virus by age group, area of residence and year of surveillance|Risk factors for confirmed cases of acute hepatitis A|Frequency of different clinical signs and symptoms of hepatitis A","https://ClinicalTrials.gov/show/NCT01159925"
205,"NCT01804829","Civacir¬Æ Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.","Recruiting","No Results Available","Hepatitis C Infection|Viruses|Hepatocellular Carcinoma|Hepatitis, Viral, Human|Liver Cirrhosis","Biological: Civacir¬Æ 10%","Biotest Pharmaceuticals Corporation","Both","Adult|Senior","Phase 3","90","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","988","March 4, 2013","June 2013","October 2015","February 4, 2015","June 2014","No Study Results Posted","null","July 2015","Determine the efficacy of Civacir¬Æ in preventing post-transplant HCV recurrence at 22 weeks post transplant|Determine the efficacy of Civacir¬Æ in preventing post-transplant HCV recurrence at 4 and 34 weeks post transplant","https://ClinicalTrials.gov/show/NCT01804829"
206,"NCT02487199","Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease","Recruiting","No Results Available","HCV|Genotype 1a|Genotype 4|Chronic Kidney Disease|Hepatitis C","Drug: Ombitasvir/Paritaprevir/Ritonavir|Drug: Dasabuvir","AbbVie","Both","Adult|Senior","Phase 3","40","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M15-461|2015-002012-33","June 29, 2015","September 2015","August 2016","October 20, 2015","October 2015","No Study Results Posted","null","May 2016","Percentage of participants with SVR12 in each arm|Number of participants with Adverse Events|Percentage of participants with on-treatment virologic failure in each treatment|Percentage of participants with post-treatment relapse within 12 weeks following end of treatment in each arm","https://ClinicalTrials.gov/show/NCT02487199"
207,"NCT01371578","Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C, Chronic","Drug: GS-5885 tablet|Drug: GS-9451 tablet|Biological: peginterferon alfa-2a|Drug: ribavirin tablet","Gilead Sciences","Both","Adult|Senior","Phase 2","163","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","GS-US-256-0124","June 9, 2011","July 2011","March 2013","January 14, 2014","January 2014","No Study Results Posted","null","March 2013","Sustained Virologic Response (SVR)|Sustained Virologic Response(SVR) of each regimen administered for 24 to 48 weeks|Safety and Tolerability|Characterize the viral dynamics of GS-5885, GS-9451 when administered in combination with PEG and RBV|Characterize the pharmacokinetics of GS-5885 and GS-9451 when administered in combination with PEG and RBV|Emergence of Viral Resistance","https://ClinicalTrials.gov/show/NCT01371578"
208,"NCT01707472","A Phase 2a Study of Simtuzumab in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis","Completed","No Results Available","Liver Fibrosis|Hepatitis C|HIV|HIV/HCV Co-infection","Biological: Simtuzumab","Gilead Sciences|National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult|Senior","Phase 2","18","Industry|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","GS-US-321-0107","September 11, 2012","August 2012","October 2014","October 27, 2014","October 2014","No Study Results Posted","null","October 2014","Incidence of adverse events following administration of simtuzumab in HIV and/or Hepatitis C-infected subjects with evidence of liver fibrosis|Change in portal pressure gradient before and after treatment|Change in liver fibrosis stage as seen on liver biopsy before and after treatment|Change in liver fibrosis as estimated by magnetic resonance (MR) elastography before and after treatment","https://ClinicalTrials.gov/show/NCT01707472"
209,"NCT00512278","Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: Infliximab|Other: Placebo","Nizar Zein|Centocor, Inc.|The Cleveland Clinic","Both","Adult|Senior","Phase 2","149","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","PARTNER","August 3, 2007","July 2007","May 2012","November 14, 2012","November 2012","No Study Results Posted","PARTNER","May 2012","Compare proportion of chronic hepatitis C subjects (treatment naive,Genotype 1) who achieve SVR at week 72, after 48 weeks of treatment.|Compare proportion with non-detectable HCV-RNA after 24 and 48 wks of therapy. Compare the proportion with normal ALT after 12 , 24, 48 wks and after 24 wks of tx-free FU after 48 wks of tx.","https://ClinicalTrials.gov/show/NCT00512278"
210,"NCT00186836","Efficacy Study of Combined Hepatitis A and Hepatitis B Vaccine to Protect Against Hepatitis B in Hemodialysis Patients","Completed","No Results Available","Hepatitis B","Biological: Engerix-B and Twinrix","St. Joseph's Health Care London|St. Joseph's Healthcare Hamilton","Both","Adult|Senior","Phase 4","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind","2400","September 13, 2005","November 2004","November 2006","April 19, 2007","April 2007","No Study Results Posted","null","null","Hepatitis B antibody response at month 7 (Significant antibody response defined as anti-HBs Ab greater than or equal to 10mIU/mL ).|Anti-HBs geometric mean response at 7 months.|Efficacy of Twinrix¬Æ in achieving seroprotection against HAV in hemodialysis patients(Significant antibody response defined as at least 20mIU/mL concentration of anti-HAV.)|Frequency of adverse events associated with vaccine administration","https://ClinicalTrials.gov/show/NCT00186836"
211,"NCT00255008","Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)","Terminated","Has Results","Hepatitis C, Chronic","Biological: peginterferon alfa-2b|Drug: ribavirin|Biological: peginterferon alfa-2b|Drug: ribavirin","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 4","121","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P04212","November 15, 2005","March 2005","December 2007","February 4, 2015","February 2015","December 5, 2008","null","December 2007","Number of Subjects Who Achieved a Sustained Virologic Response (SVR)","https://ClinicalTrials.gov/show/NCT00255008"
212,"NCT00148031","Improving Hepatitis C Treatment in Injection Drug Users","Completed","No Results Available","Hepatitis C|Liver Diseases|Drug Abuse|Alcoholism","Drug: Pegylated Interferon and Ribavirin|Behavioral: Psychosocial|Behavioral: On-site (MMT Clinic) HCV evaluation and treatment|Behavioral: Off-site HCV evaluation and treatment","State University of New York - Upstate Medical University","Both","Adult","Phase 4","111","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","SUNY UMU IRB # 4929|R01 DA016764","September 2, 2005","September 2003","March 2007","April 23, 2013","April 2013","No Study Results Posted","null","March 2007","Efficacy of On-site versus Off-site delivery of HCV medical care for methadone maintenance treatment (MMT) patients, as evaluated by the proportion of patients achieving sustained virological response (SVR).|psychiatric diagnoses and symptom severity","https://ClinicalTrials.gov/show/NCT00148031"
213,"NCT02190253","Seroprevalence of Hepatitis E in People With an Organ Transplant","Recruiting","No Results Available","Hepatitis E","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Georgetown University|University of Pennsylvania|University of Wisconsin, Madison|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","","600","NIH|Other","Observational","Time Perspective: Prospective","999914148|14-DK-N148","July 12, 2014","July 2014","July 2017","January 17, 2015","January 2015","No Study Results Posted","null","July 2017","Prevalence of Hep E|Outcome of Chronic Hepatitis E","https://ClinicalTrials.gov/show/NCT02190253"
214,"NCT00575627","Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels","Recruiting","No Results Available","Chronic Hepatitis C","Drug: Peg-Interferon alpha2a plus Ribavirin","University of Turin, Italy","Both","Adult|Senior","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","pNNALTHCV|NNALT","December 14, 2007","September 2007","September 2010","June 3, 2008","June 2008","No Study Results Posted","null","September 2009","To evaluate the efficacy of treatment and the outcome of treated patients compared with a control group of untreated patients.|evaluation of liver fibrosis by Fibroscan after 48-72 weeks of inclusion","https://ClinicalTrials.gov/show/NCT00575627"
215,"NCT00964665","Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects","Terminated","No Results Available","Chronic Hepatitis B","Drug: albinterferon alfa-2b|Drug: albinterferon alfa-2b|Drug: albinterferon alfa-2b|Drug: albinterferon alfa-2b|Drug: Pegasys¬Æ","Novartis Pharmaceuticals|Human Genome Sciences Inc.|Novartis","Both","Adult|Senior","Phase 1|Phase 2","141","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CABF656A2206|EudraCT 2008-006933-29","August 24, 2009","July 2009","null","January 5, 2011","January 2011","No Study Results Posted","null","November 2010","Evaluate the safety, tolerability and pharmacodynamic effect of various doses of albinterferon alfa-2b in hepatitis B patients on seroconversion of hepatitis markers. Measure: Clinical laboratory. HBV DNA level and HBeAg seroconversion rate.|Evaluate the pharmacokinetics at different doses of albinterferon alfa-2b in patients with chronic hepatitis B infection. Measure: Serum concentration of albinterferon alfa-2b","https://ClinicalTrials.gov/show/NCT00964665"
216,"NCT02375906","The Hepatitis Delta International Network","Recruiting","No Results Available","Hepatitis D","","HepNet Study House, German Liverfoundation|German Center for Infection Research","Both","Child|Adult|Senior","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","HepNet-HDIN","February 19, 2015","November 2013","November 2023","August 26, 2015","August 2015","No Study Results Posted","HDIN","December 2018","Proportion of chronic hepatitis B patients with chronic hepatitis D infection worldwide|HDV-RNA HBsAg|HBV-DNA|Proportion of treated chronic hepatitis B patients with chronic hepatitis D infection worldwide","https://ClinicalTrials.gov/show/NCT02375906"
217,"NCT01641536","Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients","Completed","No Results Available","Hepatitis B, Chronic","Genetic: HB-110","Genexine, Inc.","Both","Adult","Phase 1","9","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","HB110_HB_I_EP","June 28, 2012","November 2011","April 2013","June 19, 2013","June 2013","No Study Results Posted","null","December 2012","Frequency of Adverse Events|Degree of Adverse Events|Level of HBV antigen-specific T-cell ex-vivo ELISPOT|Level of HBV antigen-specific T-cell cultured ELISPOT|Maintenance of HBeAg seroconversion if they had HBeAg seroconversion at Screening Visit, otherwise occurence of HBeAg seroconversion at Follow-up Visit|HBsAg loss and HBsAg seroconversion rate at Follow-up Visit|ALT level|level of HBsAg titer|Number of HBV DNA Copies","https://ClinicalTrials.gov/show/NCT01641536"
218,"NCT01160081","Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis","Completed","No Results Available","Viral Hepatitis Vaccines|Hepatitis A|Cytomegalovirus|Varicella-Zoster Virus|Bordetella Pertussis Infection|Herpes Simplex (1 and 2)","Other: Serum sample","GlaxoSmithKline","Both","Child|Adult|Senior","","3658","Industry","Observational","Time Perspective: Prospective","113564","July 8, 2010","March 2010","September 2010","January 22, 2011","November 2010","No Study Results Posted","null","September 2010","Anti-HAV seropositivity status: Subjects with anti-HAV antibody titers >= assay cut-off.|Anti-Pertussis Toxin seropositivity status for IgG and IgA: Subjects with anti-Pertussis Toxin antibody titers >= assay cut-off for IgG, Subjects with anti-Pertussis Toxin antibody titers >= assay cut-off for IgA|Anti-VZV seropositivity status: Subjects with anti-VZV antibody titers >= assay cut-off|Anti-CMV seropositivity status: Subjects with anti-CMV antibody titers >= assay cut-off|Anti-HSV seropositivity status (defined as the percentage of subjects with anti-HSV 1 and 2 titers >= assay cut-off): Subjects with anti-HSV antibody titers >= assay cut-off|Difference in HAV, VZV, CMV , HSV and BP seropositivity rates according to socioeconomic status, age group, gender, region, risk group, area and pertussis vaccination status (only for BP analysis)","https://ClinicalTrials.gov/show/NCT01160081"
219,"NCT01513941","An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)","Completed","No Results Available","Chronic Hepatitis C","Drug: Telaprevir|Drug: Ribavirin|Drug: Pegylated-Interferon-alfa-2a","Janssen-Cilag International NV","Both","Adult|Senior","Phase 3","163","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CR100778|VX-950HPC3008|2011-004928-35","January 16, 2012","April 2012","June 2014","May 22, 2015","May 2015","No Study Results Posted","INSIGHT","March 2014","Proportion of patients achieving undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels|Change from baseline in log HCV RNA values|Proportiond of patients achieving undetectable HCV RNA levels|Proportion of patients achieving undetectable HCV RNA levels at Week 4|Proportion of patients achieving undetectable HCV RNA levels at Week 12|Proportion of patients achieving undetectable HCV RNA levels at Week 4 and Week 12 (eRVR)|Proportion of patients achieving undetectable HCV RNA at the actual end of treatment|Proportion of patients achieving less than 25 IU/mL|Proportion of patients with on-treatment virologic failure|Proportion of patients with relapse achieving detectable HCV RNA levels after previously undetectable HCV RNA levels|Proportion of patients with relapse achieving detectable HCV RNA levels after previous HCV RNA levels","https://ClinicalTrials.gov/show/NCT01513941"
220,"NCT01316185","Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)","Recruiting","No Results Available","Hepatitis D","Drug: EBP921","Eiger BioPharmaceuticals","Both","Adult|Senior","Phase 1","8","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","EBP-HDV 01-921-01","March 14, 2011","January 2011","May 2011","March 14, 2011","March 2011","No Study Results Posted","null","April 2011","Change in HDV-RNA|Change in HDV RNA from baseline to Day 7, 14, 28 and post therapy weeks 1,2,4,8","https://ClinicalTrials.gov/show/NCT01316185"
221,"NCT00412763","Efficacy of Silymarin for Acute Hepatitis","Completed","No Results Available","Hepatitis","Drug: Silymarin (Silybum marianum)","University of Maryland","Both","Child|Adult|Senior","Phase 4","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","H-21829","December 15, 2006","July 2003","October 2005","December 15, 2006","December 2006","No Study Results Posted","null","null","Primary outcomes were symptoms and signs of acute hepatitis and results of liver function tests on days 3, 5 and 7 in the hospital and in the outpatient clinic at weeks 2, 4, and 8.|Side-effects and adverse events were ascertained by self-report on days 3, 5 and 7 in the hospital and in the outpatient clinic at weeks 2, 4, and 8. .","https://ClinicalTrials.gov/show/NCT00412763"
222,"NCT01773070","A Follow up Study Designed to Obtain Long Term Data on Subjects Who Either Achieved a Sustained Virologic Response or or Did Not Achieve a Sustained Virologic Response in an Abbott Sponsored Hepatitis C Study","Active, not recruiting","No Results Available","Hepatitis C","Drug: ABT-450/ritonavir|Drug: ABT-333|Drug: ABT-267","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior","Phase 3","500","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","M13-102|2012-003073-26","November 19, 2012","June 2013","October 2016","October 10, 2015","October 2015","No Study Results Posted","null","October 2016","Durability of treatment response|Persistence of resistance mutations","https://ClinicalTrials.gov/show/NCT01773070"
223,"NCT00736190","A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection","Completed","Has Results","Chronic Hepatitis B","Drug: Tenofovir disoproxil fumarate","Gilead Sciences","Both","Adult|Senior","Phase 4","90","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","GS-US-174-0123","August 13, 2008","August 2008","July 2010","November 30, 2011","November 2011","July 7, 2011","null","July 2010","Number of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/mL (<69 IU/mL)|Number of Participants With Alanine Aminotransferase (ALT) Normal at Week 48|Number of Participants With ALT Normalized (Baseline Values > ULN [34 U/L] and <= ULN at a Subsequent Visit) at Week 48|Number of Participants With Composite Endpoint of Hepatitis B Virus (HBV) DNA <400 Copies/mL (<69 IU/mL) and Normal ALT at Week 48|Change From Baseline in FibroTest Value|Number of Participants With HBeAg/Hepatitis B Surface Antigen (HBsAg) Loss and Seroconversion|Number of Participants With HBV DNA < 169 Copies/mL (<29 IU/mL) at Week 48|Number of Participants With Composite Endpoint of HBV DNA <400 Copies/mL (<69 IU/mL), Normal ALT, and HBeAg Loss|Number of Participants With Composite Endpoint of HBV DNA <400 Copies/mL (<69 IU/mL), Normal ALT, and Seroconversion to Anti-HBe|Summary of Resistance Surveillance for Participants Without Virologic Breakthrough|Summary of Resistance Surveillance for Participants With Virologic Breakthrough|Summary of Resistance Surveillance for Participants Who Discontinued the Study Early","https://ClinicalTrials.gov/show/NCT00736190"
224,"NCT01271790","A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys¬Æ and Copegus¬Æ With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic","Drug: Tegobuvir (GS-9190)|Drug: GS-9451|Biological: Pegasys¬Æ|Drug: Copegus¬Æ|Drug: GS-9451|Drug: Tegobuvir placebo|Biological: Pegasys¬Æ|Drug: Copegus¬Æ|Drug: Tegobuvir placebo|Drug: GS-9451 placebo|Biological: Pegasys¬Æ|Drug: Copegus¬Æ","Gilead Sciences","Both","Adult|Senior","Phase 2","245","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","GS-US-196-0140","January 5, 2011","October 2010","September 2013","January 8, 2014","January 2014","No Study Results Posted","null","January 2013","Sustained virologic response|Safety and tolerability of therapy|Emergence of viral resistance following initiation of therapy with GS 9190 and GS 9451|Viral dynamics and steady state pharmacokinetics|Durability of response in subjects who achieve SVR","https://ClinicalTrials.gov/show/NCT01271790"
225,"NCT00140725","Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)","Completed","No Results Available","Chronic Hepatitis B","Drug: Lamivudine plus Polyethylene glyco-interferon alfa-2b|Drug: Lamivudine","GlaxoSmithKline","Both","Adult","Phase 3","160","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","NUC30938","August 31, 2005","April 2000","null","October 15, 2008","October 2008","No Study Results Posted","null","null","Proportion of patients with HBeAg seroconversion to anti-HBe|Normalization of alanine aminotransferase (ALT)|Undetectable HBV DNA|Histologic improvement|Tyrosine, methionine, aspartate, aspartate (YMDD) mutants among the viremic relapsers at the end of therapy and safety of treatment","https://ClinicalTrials.gov/show/NCT00140725"
226,"NCT02239562","sPIF CLINICAL STUDY PROTOCOL FOR AUTOIMMUNE HEPATITIS","Recruiting","No Results Available","Autoimmune Hepatitis","Drug: sPIF|Drug: Placebo","Christopher O'Brien|BioIncept LLC|University of Miami","Female","Adult|Senior","Phase 1","18","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","20140114|119219","September 10, 2014","August 2014","null","October 5, 2015","October 2015","No Study Results Posted","null","December 2015","Safety|Pharmacokinetics","https://ClinicalTrials.gov/show/NCT02239562"
227,"NCT00189163","Pioglitazone in Hepatitis C","Recruiting","No Results Available","Chronic Hepatitis C","Drug: Pioglitazone","University of Michigan","Both","Adult|Senior","Phase 4","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","pio-hcv-108|IRB Protocol Number: 2004-0883|GCRC Protocol Number: 2085","September 13, 2005","null","null","February 15, 2006","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00189163"
228,"NCT02442271","A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil","Recruiting","No Results Available","Chronic Hepatitis C Infection","Drug: Ombitasvir/Paritaprevir/Ritonavir|Drug: Dasabuvir|Drug: Ribavirin","AbbVie","Both","Adult|Senior","Phase 3","220","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-225","May 11, 2015","April 2015","October 2016","October 10, 2015","October 2015","No Study Results Posted","null","May 2016","Percentage of participants achieving sustained virologic response SVR12|Percentage of participants achieving SVR12|Change in general health-related quality of life using the HCV-Patient Related Outcome (HCV PRO) scores|Change in general health-related quality of life using the SF36V2 Physical Component Summary (PCS) scores|Change in general health-related quality of life using the SF36V2 Mental Component Summary (MCS) scores","https://ClinicalTrials.gov/show/NCT02442271"
229,"NCT02203357","A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults","Recruiting","No Results Available","Hepatitis B","Biological: Hepatitis B vaccine","Peking University|Guangxi Center for Disease Control and Prevention|Liuzhou City Center for disease control and prevention|Shenzhen Kangtai Biological Products Co., LTD","Both","Adult","Phase 4","354","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","HepB-2014","July 18, 2014","March 2014","July 2016","October 27, 2015","July 2014","No Study Results Posted","null","March 2016","immunogenicity of hepatitis B vaccine with different doses and schedules in healthy young adults","https://ClinicalTrials.gov/show/NCT02203357"
230,"NCT02421211","A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection","Recruiting","No Results Available","Hepatitis C, Chronic","Drug: Simeprevir (SMV)|Drug: Ledipasvir (LDV)|Drug: Sofosbuvir (SOF)","Janssen Sciences Ireland UC","Both","Adult|Senior","Phase 2","40","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label","CR106992|TMC435HPC2017|2015-000459-25","April 15, 2015","May 2015","December 2015","October 26, 2015","October 2015","No Study Results Posted","null","November 2015","Minimum Plasma Concentration (Cmin) of Simeprevir and Ledipasvir|Maximum Plasma Concentration (Cmax) of Simeprevir and Ledipasvir|Area Under the Curve Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Simeprevir and Ledipasvir|Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-emergent Grade 1-4 Laboratory Abnormalities|Percentage of Participants With On-treatment Virologic Response|Percentage of Participants with Sustained Viral Response 4 Weeks After the Actual EOT (SVR4) and 12 Weeks After Actual EOT (SVR12)|Percentage of Participants With On-treatment Failure|Percentage of Participants With Viral Relapse|Change From Baseline in HCV Nonstructural Protein (NS3/4A), Nonstructural Protein 5A (NS5A) and Nonstructural Protein 5B (NS5B) Sequence in Participants not Achieving SVR","https://ClinicalTrials.gov/show/NCT02421211"
231,"NCT01318694","Efficacy and Safety Study of DEB025/Alisporivir Combined to Peg-IFN and Ribavirin in Chronic Hepatitis C Genotype 1 Treatment-na√Øve Patients","Completed","No Results Available","Hepatitis C, Chronic","Drug: Peg-IFN once weekly + Ribavirin BID + DEB025 600 mg QD|Drug: Peg-IFN once weekly + Ribavirin BID + DEB025 400 mg BID|Drug: Peg-IFN once weekly + Ribavirin BID + DEB025 600 mg QD|Drug: PegIFN once weekly + Ribavirin + Placebo","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 3","1073","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","CDEB025A2301|2010-022867-37","March 17, 2011","March 2011","August 2013","October 13, 2015","October 2015","No Study Results Posted","null","August 2013","Sustained Viral Response Week 12 (SVR 12) defined as serum HCV RNA undetectable by limit of detection (LOD) 24 weeks after treatment completion|Rapid Virological response by limit of detection (RVR4LOD), Rapid Virological response by limit of quantification (RVR4LOQ) - defined as serum HCV RNA below LOD or LOQ respectively after 4 weeks of treatment|Early Virological Response (EVR): serum HCV RNA reduction by at least 2Log10 or serum HCV RNA below LOQ 12 weeks after treatment start|End of treatment response (ETR) - defined as HCV RNA undetectable by limit of detection|Change in liver enzyme (ALT and bilirubin) and hematological patient profiles (platelets, neutrophils, hemoglobin) during treatment phase.","https://ClinicalTrials.gov/show/NCT01318694"
232,"NCT01192698","Intravenous Interferon During the Anhepatic Phase of Liver Transplantation and Prevention of Recurrence of Hepatitis C Virus","Completed","No Results Available","Hepatitis C|Liver Transplant","Drug: IV interferon","Carolinas Healthcare System|American College of Gastroenterology","Both","Adult|Senior","","15","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","04-05-09A","August 30, 2010","October 2009","February 2013","March 31, 2014","March 2014","No Study Results Posted","null","February 2013","HCV RNA result","https://ClinicalTrials.gov/show/NCT01192698"
233,"NCT00715715","Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B Patients","Withdrawn","No Results Available","Chronic Hepatitis B","Drug: Prednisone Priming","Maimonides Medical Center","Both","Child|Adult|Senior","","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)","08-01-IVA6","July 11, 2008","April 2008","February 2011","April 18, 2012","April 2012","No Study Results Posted","null","February 2011","The primary efficacy end points at week 48 include the reduction in HBV DNA, HBeAg seroconversion, normalization of ALT.|Secondary efficacy end point is the proportion of patients with histologic improvement.","https://ClinicalTrials.gov/show/NCT00715715"
234,"NCT02486406","A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects","Recruiting","No Results Available","Chronic Hepatitis C Infection","Drug: ombitasvir|Drug: paritaprevir|Drug: ritonavir|Drug: dasabuvir|Drug: ribavirin","AbbVie","Both","Child","Phase 3","186","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-748|2015-000111-41","June 17, 2015","October 2015","January 2023","October 16, 2015","October 2015","No Study Results Posted","ZIRCON","September 2019","Part1: Maximum plasma concentration (Cmax) of OBV|Part 1: Maximum plasma concentration (Cmax) of PTV|Part 1: Maximum plasma concentration (Cmax) of DSV|Part 1: Maximum plasma concentration (Cmax) of RTV|Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of OBV|Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of PTV|Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of DSV|Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of RTV|Part 1: Lowest plasma concentration (Ctrough) of OBV|Part 1: Lowest plasma concentration (Ctrough) of PTV|Part 1: Lowest plasma concentration (Ctrough) of DSV|Part 1: Lowest plasma concentration (Ctrough) of RTV|Part 2: Percentage of treatment-na√Øve participants with sustained virologic response 24 weeks after the last actual dose of study drug (SVR24)|Part 3: Percentage of participants who relapse out of participants who achieved sustained virologic response (SVR) in Part 1 or Part 2 of the study.|Part 3: Percentage of participants who have new HCV infection|Part 1: Percentage of participants achieving sustained virologic response 12 weeks after the last actual dose of study drug (SVR12)|Part 1: Percentage of participants achieving SVR24|Part 2: Percentage of treatment-naive participants achieving SVR12|Part 2: Percentage of participants with Alanine aminotransferase (ALT) normalization during treatment|Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on height|Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on waist circumference|Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on tanner staging","https://ClinicalTrials.gov/show/NCT02486406"
235,"NCT00790673","A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1","Completed","Has Results","Chronic Hepatitis C","Drug: CF 102|Drug: Placebo","Can-Fite BioPharma","Both","Adult","Phase 1|Phase 2","32","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","CF102-103HCV","September 17, 2008","July 2009","July 2011","March 31, 2015","March 2012","March 5, 2015","null","June 2011","Adverse Event Profile of Repeated Dosing of CF102|Effect of Viral Load|Pharmacokinetic Behavior of CF102 During Repeated Dosing|Evaluation of the Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell Adenosine 3 Receptor (A3R) Expression and Clinical Effects","https://ClinicalTrials.gov/show/NCT00790673"
236,"NCT01674725","A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in People With Chronic Hepatitis C","Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior","Phase 3","187","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M13-389|2011-005740-95","July 27, 2012","August 2012","October 2014","December 23, 2014","December 2014","December 23, 2014","PEARL-II","January 2014","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses|Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment|Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Secondary Analyses|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants With Virologic Relapse After Treatment","https://ClinicalTrials.gov/show/NCT01674725"
237,"NCT02417207","Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation","Not yet recruiting","No Results Available","Hepatitis B|Liver Transplantation","Drug: Entecavir combined long-term low-dose HBIG group intramuscular|Drug: Entecavir combined HBIG group short-term high-dose intravenous","Third Affiliated Hospital, Sun Yat-Sen University","Both","Child|Adult|Senior","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)","(2014)2-127","April 7, 2015","April 2015","April 2018","April 10, 2015","April 2015","No Study Results Posted","null","April 2018","hepatitis B recurrence after liver transplantation","https://ClinicalTrials.gov/show/NCT02417207"
238,"NCT01548326","Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine","Enrolling by invitation","No Results Available","Hepatitis B|Vaccination Failure","Drug: Atorvastatin|Drug: placebo","Nematollah Jonaidi Jafari|Baqiyatallah Medical Sciences University","Both","Child|Adult|Senior","Phase 4","52","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","behdasht-90-6-16|IRCT201109147556N1","February 27, 2012","September 2011","July 2012","March 6, 2012","March 2012","No Study Results Posted","null","July 2012","Change from baseline in serum HBsAb level|IL-4 level in WBC culture|IL 17 level in WBC culture|TGF-beta level in WBC culture|IFN-gamma level in WBC culture","https://ClinicalTrials.gov/show/NCT01548326"
239,"NCT01131065","Efficacy and Safety of Niuliva¬Æ for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients","Completed","No Results Available","Hepatitis B|Liver Transplantation","Drug: Hepatitis B immune globulin","Instituto Grifols, S.A.|Grifols Biologicals Inc.","Both","Adult|Senior","Phase 3","15","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","IG 0907","May 25, 2010","September 2010","June 2015","June 10, 2015","June 2015","No Study Results Posted","null","June 2014","HBV recurrence|HBsAb pre-infusion levels (through levels before each Niuliva administration)|Safety and tolerance","https://ClinicalTrials.gov/show/NCT01131065"
240,"NCT00005657","Genetics of Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C|Liver Disease","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Child|Adult|Senior","","870","NIH","Observational","","000125|00-DK-0125","May 6, 2000","May 2000","April 2011","September 26, 2015","April 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005657"
241,"NCT02014571","Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.","Completed","No Results Available","Hepatitis C, Chronic","Drug: GSK2878175|Drug: Placebo","GlaxoSmithKline|PPD","Both","Adult","Phase 1","37","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)","116976","December 12, 2013","December 2013","January 2015","September 14, 2015","September 2015","No Study Results Posted","null","July 2014","Safety as assessed by the collection of adverse events (AEs).|Safety as assessed by hematology, clinical chemistry, urinalysis, vital signs, electrocardiogram (ECG) intervals, ECG rhythm telemetry, pulmonary function tests, respiratory rate and lung auscultation.|Composite of PK parameters (Day 1) following repeat dose administration of GSK2878175.|Composite of PK parameters (Day 2) following repeat dose administration of GSK2878175.|Antiviral activity as assessed by HCV RNA viral load.|Antiviral activity as assessed by HCV RNA maximum change.|Antiviral activity as assessed by Time course of HCV viral load.|Viral quasi-species population.|IL28B rs12979860 status on GSK2878175 pharmacokinetics.|Exposure-response relationships for various safety parameters, if appropriate.|Exposure-response relationship for antiviral effect.","https://ClinicalTrials.gov/show/NCT02014571"
242,"NCT01170351","Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis","Recruiting","No Results Available","Autoimmune Hepatitis","Drug: Cyclosporine-A","Tehran University of Medical Sciences","Both","Child|Adult","Phase 3","70","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","DDRC-301174","July 24, 2010","December 2005","December 2014","July 26, 2010","July 2010","No Study Results Posted","null","December 2013","Remission|Treatment failure|Frequency of adverse events|Serious adverse event","https://ClinicalTrials.gov/show/NCT01170351"
243,"NCT00722332","Evaluation of HepaGam B¬Æ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients","Completed","No Results Available","Hepatitis B|Liver Transplantation","Biological: HepaGam B","Cangene Corporation","Both","Child|Adult|Senior","Phase 4","9","Industry","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","HB-009","July 23, 2008","February 2008","October 2013","October 30, 2013","October 2013","No Study Results Posted","null","October 2013","Efficacy of HepaGam B in combination with antiviral therapy|Pharmacokinetic profile and safety of HepaGam B in combination with antiviral therapy","https://ClinicalTrials.gov/show/NCT00722332"
244,"NCT01349465","3-year Follow-up Study in Patients Previously Treated With a TMC435 for the Treatment of Hepatitis C Virus (HCV) Infection","Active, not recruiting","No Results Available","Hepatitis C","Drug: No treatment","Janssen R&D Ireland","Both","Adult|Senior","Phase 3","249","Industry","Interventional","","CR017365|TMC435HPC3002|2010-019843-20","April 26, 2011","July 2011","February 2016","August 21, 2015","August 2015","No Study Results Posted","null","February 2016","Number of patients who achieved sustained virologic response (SVR) at the last visit of previous study|Change in sequence of HCV NS3/4A region over time in patients with confirmed detectable HCV RNA at the last visit of the previous study|Change in sequence of the HCV NS3/4A region in patients with late relapse|Assessment of development of liver disease progression in patients previously treated with a TMC435-containing regimen","https://ClinicalTrials.gov/show/NCT01349465"
245,"NCT02169674","Hepatitis B Booster Study in Adolescence","Active, not recruiting","No Results Available","Hepatitis B","","University of British Columbia|Canadian Immunization Research Network|Canadian Institutes of Health Research (CIHR)","Both","Child","","360","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H13-00049","June 11, 2014","September 2014","November 2015","July 14, 2015","July 2015","No Study Results Posted","null","August 2015","Serum anti-HBs concentration 10 IU/L or greater|Recollection of anti-HBs titer >10 IU/L after booster","https://ClinicalTrials.gov/show/NCT02169674"
246,"NCT00371579","Rosuvastatin for Hepatitis C","Withdrawn","No Results Available","Hepatitis C","Drug: rosuvastatin","UMC Utrecht","Both","Adult","","0","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label","06-125","September 1, 2006","October 2006","October 2007","June 2, 2015","February 2009","No Study Results Posted","null","October 2007","occurrence of serious side effects like rhabdomyolysis and hepatotoxicity during treatment|decrease of HCV-RNA viral load during treatment|decrease of LDL during treatment","https://ClinicalTrials.gov/show/NCT00371579"
247,"NCT01453348","Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM","Completed","Has Results","Meningococcal Disease|Meningococcal Meningitis|Hepatitis A|Hepatitis B","Biological: MenACWY-CRM|Biological: Combined inactivated hepatitis A and recombinant hepatitis B vaccine|Biological: Recombinant hepatitis B vaccine|Biological: Inactivated hepatitis A vaccine","Novartis|Novartis Vaccines","Both","Adult","Phase 3","252","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","V59_53|2011-001333-17","October 3, 2011","October 2011","January 2012","February 6, 2014","February 2014","October 22, 2013","null","January 2012","Geometric Mean antiHAV and antiHBV Concentrations, 28 Days After Primary and Booster Vaccination|Percentages of Subjects With antiHAV and antiHBsAg Antibodies Concentrations Above Seroprotection Level 28 Days After Primary or Booster Vaccination|Percentages of Subjects With Seroresponse Against N Meningitidis A, C, W and Y Serogroups at Day 29|Geometric Mean Human Serum Bactericidal Assay Titers Against N Meningitidis A, C, W and Y Serogroups at Day 29|Percentages of Subjects With Unsolicited Adverse Events","https://ClinicalTrials.gov/show/NCT01453348"
248,"NCT01623336","BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys¬Æ (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C","Recruiting","No Results Available","Chronic Hepatitis C","Drug: BIP 48 (Peginterferon alfa 2b 48kDA)|Drug: Peginterferon alfa 2a 40kDA|Drug: BIP 48 (Peginterferon alfa 2b 48kDA)","The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Hospital de Clinicas de Porto Alegre","Both","Adult|Senior","Phase 2|Phase 3","740","Other","Interventional","Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","11/0468","June 13, 2012","January 2012","December 2016","June 15, 2012","November 2011","No Study Results Posted","BIP48II/III","August 2016","The rate of sustained virologic response - SVR - measured by PCR at 24 weeks after treatment.|Frequency of adverse events|Virologic response at the end of treatment","https://ClinicalTrials.gov/show/NCT01623336"
249,"NCT00763568","4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: Nitazoxanide|Biological: Peginterferon alfa-2a","Romark Laboratories L.C.","Both","Adult|Senior","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","RM01-3037","September 26, 2008","August 2006","September 2008","September 26, 2008","September 2008","No Study Results Posted","null","September 2008","Sustained virologic response|End of treatment virologic response|Early virologic response|Rapid virologic response|ALT normalization","https://ClinicalTrials.gov/show/NCT00763568"
250,"NCT01821625","Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C","Recruiting","No Results Available","Thrombocytopenia|Hepatitis C","Drug: Eltrombopag","University of Texas Southwestern Medical Center|GlaxoSmithKline","Both","Adult|Senior","Phase 2|Phase 3","30","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","STU 032013-020","March 23, 2013","April 2013","null","August 15, 2013","March 2013","No Study Results Posted","SQUELCH-C","April 2016","Percentage of study patients completing antiviral therapy, as per boceprevir prescribing guidelines.","https://ClinicalTrials.gov/show/NCT01821625"
251,"NCT01973582","Hepatitis B Seroepidemiology Among Young Adults","Recruiting","No Results Available","Hepatitis B","","National Taiwan University Hospital|National Science Council, Taiwan","Both","Adult","","6000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201012127RB","October 20, 2013","July 2011","December 2014","October 25, 2013","October 2013","No Study Results Posted","null","July 2014","serostatus of hepatitis B viral markers","https://ClinicalTrials.gov/show/NCT01973582"
252,"NCT00697970","Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine","Completed","No Results Available","Hepatitis B","Biological: HBsAg formulated with different concentrations of MPL and Aluminium Salts|Biological: Engerix‚Ñ¢-B","GlaxoSmithKline","Both","Adult","Phase 3","321","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator)","208129/006","June 12, 2008","November 1993","April 1995","June 13, 2008","June 2008","No Study Results Posted","null","April 1995","Anti-HBs antibody concentrations|Occurrence and intensity of local and general solicited symptoms|Occurrence of unsolicited adverse events|Occurrence of serious adverse events","https://ClinicalTrials.gov/show/NCT00697970"
253,"NCT01957085","Undiagnosed Hepatitis C Infection in an Urban Hospital","Active, not recruiting","No Results Available","Hepatitis C","Other: Observation only, no intervention","Temple University|Janssen Services, LLC","Both","Adult|Senior","","500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Undiagnosed HCV","September 24, 2013","June 2014","January 2016","May 12, 2015","May 2015","No Study Results Posted","null","December 2015","Incidence of hepatitis C infection","https://ClinicalTrials.gov/show/NCT01957085"
254,"NCT00037076","Prevalence of Hepatitis C Virus Infection in HIV-Infected Children","Completed","No Results Available","HIV Infections|Hepatitis C","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Both","Child|Adult","","600","NIH","Observational","","PACTG P1028S|11657","May 14, 2002","null","July 2003","October 30, 2012","October 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00037076"
255,"NCT00033163","A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV","Completed","No Results Available","HIV Infections|Hepatitis B","Drug: Adefovir dipivoxil|Drug: Tenofovir disoproxil fumarate","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult|Senior","Phase 2","90","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","A5127|10678|ACTG A5127|AACTG A5127","April 8, 2002","null","May 2005","May 17, 2012","May 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00033163"
256,"NCT01701336","Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients","Completed","No Results Available","Hepatitis C","Biological: Ad6NSmut, MVA-NSmut","ReiThera Srl|European Commission","Both","Adult","Phase 1","9","Industry|Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","HCV004|2010-022700-49","August 28, 2012","March 2012","February 2013","August 28, 2013","August 2013","No Study Results Posted","HCV004","October 2012","Number and severity of adverse events|IFNŒ≥ ELISpot. Unit: IFNŒ≥ spot forming cells (SFC)/ million splenocytes","https://ClinicalTrials.gov/show/NCT01701336"
257,"NCT00299936","Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Na√Øve Subjects","Completed","No Results Available","Chronic Hepatitis C","Drug: Ribavirin, PEG-Intron","Weill Medical College of Cornell University|Schering-Plough","Both","Adult|Senior","Phase 3","5000","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P02314|WIN-R","March 3, 2006","null","null","March 3, 2006","March 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00299936"
258,"NCT00363155","KRN7000 in Chronic Hepatitis B","Completed","No Results Available","Hepatitis B, Chronic","Drug: KRN7000","Foundation for Liver Research","Both","Adult|Senior","Phase 1|Phase 2","28","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","KRN7000/02-B01","August 10, 2006","March 2003","July 2006","August 10, 2006","August 2006","No Study Results Posted","null","null","To determine safety and tolerability|To evaluate effectiveness in reducing HBV DNA load|To evaluate effectiveness in inducing immunological responses|TO evaluate effectiveness in normalization of ALT","https://ClinicalTrials.gov/show/NCT00363155"
259,"NCT01704755","A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis","Completed","Has Results","Chronic Hepatitis C Infection|Compensated Cirrhosis","Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin (RBV)","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior","Phase 3","381","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M13-099|2012-003088-23","September 28, 2012","October 2012","September 2014","September 24, 2015","September 2015","December 23, 2014","TURQUOISE-II","January 2014","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment|Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 24-week Arm Compared to the 12-week Arm|Percentage of Participants in Each Arm With On-treatment Virologic Failure During the Treatment Period|Percentage of Participants With Virologic Relapse After Treatment","https://ClinicalTrials.gov/show/NCT01704755"
260,"NCT00703872","HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients","Active, not recruiting","No Results Available","Chronic Hepatitis C","Drug: Oral HDV-Interferon + ribavarin|Drug: Injectable HDV-Interferon + ribavarin","Hepasome Pharmaceuticals","Both","Adult|Senior","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HP 01-2006-01","June 23, 2008","May 2008","December 2009","January 8, 2009","January 2009","No Study Results Posted","null","December 2009","Rapid Virologic Response|Early Virologic Response|Sustained Virologic Response","https://ClinicalTrials.gov/show/NCT00703872"
261,"NCT01854697","A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","Completed","No Results Available","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin|Drug: Telaprevir|Drug: Pegylated Interferon alpha 2-alpha (PegIFN)","AbbVie","Both","Adult","Phase 3","311","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M13-774|2012-003754-84","April 8, 2013","March 2013","July 2015","July 20, 2015","July 2015","No Study Results Posted","MALACHITE 1","November 2014","The percentage of all dosed subjects with sustained virologic response following the last actual dose of study drug.|Change in general health-related quality of life using the Short-Form 36 Version 2 health status survey (SF-36V2) Mental Component Summary (MCS)|Change in general health-related quality of life using the SF-36V2 Physical Component Summary (PCS) scores|Percentage of subjects with sustained virologic response 12 weeks post-treatment|Percentage of subjects with virologic failures during treatment|Percentage of subjects with post-treatment relapse","https://ClinicalTrials.gov/show/NCT01854697"
262,"NCT01349283","Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns","Completed","No Results Available","Hepatitis B","Biological: HepavaxGene (thiomersal free)|Biological: Engerix B","Crucell Holland BV","Both","Child","Phase 3","1738","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)","HVG-V-A002","May 5, 2011","May 2011","November 2013","March 3, 2014","January 2013","No Study Results Posted","null","November 2012","Seroconversion rate for subjects in Stratum 2|Positivity for HBsAg for subjects in Stratum 1|Seroconversion rate for subjects in Stratum 1|Solicited adverse events|Positivity for HBsAg for subjects in Stratum 2","https://ClinicalTrials.gov/show/NCT01349283"
263,"NCT01263587","Hepatitis B Research Network Adult Cohort Study","Recruiting","No Results Available","Hepatitis B","","University of Pittsburgh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","Adult|Senior","","2500","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","DK082864|U01DK082864","December 14, 2010","December 2010","May 2015","January 30, 2015","January 2015","No Study Results Posted","HBRN","May 2015","Hepatitis Exacerbation marked by alanine aminotransferase (ALT) Flare|Antigen loss: e and s|Cirrhosis|Hepatic decompensation|Hepatocellular carcinoma (HCC)|Death|Liver transplantation","https://ClinicalTrials.gov/show/NCT01263587"
264,"NCT00150904","Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP)","Completed","No Results Available","Hepatitis C|HIV Infections","Procedure: venous blood puncture","UMC Utrecht|Hoffmann-La Roche","Both","Adult|Senior","","28","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","04-247E","September 6, 2005","August 2005","January 2009","February 13, 2009","February 2009","No Study Results Posted","null","September 2008","","https://ClinicalTrials.gov/show/NCT00150904"
265,"NCT00697242","Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults","Completed","No Results Available","Hepatitis B","Biological: Engerix‚Ñ¢-B|Biological: Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL","GlaxoSmithKline","Both","Adult|Senior","Phase 3","362","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator)","208129/009","June 11, 2008","January 1994","November 1995","June 11, 2008","June 2008","No Study Results Posted","null","November 1995","Anti-hepatitis B surface antigen (HBs) antibody concentrations|Anti-pre-S1 antibody concentrations|Anti-HBs antibody concentrations|Occurrence and intensity of local and general solicited symptoms|Cell mediated immunity|Occurrence of unsolicited adverse events|Occurrence of serious adverse events","https://ClinicalTrials.gov/show/NCT00697242"
266,"NCT00038974","Hepatitis C Antiviral Resistance in African-Americans","Completed","No Results Available","Hepatitis C","Drug: Pegylated interferon|Drug: Ribavirin","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","Adult|Senior","Phase 3","400","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","Virahep-C (completed)|U01 DK60329","June 5, 2002","August 2002","null","March 15, 2011","March 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00038974"
267,"NCT00854802","A Study of Debio 025 (Alisporivir) Combined With Peg-IFNŒ±2a and Ribavirin in Treatment na√Øve Chronic Hepatitis C Genotype 1 Patients","Completed","No Results Available","Chronic Hepatitis C","Drug: Debio 025|Drug: Peg-IFNŒ±2a|Drug: Ribavirin|Drug: Debio 025 placebo","Debiopharm International SA|Parexel","Both","Adult","","290","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)","Debio 025-HCV-205|2008-004605-34","March 2, 2009","January 2009","September 2010","January 13, 2015","January 2015","No Study Results Posted","null","September 2010","Percentage of participants achieving sustained viral response (SVR) 72 weeks after treatment start|Percentage of participants achieving a rapid viral response (RVR) after 4 weeks of treatment|Percentage of participants achieving a complete early viral response (cEVR) after 12 weeks of treatment|Percentage of participants achieving an early viral response (EVR) after 12 weeks of treatment|Percentage of participants achieving an end-of-treatment response (ETR) at treatment end|Percentage of participants achieving a sustained viral response 12 weeks after the end of treatment (SVR 12)|Percentage of participants with sustained viral response 24 weeks after the end of treatment (SVR 24)","https://ClinicalTrials.gov/show/NCT00854802"
268,"NCT00697125","Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants","Completed","No Results Available","Hepatitis B","Biological: Engerix‚Ñ¢-B|Biological: HBV-MPL vaccine (208129)|Biological: Hepatitis B vaccine, experimental formulation","GlaxoSmithKline","Both","Adult","Phase 2","60","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator)","208129/005","June 11, 2008","June 1993","July 1994","June 11, 2008","June 2008","No Study Results Posted","null","July 1994","Occurrence and intensity of solicited local and general symptoms|Anti-HBs antibody concentrations|Occurrence, intensity of unsolicited adverse events|Occurrence of serious adverse events","https://ClinicalTrials.gov/show/NCT00697125"
269,"NCT00994773","Simvastatin for the Treatment of Chronic Hepatitis B","Completed","No Results Available","Hepatitis B","Drug: Simvastatin|Drug: Tenofovir|Drug: Entecavir","Bader, Ted, M.D.","Both","Adult|Senior","Phase 1","32","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","HBV 14934|Simvastatin against HepB","October 10, 2009","December 2009","December 2011","August 15, 2012","August 2012","No Study Results Posted","null","October 2011","Reduction of HBV DNA by one log.|Alanine aminotransferase (ALT) reduction","https://ClinicalTrials.gov/show/NCT00994773"
270,"NCT02052661","This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix‚Ñ¢ Hexa","Completed","Has Results","Hepatitis B","Biological: Engerix‚Ñ¢-B Kinder","GlaxoSmithKline","Both","Child","Phase 4","301","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","106793|2013-002821-41","January 30, 2014","February 2014","September 2014","September 17, 2015","September 2015","July 31, 2015","null","September 2014","Anti-HBs Immune Response|Anti-HBs Antibody Concentrations at 12-13 Years of Age, After Previous Vaccination With Infanrix‚Ñ¢ Hexa.|Number of Subjects With Anti-HBs Antibody Concentrations ‚â• 6.2 mIU/ml, ‚â• 10 mIU/ml, 10 to < 100 mIU/ml and ‚â• 100 mIU/ml.|Number of Subjects With Anti-HBs Antibody Concentrations ‚â• 6.2 mIU/ml and ‚â• 10 mIU/ml.|Number of Subjects With an Anamnestic Response to the Single Challenge Dose of Engerix‚Ñ¢-B Kinder Vaccine.|Number of Subjects With Any Solicited Local Symptoms.|Number of Subjects With Any Solicited General Symptoms.|Number of Subjects With Any Unsolicited Adverse Events (AEs).|Number of Subjects With Serious Adverse Events (SAEs).","https://ClinicalTrials.gov/show/NCT02052661"
271,"NCT00240526","LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers","Completed","Has Results","Hepatitis B","Biological: Engerix‚Ñ¢ -B|Biological: Hepatitis B immunoglobulin (HBIg)","GlaxoSmithKline","Both","Child|Adult","Phase 4","79","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","100450","October 13, 2005","October 2003","March 2010","February 17, 2011","February 2011","June 14, 2010","null","March 2010","Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration|Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Pre-defined Cut-off Values|Number of Subjects With Positive Results for Serological Markers for Hepatitis B Infection|Number of Subjects With Different Hepatitis B Infection Statuses","https://ClinicalTrials.gov/show/NCT00240526"
272,"NCT00697931","Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix‚Ñ¢-B in Adult Non-Responders","Completed","No Results Available","Hepatitis B","Biological: Recombinant MPL- adjuvanted hepatitis B vaccine|Biological: Engerix‚Ñ¢-B","GlaxoSmithKline","Both","Adult|Senior","Phase 3","116","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject)","208129/021","June 12, 2008","May 1997","June 1998","June 13, 2008","June 2008","No Study Results Posted","null","June 1998","Anti-HBs antibody concentrations|Occurrence and intensity of solicited local symptoms|Occurrence, intensity and relationship of solicited general symptoms|Occurrence, intensity and relationship to vaccination of unsolicited symptoms|Incidence of serious AEs|Cell mediated immunity","https://ClinicalTrials.gov/show/NCT00697931"
273,"NCT00697840","Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix‚Ñ¢-B","Completed","No Results Available","Hepatitis B","Biological: Engerix‚Ñ¢-B|Biological: HBV-MPL 208129|Biological: Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation","GlaxoSmithKline","Both","Adult","Phase 3","150","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator)","208129/019","June 12, 2008","June 1995","January 1996","June 13, 2008","June 2008","No Study Results Posted","null","January 1996","Anti-HBs antibody concentrations|Occurrence and intensity of solicited local and general symptoms|Occurrence of unsolicited adverse events|Incidence of serious adverse events|Anti-Hbs antibody concentrations","https://ClinicalTrials.gov/show/NCT00697840"
274,"NCT00698087","Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix‚Ñ¢-B","Completed","No Results Available","Hepatitis B","Biological: MPL-Adjuvanted recombinant hepatitis B vaccine|Biological: Engerix‚Ñ¢-B","GlaxoSmithKline","Both","Adult","Phase 3","60","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator)","208129/016","June 12, 2008","January 1995","February 1996","June 13, 2008","June 2008","No Study Results Posted","null","February 1996","Anti-HBs antibody concentrations|Occurrence of local and general solicited symptoms|Occurrence of unsolicited symptoms|SAEs","https://ClinicalTrials.gov/show/NCT00698087"
275,"NCT02452528","Study of ARC-520 in Patients With HBeAg (Hepatitis B e Antigen) Positive Chronic Hepatitis B Virus","Recruiting","No Results Available","Chronic Hepatitis B","Drug: ARC-520|Drug: Placebo|Drug: Entecavir|Drug: Tenofovir","Arrowhead Research Corporation","Both","Adult|Senior","Phase 2","12","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)","Heparc-2004","May 15, 2015","May 2015","December 2015","September 23, 2015","May 2015","No Study Results Posted","null","October 2015","Change from baseline in quantitative hepatits B surface antigen (log qHBsAg) at Day 85 in response to multiple doses of ARC-520 versus placebo as a measure of efficacy.|Incidence and frequency of adverse events as a measure of safety and tolerability|Pharmacokinetics of ARC-520: AUC0-24|Pharmacokinetics of ARC-520: AUClast|Pharmacokinetics of ARC-520 - AUCinf: Change over time|Pharmacokinetics of ARC-520 - Cmax: Change over time|Pharmacokinetics of ARC-520 - CL: Change over time|Pharmacokinetics of ARC-520- V: Change over time|Pharmacokinetics of ARC-520 - kel: Change over time|Pharmacokinetics of ARC-520 - t1/2: Change over time|Pharmacokinetics of entecavir or tenofovir - AUC0-24: Change over time|Pharmacokinetics of entecavir or tenofovir - AUClast: Change over time|Pharmacokinetics of entecavir or tenofovir - Cmax: Change over time|Pharmacokinetics of entecavir or tenofovir - tmax: Change over time","https://ClinicalTrials.gov/show/NCT02452528"
276,"NCT00493610","Mucomyst for Hepatitis C","Suspended","No Results Available","Hepatitis C","Drug: N-acetylcysteine(Mucomyst)","VA Office of Research and Development|West Virginia University","Both","Adult|Senior","","5","U.S. Fed|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","0031","June 26, 2007","November 2006","June 2008","January 7, 2010","June 2008","No Study Results Posted","null","June 2008","Measurable oxidant stress|Reduction in viral load of Hep C and changes in Liver Function tests","https://ClinicalTrials.gov/show/NCT00493610"
277,"NCT01027065","Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients","Active, not recruiting","No Results Available","Chronic Hepatitis B","Drug: CYT107+GenHevac+entecavir or tenofovir|Drug: CYT107+ entecavir or tenofovir","Cytheris SA","Both","Adult|Senior","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CLI-107-10|2009-010709-35","December 4, 2009","December 2009","March 2013","October 17, 2012","October 2012","No Study Results Posted","CONVERT","November 2012","To determine the short and long-term safety and biological activity of CYT107 in patients with a HBeAg-negative chronic hepatitis B who have, at screening a HBV DNA undetectable stable for at least 3 months with antiviral treatment.|To characterize the pharmacokinetics and pharmacodynamics of CYT107 in humans chronically infected with HBV.|To assess the effects of the tri-therapy (CYT107 + HBV vaccine + antiviral treatment) versus bi-therapy (CYT107 + antiviral treatment) versus control (antiviral treatment) on the markers of the HBV infection (antiviral activity)at W16 weeks and W52|To quantify the effects of the tri-therapy (CYT107 + HBV vaccine + antiviral treatment) versus bi-therapy (CYT107 + antiviral treatment) versus control (antiviral treatment) on the immune system at W16 weeks","https://ClinicalTrials.gov/show/NCT01027065"
278,"NCT00165919","Immune Response to Hepatitis C Virus","Withdrawn","No Results Available","Hepatitis C|HIV Infections","Other: None. Not a clinical trial. Specimens taken for basic research in laboratory.","Emory University","Both","Adult|Senior","Phase 1","0","Other","Observational","","1358-2004","September 9, 2005","September 2005","September 2005","November 12, 2013","November 2013","No Study Results Posted","null","September 2005","This is NOT a clinical trial; thus no outcomes. Specimens from human subjects taken at clinical site and sent unidentified to laboratory for assays.","https://ClinicalTrials.gov/show/NCT00165919"
279,"NCT00001982","History of Hepatitis C in Volunteer Blood Donors","Completed","No Results Available","Hepatitis C","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Child|Adult|Senior","","60","NIH","Observational","","930159|93-DK-0159","January 21, 2000","June 1993","April 2000","March 3, 2008","May 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001982"
280,"NCT00192569","Australian Trial in Acute Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: Pegylated Interferon alfa 2a|Drug: Ribavirin (HIV conifected patients only)","Kirby Institute|The University of New South Wales|National Institutes of Health (NIH)","Both","Child|Adult|Senior","Phase 4","167","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","1R01DA 15999-01|ATAHC","September 11, 2005","July 2004","June 2010","April 13, 2011","October 2009","No Study Results Posted","null","June 2010","Efficacy of peg-interferon alpha 2a (and ribavirin for HIV/HCV coifection)|Natural history of acute hepatitis C","https://ClinicalTrials.gov/show/NCT00192569"
281,"NCT00980161","Micro RNA-122 and the Clinical Course of Patients With Chronic Hepatitis C","Recruiting","No Results Available","Hepatitis C","","National Taiwan University Hospital|National Science Council, Taiwan|Department of Health, Executive Yuan, R.O.C. (Taiwan)","Both","Adult|Senior","","200","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","200908039R","September 16, 2009","September 2009","December 2010","March 25, 2010","March 2010","No Study Results Posted","null","September 2010","Serum micro RNA-122 and sustained virologic response (SVR)","https://ClinicalTrials.gov/show/NCT00980161"
282,"NCT01405183","Association Between Hepatitis C Infection and Renal Cell Carcinoma","Completed","No Results Available","Hepatitis C|Renal Cell Carcinoma|Colorectal Cancer","Other: Hepatitis C testing","Henry Ford Health System|Schering-Plough","Both","Adult|Senior","","240","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","P08406","July 28, 2011","January 2011","September 2013","September 16, 2014","September 2014","No Study Results Posted","null","August 2013","Prevalence of hepatitis C in renal cell carcinoma patients","https://ClinicalTrials.gov/show/NCT01405183"
283,"NCT00962442","N-Acetylcysteine in Severe Acute Alcoholic Hepatitis","Completed","No Results Available","Alcoholic Hepatitis","Drug: N-Acetylcysteine|Drug: placebo","Erasme University Hospital","Both","Adult|Senior","Phase 3","44","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","AAH-LYSO","August 19, 2009","September 2000","null","August 19, 2009","August 2009","No Study Results Posted","null","January 2006","Six months survival|Rate of infections, clinical and biological parameters","https://ClinicalTrials.gov/show/NCT00962442"
284,"NCT01311947","Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B","Completed","No Results Available","Hepatitis B, Chronic","Drug: Peginterferon alfa-2a","China Medical University Hospital","Both","Adult","","103","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","DMR99-IRB-313","March 8, 2011","March 2011","March 2012","July 29, 2013","July 2013","No Study Results Posted","null","March 2012","Therapeutic response to Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B","https://ClinicalTrials.gov/show/NCT01311947"
285,"NCT02356562","A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With Sofosbuvir in DAA Treatment-experienced Adults With Chronic Hepatitis C Virus Infection","Active, not recruiting","No Results Available","Chronic Hepatitis C Infection","Drug: Ombitasvir/ABT-450/r|Drug: Dasabuvir|Drug: Sofosbuvir|Drug: Ribavirin","AbbVie","Both","Adult|Senior","Phase 2","20","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-224","February 2, 2015","February 2015","August 2016","October 10, 2015","October 2015","No Study Results Posted","null","February 2016","Percentage of subjects with sustained virologic response 12 weeks post-treatment|Percentage of subjects with virologic failure during treatment|Percentage of subjects with virologic relapse after treatment","https://ClinicalTrials.gov/show/NCT02356562"
286,"NCT00792610","The Hepatitis B Vaccine Booster Response Among the Youth Who Had Completed Neonatal Hepatitis B Vaccines","Completed","Has Results","Hepatitis B","Biological: hepatitis B vaccine","National Taiwan University Hospital|National Science Council, Taiwan","Both","Adult","","127","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","200701049M|NSC96-2314-B-0020115","November 16, 2008","August 2007","February 2009","October 5, 2009","August 2009","August 16, 2009","null","January 2009","Hepatitis B Surface Antibody Seroprotective Rate(Seroprotective: for Those Who Had Anti-HBs(Surface Antibody Against Hepatitis B) Titer Higher Than 10 mIU/mL)","https://ClinicalTrials.gov/show/NCT00792610"
287,"NCT01854528","A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","Completed","No Results Available","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavrin|Drug: Pegylated Interferon alpha 2-alpha (PegINF)|Drug: Telaprevir","AbbVie","Both","Adult","Phase 3","154","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M13-862|2012-003738-18","May 13, 2013","June 2013","July 2015","July 29, 2015","July 2015","No Study Results Posted","null","November 2014","Percentage of subjects with sustained virologic response 12 weeks post-treatment|Change in Mental Component Summary (MCS) of the SF-36 v.2|Change in Physical Component Summary (PCS) of the SF-36 v.2|Percentage of subjects with virologic failure during treatment|Percentage of subjects with post-treatment relapse","https://ClinicalTrials.gov/show/NCT01854528"
288,"NCT00524173","Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B","Recruiting","No Results Available","Hepatitis B","Drug: Tenofovir/ & amp; Emtricitabine|Drug: Tenofovir","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","100","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","070207|07-DK-0207","August 31, 2007","August 2007","January 2019","May 5, 2015","April 2015","No Study Results Posted","null","January 2016","HBV DNA & lt; 1000 IU/ml|Normalization of ALT|Histological improvements|Loss of HBeAg|Loss of HBsAg","https://ClinicalTrials.gov/show/NCT00524173"
289,"NCT01112033","Biliverdin Reductase A in Chronic Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C, Chronic","","Charles University, Czech Republic|Military University Hospital, Prague|General University Hospital, Prague|Institute for Clinical and Experimental Medicine","Both","Adult","","113","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","BLVRA1","April 23, 2010","June 2010","June 2013","August 5, 2015","August 2015","No Study Results Posted","null","March 2013","To assess differences in BLVRA expression in the liver and PBMC in HCV infected patients in responders and non-responders to standard antiviral therapy.|To analyze the association of genetic polymorphisms of BLVRA with disease progression and treatment response in HCV infected patients.","https://ClinicalTrials.gov/show/NCT01112033"
290,"NCT01651403","Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection","Recruiting","No Results Available","Chronic Hepatitis B Infection","Drug: Tenofovir DF|Drug: Placebo to match TDF","Gilead Sciences","Both","Child","Phase 3","100","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","GS-US-174-0144|2012-000586-20","July 25, 2012","December 2012","June 2019","October 2, 2015","October 2015","No Study Results Posted","null","March 2017","Proportion of participants with serum HBV DNA < 400 copies/mL at week 72|Proportion of participants with hepatitis B e antigen (HBeAg) seroconversion at Week 72|Cumulative Incidence of at least 4% decrease from baseline in bone mineral density of lumbar spine|Percent change from baseline in bone mineral density of lumbar spine|Proportion of participants with normal ALT and normalization of ALT|Composite endpoint of proportion of participants with HBV DNA < 400 copies/mL and normal ALT|Genotypic changes from baseline within the HBV polymerase for patients who were viremic (HBV DNA > or equal 400 copies/mL) with confirmed virologic breakthrough|Proportion of participants with HBV DNA < 169 copies/mL|Proportion of participants with HBsAg loss and seroconversion","https://ClinicalTrials.gov/show/NCT01651403"
291,"NCT00760721","Increasing Hepatitis B Screening Among Korean Church Attendees","Completed","No Results Available","Hepatitis B","Behavioral: Educational Small Group Session","University of California, Los Angeles|National Institutes of Health (NIH)|National Cancer Institute (NCI)","Both","Adult","Phase 3","1123","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Screening|Masking: Single Blind (Subject)","P01CA109091-01A1","September 25, 2008","September 2006","August 2012","June 4, 2015","June 2015","No Study Results Posted","null","August 2011","Obtaining HBV Screening Test|Knowledge and Attitudes Regarding HBV Screening","https://ClinicalTrials.gov/show/NCT00760721"
292,"NCT00590564","SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study","Completed","No Results Available","Hepatitis C","Drug: Sho-saiko-to","Memorial Sloan Kettering Cancer Center","Both","Adult|Senior","Phase 2","41","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","02-073","December 21, 2007","October 2002","February 2011","April 28, 2015","April 2015","No Study Results Posted","null","February 2011","To determine the effects of Sho-saiko-to on hepatic injury in patients with chronic hepatitis C who are intolerant or have a specific contraindication to interferon-based therapy.|To determine the effects of SST therapy on liver function and viral load","https://ClinicalTrials.gov/show/NCT00590564"
293,"NCT00144313","VaxTeen Hepatitis B Vaccine Booster Study","Completed","No Results Available","Hepatitis","Biological: hepatitis B vaccine","Centers for Disease Control and Prevention|Alaska Native Medical Center","Both","Child","Phase 4","60","U.S. Fed|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","CDC-NCID-4127|U50/CCU022279-01","September 2, 2005","August 2005","January 2006","September 20, 2007","September 2007","No Study Results Posted","null","null","anti-HBs concentration|side effects|anti-HBc and/or HBsAg following primary vaccine series in infancy","https://ClinicalTrials.gov/show/NCT00144313"
294,"NCT00006301","Immune Response to Hepatitis C Virus","Completed","No Results Available","Hepatitis C","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","","46","NIH","Observational","Time Perspective: Prospective","000221|00-DK-0221","September 27, 2000","September 2000","March 2015","March 25, 2015","March 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006301"
295,"NCT01921400","The Pathogenesis of Hepatitis C Virus Vertical Transmission","Recruiting","No Results Available","Hepatitis C|Infection Transmission, Maternal-Fetal","","University of North Carolina, Chapel Hill|University of Maryland|Cairo University|Merck Sharp & Dohme Corp.","Female","Child|Adult|Senior","","50","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","13-0958","August 8, 2013","January 2013","July 2016","April 2, 2015","April 2015","No Study Results Posted","null","July 2016","To evaluate for the presence of HCV Core protein, HCV RNA and SPP in the placenta and fetal membranes using paraffin-embedded sections and post-delivery specimens respectively.","https://ClinicalTrials.gov/show/NCT01921400"
296,"NCT01045278","Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy","Completed","No Results Available","Hepatitis C","Drug: Pegylated interferon-alfa-2b and ribavirin","Region Skane","Both","Child|Adult|Senior","Phase 4","277","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","EU-nr 2007-001130-13","September 11, 2009","April 2008","September 2013","October 1, 2013","October 2013","No Study Results Posted","null","September 2013","To determine the completion rates of HCV treatment with pegylated interferon-alfa-2b and ribavirin in patients who are under opiate maintenance treatment and eligible for HCV therapy.|Prevalence of chronic HCV infection in the patient population eligible for part I in the study.|Clinical and histological characteristics of chronic hepatitis C.|Prevalence of hepatic decompensation and cirrhosis/advanced liver disease.|Risk factors for advanced liver disease.|Proportion of sustained virological responders, defined as a plasma HVC RNA level below Lower Level of Quantification at 24 week post-treatment.|Rates of relapse in opiate drug abuse.|Prevalence of depressive symptoms and assessment of quality of life before, under and after HCV treatment.|Potential pharmacokinetic interactions between ribavirin and methadone or buprenorphine.","https://ClinicalTrials.gov/show/NCT01045278"
297,"NCT01938625","A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation","Completed","No Results Available","Hepatitis C, Chronic","Drug: Simeprevir|Drug: Daclatasvir|Drug: Ribavirin","Janssen R&D Ireland","Both","Adult|Senior","Phase 2","35","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CR102639|TMC435HPC3016|2013-002726-23","September 5, 2013","December 2013","July 2015","September 24, 2015","September 2015","No Study Results Posted","null","April 2015","Number of participants with a sustained virologic response (SVR)12 Weeks after the end of treatment|Maximum Observed Plasma Concentration (Cmax) of cyclosporine and tacrolimus|Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[last]) of cyclosporine and tacrolimus|Maximum Observed Plasma Concentration (Cmax) of simprevir and daclatasvir|Time to Reach Maximum Observed Plasma Concentration (Tmax) of simprevir and daclatasvir|Predose (trough) concentration (C0h) of simprenavir and daclatasvir|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of simprevir and daclatasvir|Number of participants with dose adjustment of cyclosporine and tacrolimus during treatment with regimen simeprevir, daclatasvir and RBV|Number of patients with a sustained virological response SVR4 after the end of treatment|Number of participants with a sustained virologic response SVR24 after the end of treatment|Number of participants with adverse events|Number of participants with Undetectable HCV RNA (less than 25 IU/mL undetectable) and HCV RNA less than 25 IU/mL detectable|Number of participants with HCV RNA level less than 100 IU/mL|Number of participants with on-treatment failure after treatment with regimen simeprevir, daclatasvir and RBV|Number of participants with viral relapse after treatment with regimen simeprevir, daclatasvir and RBV|Number of participants with HCV NS3/4A and NS5A sequences","https://ClinicalTrials.gov/show/NCT01938625"
298,"NCT00107042","Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths","Completed","Has Results","Hepatitis B","Biological: Recombivax|Biological: Twinrix","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","Both","Child","Phase 2","123","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject)","ATN 025","April 4, 2005","February 2004","July 2008","February 12, 2015","December 2014","September 5, 2011","null","July 2008","Qualitative Seroresponsiveness to Hepatitis B Surface Antigen|Safety and Tolerability of Vaccine Regimens of Recombivax and Twinrix (Number of Participants With >=1 Adverse Event (AE))|Safety and Tolerability of Vaccine Regimens of Recombivax and Twinrix: Serious Adverse Events (SAE)(Number of Subjects With >= 1 SAE)|Quantitative Vaccine Response|Unadjusted Relationship of Hepatitis B Vaccine Response (Log10 Titer) and Potential Impact Factors Among Subjects Whose Week 28 Antibody Results Are Within Week 28 Visit Window.|Outcome Measure: Qualitative Vaccine Response to Hepatitis B (Hep B) Surface Antigen (Binary); Predictor: STUDY ARM.|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: SITE EFFECT|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: AGE|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: GENDER|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: HISPANIC ETHNICITY|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: RACE|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TANNER STAGE FOR FEMALES|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TANNER STAGE FOR MALES|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: BMI at Baseline|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: EVER SMOKED CIGARETTES|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: SEXUAL IDENTITY|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: AGE AT WHICH SUBJECT FIRST HAD SEX (NOT FORCED)|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TOTAL LIFETIME SEX PARTNERS|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TOTAL LIFETIME MALE SEX PARTNERS|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TOTAL LIFETIME FEMALE SEX PARTNERS|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: EVER DRANK ALCOHOL|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: EVER SMOKED MARIJUANA|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: EVER USED DRUGS NOT PRESCRIBE|Immunogenicity to Hep B 18 Months After First Immunization|Immunogenicity to Hep A in the Twinrix Arm: One Month Post 2nd Vaccination|Immunogenicity to Hep A in Twinrix Arm: Twelve Months Post 2nd Vaccination|Immunogenicity to Hep A in Twinrix Arm: Overall Response (1-month or 12-month After 2nd Vaccination)|As Treated Analysis - Adequate Antibody Response to Hep B Surface Antigen|Assessment of Youth Understanding of Vaccine Trial and Informed Consent","https://ClinicalTrials.gov/show/NCT00107042"
299,"NCT00547716","Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection","Withdrawn","No Results Available","Hepatitis C","Dietary Supplement: Omega-3 Fatty Acids|Drug: Placebo comparator","Truman Medical Center|Reliant Pharmaceuticals|Saint Luke's Health System Foundation","Both","Adult|Senior","","0","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","07-48","October 19, 2007","June 2009","August 2012","September 13, 2013","September 2013","No Study Results Posted","null","August 2012","To assess whether omega-3 fatty acids can improve early and sustained viral responses to treatment with interferon in patients with chronic infection.|To look at the effect of treatment of Hepatitis C on insulin resistance.","https://ClinicalTrials.gov/show/NCT00547716"
300,"NCT02275195","Immune Cell Dysfunction in Severe Alcoholic Hepatitis","Recruiting","No Results Available","Hepatitis","","Basildon and Thurrock University Hospitals NHS Foundation Trust","Both","Adult","","50","Other","Observational","Time Perspective: Prospective","B663","October 17, 2014","November 2013","July 2016","July 8, 2015","July 2015","No Study Results Posted","null","July 2016","To determine and changes to immune cell responses for outpatients with Alcoholic Hepatitis|Change from baseline to end of study in flow cytometry for patients with Alcoholic Hepatitis|Change from baseline to end of study in real time PCR for patients with Alcoholic Hepatitis|Change from baseline to end of study in cell cultures for patients with Alcoholic Hepatitis","https://ClinicalTrials.gov/show/NCT02275195"
301,"NCT02327663","Emtricitabine for Naive Chinese Chronic Hepatitis B Patients","Not yet recruiting","No Results Available","Hepatitis B, Chronic","Drug: Emtricitabine","Asian-Pacific Alliance of Liver Disease, Beijing|Beijing Ditan Hospital|Hebei Medical University Pharmaceutical Factory|National Health and Family Planning Commission, P.R.China","Both","Adult|Senior","Phase 4","2000","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","FTC-01","December 23, 2014","December 2014","December 2017","December 29, 2014","December 2014","No Study Results Posted","null","June 2017","virological response rate|HBV DNA decrease level|HBV DNA negativity rate|biochemical response|HBeAg loss|HBeAg seroconversion|HBeAg reversion|HBsAg loss|HBsAg seroconversion|adverse event|HBV genetic resistance to emtricitabine and adefovir","https://ClinicalTrials.gov/show/NCT02327663"
302,"NCT01074645","Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure","Completed","No Results Available","Acute on Chronic Liver Failure|Hepatitis B","Drug: Tenofovir disoproxil fumarate (TDF)","Govind Ballabh Pant Hospital","Both","Child|Adult|Senior","Phase 4","27","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","Hitendra garg","February 22, 2010","November 2007","October 2009","February 23, 2010","October 2009","No Study Results Posted","ACLF","June 2009","Reduction in HBV DNA levels, survival|Improvement in CTP, MELD scores","https://ClinicalTrials.gov/show/NCT01074645"
303,"NCT00004848","A Controlled Prospective Study of Transfusion-Associated Hepatitis","Completed","No Results Available","Hepatitis","","National Institutes of Health Clinical Center (CC)","Both","Child|Adult|Senior","","2000","NIH","Observational","","810110|81-CC-0110","March 2, 2000","July 1981","May 2000","March 3, 2008","July 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004848"
304,"NCT01272479","Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C","Completed","No Results Available","Renal Failure Chronic Requiring Hemodialysis|Hepatitis C","","Istanbul University","Both","Adult|Senior","","80","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","1692","January 6, 2011","August 2008","March 2010","January 6, 2011","November 2009","No Study Results Posted","null","March 2010","Association of prohepcidin and inflammation","https://ClinicalTrials.gov/show/NCT01272479"
305,"NCT01998620","Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis","Recruiting","No Results Available","Hepatitis B|Cholestasis","Drug: Ademetionine 2|Drug: Ademetionine 1|Drug: Ademetionine 3","Zhejiang Hisun Pharmaceutical Co. Ltd.","Both","Adult","Phase 4","240","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","XMX-HBV-001","November 14, 2013","November 2013","May 2015","May 28, 2014","May 2014","No Study Results Posted","null","May 2015","levels of serum total bilirubin declined from baseline|Alkaline Phosphatase|Gamma-Glutamyl Transpeptidase|level of serum direct bilirubin decline from baseline|level of serum bile acids decline from baseline|glutamic pyruvic transaminase|glutamic oxaloacetic transaminase","https://ClinicalTrials.gov/show/NCT01998620"
306,"NCT02393365","Prevalence and Screening of Hepatitis C in Belgium in 2015","Not yet recruiting","No Results Available","Hepatitis C","Other: Questionnaire|Procedure: HCV serology","Brugmann University Hospital","Both","Adult|Senior","","10000","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label","CHUB-HCV screening","March 9, 2015","September 2015","February 2016","July 16, 2015","July 2015","No Study Results Posted","null","February 2016","HCV risk factors questionnaire|Positive/Negative Hepatitis C serology","https://ClinicalTrials.gov/show/NCT02393365"
307,"NCT00197119","Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years","Completed","Has Results","Hepatitis B|Hepatitis A","Biological: Twinrix‚Ñ¢ Adult|Biological: Twinrix‚Ñ¢ Junior","GlaxoSmithKline","Both","Child","Phase 3","244","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","100566|100567|100568|100569|100570","September 14, 2005","May 2004","July 2008","November 3, 2011","November 2011","July 2, 2009","null","July 2008","Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value|Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-Off Value|Serious Adverse Events (SAE) Causally Related to Primary Vaccination or Related to Hepatitis A or B Infection or Related to Study Participation (Blood Sampling)","https://ClinicalTrials.gov/show/NCT00197119"
308,"NCT00502099","Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4","Completed","No Results Available","Hepatitis C","Drug: Pegylated interferon alpha 2a|Drug: Ribavirin|Drug: Pegylated interferon alpha 2 b plus ribavirin","Amr Hafez|Ain Shams University","Both","Adult","Phase 4","217","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","LG161190-06","July 15, 2007","January 2006","May 2009","October 21, 2012","October 2012","No Study Results Posted","null","May 2009","SVR, defined as undetectable serum HCV RNA|histological response|biochemical response","https://ClinicalTrials.gov/show/NCT00502099"
309,"NCT00496912","Management of Hepatitis C in HIV-Infected and Uninfected IDUs","Completed","No Results Available","Hepatitis C Virus|HIV Infections","Drug: Peginterferon/Ribavirin","National Institute on Drug Abuse (NIDA)","Both","Adult|Senior","Phase 4","410","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","RO1 DA016065-01","July 5, 2007","January 2004","June 2008","April 17, 2009","April 2009","No Study Results Posted","null","June 2008","1. The proportion of IDUs who have clear medical contraindications to HCV treatment. 2. The prevalence of significant hepatic fibrosis among treatment eligible IDUs. 3. The proportion of treatment-eligible IDUs who initiate PEG/RBV therapy.|The proportion of IDUs without clear contraindications who might be excluded by each of the 7 controversial contraindications.","https://ClinicalTrials.gov/show/NCT00496912"
310,"NCT00361179","Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C","Completed","No Results Available","Coinfection With Hepatitis B Virus and Hepatitis C Virus|Monoinfection With Hepatitis C Virus","","National Taiwan University Hospital|Hoffmann-La Roche","Both","Adult|Senior","","320","Other|Industry","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Prospective","9561706020","August 4, 2006","May 2006","December 2011","August 4, 2006","August 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00361179"
311,"NCT00444002","Oxidative Stress and Fatty Acids in Hepatitis C","Completed","No Results Available","Hepatitis C|Hepatic Steatosis","","Johane Allard|Canadian Association of Gastroenterology|University Health Network, Toronto","Both","Adult|Senior","","105","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","05-0305 AE","March 6, 2007","July 2005","July 2010","January 9, 2014","January 2014","No Study Results Posted","null","July 2008","Lipid peroxidation (LPO) in the liver|Hepatic fatty acid composition|Antioxidant power in the liver|Plasma vitamin C|Tocopherols in plasma","https://ClinicalTrials.gov/show/NCT00444002"
312,"NCT00006164","Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment","Completed","Has Results","Chronic Hepatitis C|Cirrhosis, Liver|Fibrosis, Liver|Hepatic Cirrhosis","Drug: Peginterferon alfa-2a + Ribavirin|Drug: Peginterferon alfa-2a","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute on Minority Health and Health Disparities (NIMHD)|National Cancer Institute (NCI)|Hoffmann-La Roche","Both","Adult|Senior","Phase 3","1050","NIH|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","HALT C|N01-DK-9-2328|N01-DK-9-2323|N01-DK-9-2324|N01-DK-9-2325|N01-DK-9-2326|N01-DK-9-2321|N01-DK-9-2327|N01-DK-9-2319|N01-DK-9-2318|N01-DK-9-2320|N01-DK-9-2322","August 8, 2000","June 2000","October 2009","January 12, 2010","January 2010","June 9, 2009","HALT-C","April 2007","Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points|Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies|Death From Any Cause|Development of Hepatocellular Carcinoma (HCC)|Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits|Variceal Hemorrhage|Ascites|Spontaneous Bacterial Peritonitis|Hepatic Encephalopathy|Serious Adverse Events|Events Requiring Dose Reductions (in Both Treatment Groups).|Changes in Fibrosis From Baseline at Year 2 or Year 4 Biopsy.|Presumed Hepatocellular Carcinoma (HCC)|Quality of Life","https://ClinicalTrials.gov/show/NCT00006164"
313,"NCT01852604","Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)","Completed","No Results Available","Chronic Hepatitis C Virus","Drug: Samatasvir|Drug: Simeprevir|Drug: Ribavirin (RBV)|Drug: TMC647055|Drug: Ritonavir (RTV)|Biological: Pegylated interferon (Peg-IFN)|Other: Samatasvir matching placebo","Merck Sharp & Dohme Corp.|Janssen Research & Development, LLC","Both","Adult","Phase 2","143","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","1894-005|IDX-06A-005","May 6, 2013","March 2013","April 2015","April 22, 2015","April 2015","No Study Results Posted","null","April 2015","Percentage of participants who experienced an adverse event (AE)|Percentage of participants who experienced a serious adverse event (SAE)|Percentage of participants who experienced a Grade 1-4 laboratory abnormality|Percentage of participants who experienced sustained virologic response 4 weeks after the end of treatment (SVR4)|Percentage of participants who experienced rapid virologic response (RVR)|Percentage of participants who experienced early virologic response (EVR)|Percentage of participants who experienced sustained virologic response 8 weeks after the end of treatment (SVR8)|Percentage of participants who experienced sustained virologic response 12 weeks after the end of treatment (SVR12)|Percentage of participants who experienced sustained virologic response 24 weeks after the end of treatment (SVR24)|Pharmacokinetic Parameter:Area under the concentration-time curve from time zero to t|Pharmacokinetic Parameter: Maximum observed drug concentration (Cmax)|Pharmacokinetic Parameter: Trough drug concentration (Ctrough)","https://ClinicalTrials.gov/show/NCT01852604"
314,"NCT01062321","Role of Cytokines in Hepatitis E Virus Infection During Pregnancy","Completed","No Results Available","Hepatitis|Cytokines|Pregnancy","","Maulana Azad Medical College|Indian Council of Medical Research","Female","Adult","","491","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","5/7/239/07/RHN","February 3, 2010","August 2009","July 2012","April 10, 2015","July 2011","No Study Results Posted","null","July 2012","To correlate the levels of cytokines and its genes polymorphisms with the severity of hepatitis in HEV and non-HEV pregnant women.|To correlate the outcome of pregnancy with the levels of maternal cytokines and its genes polymorphisms.","https://ClinicalTrials.gov/show/NCT01062321"
315,"NCT00744289","Hepatitis B Acceptability and Vaccination Incentive Trial","Completed","No Results Available","Hepatitis B","Other: Incentive condition","Kirby Institute","Both","Child|Adult|Senior","","204","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Caregiver)","X08-0161","August 26, 2008","September 2008","May 2011","June 14, 2011","June 2011","No Study Results Posted","HAVIT","May 2011","Determine, relative to a 'standard of care' control condition, the efficacy of incentive payments to increase HBV vaccine completion using an accelerated schedule (0, 7, and 21 days).|Assess the relative cost effectiveness of standard care compared to incentive payments as methods of improving rates of successful vaccine series completion and vaccine-induced immunity|Identify the correlates of immunity (defined as hepatitis B surface antibody levels greater than 10 mIU/ml)|Assess the acceptability of vaccines, including HBV vaccines, barriers to immunisation uptake and willingness to participate in vaccine trials among PWID|Assess hepatitis B-related knowledge in this group","https://ClinicalTrials.gov/show/NCT00744289"
316,"NCT01033045","Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure","Completed","No Results Available","Hepatitis C","","Fundacion IMIM","Both","Adult|Senior","","2178","Other","Observational","Time Perspective: Prospective","AGORA","December 15, 2009","September 2009","July 2013","October 20, 2015","October 2015","No Study Results Posted","null","July 2013","Describe the management of patients with chronic hepatitis C and previous treatment failure|To know the frequency of the causes for not responding to the previous treatment: lack of adherence to treatment, incomplete dose of antiviral treatment, insufficient treatment duration or treatment resistance.|To assess the percentage of patients with previous treatment failure who are not candidates for re-treatment and its causes.|To evaluate the implementation of current recommendations based on the cause of the previous therapeutic failure, in patients with chronic hepatitis C in whom a new course of the antiviral treatment is decided to be administered.|To know the causes of the dose modifications and withdrawal of treatment during the follow-up period in patients who start re-treatment.|To know the percentage of patients that achieve sustained viral response when implementing the recommendations based on the cause of the previous therapeutic failure.|To determine the presence of the polymorphism rs12979860 in the gene IL 28B located on chromosome 19.|Compare the management of patients with chronic hepatitis C prior treatment failure before and after the appearance of new treatments.","https://ClinicalTrials.gov/show/NCT01033045"
317,"NCT01779518","Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C","Approved for marketing","No Results Available","Post-transplant Hepatitis C","Drug: Sofosbuvir|Drug: Ribavirin|Drug: Pegylated Interferon","Gilead Sciences","Both","Adult|Senior","","null","Industry","Expanded Access","","GS-US-334-0139","January 23, 2013","null","null","January 15, 2014","January 2014","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01779518"
318,"NCT02002065","The Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children","Completed","No Results Available","Hepatitis A","Biological: Inactivated HAV vaccine|Biological: Attenuated alive HAV vaccine","Sinovac Biotech Co., Ltd","Both","Child","","300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRO-HA-4013 version 2.0","November 28, 2013","October 2008","June 2014","May 28, 2015","May 2015","No Study Results Posted","null","November 2013","The geometric mean concentration (GMC) of anti-hepatitis A virus (HAV) antibodies in serum 60 months after vaccination","https://ClinicalTrials.gov/show/NCT02002065"
319,"NCT00422838","Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.","Completed","No Results Available","Hepatitis C|Liver|Immunology|Regulation","Procedure: fine-needle aspiration biopsy","Foundation for Liver Research","Both","Adult|Senior","","27","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIRES","January 15, 2007","January 2007","November 2010","September 6, 2011","September 2011","No Study Results Posted","CIRES","June 2010","","https://ClinicalTrials.gov/show/NCT00422838"
320,"NCT01137383","Pegaferon and Ribavirin for Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: Pegaferon (pegylated interferon alpha 2a) + ribavirin","Tehran University of Medical Sciences|Pars No Tarkib Co","Both","Child|Adult","Phase 3","108","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","DDRC.86.90","June 3, 2010","December 2007","February 2010","June 28, 2010","June 2010","No Study Results Posted","null","December 2009","Sustained viral response|Adverse drug events","https://ClinicalTrials.gov/show/NCT01137383"
321,"NCT00720668","The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma","Recruiting","No Results Available","Hepatitis B|Hepatocellular Carcinoma","Procedure: radiofrequency ablation","Sun Yat-sen University","Both","Adult|Senior","","200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","RFA006","July 21, 2008","June 2006","May 2010","February 6, 2009","February 2009","No Study Results Posted","HBV-HCC","March 2009","The Rate of Exacerbation of chronic hepatitis B after RFA|survival|mortality","https://ClinicalTrials.gov/show/NCT00720668"
322,"NCT00300807","Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection","Active, not recruiting","No Results Available","Hepatitis C","Drug: XTL 6865","XTL Biopharmaceuticals","Both","Adult","Phase 1","36","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Primary Purpose: Treatment|Masking: Double-Blind","XTL2005-16|XTL6865","March 7, 2006","October 2005","April 2007","March 6, 2007","March 2007","No Study Results Posted","null","null","log change in serum concentrations of HCV RNA|change in serum anti-E2 concentrations","https://ClinicalTrials.gov/show/NCT00300807"
323,"NCT01732354","Study for Consolidation Period of Chronic Hepatitis B","Recruiting","No Results Available","Hepatitis B","","Tainan Municipal Hospital","Both","Adult|Senior","","136","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IX-US-174-0206","November 18, 2012","November 2012","November 2018","November 14, 2014","November 2014","No Study Results Posted","null","November 2018","HBeAg seroconversion was defined as loss of HBeAg with concurrent appearance of HBeAb.","https://ClinicalTrials.gov/show/NCT01732354"
324,"NCT01146626","Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?","Not yet recruiting","No Results Available","Hepatitis C","Drug: Peg+ Vitamin D+ Ribavirine|Drug: Peg+ Ribavirine","Ziv Hospital|Hillel Yaffe Medical Center","Both","Adult","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HCV +Vitamin D","June 16, 2010","August 2011","May 2012","April 27, 2011","June 2010","No Study Results Posted","null","February 2012","SVR rate","https://ClinicalTrials.gov/show/NCT01146626"
325,"NCT02243280","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection","Active, not recruiting","No Results Available","Chronic Hepatitis C|Hepatitis C Virus|HCV","Drug: ABT-493|Drug: ABT-530","AbbVie","Both","Adult|Senior","Phase 2","170","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-867|2014-002925-36","September 4, 2014","August 2014","March 2016","October 10, 2015","October 2015","No Study Results Posted","null","March 2016","Percentage of subjects with sustained virologic response (SVR) 12|Percentage of subjects with sustained virologic response (SVR) 4|Percentage of subjects with virologic failure during treatment|Percentage of subjects with Post-Treatment relapse","https://ClinicalTrials.gov/show/NCT02243280"
326,"NCT01690845","Molecular Adsorbent Recirculating System (MARS¬Æ) in Hypoxic Hepatitis","Recruiting","No Results Available","Hypoxic Hepatitis|Ischemic Hepatitis|Shock Liver|Hypoxic Liver Injury|Acute Liver Failure","Device: MARS","Medical University of Vienna","Both","Adult|Senior","Phase 2","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","10712010","September 16, 2012","June 2012","null","September 19, 2012","September 2012","No Study Results Posted","MARS in HH","September 2014","difference of the indocyanine plasma disappearance rate (ICG-PDR)|duration of vasopressor support|ICU - length of stay|hospital - length of stay|7-day mortality|28 day mortality|number of organ failure on day 7|number of organ failure on day 28|markers of liver function|number of vasopressor free days|systemic hemodynamics|number of complications of HH|biomarkers|duration of mechanical ventilation|necessity of renal replacement therapy|duration of renal replacement therapy|90 days mortality","https://ClinicalTrials.gov/show/NCT01690845"
327,"NCT02327676","Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients","Not yet recruiting","No Results Available","Hepatitis B, Chronic","Drug: Emtricitabine","Asian-Pacific Alliance of Liver Disease, Beijing|Beijing Ditan Hospital|Hebei Medical University Pharmaceutical Factory|National Health and Family Planning Commission, P.R.China","Both","Child","Phase 4","200","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","FTC-01-child patients","December 23, 2014","January 2015","July 2016","December 29, 2014","December 2014","No Study Results Posted","null","July 2015","virological response rate|HBV DNA negativity rate|HBV DNA decrease level|biochemical response|HBeAg loss|HBeAg seroconversion|HBeAg reversion|HBsAg loss|HBsAg seroconversion|HBV genetic resistance to emtricitabine|adverse event","https://ClinicalTrials.gov/show/NCT02327676"
328,"NCT00139113","Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children","Completed","No Results Available","Hepatitis A","Biological: hepatitis A vaccine","Centers for Disease Control and Prevention|Alaska Native Medical Center|GlaxoSmithKline","Both","Child","Phase 4","248","U.S. Fed|Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject)","CDC-NCID-1358|U50/CCU022279","August 29, 2005","September 1996","June 2001","August 29, 2012","August 2012","No Study Results Posted","null","June 2001","concentration of antibody to hepatitis A virus|reported side effects and adverse events|antibodies to routine childhood vaccinations","https://ClinicalTrials.gov/show/NCT00139113"
329,"NCT00230477","Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT","Completed","No Results Available","Hepatitis B","Drug: Hepsera|Drug: Hepsera and lamivudine","University of Washington|Gilead Sciences|GlaxoSmithKline","Both","Adult|Senior","Phase 4","19","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","03-5944-A03","September 12, 2005","April 2003","August 2007","November 14, 2007","November 2007","No Study Results Posted","null","null","Subjects treated with combination therapy will have a decrease in the viral DNA that is greater than the subjects treated with monotherapy.|Subjects treated with combination therapy will have an improved HBeAg conversion rate compared to historical controls treated with either lamivudine or adefovir dipivoxil monotherapy.","https://ClinicalTrials.gov/show/NCT00230477"
330,"NCT01838070","Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)","Active, not recruiting","No Results Available","Hepatitis A","","Sanofi Pasteur, a Sanofi Company|Sanofi","Both","Child|Adult|Senior","Phase 4","626","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HAF85|U1111-1127-7211","April 18, 2013","April 2013","May 2016","October 8, 2015","October 2015","No Study Results Posted","null","November 2015","Safety profile in terms of solicited and unsolicited adverse events following the administration of AVAXIM 160U vaccine","https://ClinicalTrials.gov/show/NCT01838070"
331,"NCT00587119","Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis","Withdrawn","No Results Available","Primary Biliary Cirrhosis|Autoimmune Hepatitis","Drug: Budesonide","Mayo Clinic","Both","Adult|Senior","","0","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","07-003586|Budesonide","December 21, 2007","December 2007","July 2009","October 1, 2010","October 2010","No Study Results Posted","PBC","July 2009","The main endpoint will be the percentage of patients with improvement in alkaline phosphatase to less than 1.5 times normal over one year and the percentage of patients with a reduction in their Mayo Risk Score over one year.|Effects of UDCA & budesonide on serum levels of alk phos, AST, total bilirubin, albumin, and prothrombin time, Mayo risk score and toxicity and tolerability of the budesonide/UDCA regimen, including effects on bone density.","https://ClinicalTrials.gov/show/NCT00587119"
332,"NCT00821587","Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation","Completed","Has Results","Hepatitis C","Drug: Cyclosporine|Drug: Tacrolimus","University of Florida|Novartis Pharmaceuticals","Both","Adult|Senior","Phase 4","39","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","20040658","January 9, 2009","June 2004","May 2008","November 2, 2011","November 2011","August 4, 2011","null","May 2008","Hepatitis C Viral Level","https://ClinicalTrials.gov/show/NCT00821587"
333,"NCT00001879","Collections of Blood and Stool Samples in Patients With Acute Hepatitis","Completed","No Results Available","Hepatitis","","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","Both","Child|Adult|Senior","","200","NIH","Observational","","990060|99-H-0060","November 3, 1999","March 1999","March 2001","March 3, 2008","February 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001879"
334,"NCT02327702","Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients","Not yet recruiting","No Results Available","Hepatitis B, Chronic|Pregnancy","Drug: Emtricitabine","Asian-Pacific Alliance of Liver Disease, Beijing|Beijing Ditan Hospital|Hebei Medical University Pharmaceutical Factory|National Health and Family Planning Commission, P.R.China","Female","Adult|Senior","Phase 4","200","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","FTC-02-pregnant CHB patients","December 23, 2014","January 2015","July 2017","December 29, 2014","December 2014","No Study Results Posted","null","July 2015","virological response rate|HBV DNA decrease level|biochemical response|HBeAg loss|HBeAg seroconversion|HBeAg reversion|HBsAg loss|HBsAg seroconversion|HBV genetic resistance to emtricitabine|adverse event|birth defect in newborns|HBsAg positive rate in newborns","https://ClinicalTrials.gov/show/NCT02327702"
335,"NCT00291954","Compare the Immune Response & Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine vs Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis & Dialysis Patients Who Did Not Respond to Previous Hepatitis B Vaccination","Completed","No Results Available","Hepatitis B","Biological: HB-AS02V|Biological: HBVAXPRO vaccine","Henogen|GlaxoSmithKline","Both","Child|Adult|Senior","Phase 3","257","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","HN017/HBV-003 (105762)","February 14, 2006","March 2006","October 2007","August 27, 2008","August 2008","No Study Results Posted","null","October 2007","Anti-HBs seroprotection rate|Anti-HBs Seroprotection rates for all subjects.|Anti-HBs Seropositivity rates for all subjects.|Percentage of subjects with anti-HBs antibody concentrations superior or equal to 100 mIU/ml for all subjects|Anti-HBs Geometric Mean Concentrations calculated for all subjects.|Occurrence and intensity of solicited local signs and symptoms, relationship to vaccination of solicited general signs and symptoms reported during the 4-day follow-up period after each vaccination and overall|Occurrence, intensity and relationship to vaccination of unsolicited signs and symptoms during the 31-day (Day 0 to Day 30) follow-up period after each vaccination and overall|Occurrence, intensity and relationship to vaccination of all serious adverse events (SAEs) up to Month 2","https://ClinicalTrials.gov/show/NCT00291954"
336,"NCT01413490","Hepatitis C Rimantadine and Antiviral Combination Therapy","Completed","No Results Available","Hepatitis C","Drug: rimantadine","The Leeds Teaching Hospitals NHS Trust|Cancer Research UK","Both","Adult","Phase 2","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2011-002781-21","August 9, 2011","May 2012","March 2015","March 30, 2015","March 2015","No Study Results Posted","HepRiACT","March 2015","","https://ClinicalTrials.gov/show/NCT01413490"
337,"NCT00755742","Lifestyle Intervention Targetting Obesity and Insulin Resistance in Chronic Hepatitis C","Completed","No Results Available","Obesity|Insulin Resistance|Metabolic Syndrome|Hepatitis C","Other: Lifestyle intervention","University Health Network, Toronto","Both","Adult","","24","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","08-0545-AE","September 17, 2008","November 2008","August 2011","September 21, 2011","September 2011","No Study Results Posted","null","January 2011","HOMA-IR|TNF-alpha|leptin|adiponectin|fatigue score|mood score|cholesterol|triglycerides|HDL-cholesterol|LDL-cholesterol|RBC fatty acid composition|BMI|Waist circumference|Metabolic Syndrome|CLDQ (Chronic Liver Disease Questionnaire)|Liver and Peripheral Insulin Resistance","https://ClinicalTrials.gov/show/NCT00755742"
338,"NCT02025842","Hepatitis B Virus HBeAg-negative Genotype D Patients and Hepatocellular Carcinoma","Completed","No Results Available","Hepatocellular Carcinoma|Hepatitis B","","Azienda Ospedaliera San Camillo Forlanini","Both","Adult|Senior","","306","Other","Observational","Observational Model: Cohort","02","December 31, 2013","January 2000","December 2013","December 31, 2013","December 2013","No Study Results Posted","HBV/HCC","December 2013","risk for hepatocellular carcinoma|survival","https://ClinicalTrials.gov/show/NCT02025842"
339,"NCT01292161","Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: Silymarin","Isfahan University of Medical Sciences","Both","Child|Adult|Senior","Phase 2","55","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)","ASD-1213-15","February 8, 2011","March 2006","September 2006","February 8, 2011","September 2006","No Study Results Posted","null","September 2006","Serum aminotransferases (ALT, AST)|HCV-RNA","https://ClinicalTrials.gov/show/NCT01292161"
340,"NCT02395198","Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients","Recruiting","No Results Available","Hepatitis C","","Prof. Dr. med. Jens Reimer|Janssen-Cilag G.m.b.H|Universit√§tsklinikum Hamburg-Eppendorf","Both","Adult|Senior","","2500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","12748","March 16, 2015","August 2014","September 2016","March 23, 2015","March 2015","No Study Results Posted","ECHO","May 2016","National annual prevalence and incidence of current HCV infections among opioid dependent individuals in substitution treatment|Patient questionnaire: Patient Reported Outcomes|Clinician questionnaire: Clinician Reported Outcomes and Data from Routine Patient Care","https://ClinicalTrials.gov/show/NCT02395198"
341,"NCT00441493","Fluvastatin Versus Hepatitis C Virus","Completed","No Results Available","Hepatitis C","Drug: fluvastatin","Bader, Ted, M.D.|VA Office of Research and Development","Both","Adult|Senior","","32","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","13035|13134","February 27, 2007","September 2006","September 2007","July 26, 2012","September 2006","No Study Results Posted","null","March 2007","Viral Load Reduction, Liver test changes","https://ClinicalTrials.gov/show/NCT00441493"
342,"NCT00983164","Blood Antioxidant Status in Chronic Hepatitis C Patients Before and After Antioxidant Supplementation: a Randomized Clinical Trial","Completed","No Results Available","Hepatitis C|Oxidative Stress","Dietary Supplement: Antioxidant Supplementation","Universidade do Sul de Santa Catarina","Both","Adult","","32","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care|Masking: Open Label","120/07 CEP","September 22, 2009","January 2007","April 2009","September 22, 2009","September 2009","No Study Results Posted","HepCAntSup","December 2007","","https://ClinicalTrials.gov/show/NCT00983164"
343,"NCT01438320","Q-Trial in Patients With Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Dietary Supplement: Quercetin","University of California, Los Angeles|American Association for Cancer Research|Tower Cancer Research Foundation|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","Adult","Phase 1","34","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)","IRB#10-04-063-01|1R01DK090794-01A1","September 14, 2011","July 2011","June 2014","March 18, 2015","March 2015","No Study Results Posted","Q","June 2014","Adverse Event Score Assessment of Quercetin Given over 28 days in hepatitis C patients who have contraindications to standard antiviral treatment|Hepatitis C Viral Load Assessment with Quercetin Given Over 28 days","https://ClinicalTrials.gov/show/NCT01438320"
344,"NCT00909129","Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment","Completed","No Results Available","Human Immunodeficiency Virus|Chronic Hepatitis C","Drug: pegylated interferon-alpha (Pegasys)|Drug: ribavirin (COPEGUS)","Karolinska Institutet|The Swedish Research Council|Hoffmann-La Roche","Both","Adult|Senior","","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label","03-541","May 15, 2009","null","null","May 26, 2009","May 2009","No Study Results Posted","DICO","null","Sustained virological response|T-cell mediated immune responses","https://ClinicalTrials.gov/show/NCT00909129"
345,"NCT00596960","Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients","Completed","Has Results","Alcohol Dependence|Chronic Hepatitis C","Behavioral: Motivational Enhancement Therapy (MET)|Behavioral: Health education","VA Office of Research and Development","Both","Adult|Senior","","139","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)","NEUA-009-07S","January 8, 2008","November 2008","July 2012","November 26, 2014","November 2014","November 12, 2014","null","June 2012","The Number of Alcohol Drinks Per Week (as Measured by the Time Line Follow Back Procedure) at the 6 Month Follow-up.|Percent Days Abstinent From Alcohol at 6 Months|Heavy Drinking Days (Greater or Equal to 4 Drinks)","https://ClinicalTrials.gov/show/NCT00596960"
346,"NCT02247401","Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt","Active, not recruiting","No Results Available","HCV|Hepatitis C Infection|Genotype 4","Drug: 2 DAA|Drug: RBV","AbbVie","Both","Adult|Senior","Phase 3","160","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-250","September 19, 2014","November 2014","August 2016","October 16, 2015","October 2015","No Study Results Posted","null","June 2016","Percentage of subjects with sustained virologic response 12 weeks post-treatment (SVR12) in each arm|Incidence of Adverse Events|Percentage of subjects with on-treatment virologic failure in each treatment arm|Percentage of subjects with post-treatment relapse within 12 weeks following end of treatment in each arm","https://ClinicalTrials.gov/show/NCT02247401"
347,"NCT00229580","Health Behavior Feedback Study for Veterans With Hepatitis C","Completed","No Results Available","Alcoholism|Alcohol Abuse|Hepatitis C|Liver Disease","Behavioral: 3 session brief intervention with health behavior feedback|Other: treatment as usual","University of Washington|Alcoholic Beverage Medical Research Foundation","Both","Adult|Senior","Phase 1","12","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","03-8752-V 03","September 27, 2005","December 2003","January 2006","November 28, 2007","November 2007","No Study Results Posted","null","null","Reduction in alcohol consumption|Engagement in substance use treatment and hepatitis C specialty care. Detection of elevated CDT in blood serum compared with self-reported heavy drinking.","https://ClinicalTrials.gov/show/NCT00229580"
348,"NCT01451801","Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders","Active, not recruiting","No Results Available","Hepatitis B","Biological: Twinrix","University of Aarhus|Aarhus University Hospital|Monash Medical Centre","Both","Adult|Senior","Phase 4","400","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","SJF0001","October 10, 2011","October 2011","July 2013","October 25, 2012","October 2012","No Study Results Posted","null","July 2013","Estimate the CMI response in serologic non-responders after receiving a standard course of HBV immunization|Establish the prevalence of serological non-responders after a standard course of HBV vaccination defined by anti-HBs <10 mIU / ml|Assess the safety of the vaccine by evaluating the numbers and intensity of adverse and Serious adverse events|Evaluate predictors of serologic non-response in young, healthy individuals receiving a standard course of HBV immunization|Compare the immunological profile before and after a standard HBV vaccination regimen, with com-parison of serological non-responders and serological responders|Establish a rapid test for measuring HBsAg specific CMI by use of an IFN-gamma based assay.","https://ClinicalTrials.gov/show/NCT01451801"
349,"NCT01508286","Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects","No longer available","No Results Available","Hepatitis C","Drug: Telaprevir + peginterferon alfa + ribavirin|Drug: peginterferon alfa + ribavirin|Drug: peginterferon alfa + ribavirin","Janssen-Cilag International NV","Both","Adult|Senior","Phase 3","null","Industry","Expanded Access","","CR017857|VX-950HEP3002|2010-023669-23","January 9, 2012","null","null","July 22, 2015","July 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01508286"
350,"NCT02176980","Hepatitis C Alcohol Reduction Treatment","Recruiting","No Results Available","Hepatitis C Infected Subjects Who Consume Alcohol","Behavioral: Brief alcohol counseling|Behavioral: Group and Individual Therapy Sessions","Duke University|University of North Carolina, Chapel Hill|Durham VA Medical Center","Both","Adult|Senior","","230","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","Pro00046518","June 26, 2014","October 2014","March 2019","October 27, 2014","October 2014","No Study Results Posted","Hep ART-RCT","March 2019","Alcohol abstinence rates at 6 months after consent|Relapse rate at 12 months after consent|Other alcohol use indicators|Illicit drug use","https://ClinicalTrials.gov/show/NCT02176980"
351,"NCT00305383","Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C","Terminated","No Results Available","Hepatitis C, Chronic","Drug: Viramidine|Drug: Peginterferon alfa-2b","Valeant Pharmaceuticals International, Inc.","Both","Adult|Senior","Phase 2","100","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","RNA003142-202","March 17, 2006","November 2005","May 2007","June 21, 2012","June 2012","No Study Results Posted","null","null","Efficacy: The proportion of patients with hepatitis C virus (HCV) RNA undetectable or with at least a 2-log drop from baseline at CT Week 4 in the viramidine pre-load group versus the viramidine standard dosing group.|Safety: Evaluation of adverse events (AEs).|Safety: Physical exams|Safety: Vital signs|Safety: Laboratory tests|Efficacy: HCV RNA Response at CT Week 12, 24, end of treatment and at follow-up Week 24.","https://ClinicalTrials.gov/show/NCT00305383"
352,"NCT01492998","Role of FXR in Hepatitis C Virus Replication","Terminated","No Results Available","Chronic Hepatitis C","Other: guggulsterone, a natural FXR antagonist.","Hospices Civils de Lyon","Male","Adult","","15","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","2008.501-02","September 23, 2010","January 2010","null","December 14, 2011","September 2010","No Study Results Posted","GGST","March 2010","Evolution of the HCV plasmatic viral load while taking the FXR inhibitor guggulsterone.|Modification of the fraction of the circulating viral forms associated with apolipoprotein B","https://ClinicalTrials.gov/show/NCT01492998"
353,"NCT00152880","Apoptosis and Hepatitis B: The Role of Apoptosis in Patients Who Are HBeAg Negative","Recruiting","No Results Available","Hepatitis B","","University Health Network, Toronto","Both","Adult|Senior","","30","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Cross-Sectional|Time Perspective: Prospective","05-0337-T","September 8, 2005","July 2005","null","November 29, 2005","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00152880"
354,"NCT00244751","Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects","Completed","No Results Available","Hepatitis C","Drug: GI262570","GlaxoSmithKline","Both","Adult|Senior","Phase 2","225","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","FBX104114","October 25, 2005","November 2005","February 2008","November 5, 2009","November 2009","No Study Results Posted","null","February 2008","Change from baseline in liver biopsy immunohistochemical markers. Change from baseline in fibrosis in liver biopsy. Histological assessment of paired biopsies (baseline and Week 52). Safety and tolerability of two doses of GI262570.|Proportion of subjects progressing at least 1 point in fibrosis score. Proportion of subjects regressing at least 1 point in fibrosis score. Change from baseline in markers of liver fibrosis.|¬∑Proportion of subjects progressing at least 1 point on the Ishak fibrosis score at Week 52 on each arm of the study. Progression is defined as an increase of at least one point in the fibrosis score.|¬∑Proportion of subjects regressing at least 1 point on the Ishak fibrosis score at Week 52 on each arm of the study.|¬∑Proportion of subjects whose Ishak fibrosis score remains unchanged at Week 52 on each arm of the study.|¬∑Change from baseline in total Ishak Score (necroinflammatory score and fibrosis score) at Week 52.|¬∑Change from baseline in Metavir scores.|¬∑Change from baseline in serum FibroSure (FibroTest/ActiTest) score.|¬∑Change from baseline in serum ALT levels.|¬∑Change from baseline in measures of insulin resistance.|¬∑Median serum ALT over time.|¬∑Change from baseline in serum HCV RNA levels.|¬∑Median serum HCV RNA levels over time.|¬∑Pharmacokinetic measures:|¬∑GI262570 serum PK parameters on Week 2 in a subset of subjects.|¬∑GI262570 serum concentrations on Week 2, 16, 28, 40, and Week 52.","https://ClinicalTrials.gov/show/NCT00244751"
355,"NCT00147459","Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation","Recruiting","No Results Available","Liver Transplantation|Hepatitis B","Biological: HBV vaccine booster","National Taiwan University Hospital|National Science Council, Taiwan","Both","Child|Adult|Senior","","31","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label","931205","September 5, 2005","September 2005","December 2012","December 4, 2012","December 2012","No Study Results Posted","null","December 2006","Persistence of anti-HBs in those primarily vaccinated and who underwent liver transplantation|The necessity of a booster dose of HBV vaccine for those primarily vaccinated and who underwent liver transplantation","https://ClinicalTrials.gov/show/NCT00147459"
356,"NCT00248339","Trial of Peg-Interferon Plus Epoetin-Alfa for Treatment of Chronic Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C","Drug: Peginterferon-alpha-2b (PEG-Intron)|Drug: Ribavirin|Drug: Epoetin-alpha (Procrit)","Virginia Commonwealth University|Ortho Biotech, Inc.","Both","Adult|Senior","Phase 3","150","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","1988 WIRB","November 2, 2005","May 2002","July 2005","December 14, 2007","November 2005","No Study Results Posted","null","null","The mean dose of ribavirin utilized in each of the 3 treatment arms will be compared.|Number of patients in each group who required a dose reduction of ribavirin|Rate of virologic response and sustained virologic response observed in each group|Rate of decline in HCV RNA titer in each group","https://ClinicalTrials.gov/show/NCT00248339"
357,"NCT01937728","Tailored Regimens of PEGASYS¬Æ and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)","Recruiting","No Results Available","Hepatitis C","Drug: A: Peg-interferon alpha-2a & Ribavirin|Drug: B: Peg-interferon alpha-2a & Ribavirin|Drug: C: Peg-interferon alpha-2a & Ribavirin|Drug: D: Peg-interferon alpha-2a & Ribavirin|Drug: E: Peg-interferon alpha-2a & Ribavirin|Drug: F: Peg-interferon alpha-2a & Ribavirin","Kaohsiung Medical University Chung-Ho Memorial Hospital","Both","Adult|Senior","Phase 4","750","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","KMUH-IRB-970119","June 21, 2013","March 2010","December 2015","September 4, 2013","September 2013","No Study Results Posted","null","December 2013","Efficacy|Safety","https://ClinicalTrials.gov/show/NCT01937728"
358,"NCT02167945","A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","Active, not recruiting","No Results Available","Chronic Hepatitis C Virus (HCV) Infection Genotype 1","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin (RBV)","AbbVie","Both","Adult|Senior","Phase 3","600","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-222","June 18, 2014","June 2014","March 2020","October 22, 2015","October 2015","No Study Results Posted","(TOPAZ II)","July 2015","Incidence of pre-defined clinical outcomes observed during the study|Percentage of subjects with sustained virologic response 12 weeks post-treatment (SVR12)|Change in fatigue|Change in Quality of Life|Evaluation of adherence to study drug regimens","https://ClinicalTrials.gov/show/NCT02167945"
359,"NCT00926146","Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV","Completed","No Results Available","Hepatitis B|Hepatitis C|HIV|HIV Infections","Behavioral: NCMIT|Behavioral: SCMIT","University of California, Los Angeles","Male","Adult","","451","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","090602901|DA016147","June 22, 2009","July 2009","February 2015","May 26, 2015","May 2015","No Study Results Posted","HBV","January 2014","Compare the NCMIT and SCMT programs among homeless young gay and bisexual stimulant using men with respect to completion of a HBV vaccination series administered in three doses over a four-month period.|Document the occurrences of HCV and HIV infections as baseline among these homeless HBV antibody negative stimulant users, and the factors associated with these infections at baseline.","https://ClinicalTrials.gov/show/NCT00926146"
360,"NCT01272310","Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.","Not yet recruiting","No Results Available","Chronic Hepatitis C","Biological: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin","Sheba Medical Center","Both","Adult|Senior","Phase 1|Phase 2","36","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","SHEBA-10-8033-YM-CTIL|HCQ-001-IL","January 3, 2011","January 2011","July 2013","January 6, 2011","January 2011","No Study Results Posted","null","January 2012","Change from baseline in physical examination|Change from baseline in vital Signs|Change from baseline in clinical laboratory parameters|Change from baseline in adverse events|HCV RNA level","https://ClinicalTrials.gov/show/NCT01272310"
361,"NCT01289496","Ribavirin Dose Optimization for the Treatment of Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: Peg-interferon alpha-2a, Ribavirin","Centre hospitalier de l'Universit√© de Montr√©al (CHUM)|Hoffmann-La Roche|Centre de Recherche du Centre Hospitalier de l'Universit√© de Montr√©al","Both","Adult|Senior","Phase 2","13","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ML25553|Control Number: 143155","January 25, 2011","February 2011","August 2013","February 24, 2014","August 2012","No Study Results Posted","null","August 2013","Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) analysis assay|Viral Kinetics|Neutrophils|Hemoglobin","https://ClinicalTrials.gov/show/NCT01289496"
362,"NCT00407732","Overcoming Psychiatric Barriers to the Treatment of Hepatitis C","Completed","No Results Available","Hepatitis C|Substance Use Disorders|Mental Disorder","Behavioral: psychosocial intervention","University of North Carolina, Chapel Hill|Roche Pharma AG","Both","Adult|Senior","","101","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)","05-2944 PEG228","December 4, 2006","January 2007","October 2011","January 24, 2012","January 2012","No Study Results Posted","null","February 2010","Whether or not the patient is deemed an appropriate candidate for interferon therapy at the end of the 9-month intervention.","https://ClinicalTrials.gov/show/NCT00407732"
363,"NCT01724086","A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus","Completed","No Results Available","Chronic Hepatitis C","Drug: TMC647055|Drug: TMC435|Drug: Ritonavir|Drug: Ribavirin|Drug: Pegylated interferon alpha-2a (PegIFN)|Drug: GSK2336805","Janssen R&D Ireland","Both","Adult|Senior","Phase 2","90","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CR100882|TMC647055HPC2001|2012-002555-42","September 26, 2012","October 2012","December 2014","January 23, 2015","January 2015","No Study Results Posted","null","September 2014","Number of patients with a sustained virologic response (SVR) 12 Weeks after the actual end of treatment|Number of patients with adverse events|Number of patients with a sustained virological response (SVR at 4 and/or 24 Weeks after the actual end of treatment)|HCV RNA levels over time|Number of patients with undetectable hepatitis C virus (HCV) RNA (less than 25 IU/mL undetectable) and/or HCV RNA levels less than 25 IU/mL at all time points|Number of patients with on-treatment virologic failure|Number of patients with viral relapse|Number of patients with presence of HCV variants associated with reduced susceptibility to investigational treatment|Maximum plasma analyte concentration of TMC435|Minimum plasma analyte concentration of TMC435|Area under the plasma concentration-time curve of TMC435|Maximum plasma analyte concentration of TMC647055|Minimum plasma analyte concentration of TMC647055|Area under the plasma concentration-time curve of TMC647055|Maximum plasma analyte concentration of ritonavir (RTV)|Minimum plasma analyte concentration of RTV|Area under the plasma concentration-time curve of RTV|Minimum and maximum plasma concentrations of GSK233680k|Area under the plasma concentration-time curve of GSK233680k","https://ClinicalTrials.gov/show/NCT01724086"
364,"NCT00582738","Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection","Terminated","Has Results","Recurrent Hepatitis C","Drug: CsA-TAC (standard Treatment)|Drug: Everolimus","Novartis Pharmaceuticals|Novartis","Both","Adult","Phase 2","43","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CRAD001H2301","December 12, 2007","December 2007","January 2010","August 2, 2012","August 2012","January 10, 2012","REVERT","January 2010","Change From Baseline in Fibrosis Staging Score (Measured by the Ishak-Knodell Staging Score) Between Baseline and 24 Months Post-transplant.|Change From Baseline in Fibrosis Metavir Scoring at 12 and 24 Months Post Randomization|Percentage of Patients With Death, Graft Loss and Biopsy Proven Acute Rejection (BPAR) Between Study Groups|Number of Patients With Events (Progression to Cirrhosis, Retransplantation, HCV Related Death, First BPAR, Graft Loss)at 12 and 24 Months|Comparison of Renal Function (Glomerular Filtration Rate [GFR] Calculated Using the Modification of Diet in Renal Disease Study Group [MDRD] Formula) Between Study Groups|Comparison of the Effect of Both Regimens in the Necroinflammatory Grading Score (Ishak-Knodell) (Portal Inflammation)|Comparison of the Effect of Both Regimens on the Inflammatory (Acti-test) and Fibrosis (Fibro-test) Components of Fibrosure, and on Fibrosis Area Assessed by Histomorphometry|Percentage of Patients in Each Study Arm With Increase of ‚â•1 Point in the Ishak-Knodell Staging Score in Fibrosis|Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Viral Load at 12 and 24 Months Post Randomization","https://ClinicalTrials.gov/show/NCT00582738"
365,"NCT00155103","Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular Carcinoma","Recruiting","No Results Available","Hepatitis B|Carcinoma, Hepatocellular|Polymorphism, Genetic","","National Taiwan University Hospital|National Science Council, Taiwan","Both","Adult|Senior","","1600","Other","Observational","Observational Model: Case Control|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Retrospective","9361700927|NSC 93-2314-B-002-226","September 9, 2005","August 2004","null","March 20, 2007","July 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00155103"
366,"NCT02108301","Hepatitis C in Renal Transplant Recipients","Active, not recruiting","No Results Available","Chronic Hepatitis C-virus Infection|Renal Transplantation","Drug: tacrolimus-cyclosporine A","Prof. Dr. Alice Schmidt|Medical University of Vienna","Both","Adult|Senior","Phase 4","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","EK477/2011","April 1, 2014","December 2011","null","April 10, 2014","April 2014","No Study Results Posted","null","June 2013","change in Hepatitis C-virus load at 12 weeks|change in oral glucose insulin sensitivity (OGIS) index at 12 weeks|change in serum hepcidin levels at 12 weeks","https://ClinicalTrials.gov/show/NCT02108301"
367,"NCT02207088","Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease","Recruiting","No Results Available","Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis|Severe Renal Impairment|End-stage Renal Disease","Drug: ombitasvir/paritaprevir/ritonavir|Drug: dasabuvir|Drug: Ribavirin","AbbVie","Both","Adult|Senior","Phase 3","70","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-226|2014-001527-77","July 31, 2014","September 2014","December 2016","October 16, 2015","October 2015","No Study Results Posted","null","December 2016","Percentage of subjects with Sustained Virologic Response 12 weeks post-treatment|Percentage of subjects with on-treatment virologic failure|Percentage of subjects with post-treatment relapse","https://ClinicalTrials.gov/show/NCT02207088"
368,"NCT01724723","Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment","Not yet recruiting","No Results Available","Hepatitis|Tuberculosis|hepatitisB","Drug: entecavir (BARACLUDE¬Æ)","National Taiwan University Hospital","Both","Adult|Senior","Phase 4","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","NTUH-IRB-201109046MB","May 2, 2012","December 2012","June 2014","November 7, 2012","November 2012","No Study Results Posted","HBV","June 2014","incidence of hepatitis|HBV viral load","https://ClinicalTrials.gov/show/NCT01724723"
369,"NCT00277862","Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4","Completed","No Results Available","Hepatitis C","Drug: Pegylated IFN- alpha 2b|Drug: Ribavirin","Ain Shams University|Schering-Plough|Fulbright|TEMPUS|International Society for Infectious Diseases","Both","Adult","Phase 4","280","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","G43230832638","January 15, 2006","April 2002","April 2007","February 25, 2008","February 2008","No Study Results Posted","null","March 2007","sustained virologic response defined as undetectable serum HCV RNA levels (Amplicor HCV, Roche Molecular Systems; lower limit of detection (LLD) of 50 IU/mL)|Virologic response at the end of treatment (EOT) defined as undetectable HCV RNA serum levels (50 IU/ml) at the end of the scheduled treatment period|sustained virologic response (primary) histological response (secondary) biochemical response (secondary)","https://ClinicalTrials.gov/show/NCT00277862"
370,"NCT01341106","Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection","Terminated","No Results Available","Hepatitis B, Chronic|Liver Fibrosis","Drug: Treatment with entecavir(Baraclude¬Æ)","RWTH Aachen University|Hannover Medical School|Hannover Clinical Trial Center GmbH","Both","Adult|Senior","Phase 4","7","Other","Interventional","Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label","CTC-A 11-018|2010-019884-12|11-018","April 20, 2011","April 2011","April 2015","September 22, 2015","September 2015","No Study Results Posted","INFIRE","January 2015","Changes of liver stiffness measurement (LSM) and hyaluronan measurement in blood|Changes on Pro-Collagen-III-N-Peptid, Tissue Inhibitor of Metalloproteinases (TIMP-1) and Chitinase-3-like protein 1(YKL-40) in serum|Sensitivity and specificity of non-invasive marker at the baseline in comparison to liver biopsy as a gold standard|Changes on FibroScan-measurement (LSM) and serum parameter|Decrease of hepatitis B virus-DNA and quota of patients with non-detectable hepatitis B virus-DNA at separate timepoints.|Quota of patients with normalization of Alanine transaminase(ALT)-measurement in blood at separate timepoints|Quota of patients with hepatitis B viral protein loss, antibodies to the the hepatitis B 'e' antigen seroconversion, surface antigen of the Hepatitis-B-Virus loss and antibodies to the hepatitis B core antigen seroconversion at separate timepoints|Incidence of side effects","https://ClinicalTrials.gov/show/NCT01341106"
371,"NCT01431898","Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C","Drug: GS-9669 tablets|Drug: Placebo to Match GS-9669 tablet","Gilead Sciences","Both","Adult","Phase 1","82","Industry","Interventional","Primary Purpose: Treatment|Masking: Single Blind (Subject)","GS-US-257-0102","September 1, 2011","September 2011","May 2012","July 23, 2012","March 2012","No Study Results Posted","null","December 2011","Safety and Tolerability|Antiviral Activity|Viral Dynamics and Pharmacodynamics|composite of Pharmacokinetics|Genotypic Changes","https://ClinicalTrials.gov/show/NCT01431898"
372,"NCT02139722","Patient-Centered Care and Asian Americans","Active, not recruiting","No Results Available","Hepatitis B|Hepatitis C|Liver Disease","Behavioral: Video Doctor, PA + PPN","University of California, San Francisco|San Francisco General Hospital|San Francisco Hep B Free Campaign","Both","Adult|Senior","","416","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Screening|Masking: Double Blind (Investigator, Outcomes Assessor)","AD-11-4615","May 6, 2014","September 2013","August 2016","May 13, 2014","May 2014","No Study Results Posted","null","August 2016","EHR-documented hepatitis B surface antigen (HBsAg) test|Knowledge about hepatitis B virus (HBV) and hepatitis C virus (HCV)","https://ClinicalTrials.gov/show/NCT02139722"
373,"NCT00403533","Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus","Completed","No Results Available","Hepatitis C","Drug: 20 mg of atorvastatin daily","Massachusetts General Hospital","Both","Adult|Senior","Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","2006-P-000138/1|AASLD advanced hepato. grant","November 21, 2006","February 2006","July 2006","November 22, 2006","November 2006","No Study Results Posted","null","null","Paired comparison of pretreatment viral load to post-treatment 12 week viral load|Paired comparison of pretreatment viral load to post-treatment 4 week viral load","https://ClinicalTrials.gov/show/NCT00403533"
374,"NCT01890083","A Health Intervention to Prevent Depression Hepatitis C Patients","Terminated","No Results Available","Hepatitis C|Major Depressive Disorder","Behavioral: Exercise|Behavioral: Health Education","University of Texas Southwestern Medical Center","Both","Adult","Phase 2|Phase 3","1","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor)","K01MH097847","June 5, 2013","June 2013","December 2016","October 23, 2015","October 2015","No Study Results Posted","null","June 2016","Change in Depressive Symptoms over 6 months|Change in Sleep Quality over 6 months|Change in blood biomarkers over 6 months","https://ClinicalTrials.gov/show/NCT01890083"
375,"NCT01429155","Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B","Completed","No Results Available","Hepatitis C","Genetic: Interleukin 28B genotype","Henry Ford Health System","Both","Adult|Senior","","36","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","6975","September 2, 2011","August 2011","March 2013","September 16, 2014","September 2014","No Study Results Posted","null","January 2013","Sustained virological response after living donor liver transplant|Liver retransplantation","https://ClinicalTrials.gov/show/NCT01429155"
376,"NCT01097395","Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C Virus","Drug: ribavirin","University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","Adult|Senior","","15","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","08-1198|K23DK082621","March 30, 2010","February 2010","August 2015","August 6, 2015","August 2015","No Study Results Posted","null","August 2015","ribavirin AUC-12 variability|safety - absolute hemoglobin declines|efficacy - early and sustained virologic response","https://ClinicalTrials.gov/show/NCT01097395"
377,"NCT02075294","Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B","Completed","No Results Available","Hepatitis B, Chronic","Drug: Adefovir dipivoxil or Entecavir","Ying-Jie Ji|Beijing 302 Hospital","Both","Adult|Senior","","242","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","YNKT201313","February 27, 2014","January 2010","October 2012","October 26, 2014","October 2014","No Study Results Posted","null","October 2012","the rates of serum HBVDNA undetectable and Renal dysfunction|the rate of normalisation of ALT|the rate of HBsAg negative|the rate of HBeAg seroconversion|the rate of HBeAg negative","https://ClinicalTrials.gov/show/NCT02075294"
378,"NCT01023230","A Study to Assess DV-601 in Subjects With Chronic Hepatitis B","Completed","No Results Available","Hepatitis B, Chronic","Drug: DV-601|Drug: Entecavir","Dynavax Technologies Corporation","Both","Adult","Phase 1","14","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","DV4-HBT-02|2009-010142-66","November 30, 2009","September 2009","May 2011","August 19, 2015","August 2015","No Study Results Posted","null","May 2011","Patient diaries, adverse events, physical exams, and lab tests|HBV-DNA levels","https://ClinicalTrials.gov/show/NCT01023230"
379,"NCT01014845","Clinical Trial of Recombinant Hepatitis E Vaccine","Active, not recruiting","No Results Available","Hepatitis E","Biological: hepatitis E vaccine|Biological: Hepatitis B vaccine","Xiamen University|Xiamen Innovax Biotech Co., Ltd|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.|National Institute of Diagnostics and Vaccine Development in infectious disease|Jiangsu Provincial Center for Disease Control and Prevention","Both","Child|Adult","Phase 3","112604","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","Pro-HE-003|2006AA02A209","November 13, 2009","August 2007","June 2017","February 21, 2014","February 2014","No Study Results Posted","null","June 2017","Rate of confirmed hepatitis E cases|IgG anti-HEV seroconversion rate|Persistency of IgG anti-HEV","https://ClinicalTrials.gov/show/NCT01014845"
380,"NCT01777074","Acceptability of Hepatitis B Vaccination in General Practitioners and Paediatricians","Completed","No Results Available","Hepatitis B","Other: Data collection","GlaxoSmithKline","Both","Child|Adult|Senior","","474","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","113385","January 24, 2013","November 2009","April 2012","January 31, 2013","January 2013","No Study Results Posted","PRALINE","April 2012","Change in the proportion of physicians with at least 50% of infants immunized against Hepatitis B.|Type of physicians, based on the questionnaire regarding immunization practices and established at each measurement time point.","https://ClinicalTrials.gov/show/NCT01777074"
381,"NCT00917358","Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: Pegylated interferon alfa-2a","National Taiwan University Hospital|National Science Council, Taiwan","Both","Adult","Phase 4","42","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","940215","June 8, 2009","July 2005","June 2008","December 19, 2012","December 2012","No Study Results Posted","null","June 2008","Sustained virologic response (SVR)","https://ClinicalTrials.gov/show/NCT00917358"
382,"NCT00187473","Natural History of Hepatitis C in Patients With Normal Liver Tests","Active, not recruiting","No Results Available","Chronic Hepatitis C","Procedure: liver biopsy","University of California, San Francisco","Both","Adult|Senior","","92","Other","Observational","Observational Model: Cohort","H10102-17633","September 13, 2005","June 2000","null","July 18, 2014","July 2014","No Study Results Posted","null","December 2014","ALT","https://ClinicalTrials.gov/show/NCT00187473"
383,"NCT01065363","Health Promotion and Management for Hepatitis B Carriers","Active, not recruiting","No Results Available","Chronic Hepatitis B","Behavioral: standardized exercise program and dietary counseling","National Taiwan University Hospital|National Taiwan University","Both","Adult|Senior","","160","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","200906036R","February 8, 2010","August 2009","December 2010","February 8, 2010","February 2010","No Study Results Posted","null","July 2010","Reduction of relative serum HBV DNA levels|anthropometric index","https://ClinicalTrials.gov/show/NCT01065363"
384,"NCT01341743","Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy","Active, not recruiting","No Results Available","Hepatitis B","Drug: Entecavir|Drug: Entecavir, Adefovir|Drug: Entecavir, Adefovir","Nanfang Hospital of Southern Medical University|JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd","Both","Adult","Phase 4","360","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","MOH-04","February 16, 2011","December 2010","December 2014","October 28, 2013","September 2013","No Study Results Posted","null","June 2014","proportion of subjects with hepatitis B virus (HBV)DNA<300copies/ml at week 104|serum HBV DNA reduction from baseline at week 104|The proportion of subjects with ALT normalization at week 104|The proportion of subjects with HBeAg loss and seroconversion at week 104|The proportion of subject with HBsAg loss and seroconversion at week 104|The proportion of subjects with mutations of rtN236T/A181V, rtL180M/rtM204V/rtT184/rtS202 and/or rtM250 at week 104","https://ClinicalTrials.gov/show/NCT01341743"
385,"NCT00621296","Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C","Completed","Has Results","Hepatitis C","Drug: MP-424 (Telaprevir)","Mitsubishi Tanabe Pharma Corporation|Vertex Pharmaceuticals Incorporated","Both","Adult|Senior","Phase 2","15","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","G060-A7","February 12, 2008","January 2008","February 2009","April 16, 2014","April 2014","September 19, 2012","null","February 2009","Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration","https://ClinicalTrials.gov/show/NCT00621296"
386,"NCT00291980","A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.","Completed","No Results Available","Hepatitis B","Biological: HB-AS02V vaccine|Biological: HBVAXPRO vaccine","Henogen|GlaxoSmithKline","Both","Child|Adult|Senior","Phase 3","185","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","HN018/HBV-004 (105754)","February 14, 2006","March 2006","October 2007","August 27, 2008","August 2008","No Study Results Posted","null","October 2007","Anti-HBs antibody geometric mean concentrations.|Seroprotection rates for all subjects|Seropositivity rates for all subjects|Percentage of subjects with anti-HBs antibody concentrations superior or equal to 100 mIU/ml for all subjects|Geometric Mean Concentration of anti-HBs antibodies for all subjects and for seropositive subjects|Occurrence and intensity of solicited local signs and symptoms, relationship to vaccination of solicited general signs and symptoms during the 4-day follow-up after vaccination|Occurrence, intensity and relationship to vaccination of unsolicited local and general signs and symptoms during the 31-day (Day 0 to Day 30) follow-up period after vaccination|Occurrence, intensity and relationship to vaccination of all serious adverse events up to Month 1","https://ClinicalTrials.gov/show/NCT00291980"
387,"NCT01421212","Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation","Completed","No Results Available","Hepatitis B Virus (HBV) Associated Liver Disease.","Biological: Hepatitis B Immune Globulin (Boca HBVIg)","Biotest Pharmaceuticals Corporation","Both","Adult|Senior","Phase 1|Phase 2","30","Industry","Interventional","Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","Nabi-4204","August 18, 2011","November 1999","February 2002","August 19, 2011","August 2011","No Study Results Posted","null","February 2002","Number of hepatitis B virus positive liver transplant recipients with no hepatitis B virus recurrence after liver transplantation.|Number of participants who maintain a protective trough titer of anti hepatitis B antibodies beginning at 12 weeks post liver transplantation.|Change in anti hepatitis B antibodies levels with administration of Boca hepatitis B immune globulin concomitantly with Lamivudine.","https://ClinicalTrials.gov/show/NCT01421212"
388,"NCT01567540","A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients","Terminated","No Results Available","Hepatitis C","Drug: Sitagliptin","Institut National de la Sant√© Et de la Recherche M√©dicale, France","Both","Adult|Senior","Phase 1","3","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","C10-54|2011-000823-34","March 2, 2012","March 2013","January 2014","January 17, 2014","January 2014","No Study Results Posted","null","January 2014","Safety (Number of adverse events, Toxicity grade > 3)|Change in Viral Load as compared to baseline|Metabolic studies: Oral glucose tolerance will be assessed|Immunologic study","https://ClinicalTrials.gov/show/NCT01567540"
389,"NCT00845403","Antigen-specific Immune Response to Hepatitis B Virus in Utero","Recruiting","No Results Available","Hepatitis B","","National University Hospital, Singapore","Female","Adult","","60","Other","Observational","Time Perspective: Prospective","DSRB D/08/376","February 16, 2009","September 2008","December 2016","January 10, 2014","January 2014","No Study Results Posted","null","December 2016","Anti - viral immune response in cord blood of newborn infants born to HBV+ mothers|Expression of immune genes from immune cells","https://ClinicalTrials.gov/show/NCT00845403"
390,"NCT01434212","Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy","Active, not recruiting","No Results Available","Hepatitis","Drug: Interferon Alfa-2b, Ribavirin","First Hospital of Jilin University|Chinese Academy of Sciences","Both","Adult|Senior","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2008ZX10004-002-jida01|2008ZX10002-014-jida01|2009ZX10004-105-jida01","September 8, 2011","May 2010","December 2011","October 27, 2011","October 2011","No Study Results Posted","sIFN-pred1","December 2011","Blood HCV RNA Copies|IL-28B polymorphism|Microarray Analysis of PBMC Gene Expression|HCV genotype|Blood Anti-HCV,HBV Antibody|HCV genome sequencing|Alanine Aminotransferase (ALT) and Aspartate transaminase (AST)|Fibrosis stage|Regular blood test|Electrocardiography|Alcohol ,smoking condition|Drug abuse history","https://ClinicalTrials.gov/show/NCT01434212"
391,"NCT00194480","Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users","Completed","No Results Available","Substance-Related Disorders|Hepatitis","Drug: Pegylated Interferon","National Institute on Drug Abuse (NIDA)|University of Washington","Both","Child|Adult|Senior","Phase 4","21","NIH|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","NIDA-16066-1|R21 DA016066-01","September 12, 2005","April 2003","June 2007","October 24, 2008","October 2008","No Study Results Posted","null","December 2006","Sustained viral response rate in treatment group versus control (measured at Week 24)|Adherence rate in the treatment group (measured at Week 24)","https://ClinicalTrials.gov/show/NCT00194480"
392,"NCT01195987","Immune Dysregulation in Hepatitis C Patients With or Without Arthritis","Recruiting","No Results Available","Hepatitis C Patients","","The Center for Rheumatic Disease, Allergy, & Immunology|St Luke's Hospital","Both","Adult|Senior","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","09-290","September 3, 2010","June 2010","August 2011","September 7, 2010","September 2010","No Study Results Posted","null","August 2011","","https://ClinicalTrials.gov/show/NCT01195987"
393,"NCT01782794","Acceptability of Hepatitis B Vaccination in General Population","Completed","No Results Available","Hepatitis B","Other: Data collection","GlaxoSmithKline","Both","Child","","2413","Industry","Observational","Observational Model: Family-Based|Time Perspective: Cross-Sectional","113269","January 24, 2013","May 2009","June 2012","January 31, 2013","January 2013","No Study Results Posted","PopCorn","June 2012","Proportion of infants receiving Hepatitis B vaccination.|Evaluation of the immunization coverage levels by other vaccines.|Acceptability of vaccinating against Hepatitis B.","https://ClinicalTrials.gov/show/NCT01782794"
394,"NCT00560690","The Effect of Adding Metformin to the Treatment of Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: Metformin|Drug: pegylated interferon|Drug: Ribavirin","Tehran University of Medical Sciences","Both","Child|Adult","Phase 4","140","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","83/53","November 19, 2007","December 2007","December 2010","April 2, 2015","April 2015","No Study Results Posted","null","September 2010","Sustained viral response, defined as undetectable virus RNA 6 months after end of treatment|adverse effects leading to discontinuation of treatment|Rapid viral response, defined as undetectable viral RNA one month after start of treatment|Early viral response, defined as undetectable viral RNA or 2 log drop in viral count three month after start of treatment","https://ClinicalTrials.gov/show/NCT00560690"
395,"NCT00139139","A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis A","Completed","No Results Available","Hepatitis A","Biological: Hepatitis A vaccine","Centers for Disease Control and Prevention|University of Michigan|Ministry of Health, Kazakhstan","Both","Child|Adult","","1500","U.S. Fed|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Double-Blind","CDC-NCID-2643|ASPHS196421/21","August 29, 2005","September 2003","May 2005","August 29, 2005","August 2005","No Study Results Posted","null","null","clincal hepatitis A disease|1) subclinical hepatitis A|2) asymptomatic hepatitis A virus infection, with hepatitis A virus viremia","https://ClinicalTrials.gov/show/NCT00139139"
396,"NCT00876174","Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C","Terminated","No Results Available","Chronic Hepatitis C","Procedure: Blood sampling of peripheral blood mononuclear cells|Procedure: Blood draw, 20ml peripheral blood mononuclear cells","University of Nebraska","Both","Adult|Senior","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","143-09-EP","April 2, 2009","May 2009","January 2010","January 11, 2010","January 2010","No Study Results Posted","null","null","To investigate the prognostic criteria for sensitivity of Chronic Hepatitis C patients to interferon alpha treatment|To determine the effects of antiviral treatment on interferon gene signaling in peripheral blood mononuclear cells","https://ClinicalTrials.gov/show/NCT00876174"
397,"NCT01292824","Pilot Study of Hepatitis C Virus Entry Inhibitor (ITX 5061) in Liver Transplant Recipients","Completed","No Results Available","Hepatitis C|Evidence of Liver Transplantation","Drug: ITX 5061","University of Birmingham|University Hospital Birmingham|National Institute for Health Research, United Kingdom","Both","Adult","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","RG_10-104|2010-020358-32","February 9, 2011","February 2011","May 2013","October 10, 2013","October 2013","No Study Results Posted","null","January 2013","To determine the safety of ITX 5061 in liver transplant recipients|To determine whether treatment leads to an alteration in HCV RNA kinetics in the first week after liver transplantation|To determine whether any change in early viral kinetics is sustained","https://ClinicalTrials.gov/show/NCT01292824"
398,"NCT00718172","Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic","Procedure: Liver Biopsy|Drug: Peginterferon & amp; Ribavirin for Hepatitis C|Drug: Pre-treatment Ribavirin","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 1","81","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","080182|08-DK-0182","July 16, 2008","July 2008","August 2014","August 20, 2014","August 2014","No Study Results Posted","null","null","Improved viral kinetics with ribavirin pretreatment.|Changes in gene expression during peginterferon and/or ribavirin thereapy, effect of treatment on NK cell function.","https://ClinicalTrials.gov/show/NCT00718172"
399,"NCT00096785","Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection","Completed","Has Results","Hepatitis B|Chronic Disease","Drug: entecavir|Drug: adefovir","Bristol-Myers Squibb","Both","Child|Adult|Senior","Phase 3","69","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","AI463-079","November 15, 2004","December 2004","April 2008","August 4, 2010","June 2010","July 2, 2009","null","January 2006","Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12|Change From Baseline in HBV DNA by PCR Assay at Week 48|Viral Load Undetectable (HBV DNA <300 Copies/mL)|Alanine Aminotransferase (ALT) Normalization|HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Efficacy in Blocking Virus Production and de Novo Infections|HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Viral Clearance Rate and Infected Cell Death Rate|HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Half-Life of Free Virus|HBV DNA Viral Kinetics - Spline Model|Summary of Safety - Most Frequent (> 10%) Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Deaths|Summary of Safety - Laboratory Abnormalities Reported as Clinical AEs","https://ClinicalTrials.gov/show/NCT00096785"
400,"NCT00119119","Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C","Terminated","No Results Available","Hepatitis C, Chronic|Liver Fibrosis","Drug: pentoxyphilline|Drug: tocopherol","French National Agency for Research on AIDS and Viral Hepatitis","Both","Adult|Senior","Phase 3","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","ANRSHC10 PENTO","July 4, 2005","February 2002","December 2006","January 11, 2007","January 2007","No Study Results Posted","null","null","Variation of the percentage of liver fibrosis evaluated with morphometric analysis between the liver biopsies performed at the end and before the trial (defined as significant if over 5 percent).|Variation of fibrosis Metavir score between the two biopsies|Variation of activity Metavir score between the two biopsies|Variation of liver markers of fibrosis : hyaluronate, N-terminal peptide of procollagen III, TNF-alfa and fibrotest|Variation of ALT","https://ClinicalTrials.gov/show/NCT00119119"
401,"NCT00275938","Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: interferon alpha 2b plus ribavirin|Drug: interferon alpha 2b plus placebo","National Taiwan University Hospital|Schering-Plough","Both","Adult","Phase 2|Phase 3","120","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","145R3","January 11, 2006","October 1998","June 2001","January 11, 2006","January 2006","No Study Results Posted","null","null","Undetected serum HBV DNA level (i.e. less than 2.5 pg/ml) at the end of the 24-week follow-up period|HBV DNA level at the end of treatment|clearance of HBeAg and rate of ALT normalization both at the end of the 32-week treatment period and at the end of the 24-week follow-up","https://ClinicalTrials.gov/show/NCT00275938"
402,"NCT01094873","Study of a Novel Therapeutic Vaccine for Hepatitis C Virus","Completed","No Results Available","Hepatitis C","Biological: AdCh3NSmut|Biological: Ad6NSmut","ReiThera Srl|University of Oxford","Both","Adult","Phase 1","35","Industry|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HCV002TV|2008-006127-32|GTAC162","March 25, 2010","November 2009","April 2013","April 22, 2015","August 2013","No Study Results Posted","null","April 2013","Safety and immunogenicity","https://ClinicalTrials.gov/show/NCT01094873"
403,"NCT01100749","Chronic Hepatitis C (CHC) - Genotype 3 Infection in Canada","Terminated","No Results Available","Chronic Hepatitis C - Genotype 3","","University Health Network, Toronto","Both","Adult|Senior","","25","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Geno3-Demographics Study","April 7, 2010","February 2010","June 2013","May 27, 2015","May 2015","No Study Results Posted","null","June 2013","Factors associated with treatment outcome in genotype 3 in CHC","https://ClinicalTrials.gov/show/NCT01100749"
404,"NCT00910975","Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C","Completed","No Results Available","Chronic Hepatitis C, Genotype 1","Drug: Peg-interferon-alfa2a (Pegasys)|Drug: Ribavirin (Copegus)","G√∂teborg University|Sahlgrenska University Hospital, Sweden|Sodra Alvsborgs Hospital|Skaraborg Hospital|Uddevalla Hospital|Skane University Hospital|Lund University Hospital|Karolinska University Hospital","Both","Adult|Senior","Phase 4","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","TTG1_081119","May 28, 2009","November 2007","September 2011","September 3, 2012","September 2012","No Study Results Posted","TTG1","June 2010","Medication dose per cured patient|Sustained virological response and relapse rate","https://ClinicalTrials.gov/show/NCT00910975"
405,"NCT01726400","In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia","Recruiting","No Results Available","Hepatitis C","Drug: Pegylated interferon alpha|Drug: Ribavirin","Fremantle Hospital and Health Service","Both","Adult|Senior","","30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HEPCIDIN-11/225","November 9, 2012","December 2012","July 2014","March 7, 2013","March 2013","No Study Results Posted","null","January 2014","Hepcidin levels|iron metabolism markers|heamolysis markers|inosine triphosphatase genetic variants|erythropoiesis markers","https://ClinicalTrials.gov/show/NCT01726400"
406,"NCT01796457","HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B","Recruiting","No Results Available","Hepatitis B","","University of Pittsburgh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","Adult|Senior","","165","Other|NIH","Observational","Time Perspective: Prospective","DK082864 Immunology Treatment|U01DK082864","February 19, 2013","March 2013","March 2018","March 4, 2015","March 2015","No Study Results Posted","null","March 2016","Immune regulatory and effector responses relative to HBV DNA, ALT and clinical outcome","https://ClinicalTrials.gov/show/NCT01796457"
407,"NCT00146016","Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients","Completed","No Results Available","Chronic Hepatitis C","Drug: Amantadine","UMC Utrecht","Both","Adult|Senior","Phase 3","390","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","CIRA-study","September 1, 2005","February 2000","January 2007","September 1, 2005","September 2005","No Study Results Posted","null","null","Response rate at end of treatment and end of follow-up (sustained response rate)","https://ClinicalTrials.gov/show/NCT00146016"
408,"NCT02006823","Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","","Duke University","Both","Adult|Senior","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00035949","November 22, 2013","March 2012","July 2014","December 11, 2014","December 2014","No Study Results Posted","null","July 2014","Change in Self Management","https://ClinicalTrials.gov/show/NCT02006823"
409,"NCT00591214","Safety and PK Study of MP-424 to Treat Chronic Hepatitis C","Completed","Has Results","Chronic Hepatitis C","Drug: MP-424 (Telaprevir)","Mitsubishi Tanabe Pharma Corporation|Vertex Pharmaceuticals Incorporated","Both","Adult","Phase 1","10","Industry","Interventional","Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label","G060-A3","December 26, 2007","December 2007","October 2008","April 15, 2014","April 2014","September 19, 2012","null","October 2008","Cmax (Maximum Observed Concentration in Plasma) of MP-424|Tmax (Time of Maximum Plasma Concentration) of MP-424|AUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424|Ctrough (Plasma Trough Concentration) of MP-424|t1/2 (Half Life Period) of MP-424|Change in HCV RNA Levels of MP-424","https://ClinicalTrials.gov/show/NCT00591214"
410,"NCT02292719","A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection","Recruiting","No Results Available","Chronic Hepatitis C Virus Infection","Drug: Ombitasvir/ABT-450/r|Drug: Sofosbuvir|Drug: Ribavirin (RBV)","AbbVie","Both","Adult|Senior","Phase 2","70","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-567|2014-003147-35","November 13, 2014","December 2014","May 2017","October 16, 2015","October 2015","No Study Results Posted","null","May 2017","Percentage of participants with sustained virologic response 12 weeks (SVR12) post-treatment|Percentage of participants with on-treatment virologic failure|Percentage of participants with virologic relapse after treatment","https://ClinicalTrials.gov/show/NCT02292719"
411,"NCT02056548","Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy","Not yet recruiting","No Results Available","Lymphoma|Chronic Hepatitis B","","Seoul St. Mary's Hospital","Both","Adult|Senior","","126","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","CHSCTC-R01-HEPATO","February 3, 2014","March 2014","December 2018","February 4, 2014","February 2014","No Study Results Posted","null","December 2017","Cumulative incidence rate of hepatitis B viral reactivation|Severity of reactivation of hepatitis B","https://ClinicalTrials.gov/show/NCT02056548"
412,"NCT01360892","Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography","Recruiting","No Results Available","Chronic Hepatitis B|Chronic Hepatitis C","","Japan Liver Oncology Group","Both","Adult|Senior","","1000","Other","Observational","Time Perspective: Prospective","JLOG1003","May 21, 2011","September 2010","September 2013","May 24, 2011","August 2010","No Study Results Posted","PICTURE","August 2013","Cumulative incidence of carcinogenesis of hepatocellular carcinoma|Cancer-free survival|Overall survival|The cumulative incidence and severity of gastro-esophageal varices|The cumulative incidence and severity of decompensated cirrhosis","https://ClinicalTrials.gov/show/NCT01360892"
413,"NCT00209118","Paroxetine for the Treatment of Interferon Related Side Effects for Hepatitis C","Completed","No Results Available","Hepatitis C|Depression|Interferon-alpha Associated Side Effects","Drug: paroxetine","Emory University","Both","Adult","","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double-Blind","0112-1998","September 14, 2005","null","July 2005","January 27, 2015","January 2015","No Study Results Posted","null","null","Depressive Symptom Scores|Development of Major Depression|neurotoxicity|dosage reduction|discontinuation","https://ClinicalTrials.gov/show/NCT00209118"
414,"NCT00200746","Treatment of Alcohol-Related Hepatitis With Arginine","Withdrawn","No Results Available","Alcoholic Hepatitis","Drug: Arginine","National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS)","Both","Adult|Senior","Phase 2","0","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","R21 AT002394-01A1","September 12, 2005","April 2006","July 2009","March 11, 2013","March 2013","No Study Results Posted","null","July 2009","Percent reduction in liver endotoxin production|change in Maddrey's discriminant function (DF) score","https://ClinicalTrials.gov/show/NCT00200746"
415,"NCT00221650","Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients","Completed","No Results Available","HIV Infections|Hepatitis C, Chronic|Treatment Failure","Drug: Peginterferon alfa2a|Drug: Ribavirin","University Hospital, Bordeaux|Hoffmann-La Roche|Ministry of Health, France","Both","Adult","Phase 2","17","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","9232-01|2000-023","September 13, 2005","April 2002","June 2004","June 12, 2007","June 2007","No Study Results Posted","ROCO2","null","Proportion of patients with a sustained virological response, defined as an undetectable HCV RNA level|Proportion of patients with a virological response|Safety of treatment|Influence of anti-HCV treatment on CD4 count and HIV RNA|Proportion of patients with histological response 24 weeks after the end of anti-HCV treatment","https://ClinicalTrials.gov/show/NCT00221650"
416,"NCT01453244","Pharmacogenomic Research in Korean Patients With Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","","Inje University","Both","Adult|Senior","","373","Other","Observational","Observational Model: Cohort","11-037","October 13, 2011","July 2011","March 2013","May 30, 2013","May 2013","No Study Results Posted","null","March 2013","Sustained virological response (SVR)|Anemia","https://ClinicalTrials.gov/show/NCT01453244"
417,"NCT01850745","Multidisciplinary Support Program in Chronic Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic","Other: Multidisciplinary support program","Parc de Salut Mar","Both","Adult|Senior","","447","Other","Observational","Observational Model: Cohort","HMAR-MSP-CHC","May 7, 2013","January 2003","January 2010","May 7, 2013","May 2013","No Study Results Posted","null","January 2009","Adherence to treatment|Efficacy of treatment measured by sustained virological response","https://ClinicalTrials.gov/show/NCT01850745"
418,"NCT02065336","Study of ARC-520 in Patients With Chronic Hepatitis B Virus","Recruiting","No Results Available","Hepatitis B, Chronic","Drug: ARC-520|Drug: Placebo","Arrowhead Research Corporation|ICON Clinical Research","Both","Adult","Phase 2","58","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)","Heparc-2001","February 13, 2014","March 2014","April 2016","June 25, 2015","June 2015","No Study Results Posted","null","January 2016","Depth and duration of HBsAg reduction as a measure of efficacy","https://ClinicalTrials.gov/show/NCT02065336"
419,"NCT00686881","Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)","Terminated","Has Results","Hepatitis C, Chronic","Biological: Peginterferon alfa-2b (PegIFN-2b)|Drug: Comparator: Stronger neo minophagen C (SNMC)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 3","261","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P04773|JPC-05-356-30","May 27, 2008","December 2006","February 2011","September 4, 2015","September 2015","February 3, 2012","null","February 2011","Number of Participants With Change in Metavir Fibrosis Score|Number of Participants With Alanine Aminotransferase (ALT) Normalization of >16 Weeks Duration|Number of Participants With Change in Metavir Inflammation Score","https://ClinicalTrials.gov/show/NCT00686881"
420,"NCT00352235","Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection","Completed","No Results Available","Chronic Hepatitis C","Drug: KRN7000","Foundation for Liver Research|Kyowa Hakko Kirin Company, Limited","Both","Adult|Senior","Phase 1|Phase 2","36","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double-Blind","KRN7000 HCV","July 13, 2006","August 2003","May 2005","July 13, 2006","July 2006","No Study Results Posted","null","null","Decrease in serum hepatitis C virus ribonucleic acid (HCV RNA) levels.|Normalization of serum ALT levels.|Effect on serum cytokines IFNg and TNFa and on iNKT cells.","https://ClinicalTrials.gov/show/NCT00352235"
421,"NCT00921180","Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B","Recruiting","No Results Available","Hepatitis B, Chronic","Drug: Entecavir and peginterferon alfa-2a|Drug: Placebo and peginterferon","National Taiwan University Hospital|National Science Council, Taiwan","Both","Adult|Senior","Phase 4","148","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","950922","June 15, 2009","February 2007","December 2013","December 19, 2012","December 2012","No Study Results Posted","null","December 2013","HBeAg seroconversion rate 6 months after the cessation of therapy","https://ClinicalTrials.gov/show/NCT00921180"
422,"NCT00917761","Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B","Recruiting","No Results Available","Hepatitis B, Chronic","Drug: Entecavir and peginterferon (Pegasys) (52 weeks)|Drug: Peginterferon (Pegasys) (96 weeks)|Drug: Peginterferon (Pegasys) (48 weeks)","National Taiwan University Hospital|National Science Council, Taiwan","Both","Adult|Senior","Phase 4","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","950924","June 8, 2009","February 2007","December 2013","December 19, 2012","December 2012","No Study Results Posted","null","December 2013","HBV virologic response (HBV DNA < 2,000 IU/mL) 6 months after the cessation of treatment|ALT normalization rate (ALT < 40 IU/L) 6 months after the cessation of treatment","https://ClinicalTrials.gov/show/NCT00917761"
423,"NCT00151580","Treatment of Recurrent Hepatitis C After Liver Transplantation","Completed","No Results Available","Liver Transplantation|Hepatitis C","Drug: Ribavirin|Drug: Placebo","Rennes University Hospital|Ministry of Health, France|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)","Both","Adult|Senior","Phase 3","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Diagnostic|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","AFSSAPS 010588|PHRC/00-02|CIC0203/049","September 8, 2005","February 2002","July 2006","May 18, 2012","November 2007","No Study Results Posted","TRANSPEG","null","Negative viral PCR|Histological improvement|Biological hepatic markers|Quality of life|Intensity, severity and delay to acute transplant rejection, histologically proven|Incidence of death or graft loss|Number of patients stopping the treatment and causes|Incidence of adverse events classically related to treatment|Incidence of adverse events possibly related to treatment","https://ClinicalTrials.gov/show/NCT00151580"
424,"NCT00871845","Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients","Recruiting","No Results Available","Obesity|Insulin Resistance|Metabolic Syndrome|Hepatitis C","Drug: Orlistat|Behavioral: Dietary and Lifestyle modification educational sessions","University of Pittsburgh","Both","Adult|Senior","Phase 4","222","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","PRO07090035","March 26, 2009","September 2008","December 2011","March 26, 2009","March 2009","No Study Results Posted","null","December 2011","HCV RNA|Body weight|waist circumference|skin fold thickness|HOMA, IR","https://ClinicalTrials.gov/show/NCT00871845"
425,"NCT00097045","Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: omega interferon|Drug: Ribavirin","Intarcia Therapeutics","Both","Adult","Phase 2","90","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","Biomed 510-CLP-07","November 17, 2004","November 2004","December 2006","August 21, 2007","August 2007","No Study Results Posted","null","null","HCV RNA levels at clinically relevant timepoints","https://ClinicalTrials.gov/show/NCT00097045"
426,"NCT00348660","Screening for Hepatitis C During Pregnancy at a Toronto Inner City Prenatal Clinic","Active, not recruiting","No Results Available","Hepatitis C|Pregnancy","","St. Michael's Hospital, Toronto","Female","Child|Adult","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REB 04-095","June 30, 2006","August 2005","June 2012","September 2, 2011","December 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00348660"
427,"NCT00788918","Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)","Completed","No Results Available","Hepatitis C, Chronic|Cognition Disorders|Fatigue Syndrome, Chronic|Major Depressive Disorder","Drug: Interferon and ribavirin","Aarhus University Hospital|University of Aarhus","Both","Adult","","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","SKS-0078-HCVCNS|EudraCT 2007-005707-18","November 10, 2008","November 2008","November 2012","January 10, 2013","January 2013","No Study Results Posted","null","November 2012","Neuropsychological test results, cytokine profile and MRI findings|Interferon-induced depression","https://ClinicalTrials.gov/show/NCT00788918"
428,"NCT00433108","Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: Mitoquinone mesylate (MitoQ)","Antipodean Pharmaceuticals, Inc.","Both","Adult","Phase 2","30","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","MTQ-HC-001","February 7, 2007","March 2007","November 2007","August 12, 2008","August 2008","No Study Results Posted","null","null","Change in serum ALT concentration at Day 28 compared with baseline|Efficacy: Change in AST at Day 28 compared with baseline, change in HCV RNA viral load, plasma Mitoquinone concentration for population pharmacokinetics|Safety: Adverse events, vital signs, ECG, lab tests (biochemistry, hematology, urinalysis)","https://ClinicalTrials.gov/show/NCT00433108"
429,"NCT00132210","Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients","Completed","No Results Available","Hepatitis C|HIV Infections","Drug: pegylated interferon","University Hospital, Bonn","Both","Adult","Phase 4","200","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","BN-102/02","August 17, 2005","September 2002","June 2010","October 20, 2010","November 2009","No Study Results Posted","null","June 2010","Negative hepatitis C ribonucleic acid (HCV-RNA) in peripheral serum|Normal liver enzymes|Negative HCV-RNA","https://ClinicalTrials.gov/show/NCT00132210"
430,"NCT00988767","Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Biological: DNA vaccine","Institut National de la Sant√© Et de la Recherche M√©dicale, France","Both","Adult","Phase 1","10","Other","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","INSERM RBM99.026","October 1, 2009","February 2001","October 2004","October 2, 2009","October 2009","No Study Results Posted","RBM99026","November 2003","Safety and tolerability (local and general) of the DNA vaccine injections|Immunological responses","https://ClinicalTrials.gov/show/NCT00988767"
431,"NCT00158496","Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)","Completed","No Results Available","Chronic Hepatitis C","Drug: pegylated interferon alpha2a|Drug: ribavirin","French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche","Both","Adult","Phase 3","100","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ANRS 1211","September 8, 2005","August 2002","January 2005","April 23, 2007","April 2007","No Study Results Posted","null","null","- Disappearance of HCV RNA by qualitative PCR 24 weeks after the end of treatment|Evaluation of HCV RNA at 12 and 24 weeks|changes in HCV RNA load during treatment|Normalization of ALT during treatment and 24 weeks after the end of treatment|Study of side effects|Histological changes 24 weeks after the end of treatment (decrease by at least 1 point of the Metavir score)","https://ClinicalTrials.gov/show/NCT00158496"
432,"NCT00249860","A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects","Completed","No Results Available","Hepatitis C","Drug: Interferon-beta-1a|Drug: Placebo|Drug: Ribavirin plus Interferon-beta-1a","EMD Serono|Merck Pte. Ltd., Singapore","Both","Adult","Phase 3","257","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","23744","November 4, 2005","September 2002","August 2005","August 4, 2013","August 2013","No Study Results Posted","null","August 2005","Percentage of subjects achieving sustained viral response (SVR) at Week 24|Percentage of subjects achieving sustained viral response (SVR) at Week 48|Change from baseline in viral load (Hepatitis C virus ribonucleic acid [HCV RNA]) at Week 12, 24, and 48|Percentage of subjects with Alanine transaminase (ALT) normalization|Percentage of subjects with viral clearance|Percentage of subjects with both SVR and sustained ALT normalization|Number of subjects with improvement in the liver necroinflammation score by at least two points|Number of subjects with improvement in architectural staging (liver fibrosis) by at least one point|Number of subjects with adverse events and serious adverse events","https://ClinicalTrials.gov/show/NCT00249860"
433,"NCT01298037","HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B","Recruiting","No Results Available","Hepatitis B","","University of Pittsburgh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","Adult|Senior","","300","Other|NIH","Observational","Time Perspective: Prospective","DK082864 HBRN Immunology|U01DK082864","February 15, 2011","February 2011","May 2015","February 11, 2015","February 2015","No Study Results Posted","null","May 2015","Immune regulatory and activation measures","https://ClinicalTrials.gov/show/NCT01298037"
434,"NCT00004850","Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection","Recruiting","No Results Available","Hepatitis C","","National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","","1000","NIH","Observational","","910117|91-CC-0117","March 2, 2000","April 1991","null","November 22, 2014","November 2014","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004850"
435,"NCT01037621","Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C","Active, not recruiting","No Results Available","Hepatitis C Virus Infection|Infection|Herpesvirus 2, Human","Drug: Valacyclovir","G.V. (Sonny) Montgomery VA Medical Center","Both","Adult|Senior","Phase 1","50","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","VAL R 152|2009-00348","December 22, 2009","April 2010","February 2012","November 4, 2011","November 2011","No Study Results Posted","null","February 2012","The number of study participants who experience adverse events while receiving valacyclovir.|The effect of valacyclovir compared with placebo to serum levels of HCV RNA","https://ClinicalTrials.gov/show/NCT01037621"
436,"NCT01545544","Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)","Active, not recruiting","No Results Available","Chronic Hepatitis C","","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)","Both","Adult|Senior","","138","Other","Observational","Observational Model: Case-Only","ANRS HC13 Lympho C","February 21, 2012","November 2006","November 2014","February 6, 2014","June 2013","No Study Results Posted","Lympho C","November 2014","presentation of NHL and HCV infection, and treatments of NHL and HCV infection|Summary of intercurrents biological and clinical events|virological response|haematological response","https://ClinicalTrials.gov/show/NCT01545544"
437,"NCT01070407","A Study of a New Candidate Vaccine Against Hepatitis C Virus (HCV)","Completed","No Results Available","Hepatitis C","Biological: Ad6NSmut; AdCh3NSmut|Biological: Ad6NSmut; AdCh3NSmut|Biological: Ad6NSmut; AdCh3NSmut|Biological: AdCh3NSmut; Ad6NSmut|Biological: AdCh3NSmut; Ad6NSmut|Biological: AdCh3NSmut; Ad6NSmut|Biological: Ad6NSmut; AdCh3NSmut|Biological: AdCh3NSmut; Ad6NSmut|Biological: AdCh3NSmut; Ad6NSmut","ReiThera Srl|University of Oxford","Both","Adult","Phase 1","41","Industry|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","HCV001|2007-004259-12|GTAC144","February 16, 2010","July 2007","February 2011","April 22, 2015","April 2015","No Study Results Posted","null","August 2010","To assess the safety of AdCh3NSmut and Ad6NSmut, when administered in a prime/boost regimen to healthy volunteers. The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events.|To assess the immunogenicity of AdCh3NSmut and Ad6NSmut, when administered in prime/boost regimen to healthy volunteers. The specific endpoint of cellular immune response will be collected via IFNŒ≥ ELIspot assay and other exploratory immunological tests.","https://ClinicalTrials.gov/show/NCT01070407"
438,"NCT02189603","Phase ‚Ö£ Clinical Trial of Recombinant Hepatitis E VaccineÔºàHecolin¬ÆÔºâ","Recruiting","No Results Available","Hepatitis E","Biological: Recombinant (E. Coli) Hepatitis E Vaccine","Jun Zhang|Xiamen Innovax Biotech Co., Ltd|Xiamen Center for Disease Control and Prevention|Xiamen University","Both","Child|Adult|Senior","Phase 4","600","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","PRO-HE-05","July 9, 2014","June 2014","February 2015","July 10, 2014","July 2014","No Study Results Posted","null","December 2014","Number of Participants with Serious and Non-Serious Adverse Events|anti-HEV IgG seropositive rate|GMT of anti-HEV IgG","https://ClinicalTrials.gov/show/NCT02189603"
439,"NCT00418639","Study of Nitazoxanide in the Treatment of Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: Nitazoxanide","Romark Laboratories L.C.","Both","Adult|Senior","Phase 2","50","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","RM01-3027","January 3, 2007","February 2005","null","January 3, 2007","January 2007","No Study Results Posted","null","null","Virologic response|Sustained virologic response|Quantitative serum HCV RNA|Changes in ALT","https://ClinicalTrials.gov/show/NCT00418639"
440,"NCT01970254","Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy","Recruiting","No Results Available","Cancer|Hepatitis B|HBV","Other: HBV screening tests|Behavioral: HBV risk assessment survey","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","Both","Adult|Senior","","3441","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2012-0961|1R21CA167202-01A1","October 22, 2013","June 2013","null","August 17, 2015","August 2015","No Study Results Posted","null","December 2017","Rate of a positive result (HBsAg, anti-HBc, and anti-HBs) before first chemotherapy","https://ClinicalTrials.gov/show/NCT01970254"
441,"NCT00643695","Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis C","Enrolling by invitation","No Results Available","Hepatitis C|Depression","Behavioral: Home-based walking program|Other: Educational intervention","Portland VA Medical Center","Both","Adult|Senior","","56","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","02101","March 20, 2008","March 2008","null","March 20, 2008","March 2008","No Study Results Posted","null","June 2010","Reduction of symptoms of depression as measured by the Beck Depression Inventory II (BDI-II)|Reduction in symptoms of fatigue as measured by the Brief Fatigue Inventory (BFI)|reduce the reported level of chronic pain","https://ClinicalTrials.gov/show/NCT00643695"
442,"NCT02568540","C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study","Recruiting","No Results Available","Hepatitis C","","Children's Hospital Boston","Both","Adult|Senior","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P00018023","October 2, 2015","October 2015","September 2020","October 9, 2015","October 2015","No Study Results Posted","CTracker","September 2017","Changes in hepatitis C medication therapy|Changes in Workforce Productivity and Activity Impairment Compared to changes in hepatitis C medication therapy.|Changes in Physical Function and Limitations Due to Physical Health Compared to changes in hepatitis C medication therapy.","https://ClinicalTrials.gov/show/NCT02568540"
443,"NCT02446717","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With Genotype 1 HCV Who Failed a Prior DAA Containing Therapy","Active, not recruiting","No Results Available","Chronic Hepatitis C|Hepatitis C Virus|HCV","Drug: ABT-493|Drug: ABT-530|Drug: Ribavirin","AbbVie","Both","Adult|Senior","Phase 2","60","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M15-410","May 14, 2015","April 2015","June 2016","September 18, 2015","September 2015","No Study Results Posted","null","September 2015","Percentage of participants with sustained virologic response (SVR) 12|Percentage of participants with sustained virologic response (SVR) 4|Percentage of participants with virologic failure during treatment|Percentage of participants with Post-Treatment relapse","https://ClinicalTrials.gov/show/NCT02446717"
444,"NCT01750515","Acupuncture as an Adjunctive Treatment for Hepatitis C Patients","Not yet recruiting","No Results Available","Hepatitis C (HCV)|Acupuncture","Device: Acupuncture","Assy Nimer|Ziv Hospital","Both","Adult|Senior","","null","Other","Interventional","","0094-12-ZIV","November 26, 2012","January 2013","January 2014","December 12, 2012","December 2012","No Study Results Posted","null","January 2014","","https://ClinicalTrials.gov/show/NCT01750515"
445,"NCT01962155","Prospective Stuy in Evaluating Hepatic Fibrosis Related to Hepatitis B Virus Using Non-invasive Parameters","Recruiting","No Results Available","Hepatitis B|Liver Fibrosis","","Peking University First Hospital","Both","Adult","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2013ZX10002005","October 5, 2013","August 2013","December 2015","November 28, 2014","November 2014","No Study Results Posted","HBV","August 2015","determine whether a non-invasive test or a combination of non invasive tests may be used to accurately evaluate liver fibrosis in patients with chronic hepatitis B","https://ClinicalTrials.gov/show/NCT01962155"
446,"NCT01058512","A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy","Completed","No Results Available","Hepatitis C","Drug: NOV-205","Cellectar Biosciences, Inc.","Both","Adult|Senior","Phase 2","40","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","NOV205-C201","January 26, 2010","March 2010","December 2010","July 9, 2013","January 2011","No Study Results Posted","NOV-205","December 2010","To evaluate changes in viral load|To evaluate changes in serum ALT and AST levels|To evaluate the durability of any changes in viral load and serum ALT and AST|To establish the safety profile of NOV-205","https://ClinicalTrials.gov/show/NCT01058512"
447,"NCT00938860","Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C","Completed","Has Results","Hepatitis C|Liver Transplantation","Drug: cyclosporin (Neoral)|Drug: tacrolimus (Prograf)","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 4","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","COLO400A2430|2009-010806-12","July 13, 2009","September 2009","May 2013","May 5, 2015","May 2015","April 25, 2014","SUSTAIN","May 2013","Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted Recipients on Maintenance Therapy With Neoral or Tacrolimus|Number of Events of the Composite Endpoint of Biopsy Proven Acute Rejections (BPAR), Death or Graft Loss and of the Individual Components|Number of Participants With Fibrosis Progression (Increase in Ishak-Knodell (IK) Score by at Least One Point From the Baseline)|Number of Participants of Rapid Viral Response (RVR)|Number of Participants of Early Viral Response (EVR)|Number of Participants for the End of Treatment Response (ETR)|Number of Participants of True Non-responder Rate|Number of Participants for Relapse Rate|Number of Participants With Dose Reduction or Discontinuation of Antiviral (AV) Therapy Due to Poor Tolerability at Any Time During the Study for Any Reason","https://ClinicalTrials.gov/show/NCT00938860"
448,"NCT02216045","Effect of Camel Milk on Chronic Hepatitis C","Recruiting","No Results Available","Chronic Hepatitis C","Drug: Peginterferon, Ribavirin, camel milk|Drug: Peginterferon, Ribavirin","Mashhad University of Medical Sciences","Both","Adult|Senior","Phase 2","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","Mashhad UMS","July 26, 2014","June 2014","February 2015","August 12, 2014","August 2014","No Study Results Posted","HCV","February 2015","Early Virologic Responses(EVR)|Complete early virological response (cEVR)|o Complete early virological response (cEVR)|o Sustained virological response (SVR)|o Normalization of ALT( Alanine Aminotransferase)|o Normalization of ALT|o Adverse events(AE)","https://ClinicalTrials.gov/show/NCT02216045"
449,"NCT01672983","A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C Virus","Drug: ABT-450|Drug: ABT-267|Drug: Ritonavir","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior","Phase 2","110","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M12-536","July 27, 2012","July 2012","May 2014","May 19, 2014","May 2014","No Study Results Posted","null","May 2014","Assess the percentage of all dosed subjects in each treatment arm with sustained virologic response 24 weeks post-dosing (hepatitis C ribonucleic acid less than lower limit of quantitation at 24 weeks after the last dose of study drug).|Percentage of subjects in each treatment arm with treatment-emergent adverse events.|Assess the percentage of all dosed subjects in each treatment arm with a sustained virologic response 12 weeks post-dosing (hepatitis C ribonucleic acid less than lower limit of quantitation 12 weeks after the last dose of study drug).|Assess the percentage of subjects in each arm with end of treatment response (hepatitis C virus ribonucleic acid less than the lower limit of quantitation).","https://ClinicalTrials.gov/show/NCT01672983"
450,"NCT02540538","Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders","Recruiting","No Results Available","Hepatitis B","Biological: HBVaxPro|Biological: HBAI20","Maastricht University Medical Center|CyTuVax","Both","Adult","Phase 1","36","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","HBnr01|2014-000913-30","August 25, 2015","September 2015","July 2016","September 15, 2015","September 2015","No Study Results Posted","null","July 2016","Number of subjects with adverse events|Number of adverse events of grade 2 or higher assessed by CTCAE v4.0|Immunogenicity of Hepatitis B vaccine","https://ClinicalTrials.gov/show/NCT02540538"
451,"NCT00001117","A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection","Completed","No Results Available","HIV Infections|Hepatitis C","","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Child|Adult|Senior","Phase 2","60","NIH","Observational","","ACTG 383","November 2, 1999","null","null","July 30, 2008","June 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001117"
452,"NCT00778596","Prednisolone Priming Study in Patients With Chronic Hepatitis B","Recruiting","No Results Available","Chronic Hepatitis B","Drug: Prednisolone|Drug: Placebo priming","Yun-Fan Liaw|Chang Gung Memorial Hospital","Both","Adult","Phase 4","160","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","CST-L-1","October 21, 2008","February 2009","December 2013","May 24, 2012","May 2012","No Study Results Posted","null","December 2012","The primary endpoint will be the 1-year HBe-Ag seroconversion rate with or without prednisolone priming.","https://ClinicalTrials.gov/show/NCT00778596"
453,"NCT02064049","Surveillance and Treatment of Prisoners With Hepatitis C","Recruiting","No Results Available","Hepatitis C","Drug: Sofosbuvir and ribavirin","Kirby Institute","Male","Adult|Senior","Phase 4","650","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","VHCRP1302","February 12, 2014","October 2014","December 2017","August 31, 2015","August 2015","No Study Results Posted","SToP-C","December 2017","Hepatitis C virus (HCV) incidence|Hepatitis C virus prevalence|SVR12|ETR|Rapid Virological Response (RVR)|Very rapid virological response (vRVR)|Treatment adherence|Number of patients with adverse events|Treatment uptake|On-treatment change in illicit drug use|HCV reinfection rate","https://ClinicalTrials.gov/show/NCT02064049"
454,"NCT01098006","A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays","Completed","No Results Available","Immunologic Tests|Hepatitis B Infection","Other: Blood withdrawal","GlaxoSmithKline","Both","Adult","Phase 4","99","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","113854","April 1, 2010","April 2010","February 2012","July 19, 2012","July 2012","No Study Results Posted","null","February 2012","Frequency of Hepatitis B (HB) antigen-specific regulatory T (Treg) cells.|Presence of HB antigen-specific Treg cells in cryopreserved and fresh blood samples from the same donor.|Frequency of IL-17 positive T-cells.|Frequency of Th1 positive T-cells.","https://ClinicalTrials.gov/show/NCT01098006"
455,"NCT02156570","DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)","Recruiting","No Results Available","Hepatitis C","Drug: Sofosbuvir and ribavirin","Kirby Institute","Both","Adult|Senior","Phase 4","20","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","VHCRP1206","June 3, 2014","October 2014","December 2015","April 6, 2015","April 2015","No Study Results Posted","DARE-CII","December 2015","SVR 12|SVR 24","https://ClinicalTrials.gov/show/NCT02156570"
456,"NCT02324218","This Study Aims to Determine the Incidence, of Hepatitis B Diagnosis Among Diabetes Mellitus Patients of 0-80 Years of Age","Completed","No Results Available","Hepatitis B","Other: Data collection","GlaxoSmithKline","Both","Child|Adult|Senior","","161429","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","201335","December 11, 2014","October 2014","January 2015","April 2, 2015","April 2015","No Study Results Posted","null","January 2015","Occurrence of new HepB diagnosis among patients between 0-80 years of age previously diagnosed with DM, between 2000 and 2012, in the UK CPRD or Hospital Episodes Statistics (HES).|Occurrence of new HepB diagnosis among non-DM patients between 0-80 years of age, in the UK CPRD or HES.|Hospitalisation episode recorded in HES due to HepB infection or complications among patients between 0-80 years of age previously diagnosed with DM, in the UK, for whom CPRD-HES linkage is available.|All cause mortality among HepB cases in the DM patients between 0-80 years of age, in the UK.|HepB cause-specific mortality among DM patients between 0-80 years of age, in the UK. for whom CPRD-ONS mortality linkage is available.|New-onset or prevalent HepB diagnosis among new-onset or prevalent DM patients between 0-80 years of age, in the UK, regardless of the onset of HepB in relation to the diagnosis of DM.","https://ClinicalTrials.gov/show/NCT02324218"
457,"NCT00841243","Nutritional Support During Antiviral Therapy for Hepatitis C","Not yet recruiting","No Results Available","Hepatitis C|Weight Loss","Dietary Supplement: Nutrison (Nutricia)","UMC Utrecht","Both","Adult|Senior","Phase 4","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","08-70","February 10, 2009","March 2009","August 2010","February 10, 2009","February 2009","No Study Results Posted","null","March 2010","Weight loss","https://ClinicalTrials.gov/show/NCT00841243"
458,"NCT02417597","A Phase ‚Ö£ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)","Recruiting","No Results Available","Hepatitis E","Biological: Recombinant Hepatitis E Vaccine (Escherichia Coli)","Xiamen Innovax Biotech Co., Ltd|Xiamen University|Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.","Both","Adult|Senior","Phase 4","600","Industry|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","PRO-HE-006","April 11, 2015","April 2015","December 2015","October 11, 2015","October 2015","No Study Results Posted","null","December 2015","Adverse reactions/events|Anti-HEV antibody","https://ClinicalTrials.gov/show/NCT02417597"
459,"NCT00157534","A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection","Completed","No Results Available","Hepatitis C, Chronic","Drug: Celgosivir","BioWest Therapeutics Inc","Both","Adult","Phase 2","43","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HCV-04-001","September 7, 2005","October 2004","August 2005","September 7, 2005","September 2005","No Study Results Posted","null","null","Safety analysis|Hepatitis C viral load","https://ClinicalTrials.gov/show/NCT00157534"
460,"NCT00565539","Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C, Chronic","Drug: PEGylated recombinant interleukin 29 (PEG-rIL-29)","ZymoGenetics","Both","Adult|Senior","Phase 1","56","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","526F06","November 29, 2007","December 2007","October 2009","October 6, 2009","October 2009","No Study Results Posted","null","October 2009","Adverse events and standard clinical laboratory abnormalities|HCV RNA levels, serum concentrations of PEG-rIL-29, serum beta2-microglobulin (B2M) levels, serum 2'5' oligoadenylate synthetase (OAS) levels, the presence of anti-PEG-rIL-29 antibodies","https://ClinicalTrials.gov/show/NCT00565539"
461,"NCT02101177","Evaluation of the National Treatment Program of Hepatitis C in Egypt","Withdrawn","No Results Available","Chronic Hepatitis C","","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Institut Pasteur|National Hepatology & Tropical Medicine Research Institute","Both","Adult","","0","Other|Industry","Observational","Observational Model: Cohort","ANRS 12291","March 26, 2014","April 2014","December 2015","July 22, 2014","March 2014","No Study Results Posted","eNTC","June 2015","Estimate ""real life"" Sustained Virological Response rate|Compare the efficacy of Reiferon¬Æ, a biosimilar produced by a local company, Minapharm¬©, to that of other pegylated interferon of known efficacy (Pegasys¬Æ, Pegintron¬Æ)|Understand the determinants of not returning for follow-up among defaulting patients|Optimize selection criteria for patients to be enrolled in the National Treatment Program|Estimate ""real life"" Response rate at the end of treatment","https://ClinicalTrials.gov/show/NCT02101177"
462,"NCT00662220","High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4","Terminated","No Results Available","Chronic Hepatitis C","Drug: ribavirin|Drug: ribavirin","Foundation for Liver Research|Hoffmann-La Roche","Both","Adult|Senior","Phase 3","110","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HCV07-01|2007-005344-25","April 17, 2008","April 2008","November 2013","July 11, 2014","July 2014","No Study Results Posted","VIRID","June 2013","HCV-RNA negativity by qualitative assay 24 weeks after end of treatment (sustained virological response, SVR)|HCV-RNA negativity at week 4 (rapid virological response, RVR)|HCV-RNA negativity at week 12 (complete early virological response, cEVR)|HCV-RNA ‚â• 2log10 drop at week 12, but HCV-RNA still detectable (partial early virological response, pEVR)|HCV- RNA negativity at week 48 (end of treatment response, ETR)|Relapse rate after ETR|Safety and tolerability of high-dose daily ribavirin (serious adverse events, grade 4 NCI toxicity, percentage of patients completing treatment on full or >80% of total intended dose and reasons for dose adjustments)|Biochemical response (normalization of serum ALT at the end of therapy and at the end of follow-up)|Health related quality of life and psychopathology before, during and after treatment by SF-36 and SCL-90 questionnaires","https://ClinicalTrials.gov/show/NCT00662220"
463,"NCT00707772","Pegasys¬Æ Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C|Hemophilia","Drug: PEGASYS¬Æ (Peginterferon Alfa-2a (40KD)) Plus COPEGUS¬Æ (Ribavirin)|Drug: PEGASYS¬Æ (Peginterferon Alfa-2a (40KD)) Plus COPEGUS¬Æ (Ribavirin)","Baqiyatallah Medical Sciences University|Baqiyatallah Research Center for Gastroenterology and Liver Diseases|Tehran Hepatitis Center|Guilan Research Center for Gastroenterology and Liver Diseases|Tabriz Research Center for Gastroenterology and Liver Diseases|Shahid Beheshti Medical University|Research Center for Gastroenterology and Liver Disease, Iran University of Medical Sciences, Firoozgar Hospital","Both","Child|Adult|Senior","Phase 4","400","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","BRCGL-07-03","June 26, 2008","March 2007","September 2009","September 16, 2009","September 2009","No Study Results Posted","null","September 2009","Early Virologic Response|End of Treatment Response|Sustained Virologic Response|Rapid Virologic Response|Tolerability of drugs for whole therapy period|Biochemical response (ALT)|Laboratory Parameters","https://ClinicalTrials.gov/show/NCT00707772"
464,"NCT00302081","Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)","Completed","Has Results","Hepatitis C, Chronic","Biological: peginterferon alfa-2b (SCH 54031)|Biological: peginterferon alfa-2b (SCH 54031)|Biological: peginterferon alfa-2b (SCH 54031)|Drug: ribavirin (SCH 18908)|Drug: ribavirin (SCH 18908)","Merck Sharp & Dohme Corp.|Integrated Therapeutics Group","Both","Adult|Senior","Phase 3","696","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P03548","March 10, 2006","August 2003","April 2008","April 7, 2015","April 2015","April 29, 2009","null","April 2008","The Number of Participants Who Achieve a Sustained Virologic Response (SVR)|Virologic Response Rates at the End of Therapy. Biochemical Responses as Determined by ALT and AST Levels at the End of Treatment and at the End of Follow up.","https://ClinicalTrials.gov/show/NCT00302081"
465,"NCT00141999","Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents","Completed","No Results Available","Hepatitis","Biological: hepatitis B vaccine","Centers for Disease Control and Prevention|Alaska Native Medical Center","Both","Child","Phase 4","400","U.S. Fed|Other","Observational","Time Perspective: Prospective","CDC-NCID-2998|U50/CCU022279","September 1, 2005","May 2001","March 2008","September 26, 2012","September 2012","No Study Results Posted","null","March 2005","","https://ClinicalTrials.gov/show/NCT00141999"
466,"NCT00707850","Pegasys¬Æ Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C|Thalassemia","Drug: PEGASYS¬Æ (Peginterferon Alfa-2a (40KD)) Plus COPEGUS¬Æ (Ribavirin)","Baqiyatallah Medical Sciences University|Baqiyatallah Research Center for Gastroenterology and Liver Diseases|Tehran Hepatitis Center|Guilan Research Center for Gastroenterology and Liver Diseases|Tabriz Research Center for Gastroenterology and Liver Diseases","Both","Child|Adult|Senior","Phase 4","300","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","BRCGL-08-06","June 26, 2008","May 2007","September 2009","August 30, 2010","September 2009","No Study Results Posted","null","September 2009","Early Virologic Response|End of Treatment Response|Sustained Virologic Response|Rapid Virologic Response|Tolerability of drugs for whole therapy period|Biochemical response (ALT)|Laboratory Parameters","https://ClinicalTrials.gov/show/NCT00707850"
467,"NCT01498068","Open-Label, Bridging Study of Telaprevir in Treatment-Na√Øve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C","Completed","Has Results","Genotype 1 Chronic Hepatitis C","Drug: Telaprevir|Drug: Pegylated-interferon-alfa-2a|Drug: Ribavirin","Janssen-Cilag International NV","Both","Adult|Senior","Phase 3","36","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CR100676|VX-950HPC3007","December 6, 2011","January 2012","March 2013","January 29, 2015","January 2015","September 11, 2013","null","April 2012","Number of Participants With Extended Rapid Virologic Response (eRVR)|Median Change in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)|Number of Participants With Rapid Virologic Response (RVR) at Week 4|Number of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Less Than 25 IU/mL, (Target Not Detected) at Weeks 8, 12, 24, 32, 40 and 48|Number of Participants With Virologic Failure|Number of Participants in Each Specific Category of Treatment Outcome","https://ClinicalTrials.gov/show/NCT01498068"
468,"NCT01466790","A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients","Completed","Has Results","Hepatitis C","Drug: TMC435|Drug: PSI-7977 (GS7977)|Drug: Ribavirin","Janssen R&D Ireland|Gilead Sciences","Both","Adult|Senior","Phase 2","168","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CR018724|TMC435HPC2002","November 3, 2011","January 2012","January 2014","January 26, 2015","January 2015","October 17, 2014","COSMOS","November 2013","Number of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Planned End of Treatment (EOT)|Number of Participants With a Sustained Virologic Response (SVR) 4 Weeks After the Planned End of Treatment (EOT)|Number of Participants With a Sustained Virologic Response (SVR) 24 Weeks After the Planned End of Treatment (EOT)|Number of Participants With a Sustained Virologic Response (SVR) at Week 48|Number of Participants With Viral Breakthrough|Number of Participants With Inadequate Virologic Response|Number of Participants With Viral Relapse","https://ClinicalTrials.gov/show/NCT01466790"
469,"NCT00543244","Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan","Recruiting","No Results Available","Chronic Hepatitis C","Drug: Pegylated interferon alfa and ribavirin","National Taiwan University Hospital|National Science Council, Taiwan","Both","Adult|Senior","","300","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","200709053R","October 10, 2007","January 2006","December 2008","November 20, 2008","February 2008","No Study Results Posted","null","October 2008","Sustained virologic response (SVR)","https://ClinicalTrials.gov/show/NCT00543244"
470,"NCT00645736","CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study","Completed","No Results Available","Chronic Hepatitis B","Other: No intervention","Gilead Sciences","Both","Adult|Senior","","788","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","GS-AU-103-0185","March 25, 2008","February 2008","November 2008","November 21, 2011","November 2011","No Study Results Posted","CHARM","October 2008","Descriptive statistics for clinical and viral characteristics of the study population","https://ClinicalTrials.gov/show/NCT00645736"
471,"NCT00108563","VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients","Completed","No Results Available","Hepatitis C|Depression","Drug: Citalopram or Placebo","VA Office of Research and Development","Both","Adult|Senior","Phase 4","null","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Double-Blind","CLIN-012-02S","April 15, 2005","October 2003","September 2006","January 20, 2009","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00108563"
472,"NCT00013702","Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients","Completed","No Results Available","Hepatitis B|HIV Infection","Drug: Adefovir","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Both","Child|Adult|Senior","Phase 2","30","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","010134|01-I-0134","March 28, 2001","March 2001","February 2004","March 3, 2008","February 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00013702"
473,"NCT01380951","Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)","Recruiting","No Results Available","Liver Cirrhosis|Chronic Hepatitis B","Drug: telbivudine","The Fifth People's Hospital of Suzhou","Both","Adult","Phase 4","120","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","szwy20110610","June 23, 2011","May 2011","December 2013","June 23, 2011","June 2011","No Study Results Posted","null","December 2012","Serum HBV DNA|Serum HBeAg|Child-pugh score","https://ClinicalTrials.gov/show/NCT01380951"
474,"NCT00298714","Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C|Liver Fibrosis","Drug: Losartan","Hospital Clinic of Barcelona","Both","Adult","Phase 4","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ARAHEPC|Protocol number: 02-0491","March 2, 2006","March 2003","January 2006","November 21, 2007","November 2007","No Study Results Posted","null","null","Assessment of liver fibrogenesis by changes in gene expression of key mediators of liver fibrosis.","https://ClinicalTrials.gov/show/NCT00298714"
475,"NCT01664845","Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance","Recruiting","No Results Available","Chronic Hepatitis c|Insulin Resistance","Drug: metformin|Drug: pegylated-IFN|Drug: ribavirin","Kaohsiung Veterans General Hospital.","Both","Adult|Senior","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","VGHKS12-CT3-16","August 10, 2012","August 2012","August 2014","August 13, 2012","August 2012","No Study Results Posted","null","August 2014","sustained virological response|change of HOMA-IR","https://ClinicalTrials.gov/show/NCT01664845"
476,"NCT01567735","A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Na√Øve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients","Completed","No Results Available","Hepatitis C","Drug: TMC435","Janssen R&D Ireland","Both","Adult|Senior","Phase 3","107","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CR100695|TMC435HPC3011|2011-004097-29","January 24, 2012","March 2012","March 2014","April 13, 2015","April 2015","No Study Results Posted","RESTORE","March 2014","Proportion of participants achieving sustained virologic response 12 weeks after planned end of treatment (SVR12)|Efficacy of TMC435 with respect to proportion of participants achieving sustained virologic response 24 weeks after planned end of treatment (SVR24)|On-treatment virologic response|On-treatment virologic failure|Evaluation of the viral breakthrough rate|Evaluation of viral relapse rate|Evaluation the safety and tolerability","https://ClinicalTrials.gov/show/NCT01567735"
477,"NCT00440297","Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)","Completed","Has Results","Hepatitis B Virus Infection","Biological: Comparator: modified process hepatitis B vaccine|Biological: Comparator: ENGERIX-B‚Ñ¢","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 3","277","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","V232-060|2007_515","February 26, 2007","December 2006","May 2008","October 29, 2015","October 2015","March 24, 2009","null","May 2008","The Number of Seroprotected Participants to the Modified Process Hepatitis B Vaccine and ENGERIX-B‚Ñ¢ (Currently Licensed Vaccine) at Month 7|The Number of Seroprotected Participants to the Modified Process Hepatitis B Vaccine and ENGERIX-B‚Ñ¢ (Currently Licensed Vaccine) at Month 9|The Total Number of Participants With One or More Injection-Site Adverse Experiences|The Total Number of Participants With a Maximum Temperature >= 100.0F / 37.8C|The Total Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences","https://ClinicalTrials.gov/show/NCT00440297"
478,"NCT00881582","Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients","Completed","No Results Available","Chronic Hepatitis C|Renal Transplant","Drug: Pegylated interferon alfa-2a plus ribavarin","King Abdulaziz Medical City|Riyadh Military Hospital|King Faisal Specialist Hospital & Research Center","Both","Adult|Senior","Phase 4","32","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","RMH-01-09","April 14, 2009","January 2009","December 2011","September 13, 2012","September 2012","No Study Results Posted","null","December 2011","Sustained Virologic Response|Adverse event rate and number of cases of graft rejection","https://ClinicalTrials.gov/show/NCT00881582"
479,"NCT00158535","Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection","Terminated","No Results Available","HIV Infections|Hepatitis C","Procedure: liver transplantation","French National Agency for Research on AIDS and Viral Hepatitis","Both","Adult|Senior","Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ANRS HC08 THEVIC","September 9, 2005","June 2002","null","September 9, 2005","September 2005","No Study Results Posted","null","null","Feasibility of liver transplantation in patients with HCV-HIV coinfection: survival at one and two years.|Graft survival|Unexpected infections or neoplasia|Toxicity of antiretroviral and immunosuppressive treatments|Replicative kinetics of HIV and HVC after transplantation in blood and liver|Immune status of HIV and HVC|Quality of life","https://ClinicalTrials.gov/show/NCT00158535"
480,"NCT02152709","Study of Evaluating Safety and Immunogenicity of 10¬µg/0.5ml Hepatitis B Vaccine","Completed","No Results Available","Hepatitis B","Biological: 3 dose of 10¬µg/0.5ml hepatitis B vaccine|Biological: 3 dose of 5¬µg/0.5ml hepatitis B vaccine","Jiangsu Province Centers for Disease Control and Prevention|Beijing Tiantan Biological Products Co., Ltd","Both","Child|Adult|Senior","Phase 3","1537","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject)","JSEPI-003","May 19, 2014","November 2008","October 2010","May 28, 2014","May 2014","No Study Results Posted","null","March 2010","Number of subjects with adverse events|Geometric mean concentration of anti-hepatitis B virus surface antigen antibody|The rate of hepatitis B virus perinatal transmission|Geometric mean concentration of anti-hepatitis B virus surface antigen antibody after the second dose of hepatitis B vaccination","https://ClinicalTrials.gov/show/NCT02152709"
481,"NCT02063607","The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients","Recruiting","No Results Available","Hepatitis C","Biological: Peginterferon lambda","Nanogen Pharmaceutical Biotechnology Co., Ltd","Both","Adult","Phase 1","60","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","NNG01","February 11, 2014","December 2013","July 2014","February 13, 2014","February 2014","No Study Results Posted","null","July 2014","Area Under the Concentration-Time Curve (AUC 0-336)|Percentage of Patients achieving Rapid Virological Response (RVR)|Number of subjects with incidence of adverse events","https://ClinicalTrials.gov/show/NCT02063607"
482,"NCT01178749","Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-Œ± With Ribavirin Treatments","Recruiting","No Results Available","Chronic Hepatitis C","","National Taiwan University Hospital|National Science Council, Taiwan","Both","Adult|Senior","","390","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","200708003R","April 11, 2010","September 2007","July 2011","August 9, 2010","August 2010","No Study Results Posted","null","July 2010","symptom distress Scale|Fatigue symptom inventory|The SF-12 health survey","https://ClinicalTrials.gov/show/NCT01178749"
483,"NCT01436357","Staged Phase I/II Hepatitis C Prophylactic Vaccine","Recruiting","No Results Available","Hepatitis C","Biological: MVA-NSmut|Other: Placebo|Biological: AdCh3NSmut1","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult","Phase 1|Phase 2","540","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)","10-0069|N01AI40074","September 15, 2011","March 2012","January 2016","October 29, 2015","July 2015","No Study Results Posted","null","January 2016","Occurrence of vaccine-related serious adverse events (SAEs) from the time of first vaccination through the entire study period, per treatment arm.|Occurrence of severe local and/or systemic solicited reactogenicity signs and symptoms in the 8 days (Day 0-7) after each vaccination, per treatment arm.|Occurrence of clinical safety laboratory adverse events (AEs) assessed at baseline and 1 month following each vaccination, per treatment arm.|Incidence of chronic hepatitis C virus (HCV) infection at 6 months defined by persistent viremia over a period of 6 months after initial detection of primary infection.|Frequency of positive cell mediated immune response by treatment group (vaccine vs. placebo) measured by interferon gamma (IFN-gamma) production by T-cells in response to at least one out of the six HCV genotype 1b peptide pools in the vaccine.","https://ClinicalTrials.gov/show/NCT01436357"
484,"NCT02555475","The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital","Not yet recruiting","No Results Available","Hepatitis C","Other: community based hepatitis C care and treatment","Macfarlane Burnet Institute for Medical Research and Public Health Ltd|St Vincent's Hospital Melbourne","Both","Adult|Senior","Phase 4","380","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HREC/15/SVHM/41","September 17, 2015","October 2015","October 2017","September 18, 2015","September 2015","No Study Results Posted","null","October 2016","To measure the proportion of people attending at a Primary Health Care Service for their genotype 1 HCV infection who commence antiviral treatment (Viekira Pak and ribavirin) and have a SVR 12.|To measure the proportion of people attending a PHCS with G1 HCV infection who commence antiviral treatment (Viekira Pak and ribavirin) if they are managed at a PHCS compared to those who are referred to and managed at a tertiary hospital.|To measure the proportion of people with G1 HCV who have an SVR12 at a PHCS compared a tertiary hospital.|To measure the reduction in HCV viraemia (community viral load) among participants considering retention through the cascade of care and SVR12.|To measure the cost effectiveness of managing and treating people in a primary health service compared to a tertiary hospital.|To define the cascade of care for patients referred to a community hepatitis nurse for assessment of HCV.","https://ClinicalTrials.gov/show/NCT02555475"
485,"NCT02053727","Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background","Recruiting","No Results Available","Rheumatoid Arthritis|Chronic Hepatitis B","Drug: Abatacept|Drug: Placebo","Daniel Furst|University of California, Irvine|University of California, Los Angeles","Both","Adult|Senior","","20","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","IM101329|13-001279","November 6, 2013","July 2014","December 2017","August 15, 2014","August 2014","No Study Results Posted","RA","December 2016","Number of Participants with Serious Adverse Events|Number of Subjects with Hepatitis B Reactivation|DAS28-ESR-4 Unit|CDAI Unit|TJC Count|SJC Count|Patient Global (Visual Analogue Scale)|MD Global (Visual Analogue Scale)|Pain (measured on a 5 point Likert scale)|Global Assessment of Disease Activity (as measured on a 5 point Likert scale)|HAQ-DI Units|Fatigue (as assessed by FACIT-Fatigue Unit)|Sleep as assessed by Medical Outcomes Study Sleep Instrument Unit|ACR 20/50/70 Percentage","https://ClinicalTrials.gov/show/NCT02053727"
486,"NCT02463019","Roll-over After 3-year Trial for Tenofovir in Mild Chronic Hepatitis B","Enrolling by invitation","No Results Available","Chronic Hepatitis B|Antiviral Treatment","Drug: Tenofovir Disoproxil Fumarate","E-DA Hospital|Taipei Institute of Pathology","Both","Adult|Senior","Phase 4","160","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","EDAHospital","May 14, 2015","January 2015","January 2020","June 2, 2015","June 2015","No Study Results Posted","null","January 2019","Change of liver histopathology|Virological response|Drug resistance","https://ClinicalTrials.gov/show/NCT02463019"
487,"NCT00115908","A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1","Completed","No Results Available","Hepatitis C, Chronic","Drug: Albuferon|Drug: Ribavirin|Drug: PEG-IFNalfa2a","Human Genome Sciences Inc.","Both","Adult","Phase 2","458","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ALFR-HC-04","June 26, 2005","May 2005","May 2007","November 5, 2013","November 2013","No Study Results Posted","null","May 2007","Sustained virologic response (SVR), defined as undetectable HCV RNA at 24 weeks after the end of therapy.|Virologic response at Week 4 (VR4), defined as undetectable HCV RNA or a > 2-log reduction in HCV RNA.|Early virologic response at Week 12 (EVR12), defined as undetectable HCV RNA or a > 2-log reduction in HCV RNA.|Undetectable HCV RNA at Week 24.|End of treatment response (ETR), defined as undetectable HCV RNA at Week 48","https://ClinicalTrials.gov/show/NCT00115908"
488,"NCT01599130","Efficacy of Peg-interferon Œ±-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss","Not yet recruiting","No Results Available","Hepatitis B","Drug: Entecavir|Drug: Peginterferon alfa-2a","Sun Yat-sen University","Both","Adult","","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","Zhangyufeng","May 8, 2012","July 2012","April 2014","May 14, 2012","May 2012","No Study Results Posted","null","April 2014","HBeAg sericonversion rate|HBeAg loss rate|HBeAg quantification dynamic change|HBsAg loss rate|HBsAg seroconversion rate|HBsAg quantification dynamic change|ALT normalization rate","https://ClinicalTrials.gov/show/NCT01599130"
489,"NCT01342185","Efficacy of Medical Ozone Therapy in Patients With Chronic Hepatitis B","Enrolling by invitation","No Results Available","Chronic Hepatitis B","Device: medical ozone therapy with tianyi|Device: medical ozone therapy with humares|Drug: Diammonium glycyrrhizinate Capsules","Nanfang Hospital of Southern Medical University|Tianyi medical instruments limited company, Ningbo, China","Both","Child|Adult|Senior","Phase 3","189","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","a4xr2dv8","February 16, 2011","March 2010","July 2013","October 17, 2012","October 2012","No Study Results Posted","EMOTCHB","July 2013","HBV DNA|HBeAg","https://ClinicalTrials.gov/show/NCT01342185"
490,"NCT01326546","Therapeutic Hepatitis B Vaccine (Synthesized Peptide ŒµPA-44) Joint Entecavir in Treating Chronic Hepatitis B Patients","Active, not recruiting","No Results Available","Chronic Hepatitis B","Drug: Therapeutic HBV vaccine, entecavir|Drug: Empty liposome, entecavir","Chongqing Jiachen Biotechnology Ltd.|Third Military Medical University","Both","Adult","Phase 2","378","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","71006.04","March 28, 2011","June 2010","March 2013","June 12, 2012","June 2012","No Study Results Posted","THBVJEITCHBP","December 2012","Primary efficacy assessment is the serological conversion rate of HBeAg at week. 48|Serological response|Virological response|Biochemistry response|Histological response","https://ClinicalTrials.gov/show/NCT01326546"
491,"NCT00209755","Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C","Terminated","No Results Available","Chronic Hepatitis C","Procedure: therapeutic drug monitoring of ribavirin and dose adaptation","Hopital A Michallon|University Hospital, Grenoble|Central Hospital, Nancy, France","Both","Adult","","40","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Open Label","ribatop - afssaps #031161|N.A.","September 13, 2005","October 2003","July 2004","September 13, 2005","September 2004","No Study Results Posted","null","null","relationship between plasma ribavirin concentration and early virological response|safety|relationship between plasma ribavirin concentration and hemoglobin drop|dose effect of ribavirin on ribavirin plasma concentration","https://ClinicalTrials.gov/show/NCT00209755"
492,"NCT02112799","Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients","Recruiting","No Results Available","Chronic Hepatitis B","Drug: NVR 3-778|Drug: Placebo for NVR 3-778|Drug: Pegasys","Novira Therapeutics, Inc.","Both","Adult","Phase 1","84","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","NVR3-778-101","April 9, 2014","April 2014","January 2016","October 5, 2015","October 2015","No Study Results Posted","null","November 2015","To assess the dose-related safety and tolerability of NVR 3-778 in healthy volunteers and hepatitis B patients","https://ClinicalTrials.gov/show/NCT02112799"
493,"NCT02057263","The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults","Active, not recruiting","No Results Available","Hepatitis B","Drug: Alendronate|Drug: Hepatitis B Vaccine|Drug: Placebo","Massachusetts General Hospital","Both","Adult|Senior","Phase 1","20","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)","2014-P-000040","February 4, 2014","April 2014","February 2016","September 30, 2015","September 2015","No Study Results Posted","null","February 2016","Safety/Adverse events|Efficacy","https://ClinicalTrials.gov/show/NCT02057263"
494,"NCT01446250","Study of DEB025/Alisporivir Plus Pegylated Interferon alfa2a and Ribavirin and Boceprevir Plus Pegylated Interferon alfa2a and Ribavirin in African American Chronic Hepatitis C Genotype 1 Patients That Have Never Received Treatment for Their Hepatitis C","Completed","No Results Available","Hepatitis C|Liver Disease","Drug: DEB025 plus peg-IFN alpha 2a and ribavirin fixed duration treatment|Drug: DEB025 plus peg-IFN alpha 2a and ribavirin response guided treatment duration|Drug: Boceprevir plus peg-IFN alpha 2a and ribavirin per label response guided treatment","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 3","210","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CDEB025A2307","September 26, 2011","December 2011","May 2013","October 12, 2013","October 2013","No Study Results Posted","null","May 2013","Proportion of patients that discontinue study drug or require dose reduction or dose interruption due to treatment-emergent Adverse Events.|Proportion of patients with emergence of resistant mutations in each treatment arm.|Proportion of patients that achieve Sustained Viral Response Week 24 (SVR24) defined as serum HCV RNA undetectable by limit of detection (LOD) 24 weeks after end of treatment.","https://ClinicalTrials.gov/show/NCT01446250"
495,"NCT00230958","Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive","Completed","No Results Available","Chronic Hepatitis C","Drug: Viramidine|Drug: Ribavirin|Drug: pegylated interferon alfa-2b","Valeant Pharmaceuticals International, Inc.","Both","Adult|Senior","Phase 3","900","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","RNA003142-301","September 29, 2005","December 2003","January 2006","June 21, 2012","June 2012","No Study Results Posted","null","January 2006","- Efficacy: Undetectable plasma HCV RNA (less than 100 copies/mL) at the end of the 24-week post-treatment follow-up period.|- Safety: The proportion of patients with hemoglobin less than 10 g/dL at any time during treatment or at least 2.5 g/dL drop from baseline.|- Efficacy: Undetectable plasma HCV RNA at treatment week 24|- Efficacy: Undetectable or at least a 2-log drop from baseline at treatment weeks 12 and 24|- Safety: Monitoring of adverse events|- Safety: Monitoring of abnormal changes in laboratory parameters that are not disease-related","https://ClinicalTrials.gov/show/NCT00230958"
496,"NCT00093093","Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive","Completed","No Results Available","Chronic Hepatitis C","Drug: Viramidine|Drug: Ribavirin|Drug: pegylated interferon alfa-2a","Valeant Pharmaceuticals International, Inc.","Both","Adult|Senior","Phase 3","900","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","RNA003142-302","September 30, 2004","June 2004","May 2006","June 21, 2012","June 2012","No Study Results Posted","VISER2","May 2006","- Efficacy: Undetectable plasma HCV RNA (less than 100 copies/mL) at the end of the 24-week post-treatment follow-up period.|- Safety: The proportion of patients with hemoglobin less than 10 g/dL at any time during treatment or at least 2.5 g/dL drop from baseline.|- Efficacy: Undetectable plasma HCV RNA at treatment week 24|- Efficacy: Undetectable or at least a 2-log drop from baseline at treatment weeks 12 and 24|- Safety: Monitoring of adverse events|- Safety: Monitoring of abnormal changes in laboratory parameters that are not disease-related","https://ClinicalTrials.gov/show/NCT00093093"
497,"NCT00657657","Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine","Completed","Has Results","Hepatitis B","Biological: Engerix‚Ñ¢-B","GlaxoSmithKline","Both","Child|Adult|Senior","Phase 4","29","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","110071","April 8, 2008","April 2008","August 2008","August 6, 2009","August 2009","August 6, 2009","null","August 2008","Number of Subjects With an Immune Response to a Challenge Dose of Hepatitis B Vaccine|Number of Subjects With Anti-HBs Antibody Concentrations Above Pre-defined Cut-off Values|Concentration of Anti-HBs Antibodies|Number of Subjects Reporting Unsolicited Adverse Events|Number of Subjects Reporting Serious Adverse Events","https://ClinicalTrials.gov/show/NCT00657657"
498,"NCT01402583","Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: PEG IFN/Ribavirin","Prof. Facchinetti Fabio|Merck Sharp & Dohme Corp.|University of Modena and Reggio Emilia","Both","Adult|Senior","","1000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RSO-321","July 25, 2011","July 2011","September 2011","October 20, 2011","October 2011","No Study Results Posted","MEN_EPID","August 2011","","https://ClinicalTrials.gov/show/NCT01402583"
499,"NCT00205049","Pentoxifylline for Acute Alcoholic Hepatitis (AAH)","Terminated","Has Results","Hepatitis, Alcoholic","Drug: pentoxifylline","University of Wisconsin, Madison","Both","Adult|Senior","Phase 1","4","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","M-2004-0388","September 13, 2005","March 2005","November 2006","April 10, 2014","April 2014","August 4, 2011","null","November 2006","Survival at 28 Days","https://ClinicalTrials.gov/show/NCT00205049"
500,"NCT01517308","24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C","Withdrawn","No Results Available","Chronic Hepatitis C","Drug: pegylated interferon alpha 2a + ribavirin","Federico II University","Both","Adult|Senior","Phase 3","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","C.E. Federico II 47/11","January 17, 2012","May 2012","November 2015","March 16, 2012","March 2012","No Study Results Posted","null","November 2015","Sustained virological response (SVR)","https://ClinicalTrials.gov/show/NCT01517308"
501,"NCT02000063","Australian Trial in Acute Hepatitis C Recall Study","Completed","No Results Available","Acute Hepatitis C","","Kirby Institute|The University of New South Wales","Both","Child|Adult|Senior","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VHCRP1105","November 12, 2013","August 2012","March 2014","September 29, 2014","September 2014","No Study Results Posted","ATAHC Recall","March 2014","Long-term effects of HCV clearance|Incidence of HCV re-infection","https://ClinicalTrials.gov/show/NCT02000063"
502,"NCT01533051","Prospective Observational Cohort Study for the Durability of Anti-viral Therapy in Patients With Chronic Hepatitis B","Recruiting","No Results Available","Chronic Hepatitis B","","Yonsei University","Both","Adult|Senior","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Quit Anti-viral therapy","February 7, 2012","February 2012","March 2016","May 7, 2012","May 2012","No Study Results Posted","null","March 2015","Sustained virological response after stopping anti-viral treatment","https://ClinicalTrials.gov/show/NCT01533051"
503,"NCT00633230","Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C","Withdrawn","No Results Available","Hepatitis C Virus","Drug: standardized herbal formula, Sho-saiko-to (SST)|Other: placebo capsule identical to the active herbal formula","University of Virginia","Both","Adult","Phase 1","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","AGT006|IRB-HSR #12957","March 3, 2008","null","null","June 24, 2015","June 2015","No Study Results Posted","null","null","Reduction in HCV viral load, improvement in liver enzymes (ALT and AST), improvement in CD4+ and CD8+ T-cell counts.|Improvement in symptoms of depression/sadness, fear related to HCV disease progression, uncertainty, and hopelessness over time","https://ClinicalTrials.gov/show/NCT00633230"
504,"NCT00158522","Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)","Completed","No Results Available","Hepatitis C","Drug: pegylated interferon alpha2a","French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche","Both","Adult","Phase 3","31","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ANRS 1213","September 8, 2005","February 2003","December 2007","February 6, 2008","February 2008","No Study Results Posted","null","December 2007","Disappearance of HCV RNA by qualitative PCR 24 weeks after the end of treatment|Changes in HCV RNA load|Normalization of ALT during treatment and 24 weeks after the end of treatment|Study of side effects","https://ClinicalTrials.gov/show/NCT00158522"
505,"NCT01448044","Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","Completed","Has Results","Hepatitis C","Drug: BMS-790052 (NS5A Replication Complex Inhibitor)|Drug: Placebo matching BMS-790052|Drug: Pegylated-interferon alfa 2a|Drug: Ribavirin","Bristol-Myers Squibb","Both","Adult|Senior","Phase 3","152","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)","AI444-042|2011-002793-23","October 5, 2011","December 2011","January 2014","September 11, 2015","September 2015","August 7, 2015","null","October 2013","Percentage of Participants With 12 Week Sustained Virologic Response (SVR12)|Percentage of Participants Who Achieve HCV Ribonucleic Acid (RNA) < Limit of Quantification (LLOQ)|Percentage of Participants With Undetectable Hepatitis C Virus (HCV) RNA Levels|Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) or Sustained Virologic Response at Follow-up Week 24 (SVR24) by rs12979860 Single Nucleotide Polymorphism (SNP) in the IL28B Gene|Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died","https://ClinicalTrials.gov/show/NCT01448044"
506,"NCT00395018","Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection","Completed","Has Results","Hepatitis B, Chronic","Drug: entecavir","Bristol-Myers Squibb","Both","Child|Adult|Senior","Phase 3","109","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","AI463-109","November 1, 2006","April 2007","March 2011","April 30, 2012","April 2012","March 29, 2012","null","March 2011","Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) => 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 72|Number of Participants With HBV DNA by PCR >= 50 IU/mL Through Week 72|Distribution of ALT Levels Through 72 Weeks: Overall|Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at the End of Post-dosing Follow-up|Percentage of Participants With HBeAg Loss at Week 72 (for HBeAg-positive Participants)|Percentage of Participants With HBeAg Seroconversion at Week 72 (for HBeAg-positive Participants)|Percentage of Participants With HBsAg Loss at Week 72|Percentage of Participants With HBsAg Seroconversion at Week 72|Percentage of Participants With HBsAg Recurrence At Week 72|Total Bilirubin at Week 72|Prothrombin Time (PT) at Week 72|Number of Participants With Liver Rejection Through Week 72|Number of Participants With Re-transplantation Through Week 72|Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations From Study Drug Due to AEs (On-treatment [OT] and Off-treatment Follow-up [OF])|Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment Follow-up(OF): Hematology (All Grades)|Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF) Follow-up: Serum Chemistry (All Grades)","https://ClinicalTrials.gov/show/NCT00395018"
507,"NCT01340573","Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)","Terminated","Has Results","Chronic Hepatitis C","Drug: PegIntron Pen|Drug: Ribavirin","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","3","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P04896","November 18, 2010","March 2007","October 2007","January 20, 2015","January 2015","October 4, 2011","null","October 2007","Number of Genotype-1 Participants Who Experienced Serious Adverse Events (SAE) at Week-48 of Study Treatment|Number of Genotype-1 Participants Who Experienced Serious Adverse Events (SAE) at Week-24 Follow-up|Number of Non-genotype-1 Participants Who Experienced Serious Adverse Events (SAE) at Week-24 of Study Treatment|Number of Non-genotype 1 Participants Who Experienced Serious Adverse Events (SAE) on Week-24 Follow-up|Number of Non-genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-24 of Study Treatment|Number of Non-genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-24 Follow-up|Number of Genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-48 of Study Treatment|Number of Genotype-1 Participants Who Have Achieved Sustained Virologic Response (SVR) at Week-24 Follow-up|Participants' Overall Rating of Satisfaction and the Use of Training Materials for the Pegintron Pen, as Provided in a Study Questionnaire","https://ClinicalTrials.gov/show/NCT01340573"
508,"NCT00630058","A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C","Completed","Has Results","Hepatitis C","Drug: MP-424(H), PEG-IFN-a-2b, RBV|Drug: MP-424 (L), PEG-IFN-a-2b, RBV","Mitsubishi Tanabe Pharma Corporation|Vertex Pharmaceuticals Incorporated","Both","Adult","Phase 1","20","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label","G060-A5","February 24, 2008","April 2008","March 2009","April 16, 2014","April 2014","December 12, 2012","null","March 2009","Cmax (Maximum Observed Concentration in Plasma) of MP-424|Tmax (Time of Maximum Concentration in Plasma) of MP-424|AUC 0-8h (Area Under the Concentration-time Curve From Time Zero to 8 Hours) of MP-424|Ctrough (Minimum Observed Concentration in Plasma) of MP-424|T1/2(Time of Half-Life) of MP-424|Antiviral Effects of TVR on HCV Were Assessed by Measuring Plasma HCV RNA Levels","https://ClinicalTrials.gov/show/NCT00630058"
509,"NCT01241760","VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-na√Øve Participants With Genotype 1 Chronic Hepatitis C Virus Infection","Completed","Has Results","Genotype 1 Chronic Hepatitis C|Treatment Naive","Drug: Ribavirin|Drug: Telaprevir|Drug: Pegylated interferon alfa-2a|Drug: Telaprevir","Janssen Infectious Diseases BVBA|Vertex Pharmaceuticals Incorporated","Both","Adult|Senior","Phase 3","744","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CR013711|OPTIMIZE-HCV|VX-950-C211|2010-021628-84","October 28, 2010","December 2010","November 2012","May 14, 2014","May 2014","September 23, 2013","null","August 2012","Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)|Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned)|Percentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned)|Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected, at Different Time Points.|Percentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs|Percentage of Participants Who Relapsed During Follow-up Period|Percentage of Participants of Each IL28B Genotype Achieving Sustained Virologic Response 12 Weeks After the Last Planned Dose of Study Medication (SVR12 Planned)","https://ClinicalTrials.gov/show/NCT01241760"
510,"NCT01143662","Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: Ypeginterferon alfa-2b|Drug: Peginterferon alfa-2a","Xiamen Amoytop Biotech Co., Ltd.|Peking University First Hospital","Both","Adult","Phase 2","205","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","TB1007IFN","June 11, 2010","July 2010","April 2012","January 31, 2013","June 2010","No Study Results Posted","null","April 2011","Efficacy","https://ClinicalTrials.gov/show/NCT01143662"
511,"NCT00085917","Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients","Completed","Has Results","Hepatitis C|HIV Infections","Drug: Double dose pegylated interferon with weight based Ribavirin|Drug: standard dose pegylated interferon alfa -2a and ribavirin","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","29","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","040187|04-I-0187","June 16, 2004","June 2004","November 2008","June 21, 2011","June 2011","April 12, 2010","PIFNPK","November 2008","Number of Participants With Sustained Virologic Response (SVR)|Number of Participants With Normalization of Liver Enzymes|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00085917"
512,"NCT02268864","A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants","Active, not recruiting","No Results Available","Hepatitis C, Chronic","Drug: Simeprevir|Drug: Daclatasvir","Janssen-Cilag International NV","Both","Adult|Senior","Phase 2","106","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CR105490|2014-003413-28|TMC435HPC2019","October 15, 2014","January 2015","March 2016","September 24, 2015","September 2015","No Study Results Posted","COMMIT","November 2015","Percentage of Participants With Sustained Virologic Response 12 Weeks After end of Study Drug Treatment (SVR12)|Percentage of Participants with SVR 4 Weeks After end of Study Drug Treatment (SVR4) and SVR 24 Weeks After end of Study Drug Treatment (SVR24)|Percentage of Participants with On-treatment Failure|Percentage of Participants with viral breakthrough|Percentage of Participants With Viral Relapse","https://ClinicalTrials.gov/show/NCT02268864"
513,"NCT00943761","A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)","Completed","Has Results","Hepatitis C, Chronic","Drug: Vaniprevir 600 mg b.i.d.|Drug: Vaniprevir 300 mg b.i.d.|Drug: Pegylated interferon|Drug: Ribavirin","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","7009-028|2009_615|2009-013053-15","July 21, 2009","October 2009","May 2013","September 1, 2015","September 2015","September 26, 2014","null","May 2013","Number of Participants Who Experienced an Adverse Event|Number of Participants Who Experienced a Serious Adverse Event|Number of Participants Who Discontinued Study Treatment Due to an Adverse Event|Percentage of Participants Who Achieved Sustained Viral Response 24 Weeks After the End of Treatment (SVR24)","https://ClinicalTrials.gov/show/NCT00943761"
514,"NCT01765231","Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma","Recruiting","No Results Available","Hepatitis B","Drug: Entecavir prophylaxis|Drug: Observation arm","Peking University","Both","Adult|Senior","Phase 4","190","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","PKU-2012111305","January 9, 2013","January 2013","December 2016","January 21, 2015","January 2015","No Study Results Posted","null","December 2015","the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis|the incidence of hepatitis B virus maintained response, the incidence of hepatitis B virus sustained response, the incidence of hepatitis B virus relapse and hepatitis B virus relapse related hepatitis","https://ClinicalTrials.gov/show/NCT01765231"
515,"NCT01473849","Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients","Active, not recruiting","No Results Available","Cytomegalovirus Infection|Hepatitis C","","Sociedad Espa√±ola de Trasplante Hep√°tico|Roche Farma, S.A","Both","Adult|Senior","","179","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","VHENUS","May 30, 2011","May 2010","April 2013","December 19, 2012","December 2012","No Study Results Posted","VHENUS","March 2013","Effect of CMV replication over hepatitis C recurrence|Effect of CMV replication over fibrosis in graft after Hepatitis C recurrence after transplantation|Effect of CMV recurrence over graft and patient survival|Relationship between viral charge of CMV and HCV during study period","https://ClinicalTrials.gov/show/NCT01473849"
516,"NCT00984139","Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination","Completed","Has Results","Hepatitis B","Biological: Engerix‚Ñ¢-B Kinder","GlaxoSmithKline","Both","Child","Phase 4","306","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","112682","September 24, 2009","October 2009","April 2010","July 3, 2014","March 2012","February 3, 2011","null","April 2010","Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations as Measured by ELISA Equal to or Above Cut-off Value|Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations as Measured by ChemiLuminescence ImmunoAssay (CLIA) Equal to or Above Cut-off Value.|Number of Subjects With Anti-HBs Antibody Concentrations as Measured by ELISA Equal to or Above Cut-off Values|Number of Subjects With Anti-HBs Antibody Concentrations as Measured by CLIA Equal to or Above Cut-off Values|Number of Subjects With Solicited Local and General Symptoms|Number of Subjects With Serious Adverse Events (SAEs)|Number of Subjects With Unsolicited Adverse Events (AEs)|Number of Subjects With Anamnestic Response to the Challenge Dose as Measured by ELISA.|Number of Subjects With Anamnestic Response to the Challenge Dose as Measured by CLIA.","https://ClinicalTrials.gov/show/NCT00984139"
517,"NCT01671787","A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: GS-7340|Drug: Tenofovir disoproxil fumarate","Gilead Sciences","Both","Adult","Phase 1","51","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","GS-US-320-0101","August 21, 2012","March 2012","April 2013","May 8, 2014","May 2014","No Study Results Posted","null","April 2013","Change in serum hepatitis B virus (HBV) DNA|Change in HBV DNA for tenofovir disoproxil fumarate (TDF)|Change in HBV DNA of GS-7340 through 28 days of therapy|Pharmacokinetics (PK) of GS-7340 and/or tenofovir (TVF) following single and multiple doses of GS-7340 and TDF|Safety and Tolerability of Therapy","https://ClinicalTrials.gov/show/NCT01671787"
518,"NCT00629824","Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: pegylated interferon alpha and plus ribavirin|Drug: pegylated interferon alpha and plus ribavirin|Drug: pegylated interferon alpha and plus ribavirin","Kaohsiung Medical University Chung-Ho Memorial Hospital","Both","Adult|Senior","Phase 4","250","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","KMUH-IRB- 960047","February 26, 2008","February 2007","April 2009","September 6, 2010","February 2007","No Study Results Posted","null","April 2009","Efficacy: Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.|RVR, rapid virological response, defined as HCV RNA < 50 IU/mL at treatment week 4","https://ClinicalTrials.gov/show/NCT00629824"
519,"NCT02387684","Efficay of Extended Peginterferon Alpha 2a Treatment in HBeAg Negative Chronic Hepatitis B Patients","Active, not recruiting","No Results Available","Chronic Hepatitis B","","Beijing Ditan Hospital","Both","Adult","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DTXY007","March 1, 2015","April 2012","December 2016","March 8, 2015","March 2015","No Study Results Posted","null","December 2016","rate of sustained viral response|rate of HBsAg loss","https://ClinicalTrials.gov/show/NCT02387684"
520,"NCT01928511","Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy","Recruiting","No Results Available","Chronic Hepatitis B","Drug: peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly|Drug: Nucleos(t)ide analogue therapy","Seng Gee Lim|Tan Tock Seng Hospital|Singapore Clinical Research Institute|Merck Sharp & Dohme Corp.|National University Health System, Singapore","Both","Adult","Phase 4","310","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","MK4031-398|CIRG12may075","August 21, 2013","January 2014","January 2016","January 8, 2014","January 2014","No Study Results Posted","SWAP","January 2016","Reduction in quantitative HBsAg>1 log|HBeAg loss|HBsAg seroclearance|HBeAg seroconversion|HBsAg <200 IU/ml|undetectable HBV DNA","https://ClinicalTrials.gov/show/NCT01928511"
521,"NCT00977054","Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load","Terminated","No Results Available","Hepatitis C","Drug: DFPP + Peg-IFN + RBV|Drug: Peg-IFN + RBV","National Taiwan University Hospital|National Science Council, Taiwan|Department of Health, Executive Yuan, R.O.C. (Taiwan)","Both","Adult|Senior","Phase 4","59","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","200904053D","September 13, 2009","September 2009","December 2012","December 19, 2012","December 2012","No Study Results Posted","null","December 2012","Sustained virologic response (SVR)|Rapid virologic response (RVR)|Treatment-related withdrawal rate","https://ClinicalTrials.gov/show/NCT00977054"
522,"NCT01890772","Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1","Withdrawn","No Results Available","Hepatitis C","Drug: Telaprevir|Drug: Peginterferon alfa-2a|Drug: Ribavirin|Dietary Supplement: Vitamin D","Timothy Morgan, MD|Vertex Pharmaceuticals Incorporated|Southern California Institute for Research and Education","Both","Adult|Senior","Phase 2|Phase 3","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","1217","May 31, 2013","August 2013","null","May 13, 2014","May 2014","No Study Results Posted","null","October 2015","HCV RNA|adverse event profile","https://ClinicalTrials.gov/show/NCT01890772"
523,"NCT00148863","Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic","Drug: Peg-interferon alpha 2a (drug)|Drug: Ribavirin (drug)|Drug: Interferon gamma (drug)","French National Agency for Research on AIDS and Viral Hepatitis|InterMune|Hoffmann-La Roche","Both","Adult|Senior","Phase 2","65","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","2004-005033-19|ANRS HC16 Gammatri","September 7, 2005","June 2004","August 2007","August 29, 2007","August 2007","No Study Results Posted","null","null","Virological response as defined by an HCV RNA measure non detectable at W28 with qualitative PCR (centralized measure)|Virological response at W72|Biochemical response at W72 (ALT below normal value)|Quality of life|Immunologic response (CD4 and CD8 HCV specific)|Safety","https://ClinicalTrials.gov/show/NCT00148863"
524,"NCT00734162","Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection","Active, not recruiting","Has Results","Hepatitis B Virus (HBV)","Drug: Tenofovir disoproxil fumarate (TDF)|Drug: Placebo","Gilead Sciences","Both","Child","Phase 3","106","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","GS-US-174-0115","August 13, 2008","December 2008","January 2016","October 7, 2015","October 2015","October 8, 2012","null","March 2011","Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) < 400 Copies/mL at Week 72|Number of Participants With at Least a 6% Decrease From Baseline in Bone Mineral Density (BMD) of the Spine at Week 72|Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48|Percentage of Participants With HBV DNA < 169 Copies/mL at Week 48|Percentage of Participants With HBV DNA < 169 Copies/mL at Week 72|Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 48|Percentage of Participants With Normal ALT at Week 72|Percentage of Participants With Abnormal ALT at Baseline Who Had Normalized ALT at Week 48|Percentage of Participants With Abnormal ALT at Baseline Who Had Normalized ALT at Week 72|Percentage of Participants With HBV DNA < 400 Copies/mL and Normal ALT at Week 48|Percentage of Participants With HBV DNA < 400 Copies/mL and Normal ALT at Week 72|Percentage of Participants With HBV Surface Antigen (HBsAg) Loss at Week 48|Percentage of Participants With HBsAg Loss at Week 72|Percentage of Participants With Seroconversion to Antibody Against HBV Surface Antigen (Anti-HBs) at Week 48|Percentage of Participants With Seroconversion to Anti-HBs at Week 72|Percentage of Participants Who Were HBV Early Antigen (HBeAg) Positive at Baseline and Who Had HBeAg Loss at Week 48|Percentage of Participants Who Were HBeAg Positive at Baseline and Who Had HBeAg Loss at Week 72|Percentage of Participants Who Were HBeAg Positive at Baseline and Who Had Seroconversion to Antibody Against HBV Early Antigen (Anti-HBe) at Week 48|Percentage of Participants Who Were HBeAg Positive at Baseline and Who Had Seroconversion to Anti-HBe at Week 72|Percentage of Participants Who Were HBeAg Positive at Baseline and Who Had HBV DNA < 400 Copies/mL, Normal ALT, and HBeAg Loss at Week 48|Percentage of Participants Who Were HBeAg Positive at Baseline and Who Had HBV DNA < 400 Copies/mL, Normal ALT, and HBeAg Loss at Week 72|Percentage of Participants Who Were HBeAg Positive at Baseline and Who Had HBV DNA < 400 Copies/mL, Normal ALT, and Seroconversion to HBeAg at Week 48|Percentage of Participants Who Were HBeAg Positive at Baseline and Who Had HBV DNA < 400 Copies/mL, Normal ALT, and Seroconversion to HBeAg at Week 72|Percentage of Participants Who Had Abnormal ALT at Baseline and Who Had HBV DNA < 400 Copies/mL and ALT Normalized at Week 48|Percentage of Participants Who Had Abnormal ALT at Baseline and Who Had HBV DNA < 400 Copies/mL and ALT Normalized at Week 72|Percentage of Participants Who Were HBeAG Positive With Abnormal ALT at Baseline, and Who Had HBV DNA < 400 Copies/mL, ALT Normalized, and HBeAg Loss at Week 48|Percentage of Participants Who Were HBeAG Positive With Abnormal ALT at Baseline, and Who Had HBV DNA < 400 Copies/mL, ALT Normalized, and HBeAg Loss at Week 72|Percentage of Participants Who Were HBeAG Positive With Abnormal ALT at Baseline, and Who Had HBV DNA < 400 Copies/mL, ALT Normalized, and Seroconversion to HBeAg at Week 48|Percentage of Participants Who Were HBeAG Positive With Abnormal ALT at Baseline, and Who Had HBV DNA < 400 Copies/mL, ALT Normalized, and Seroconversion to HBeAg at Week 72|Number of Participants With at Least a 6% Decrease From Baseline in Spine BMD at Week 48|Percent Change From Baseline in Spine BMD at Week 48|Percent Change From Baseline in Spine BMD at Week 72|Change in Z-score for Spine BMD at Week 48|Change in Z-score for Spine BMD at Week 72|Percent Change From Baseline in Whole Body BMD at Week 48|Percent Change From Baseline in Whole Body BMD at Week 72|Change in Z-score for Whole Body BMD at Week 48|Change in Z-score for Whole Body BMD at Week 72|Number of Participants With Changes in Drug-resistant Mutations at Week 48|Number of Participants With Changes in Drug-resistant Mutations at Week 72","https://ClinicalTrials.gov/show/NCT00734162"
525,"NCT02387463","Efficacy of Extended Peginterferon Alpha 2a Treatment in HBeAg Positive Chronic Hepatitis B Patients","Active, not recruiting","No Results Available","Chronic Hepatitis B","","Beijing Ditan Hospital","Both","Adult","","140","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DTXY008","March 8, 2015","March 2012","December 2016","March 12, 2015","March 2015","No Study Results Posted","null","December 2016","rate of HBeAg seroconversion (defined as HBeAg loss with anti-HBe positive after PEG-IFN a-2a treatment and follow up)|rate of HBsAg loss (defined as HBsAg level lower than 0.05 IU/ml)|rate of sustained viral response (defined as serum HBV DNA undetectable at the end of treatment and the end of follow up)","https://ClinicalTrials.gov/show/NCT02387463"
526,"NCT00338780","Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)","Completed","No Results Available","Chronic Hepatitis B","Drug: Lamivudine/ Placebo 100mg daily","Chinese University of Hong Kong|GlaxoSmithKline","Both","Adult","Phase 4","null","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","NUC30934","June 19, 2006","November 2000","January 2005","October 27, 2006","October 2006","No Study Results Posted","null","null","Proportion of patients with complete response (normalisation of LAT, ie. <1xULN and disappearance of HBV DNA, lower limit of detection), at MOnth 24|Proportion of patients with partial response|Histological improvement at month 24|Proportion of patients with complete response post-treatment (at Month 30)|Proportion of patinets with partial response post-treatment (at Month 30)|Progression of fibrosis|Progression of fibrosis to cirrhosis|HBsAg seroconversion|Safety of treatment","https://ClinicalTrials.gov/show/NCT00338780"
527,"NCT02065999","Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients","Recruiting","No Results Available","Chronic Hepatitis C Infection","","Kirby Institute|The University of New South Wales|Merck Sharp & Dohme Corp.","Both","Child|Adult|Senior","","100","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","VHCRP1107","February 16, 2014","November 2012","March 2017","March 30, 2015","March 2015","No Study Results Posted","SEARCH-C","March 2017","Prevalence of HCV resistance associated variants (RAVs) and the incidence of RAVs arising during therapy.|Factors associated with treatment failure due to virological breakthrough / relapse.","https://ClinicalTrials.gov/show/NCT02065999"
528,"NCT01151397","Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?","Not yet recruiting","No Results Available","Chronic Hepatitis C","Drug: Peg + Vitamin D + Ribavirin|Drug: Peg + Ribavirin","Ziv Hospital","Both","Adult","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","Genotype 2,3 HCV +Vitamin D","June 16, 2010","August 2011","July 2012","April 27, 2011","June 2010","No Study Results Posted","null","February 2012","sustained virologic response (SVR)rate","https://ClinicalTrials.gov/show/NCT01151397"
529,"NCT00580801","An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection","Completed","Has Results","Hepatitis C","Drug: Telaprevir|Drug: Pegylated-interferon-alfa-2a|Drug: Placebo|Drug: Ribavirin","Tibotec BVBA","Both","Adult","Phase 2","24","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","CR013714|VX-950-TiDP24-C210","December 20, 2007","January 2008","January 2010","August 27, 2013","August 2013","March 7, 2013","null","January 2010","Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Day 15|Percentage of Participants With Viral Response (Undetectable HCV RNA)|Median Time to First Viral Response (Undetectable HCV RNA)|Number of Participants With Viral Breakthrough (Detectable HCV RNA)|Percentage of Participants With Sustained Viral Response (SVR)|Percentage of Participants With Relapse|Area Under the Serum Concentration-Time Curve (AUC)|Maximum Serum Concentration (Cmax) of Telaprevir|Pre-Dose Serum Concentration (C[0h]) of Telaprevir|Minimum Serum Concentration (Cmin) of Telaprevir on Day 15|Time to Reach the Maximum Serum Concentration (Tmax) of Telaprevir|Average Steady-State Serum Concentration (Css,av) of Telaprevir","https://ClinicalTrials.gov/show/NCT00580801"
530,"NCT00322179","Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C|Obesity","","Palo Alto Veterans Institute for Research|Hoffmann-La Roche","Both","Adult|Senior","","22","Other|Industry","Observational","","CHR0036|PEG215","May 4, 2006","November 2005","November 2008","March 4, 2015","March 2015","No Study Results Posted","null","November 2007","","https://ClinicalTrials.gov/show/NCT00322179"
531,"NCT00575224","Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9","Completed","No Results Available","Chronic Hepatitis C|Asian Americans|Novel Genotypes|Treatment","Drug: Pegylated interferon and ribavirin","Pacific Health Foundation|Hoffmann-La Roche","Both","Adult|Senior","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","PEG-183|IRB Protocol #20041038|IRB Study #1059635","December 15, 2007","October 2004","September 2009","November 23, 2009","November 2009","No Study Results Posted","null","September 2009","Sustained virologic response","https://ClinicalTrials.gov/show/NCT00575224"
532,"NCT00805389","Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine","Completed","Has Results","Hepatitis B","Biological: Engerix-B‚Ñ¢|Biological: Fendrix‚Ñ¢|Biological: GSK Biologicals' Hepatitis B vaccines (GSK223192A)|Biological: HBsAg (Booster injection)","GlaxoSmithKline","Both","Adult","Phase 2","713","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator)","112115","December 5, 2008","December 2008","July 2011","February 12, 2015","June 2014","December 19, 2012","null","July 2011","Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells .|Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells.|Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells.|Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells|Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells|Number of Hepatitis B (HB)-Specific Cluster of Differentiation 4 (CD4+) T Cells Expressing T Helper Cell Type 1 Response/T Helper Cell Type 2 Response (Th1/Th2) Cytokine Profile|Number of Hepatitis B (HB)-Specific Cluster of Differentiation 8 (CD8+) T Cells Expressing T Helper Cell Type 1 Response/T Helper Cell Type 2 Response (Th1/Th2) Cytokine Profile|Anti-Hepatitis B (Anti-HB) Antibody Concentrations in Serum, as Measured by Chemi Luminescence Immuno Assay (CLIA)|Number of Hepatitis B (HB)-Specific Memory B Cells|Concentrations of the Interferon-gamma (IFN-g), Interleukin (IL)-1beta, IL-5, IL-6, IL-10, Tumor Necrosis Factor-alpha, IFN-g-inducible Protein-10 and Monocyte Chemotactic Protein-1 Cytokines in Serum|Normalized Levels of White Blood Cells (WBC) and Creatine Phosphokinases (CPK)|Normalized Levels of C-reactive Protein (CRP)|Normalized Levels of White Blood Cells (WBC) and of Creatine Phosphokinases (CPK)|Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils|Normalized Levels of Red Blood Cells and Platelets|Normalized Levels of Haemoglobin, Alanine Aminotransferase and Aspartate Aminotransferase|Normalized Levels of Serum Creatinine, Urea and Lactate Dehydrogenase|Number of Subjects With Normal and Abnormal Levels of White Blood Cells, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, C-reactive Protein, and Creatine Phosphokinase.|Number of Subjects With Normal and Abnormal Levels of Red Blood Cells, Platelets, Haemoglobin, Alanine Aminotransferase, Aspartate Aminotransferase, Serum Creatinine, Urea and Lactate Dehydrogenase|Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms Following Primary Vaccination.|Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms Following Primary Vaccination.|Number of Subjects Reporting Any, Grade 3 and Related Solicited Local Symptoms Following Booster Vaccination.|Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms Following Booster Vaccination.|Number of Subjects Reporting Any, Grade 3 and/or Related Unsolicited Adverse Events (AEs) Following Primary Vaccination|Number of Subjects Reporting Any, Grade 3 and/or Related Unsolicited Adverse Events (AEs) Following Booster Vaccination|Number of Subjects Reporting Any and Related Adverse Events of Specific Interest (AESIs)|Number of Subjects Reporting Any Serious Adverse Events (SAEs) and SAEs Related to Study Vaccination|Gene Expression Signature Related to the Immune Response to the GSK223192A, Fendrix‚Ñ¢ and Engerix-B‚Ñ¢ Vaccines.","https://ClinicalTrials.gov/show/NCT00805389"
533,"NCT02591277","Use-Results Surveillance Study of Harvoni¬Æ in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection","Not yet recruiting","No Results Available","Hepatitis C","Drug: Harvoni","Gilead Sciences","Both","Child|Adult|Senior","","3000","Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","GS-US-337-1498","October 28, 2015","November 2015","November 2018","October 28, 2015","October 2015","No Study Results Posted","null","November 2018","Incidence of adverse drug reaction (ADR) under real world settings|Proportion of participants with sustained virologic response (SVR) 12 and 24 weeks after discontinuation of therapy (SVR12 and SVR24)|Proportion of participants with HCV NS5A and NS5B resistance associated variants among patients who do not achieve SVR at 12 weeks","https://ClinicalTrials.gov/show/NCT02591277"
534,"NCT00018031","Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients","Completed","Has Results","Hepatitis C|HIV Infections","Drug: Peginterferon alfa-2b|Drug: Ribavirin","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","36","NIH","Interventional","Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","010194|01-I-0194","June 27, 2001","June 2001","April 2009","September 25, 2014","September 2014","January 18, 2013","HEPCPR","April 2009","Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response","https://ClinicalTrials.gov/show/NCT00018031"
535,"NCT01768715","Liver Transplantation in Alcoholic Hepatitis","Suspended","No Results Available","Alcoholic Hepatitis","","Sociedad Espa√±ola de Trasplante Hep√°tico|Fundaci√≥n Mutua Madrile√±a","Both","Adult","","40","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","SETH-HA","December 29, 2012","January 2013","December 2017","June 2, 2014","June 2014","No Study Results Posted","SETH-HA","December 2014","Evaluate survival of patients with severe alcoholic hepatitis non responsive to therapy after liver transplantation|Evaluate the applicability of liver transplantation in patients with alcoholic hepatitis non responsive to steroid therapy|Evaluate the mortality in waiting list for transplantation of patients with alcoholic hepatitis unresponsive to steroid therapy|Evaluate the rate of alcohol recidivism after liver transplantation for alcoholic hepatitis|Evaluate survival of patients with alcoholic hepatitis after liver transplantation.","https://ClinicalTrials.gov/show/NCT01768715"
536,"NCT00342186","Genes Involved in Resistance or Susceptibility to Hepatitis B Virus","Completed","No Results Available","Hepatitis, Viral, Human","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Both","Child|Adult|Senior","","3400","NIH","Observational","Time Perspective: Cross-Sectional","999902323|02-C-N323","June 19, 2006","September 2002","null","February 4, 2015","January 2015","No Study Results Posted","null","null","Collection of 3400 samples","https://ClinicalTrials.gov/show/NCT00342186"
537,"NCT00421434","Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: Nitazoxanide|Biological: Peginterferon alfa-2a|Biological: Peginterferon alfa-2a|Drug: Ribavirin|Drug: Ribavirin","Romark Laboratories L.C.","Both","Adult|Senior","Phase 2|Phase 3","121","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","RM01-3036","January 10, 2007","June 2006","September 2008","September 23, 2008","September 2008","No Study Results Posted","STEALTHC-1","September 2008","Sustained virologic response|End of treatment virologic response|Early virologic response|Rapid virologic response|ALT normalization","https://ClinicalTrials.gov/show/NCT00421434"
538,"NCT00095121","Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B","Completed","Has Results","Chronic Hepatitis B","Drug: Placebo (PLB)|Drug: Adefovir Dipivoxil (ADV)|Drug: Lamivudine","Gilead Sciences","Both","Child","Phase 3","173","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","GS-US-103-0518","October 29, 2004","June 2004","April 2010","May 16, 2012","May 2012","April 8, 2011","null","May 2006","Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 1000 Copies/mL (Polymerase Chain Reaction [PCR]-Based Assay) and Normal Alanine Aminotransferase (ALT) at Week 48 (Missing = Failure)|Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Baseline)|Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment - Missing = Failure) (ADV Week 192)|Percentage of Participants With Serum HBV DNA < 1000 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 240)|Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Baseline)|Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 192)|Percentage of Participants With Serum HBV DNA < 400 Copies/mL (PCR-based Assay) While on Treatment (Missing = Failure) (ADV Week 240)|Adefovir (ADV) Baseline Serum HBV DNA|Change From ADV Baseline to ADV Week 192 for Serum HBV DNA|Change From ADV Baseline to ADV Week 240 for Serum HBV DNA|ADV Baseline ALT|Change From ADV Baseline to ADV Week 192 for ALT|Change From ADV Baseline to ADV Week 240 for ALT|Percentage of Participants With Normal ALT at Adefovir Baseline (Missing = Failure)|Percentage of Participants With Normal ALT at ADV Week 192 (Missing = Failure)|Percentage of Participants With Normal ALT at ADV Week 240 (Missing = Failure)|Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss or Seroconversion by End of Blinded Treatment (Study Week 48; Randomized and Treated Analysis Set)|Percentage of Participants With HBeAg Loss or Seroconversion by ADV Week 192 (Open Label Analysis Set, Participants Who Were HBeAg Positive at ADV Baseline; Missing = Excluded)|Percentage of Participants With HBeAg Loss or Seroconversion by ADV Week 240 (Open Label Analysis Set, Participants Who Were HBeAg Positive at ADV Baseline; Missing = Excluded)|Cumulative Summary of Participants With HBV Genotypic Changes From Baseline (Resistance Surveillance)|Cumulative Summary of Participants With HBV Genotypic Changes From Baseline (Resistance Surveillance) for Subjects Who Received Combination ADV + Lamivudine Therapy|Percentage of Participants With Durable HBeAg Seroconversion","https://ClinicalTrials.gov/show/NCT00095121"
539,"NCT00200343","Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C","Completed","Has Results","Chronic Hepatitis C","Drug: Ursodeoxycholic acid 150mg / day|Drug: Ursodeoxycholic acid 600mg / day|Drug: Ursodeoxycholic acid 900mg / day","Mitsubishi Tanabe Pharma Corporation","Both","Adult|Senior","Phase 3","596","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","MT711-01","September 12, 2005","July 2002","December 2004","March 7, 2012","March 2012","August 17, 2011","null","null","Alanine Aminotransferase at Baseline|Percentage Change of Alanine Aminotransferase From Baseline at Week 24|Aspartate Aminotransferase at Baseline|Percentage Change of Aspartate Aminotransferase From Baseline at Week 24|Gamma-glutamyl Transpeptidase at Baseline|Percentage Change of Gamma-glutamyl Transpeptidase From Baseline at Week 24","https://ClinicalTrials.gov/show/NCT00200343"
540,"NCT00466336","Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices","Completed","No Results Available","Chronic Hepatitis C|Hepatic Fibrosis|Cirrhosis","","National Taiwan University Hospital","Both","Adult|Senior","","503","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","200612012R","April 25, 2007","January 2003","January 2007","March 5, 2008","March 2008","No Study Results Posted","null","December 2006","","https://ClinicalTrials.gov/show/NCT00466336"
541,"NCT00834860","Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma","Active, not recruiting","No Results Available","Chronic Hepatitis C|Hepatocellular Carcinoma","Drug: peginterferon alpha-2a and ribavirin","Kaohsiung Medical University Chung-Ho Memorial Hospital","Both","Adult|Senior","Phase 4","179","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","KMUH-IRB-960043","February 1, 2009","January 2007","February 2010","February 11, 2010","February 2009","No Study Results Posted","null","December 2009","Efficacy: sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.|Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.|Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.|Safety: adverse event rate and profile.","https://ClinicalTrials.gov/show/NCT00834860"
542,"NCT00354653","A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone","Active, not recruiting","No Results Available","Chronic Hepatitis B","Drug: LAMIVUDINE","GlaxoSmithKline","Both","Child|Adult|Senior","Phase 4","100","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","NUC 30956","July 19, 2006","February 2002","null","July 24, 2007","July 2007","No Study Results Posted","null","null","Complete virologic response at Month 24 which is normalisation of alanine aminotransferase (ALT) and disappearance of HBV DNA by NAXCOR(brand name of a virus assay kit)|Partial response, histological improvement (at 24 months). Sustained complete response, sustained partial response at 30 months.","https://ClinicalTrials.gov/show/NCT00354653"
543,"NCT01183169","Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders","Completed","No Results Available","Hepatitis C Chronic","Drug: DEB025 600 mg QD + PegIFN + RBV|Drug: DEB025 800 mg QD + PegIFN + RBV|Drug: placebo + PegIFN + RBV|Drug: placebo + PegIFN + RBV|Drug: DEB025 400 mg BID + PegIFN + RBV","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 2","459","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","CDEB025A2210|2010-020033-14","August 16, 2010","August 2010","May 2013","March 19, 2015","March 2015","No Study Results Posted","null","May 2013","cEVR (complete early virologic response) i.e. HCV RNA < 25 IU/mL (by Limit of Quantitation, LOQ) ; the primary efficacy comparison is between DEB025 active plus peg-IFNŒ±2a once weekly + RBV BID and DEB025 placebo plus peg-IFNŒ±2a once weekly + RBV BID|SVR12: sustained virologic response 12 weeks following cessation of therapy, defined as HCV RNA negative (by LOQ)|cEVR after 12 week triple therapy with 600 mg DEB025 daily plus peg-IFNŒ±2a once weekly + RBV BID versus 800 mg daily plus peg-IFNŒ±2a once weekly + RBV BID versus 400 mg BID plus peg-IFNŒ±2a once weekly + RBV BID.","https://ClinicalTrials.gov/show/NCT01183169"
544,"NCT00869778","Therapeutic Hepatitis B Vaccine (Synthesized Peptide) in Treating Chronic Hepatitis B Patients","Active, not recruiting","No Results Available","Chronic Hepatitis B","Biological: The therapeutic (synthesized peptide) HBV vaccine (ŒµPA-44)|Biological: Placebo","Chongqing Jiachen Biotechnology Ltd.|Third Military Medical University","Both","Adult","Phase 2","360","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","71006.01","March 25, 2009","June 2009","June 2013","June 14, 2012","June 2012","No Study Results Posted","null","March 2013","Primary efficacy assessment is the proportion of patients about HBeAg / anti-HBe seroconversion at the end of the follow-up period.|Secondary efficacy parameters include serology response at week 12, 28, 32, 40, 52, 64,76, 95,108, 120, 144.|Virological response at each observation time point at week 12, 28, 32, 40, 52, 64, 76.|Biochemistry response at every observation point.|Virological response at each observation time point at week 95, 108, 120, 144.","https://ClinicalTrials.gov/show/NCT00869778"
545,"NCT02366208","Phase II Trial for Combination Treatment of PEG-TŒ±1 and Adefovir for HBeAg Positive Chronic Hepatitis B","Completed","No Results Available","Hepatitis B, Chronic","Drug: PEG-TŒ±1|Drug: Placebo to match PEG-TŒ±1|Drug: Adefovir","Jiangsu Hansoh Pharmaceutical Co., Ltd.|Nanjing Medical University","Both","Adult","Phase 2","116","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","HS-20046-2","February 12, 2015","May 2011","August 2013","February 12, 2015","January 2015","No Study Results Posted","PEG-TŒ±1","June 2013","loss of HBeAg|loss of HBV DNA|HBeAg seroconversion|alanine aminotransferase normalization","https://ClinicalTrials.gov/show/NCT02366208"
546,"NCT00709059","Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243)","Completed","Has Results","Hepatitis C, Chronic","Biological: PegIntron (peginterferon alfa-2b; SCH 54031)|Drug: Rebetol (ribavirin; SCH 18908)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","538","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P04243","June 23, 2008","December 2004","December 2009","January 28, 2015","January 2015","December 22, 2010","PRACTICE","December 2009","Number of Study Participants Who Had a Virological Response (VR) at Week-72","https://ClinicalTrials.gov/show/NCT00709059"
547,"NCT00252642","Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C","Completed","No Results Available","Hepatitis C|Cirrhosis|Fibrosis","Drug: Peginterferon Alpha-2a","Virginia Commonwealth University|Hoffmann-La Roche","Both","Adult|Senior","","60","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Open Label","PH-VCU-05","November 9, 2005","November 2005","September 2007","December 14, 2007","August 2006","No Study Results Posted","null","null","Changes in portal pressure after 6 moths of treatment with peginterferon alfa-2a will be calculated by comparing portal pressure at the end of HALT-C to values obtained after 6 months of peginterferon.","https://ClinicalTrials.gov/show/NCT00252642"
548,"NCT02366247","Phase ‚Ö¢ Trial for Combination Treatment of PEG-TŒ±1 and Adefovir for HBeAg-positive Chronic Hepatitis B","Active, not recruiting","No Results Available","Hepatitis B, Chronic","Drug: PEG-TŒ±1|Drug: Placebo to match PEG-TŒ±1|Drug: Adefovir","Jiangsu Hansoh Pharmaceutical Co., Ltd.|Nanjing Medical University","Both","Adult","Phase 3","463","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","HS-20046-3","February 12, 2015","August 2013","February 2016","February 12, 2015","January 2015","No Study Results Posted","PEG-TŒ±1","December 2015","Loss of HBeAg|Loss of HBV DNA|HBeAg seroconversion|Alanine aminotransferase normalization","https://ClinicalTrials.gov/show/NCT02366247"
549,"NCT00926757","Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B","Completed","No Results Available","Non Hodgkin's Lymphoma|Hepatitis B","Drug: Entecavir prophylaxis|Drug: Therapeutic entecavir","Taipei Veterans General Hospital, Taiwan|Bristol-Myers Squibb","Both","Child|Adult|Senior","Phase 4","80","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor)","VGHUST98-P1-07|VGHIRB98-01-08","June 22, 2009","April 2009","November 2012","May 27, 2013","May 2013","No Study Results Posted","HBVNHL","November 2012","The primary endpoint is the incidence of HBV reactivation during and within 12 months after chemotherapy|The incidence of HBsAg reverse seroconversion during and within 12 months after completing chemotherapy.","https://ClinicalTrials.gov/show/NCT00926757"
550,"NCT01918462","Protective Immune Mechanisms in Alcoholic Hepatitis","Recruiting","No Results Available","Alcoholic Hepatitis","","University of Aarhus","Both","Adult|Senior","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AHIL|AUH","June 25, 2013","April 2013","January 2018","August 5, 2013","August 2013","No Study Results Posted","AHIL","January 2017","Frequency of IL-22-producing cells|IL-22 binding protein|IL-22 receptor|Signalling molecules and markers of hepatocyte destruction","https://ClinicalTrials.gov/show/NCT01918462"
551,"NCT01480284","Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue","Completed","Has Results","Hepatitis B, Chronic","Drug: GSK548470 300 mg tablet|Drug: ETV 0.5 mg capsule","GlaxoSmithKline","Both","Child|Adult|Senior","Phase 3","166","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","115409","November 23, 2011","November 2011","November 2014","June 11, 2015","April 2015","August 22, 2013","null","January 2013","Mean Change From Baseline in Serum HBV DNA Level at Week 24|Mean Change From Baseline in Serum HBV DNA Level at Week 48 and Week 96|Number of Participants With Serum HBV DNA < 2.1 log10 Copies/mL at Week 24, Week 48 and Week 96|Number of Participants With Alanine Aminotransferase (ALT) Normalization at Week 24, Week 48 and Week 96|Number of Participants With HBeAg Loss at Week 24, Week 48 and Week 96|Number of Participants With HBeAg/HBeAb Seroconversion at Week 24, Week 48 and Week 96|Number of Participants Achieving HBsAg Loss at Week 24, Week 48 and Week 96|Number of Participants Achieving HBsAg/HBsAb Seroconversion at Week 24, Week 48 and Week 96|Number of Participants Achieving Each Indicated HBsAg Category at Baseline, Week 24, Week 48 and Week 96|Number of Participants Achieving Each Indicated HBcrAg Category at Baseline, Week 24, Week 48 and Week 96|Number of Participants With Virological Breakthrough Through End of the Study|Number of Participants With Resistance Related Mutations at Week 24, Week 48, Week 96 and Virological Breakthrough (Baseline to Throughout the Study)","https://ClinicalTrials.gov/show/NCT01480284"
552,"NCT00944684","High Dose Ribavirin in the Treatment of Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: High ribavirin dose|Drug: Standard ribavirin dose","University of Bern|Roche Pharma AG|University of Lausanne|Cantonal Hospital of St. Gallen|Stadtspital Waid, Z√ºrich, Switzerland|University of Basel","Both","Adult","Phase 2","32","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","091/07|ML21071|SASL-24","July 17, 2009","November 2007","April 2011","November 10, 2011","November 2011","No Study Results Posted","null","April 2011","Sustained virological response|Adverse Events|Rapid virological response at 4 weeks of treatment|Early virological response at 12 weeks of treatment","https://ClinicalTrials.gov/show/NCT00944684"
553,"NCT01023217","Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir","Completed","Has Results","Hepatitis B, Chronic","Drug: Adefovir|Drug: Entecavir|Drug: Lamivudine","Asan Medical Center","Both","Child|Adult|Senior","Phase 4","90","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","AMC-2009-0536","December 1, 2009","November 2009","September 2012","January 15, 2014","January 2014","November 23, 2013","CAESAR","July 2012","Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)|Reduction in Serum HBV DNA Levels|Genotypic Resistance to ADV or ETV|Normalization of ALT Level","https://ClinicalTrials.gov/show/NCT01023217"
554,"NCT00749138","Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy","Completed","No Results Available","Chronic Hepatitis C","Drug: tamoxifen","Bader, Ted, M.D.","Both","Adult|Senior","Phase 1","18","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","102453081873","September 4, 2008","November 2008","October 2009","March 7, 2010","March 2010","No Study Results Posted","null","May 2009","No significant changes in ALT or total bilirubin|HCV RNA reduction","https://ClinicalTrials.gov/show/NCT00749138"
555,"NCT02027116","Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection","Active, not recruiting","No Results Available","Hepatitis C, Chronic","Biological: VGX-6150","GeneOne Life Science, Inc.|Inovio Pharmaceuticals","Both","Adult","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","VGX-6150-01","January 1, 2014","January 2014","July 2015","March 12, 2015","March 2015","No Study Results Posted","VGX-6150-01","July 2015","Safety and Tolerability|Immunogenicity and virologic response","https://ClinicalTrials.gov/show/NCT02027116"
556,"NCT00735969","High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1","Completed","Has Results","Chronic Hepatitis C","Drug: Peginterferon|Drug: Ribavirin","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult","Phase 2","21","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","080149|08-DK-0149","August 14, 2008","August 2008","June 2013","October 10, 2014","October 2014","June 16, 2014","null","June 2013","Sustained Virological Response, (HCV RNA Neg.) in Serum 24 Weeks Off Therapy.","https://ClinicalTrials.gov/show/NCT00735969"
557,"NCT00135798","Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation","Completed","Has Results","Hepatitis C","Drug: LADR Treatment","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Schering-Plough|Ortho Biotech Clinical Affairs, L.L.C.","Both","Adult|Senior","Phase 2","79","NIH|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","A2ALL LADR Protocol 62498(IND)|U01DK062498|U01DK062536|U01DK062444|U01DK062467|U01DK062483|U01DK062484|U01DK062494|U01DK062496|U01DK062505|U01DK062531|CRADA through NIH-NIDDK|CTA through NIH-NIDDK|HRSA|ASTS","August 24, 2005","September 2005","December 2009","April 11, 2013","April 2013","June 13, 2012","LADR","December 2009","Patients Who Are Negative for Hepatitis C Virus (HCV) RNA at 3 Months Post-transplant: Intent-to-Treat Analysis (ITT)|Patients Who Are Negative for HCV RNA at 3 Months Post-transplant: Per-Protocol Analysis (PP)|Patients With Combined Virologic Response (CVR): Intent-to-Treat Analyses (ITT)|Patients With Combined Virologic Response (CVR): Per-Protocol Analysis (PP)","https://ClinicalTrials.gov/show/NCT00135798"
558,"NCT00728936","Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients","Completed","No Results Available","Hepatitis C","Drug: IMO-2125|Drug: placebo","Idera Pharmaceuticals, Inc.","Both","Adult","Phase 1","40","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","IMO-2125-001","August 1, 2008","September 2007","May 2010","May 15, 2012","May 2012","No Study Results Posted","null","December 2009","Evaluation of safety.|Includes evaluation of Pharmacodynamic and Pharmacokinetics","https://ClinicalTrials.gov/show/NCT00728936"
559,"NCT00597259","Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B","Recruiting","No Results Available","Chronic Hepatitis B","Drug: Pegasys plus Entecavir|Drug: Entecavir","National Taiwan University Hospital|Bristol-Myers Squibb","Both","Adult|Senior","Phase 4","294","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","200710028M|No other ID","January 9, 2008","January 2008","February 2014","June 28, 2010","June 2010","No Study Results Posted","null","February 2014","HBeAg seroconversion|Serum ALT normalization, HBeAg loss, serum HBV DNA disappearance, HBsAg disappearance, histologic change, entecavir resistance","https://ClinicalTrials.gov/show/NCT00597259"
560,"NCT01925820","Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B","Recruiting","No Results Available","Chronic Hepatitis B","Drug: Pegasys&Entecavir","National Taiwan University Hospital|Roche Pharma AG","Both","Adult|Senior","Phase 4","540","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","201205003MPC","August 16, 2013","January 2013","null","December 3, 2014","December 2014","No Study Results Posted","null","December 2018","Simultaneous achievement of HBsAg below 100 IU/mL and HBV DNA<300 IU/mL|serum HBV DNA <2000 IU/mL,HBsAg <1000 IU/mL,ALT normalization,HBsAg loss,entecavir resistance, HBsAg seroconversion,Fibrosis stages","https://ClinicalTrials.gov/show/NCT01925820"
561,"NCT01373684","PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients","Recruiting","No Results Available","Chronic Hepatitis B","Drug: Peginterferon alfa-2a|Drug: Nucleos(t)ide analogue","Foundation for Liver Research|Hoffmann-La Roche","Both","Adult|Senior","Phase 4","90","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HBV11-01","June 14, 2011","March 2012","December 2016","October 16, 2015","October 2015","No Study Results Posted","PAS","October 2016","HBsAg decline|HBsAg loss","https://ClinicalTrials.gov/show/NCT01373684"
562,"NCT00116805","A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B","Active, not recruiting","Has Results","Chronic Hepatitis B","Drug: TDF|Drug: ADV|Drug: TDF placebo|Drug: ADV placebo|Drug: FTC/TDF","Gilead Sciences","Both","Adult|Senior","Phase 3","266","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","GS-US-174-0103","June 30, 2005","June 2005","February 2016","August 21, 2015","August 2015","February 11, 2010","null","May 2007","Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48|Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48|Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96|Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384|Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, and 384|Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, and 384|Percentage of Participants With Histological Response at Week 48|Percentage of Participants With Histological Response at Week 240|Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48|Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240|Ranked Assessment of Necroinflammation and Fibrosis at Week 48|Ranked Assessment of Necroinflammation and Fibrosis at Week 240|Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48|Percentage of Participants With ALT Normalization at Week 96|Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384|Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, and 384|Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, and 384|Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss/Seroconversion at Week 48|Percentage of Participants With HBeAg Loss or Seroconversion to Anti-HBe at Week 96|Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion at Week 48|Percentage of Participants With HBsAg Loss or Seroconversion to Anti-HBs at Week 96|Percentage of Participants With HBsAg Loss or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, and 384|Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)","https://ClinicalTrials.gov/show/NCT00116805"
563,"NCT00830609","High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3","Completed","No Results Available","Chronic Hepatitis C","Drug: Peginterferon alfa 2 A|Drug: Peginterferon alfa 2 A, ribavirin + Epo Beta|Drug: ribavirin|Drug: ribavirin|Drug: Peginterferon alfa 2|Drug: ribavirin","Dr. Conrado Fernandez|Hospital Universitario Fundaci√≥n Alcorc√≥n","Both","Adult|Senior","Phase 4","101","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ROCHE FARMA S.A.","January 27, 2009","November 2008","December 2011","March 12, 2012","March 2012","No Study Results Posted","DARGEN-3","September 2011","Rate of patients with RNA-HCV negative in each arm at week 24 after the end of treatment.|Rate of patients with undetectable RNA-HCV in each arm at week 4 and 24 of treatment. Rate of adverse effects in each arm.","https://ClinicalTrials.gov/show/NCT00830609"
564,"NCT01439776","Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients","Not yet recruiting","No Results Available","Chronic Hepatitis C","Dietary Supplement: Vit D","Hanyang University|Roche Pharma AG","Both","Adult|Senior","Phase 4","222","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ML25569","September 16, 2011","September 2011","August 2013","September 22, 2011","September 2011","No Study Results Posted","Addwin","February 2013","Number of participants with Sustained virologic response (SVR)|Number of participants with End of treatment response (ETR)|Number of participants with Rapid virological response (RVR)|Number of participants with Early virological response (EVR)","https://ClinicalTrials.gov/show/NCT01439776"
565,"NCT01856426","Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects","Active, not recruiting","No Results Available","Hepatitis C","Drug: EDP239|Drug: Placebo","Enanta Pharmaceuticals","Both","Adult","Phase 1","28","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","CEDP239X2201","May 14, 2013","June 2013","October 2016","January 7, 2015","January 2015","No Study Results Posted","null","October 2016","Change from baseline Hepatitis C viral load at Day 1|Number of participants with adverse events as a measure of safety|Change from baseline in HCV RNA log|Total concentration in plasma of EDP239 in HCV Gentoype 1 infected subjects","https://ClinicalTrials.gov/show/NCT01856426"
566,"NCT00611819","Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV","Active, not recruiting","No Results Available","Chronic Hepatitis C|Co-Infection HIV-HCV","Drug: Peg interferon + Ribavirin|Drug: Peg interferon + Ribavirin","University of Valencia|Hoffmann-La Roche","Both","Adult","Phase 4","59","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","KHRONOS|2005-000203-34","January 25, 2008","November 2005","December 2008","January 25, 2008","January 2008","No Study Results Posted","null","April 2008","% of patients with RNA-HCV undetectable 24 weeks|% of patients at the end of treatment","https://ClinicalTrials.gov/show/NCT00611819"
567,"NCT00781105","Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: Telbivudine","Novartis Pharmaceuticals|Novartis","Both","Child|Adult","Phase 4","2200","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CLDT600ACN03","October 27, 2008","August 2008","null","May 3, 2012","May 2012","No Study Results Posted","Chinese PAC","September 2010","HBV DNA PCR negativity rate|DNA reduction|HBeAg loss rate|HBeAg seroconversion rate|ALT normalization rate|Incidence of AE (SAE,etc), Graded lab abnormalities","https://ClinicalTrials.gov/show/NCT00781105"
568,"NCT01560468","Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection","Active, not recruiting","No Results Available","Hepatitis C Infection","Drug: ITX 5061","Schiano, Thomas D., MD|iTherX Pharma, Inc.","Both","Adult|Senior","Phase 1","10","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","HSM 12-00045|12-0123","February 15, 2012","March 2012","October 2015","November 17, 2014","November 2014","No Study Results Posted","null","May 2015","Incidence of HCV recurrence post-transplant|Change in serum HCV RNA|Levels of ITX 5061|Viral dynamics of serum HCV RNA|Potential changes in plasma HCV E2","https://ClinicalTrials.gov/show/NCT01560468"
569,"NCT01296451","Study of a New MVA Vaccine for Hepatitis C Virus","Recruiting","No Results Available","Hepatitis C Infection","Biological: MVA-NSmut|Biological: AdCh3NSmut|Biological: AdCh3NSmut1","ReiThera Srl|University of Oxford|Oxford University Hospitals NHS Trust|University Hospital Birmingham","Both","Adult","Phase 1","48","Industry|Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HCV003|2009-018260-10","February 9, 2011","December 2010","December 2015","July 10, 2015","July 2015","No Study Results Posted","null","December 2015","Number of participant with adverse events, type and severity of adverse events|Immunogenicity","https://ClinicalTrials.gov/show/NCT01296451"
570,"NCT00371761","PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)","Completed","Has Results","Hepatitis B, Chronic (CHB)","Biological: Pegylated interferon alfa-2b (PegIntron)|Drug: Adefovir dipivoxil (adefovir)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 3","25","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P04498","August 31, 2006","September 2006","February 2009","October 7, 2015","October 2015","July 15, 2010","null","February 2009","Number of Participants With a Combined Response Consisting of All Three Responses - (a) Serological Response, (b) Virological Response, and (c) Biochemical Response","https://ClinicalTrials.gov/show/NCT00371761"
571,"NCT02023099","Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection","Active, not recruiting","No Results Available","Hepatitis C Virus","Drug: ABT-450/r/ABT-267","AbbVie","Both","Adult|Senior","Phase 3","312","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","M13-004","December 23, 2013","December 2013","October 2015","September 30, 2015","September 2015","No Study Results Posted","GIFT I","October 2014","Percentage of non-cirrhotic treatment-naive subjects who are eligible for Interferon (IFN)-based therapy and who have high viral load in the active treatment group with a sustained virologic response 12 weeks post-treatment|The percentage of subjects in the active group with on-treatment virologic failure during treatment.|The percentage of subjects in the active treatment group with post-treatment relapse|Percentage of subjects in the active treatment group with sustained virologic response 12 weeks post-treatment within different subpopulations","https://ClinicalTrials.gov/show/NCT02023099"
572,"NCT00362427","Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar¬Æ","Completed","No Results Available","Diphtheria|Pertussis|Polio|Hepatitis B|Tetanus","Biological: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|Biological: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|Biological: Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC","Sanofi Pasteur, a Sanofi Company|Merck Sharp & Dohme Corp.|Sanofi","Both","Child","Phase 2","460","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","PR504","August 9, 2006","August 2006","March 2009","January 10, 2014","January 2014","No Study Results Posted","null","February 2009","To provide information concerning the immune response of subjects that received PR5I concomitantly with Prevnar","https://ClinicalTrials.gov/show/NCT00362427"
573,"NCT01559844","Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant","Completed","Has Results","Hepatitis C|Hepatocellular Carcinoma","Drug: Sofosbuvir|Drug: Ribavirin","Gilead Sciences","Both","Adult|Senior","Phase 2","61","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","P7977-2025","March 5, 2012","March 2012","October 2014","June 2, 2015","June 2015","May 12, 2015","null","May 2014","Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12|Percentage of Participants Experiencing Any Adverse Event Leading to Permanent Discontinuation of Sobosbuvir Prior to Receiving Transplant|Percentage of Participants With Graft Loss Following Transplant|Number of Participants Who Died|Percentage of Participants With Posttransplant Virologic Response (pTVR) Through Posttransplant Week 48|Percentage of Participants With HCV RNA < LLOQ (ie, 25 mL/IU) During Treatment Through Week 48|HCV RNA and Change From Baseline in HCV RNA Through Week 8|Proportion of Participants With Virologic Failure Prior to Transplant","https://ClinicalTrials.gov/show/NCT01559844"
574,"NCT01316237","A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Na√Øve Subjects With Chronic Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C, Chronic","Drug: GS-6620|Drug: GS-6620|Drug: GS-6620|Drug: GS-6620|Drug: GS-6620|Drug: GS-6620|Drug: GS-6620 tablet, 450 mg BID|Drug: GS-6620 tablet|Drug: GS-6620 tablet","Gilead Sciences","Both","Adult","Phase 1","90","Industry","Interventional","","GS-US-119-0101","February 3, 2011","January 2011","January 2012","March 22, 2012","March 2012","No Study Results Posted","null","October 2011","Number of subjects with adverse events as a measure of safety and tolerability.|Number of subjects with HCV RNA viral response as a measure of antiviral activity.|Concentrations and pharmacokinetic parameters of GS-6620 and its metabolites will be measured.","https://ClinicalTrials.gov/show/NCT01316237"
575,"NCT01387958","A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients","Terminated","No Results Available","Hepatitis C","Drug: LCQ908|Drug: Placebo","Novartis Pharmaceuticals|Novartis","Both","Adult","Phase 2","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","CLCQ908A2214","July 1, 2011","July 2011","February 2012","May 6, 2012","May 2012","No Study Results Posted","null","February 2012","Measure: Change in hepatitis C viral load as assessed by PCR|Measure: Safety assessments will include vital signs, electrocardiograms (ECG), liver function tests, and adverse events.|Measure: LCQ908 concentrations in the blood","https://ClinicalTrials.gov/show/NCT01387958"
576,"NCT02166047","Safety and Efficacy of GS-9620 for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Subjects","Recruiting","No Results Available","Chronic Hepatitis B","Drug: GS-9620|Drug: Placebo to match GS-9620","Gilead Sciences","Both","Adult","Phase 2","150","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","GS-US-283-1059|2014-001400-22","June 16, 2014","June 2014","August 2016","October 26, 2015","October 2015","No Study Results Posted","null","February 2016","Mean change in log10 IU/ml serum hepatitis B surface antigen (HBsAg) from baseline to Week 24|Proportion of participants with hepatitis B e antigen (HBeAg) loss and seroconversion at Weeks 24 and 48|Proportion of participants with HBsAg loss and seroconversion at Weeks 24 and 48|Mean change in serum HBsAg from baseline to Weeks 4, 8, 12 and 48 (measured in log10 IU/mL)|Proportion of participants with virological breakthrough|Proportion of participants with drug resistance mutations at Week 48|Proportion of participants with ‚â• 1 log10 decline in serum HBsAg titers from baseline at Weeks 4,8,12, 24 and 48","https://ClinicalTrials.gov/show/NCT02166047"
577,"NCT01341808","Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients","Completed","No Results Available","Inflammatory Bowel Disease|Crohn's Disease|Ulcerative Colitis|Hepatitis A","Biological: Epaxal Berna (virosomal hepatitis A vaccine)","Asan Medical Center","Both","Adult","Phase 4","493","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","2011-0047","April 25, 2011","April 2011","March 2013","March 16, 2013","March 2013","No Study Results Posted","null","February 2013","antibody titer to hepatitis A vaccine|vaccine-associated adverse events and side effects","https://ClinicalTrials.gov/show/NCT01341808"
578,"NCT00172809","Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease","Completed","No Results Available","Chronic Hepatitis C|End Stage Renal Disease","Drug: Peginterferon alfa-2a|Drug: Interferon alfa-2a","National Taiwan University Hospital","Both","Adult","Phase 4","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","940209","September 12, 2005","July 2005","January 2007","March 5, 2008","June 2007","No Study Results Posted","null","June 2006","Sustained histological response and sustained virological response 6 months after the completion of the intervention|The overall tolerance of the two different regimens and the comparison of the rates of side effects","https://ClinicalTrials.gov/show/NCT00172809"
579,"NCT02023112","Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection","Completed","No Results Available","Hepatitis C Virus","Drug: ABT-450/r/ABT-267 plus Ribavirin","AbbVie","Both","Adult|Senior","Phase 3","171","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-153","December 23, 2013","January 2014","September 2015","October 10, 2015","October 2015","No Study Results Posted","GIFT II","April 2015","Percentage of non-cirrhotic, treatment-naive subjects in each treatment group with a sustained virologic response 12 weeks post-treatment|The percentage of subjects in each treatment arm with on-treatment virologic failure during the treatment period|The percentage of subjects in each arm with post-treatment relapse|The percentage of subjects with sustained virologic response 12 weeks post-treatment for each treatment arm within different subpopulations","https://ClinicalTrials.gov/show/NCT02023112"
580,"NCT00637923","Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients","Completed","Has Results","Chronic Hepatitis C","Drug: Nitazoxanide|Drug: Placebo|Biological: Peginterferon alfa-2a|Drug: Ribavirin","Romark Laboratories L.C.","Both","Adult|Senior","Phase 2","112","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","RM01-2026","March 11, 2008","March 2008","April 2010","January 9, 2014","January 2014","November 18, 2013","STEALTHC-3","April 2010","Sustained Virologic Response (HCV RNA Below Lower Limit of Detection)|End of Treatment Response (HCV RNA Below Lower Limit of Detection)|Early Virologic Response (HCV RNA Below Lower Limit of Detection)|Rapid Virologic Response (HCV RNA Below Lower Limit of Detection)|Changes in ALT","https://ClinicalTrials.gov/show/NCT00637923"
581,"NCT01871662","Randomized Study for the Assessment of Silibinin (Legalon¬Æ SIL) in the Treatment of na√Øve Genotype 4 Patients With Chronic Hepatitis C","Withdrawn","No Results Available","Hepatitis C, Chronic","Drug: Legalon¬Æ SIL (Silibinin)|Drug: Pegylated interferon alfa2b|Drug: Ribavirin","Rottapharm","Both","Adult","Phase 2|Phase 3","0","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","LEG-SIL-2-02","May 30, 2013","August 2013","February 2016","March 4, 2015","March 2015","No Study Results Posted","HEPASIL","February 2016","Undetectable HCV-RNA at 24 Weeks After the end of the Study Treatment|Undetectable HCV-RNA|HCV-RNA decrease ‚â• 2 log10 IU/mL|Normalization of Serum Alanine Aminotransferase|Number of Participants with adverse events (AEs)","https://ClinicalTrials.gov/show/NCT01871662"
582,"NCT01760122","Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: Ypeginterferon alfa-2b|Drug: Pegasys","Xiamen Amoytop Biotech Co., Ltd.|Peking University First Hospital","Both","Adult","Phase 3","820","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","TB1211IFN","December 30, 2012","March 2013","August 2015","August 28, 2015","March 2015","No Study Results Posted","null","July 2015","Proportion of patients with HBeAg seroconversion at week72|Proportion of Patients with HBeAg seroconversion at week 12,24,48|Proportion fo patients with HBeAg undetectable at week 12, 24, 48, and 72.|Average of HBV DNA decline level at week 12, 24,48 and 72|Average of HBsAg decline level at week 12, 24, 48 and 72, and Proportion of patients with HBsAg undetectable and HBsAg seroconversion at week 12, 24, 48 and 72.|Proportion of patients with ALT normalization at week 12,24, 48 and 72.","https://ClinicalTrials.gov/show/NCT01760122"
583,"NCT00031343","The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin","Completed","No Results Available","HIV Infections|Hepatitis C","Drug: highly active antiretroviral therapy (HAART)","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Both","Child|Adult|Senior","Phase 2","128","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment","020139|02-I-0139","March 2, 2002","February 2002","April 2004","March 3, 2008","April 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00031343"
584,"NCT01655966","Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c","Active, not recruiting","No Results Available","Chronic Hepatitis c","Drug: vitamin D +pegylated interferon + ribavirin|Drug: pegylated interferon + ribavirin","Cairo University","Both","Adult","Phase 3","80","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","RAIL002","July 31, 2012","May 2012","April 2014","January 28, 2014","January 2014","No Study Results Posted","null","February 2014","Sustained virologic response|rapid virologic response|End-of-treatment response|Adverse events|early virologic response","https://ClinicalTrials.gov/show/NCT01655966"
585,"NCT01911156","Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues","Recruiting","No Results Available","Chronic Hepatitis B","Drug: Continue NA treatment|Drug: Discontinue NA Treatment","University Health Network, Toronto","Both","Adult|Senior","Phase 4","66","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","Stop Study|GILEAD Sciences Canada, Inc.","June 25, 2013","July 2013","March 2016","May 27, 2015","May 2015","No Study Results Posted","Stop","January 2016","Sustained response, defined as the presence of an HBV DNA level <2000 IU/ml at week 48 in patients with a combined response at baseline","https://ClinicalTrials.gov/show/NCT01911156"
586,"NCT00540345","Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: pegylated interferon alpha 2a and plus ribavirin|Drug: Pegylated interferon alfa-2a and ribavirin|Drug: pegylated interferon alpha 2a and ribavirin|Drug: pegylated interferon alpha 2a and ribavirin","Kaohsiung Medical University Chung-Ho Memorial Hospital","Both","Adult|Senior","Phase 4","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","KMUH-IRB-960057","October 5, 2007","October 2006","December 2013","December 24, 2014","December 2014","No Study Results Posted","null","December 2013","Efficacy - Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4 Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period|Safety - adverse event rate and profile","https://ClinicalTrials.gov/show/NCT00540345"
587,"NCT01469884","Effect of Switching to Certican¬Æ in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients","Completed","No Results Available","Renal Allograft|Hepatitis C","Drug: Everolimus|Drug: Cyclosporine|Drug: Tacrolimus","Irmandade Santa Casa de Miseric√≥rdia de Porto Alegre|Novartis","Both","Adult|Senior","Phase 4","30","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label","CRAD001|CRAD001ABR20T","November 1, 2011","November 2011","April 2015","April 1, 2015","April 2015","No Study Results Posted","CONCERVIC","April 2015","Change from baseline in viral load of hepatitis C virus at 12 months after randomization.|Incidence of acute allograft rejection|Incidence of significant infections|Development of proteinuria|Development of malignance|Development of dyslipidemia|Development of liver impairment|Development of post-transplant diabetes|Development of hypertension|Graft loss survival|Patient survival","https://ClinicalTrials.gov/show/NCT01469884"
588,"NCT02562742","Use-Results Surveillance Study of Sovaldi¬Æ Plus Rebetol¬Æ in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection","Not yet recruiting","No Results Available","Hepatitis C","Drug: SOF|Drug: REB","Gilead Sciences|Merck Sharp & Dohme Corp. Japan","Both","Child|Adult|Senior","","500","Industry|Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","GS-US-334-1879","September 28, 2015","October 2015","October 2018","September 28, 2015","September 2015","No Study Results Posted","null","October 2018","Incidence of adverse drug reaction (ADR) under real world settings|Proportion of participants with sustained virologic response (SVR) 12 and 24 weeks after discontinuation of therapy (SVR12 and SVR24)|Proportion of participants with HCV NS5B resistance associated variants among patients who do not achieve SVR at 12 weeks","https://ClinicalTrials.gov/show/NCT02562742"
589,"NCT00456625","Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.","Completed","Has Results","Hepatitis B","Biological: Engerix‚Ñ¢-B","GlaxoSmithKline","Both","Adult","Phase 4","76","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","108984","April 4, 2007","April 2007","January 2008","May 21, 2009","May 2009","January 15, 2009","null","January 2008","Number of Participants With Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Specific Cut-Off Values|Occurrence, Intensity and Relationship to Vaccination of Unsolicited Adverse Events (AEs)|Number of Participants Reporting Any Serious Adverse Events (SAEs).","https://ClinicalTrials.gov/show/NCT00456625"
590,"NCT00519792","Phase 1b Study of Omega DUROS¬Æ in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment","Completed","No Results Available","Chronic Hepatitis C","Drug: Omega DUROS device","Intarcia Therapeutics","Both","Adult","Phase 1","60","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ITCA 638-CLP-08","August 21, 2007","August 2007","March 2010","June 6, 2011","June 2011","No Study Results Posted","null","March 2010","Safety","https://ClinicalTrials.gov/show/NCT00519792"
591,"NCT00023153","Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection","Completed","No Results Available","HIV Infections|Chronic Hepatitis B","Drug: Adefovir Dipivoxil","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Both","Child|Adult|Senior","Phase 3","100","NIH","Interventional","Endpoint Classification: Efficacy Study|Primary Purpose: Treatment","010239|01-I-0239","August 24, 2001","August 2001","October 2004","March 3, 2008","October 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00023153"
592,"NCT00651209","A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)","Completed","No Results Available","Hepatitis B, Chronic","Drug: Tenofovir","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 4","105","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CLDT600A2410","March 18, 2008","February 2008","null","March 6, 2014","March 2014","No Study Results Posted","null","December 2011","The primary objective of the study is to determine if telbivudine early non-responders can achieve an antiviral response with the addition of tenofovir.|To estimate the rate of virologic breakthrough up to week 48 and week 104 To assess the rate of treatment-emergent genotypically confirmed HBV resistance associated with viral breakthrough up to weeks 48 and 104 and 104","https://ClinicalTrials.gov/show/NCT00651209"
593,"NCT00226447","Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients","Completed","No Results Available","Chronic Hepatitis B","Drug: Pegylated Interferon|Drug: Lamivudine","Chinese University of Hong Kong|Hoffmann-La Roche|GlaxoSmithKline","Both","Adult","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P03227","September 23, 2005","December 2002","July 2006","October 23, 2008","October 2008","No Study Results Posted","null","July 2006","HBV DNA reduction at week 52|Normalization of ALT & negative HBV DNA at EOT, negative HBV DNA at EOT & 24 weeks after cessation of treatment, normalization of ALT at the end of treatment and 24 weeks after the cessation of treatment, Safety of treatment","https://ClinicalTrials.gov/show/NCT00226447"
594,"NCT00262379","Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: epoetin beta (NeoRecormon¬Æ)","University Hospital, Angers","Both","Adult|Senior","Phase 3","229","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CP 2005-01","December 5, 2005","December 2005","June 2009","December 11, 2014","December 2014","No Study Results Posted","null","June 2009","Sustained Viral Response (Week 72)|‚Ä¢ Viral Response at the End of Treatment (Week 48)|‚Ä¢ Quality of life|‚Ä¢ Cumulative dose of ribavirin from D0-W24 and from W24-W48 periods|‚Ä¢ Clinical and biological tolerance","https://ClinicalTrials.gov/show/NCT00262379"
595,"NCT00226382","Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment","Completed","No Results Available","Chronic Hepatitis B","Drug: Pegylated Interferon-alfa-2a","Chinese University of Hong Kong|Hoffmann-La Roche","Both","Adult|Senior","Phase 4","50","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","Pegasys Study","September 23, 2005","January 2005","April 2008","June 10, 2010","October 2008","No Study Results Posted","null","April 2008","HBeAg positive patients response is defined as HBeAg loss and presence of anti-HBe (HBeAg seroconversion), HBeAg Negative patients response is defined as DNA<20,000 copies/ml and ALT normalization both measured at week 72|Percentage of patients with HBV DNA levels <100,000 copies/ml at week 72, Percentage of patients with HBV DNA levels <10,000 copies/ml at week 72|- Percentage of patients with HBV DNA levels negative by PCR at week 72, ALT normalization at week 72, HBsAg seroconversion at week 72, Safety of treatment","https://ClinicalTrials.gov/show/NCT00226382"
596,"NCT00798460","Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients","Terminated","No Results Available","Chronic Hepatitis B","Drug: adefovir|Drug: clevudine|Drug: lamivudine","Inje University|Bukwang Pharmaceutical","Both","Adult|Senior","Phase 4","30","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","IB-0809-055","November 25, 2008","December 2008","November 2010","June 22, 2011","June 2011","No Study Results Posted","null","June 2010","HBV DNA titer < 300 copies/mL|Normalization of serum ALT, loss of HBeAg and HBsAg, incidence of adefovir resistance","https://ClinicalTrials.gov/show/NCT00798460"
597,"NCT00433069","Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone","Completed","No Results Available","Chronic Hepatitis C","Drug: Pioglitazone|Drug: Interferon Alfa-2a|Drug: Ribavirin","University Hospital, Geneva","Both","Adult|Senior","Phase 2","5","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","GE-DMI-05-116","February 8, 2007","January 2007","January 2008","May 27, 2015","May 2015","No Study Results Posted","null","December 2007","Early virological response|Undetectable serum HCV RNA after 4, 24 weeks and 48 weeks of therapy|Changes (vs. baseline) of body weight, HOMA score, after 4, 12 and 48 weeks of therapy and after 24 weeks of follow-up|Improvement (vs. baseline) of glucose tolerance parameters after 12 and 48 weeks of therapy and after 24 weeks of follow-up","https://ClinicalTrials.gov/show/NCT00433069"
598,"NCT01948193","Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth","Completed","Has Results","Diphtheria|Tetanus|Whooping Cough|Hepatitis B|Poliomyelitis|Invasive Hib Infections","Biological: Hexaxim‚Ñ¢: DTaP-IPV-Hep B-PRP~T combined vaccine","Sanofi Pasteur, a Sanofi Company|Sanofi","Both","Child","Phase 3","177","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","A3L33|U1111-1127-6936|CTRI/2013/09/003997","September 18, 2013","February 2014","June 2015","September 29, 2015","September 2015","August 26, 2015","null","December 2014","Percentage of Participants With Seroprotection After Vaccinations With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Following a Documented Dose of a Commercial Oral Poliovirus Vaccine and Recombinant Hep B Monovalent Vaccine at Birth|Percentage of Participants With Vaccine Response After Vaccinations With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Following a Documented Dose of a Commercial Oral Poliovirus Vaccine and Recombinant Hep B Monovalent Vaccine at Birth|Percentage of Participants With Seroprotection Before and After Vaccinations With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Following a Documented Dose of a Commercial Oral Poliovirus Vaccine and Recombinant Hep B Monovalent Vaccine at Birth|Geometric Mean Titers of Antibodies Against Vaccine Antigens After Vaccinations With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine After a Documented Dose of an Oral Poliovirus Vaccine and Recombinant Hep B Monovalent Vaccine at Birth|Geometric Mean Titer Ratios of Antibodies Against Vaccine Antigens After Vaccinations With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine After a Documented Dose of Oral Poliovirus Vaccine and Recombinant Hep B Monovalent Vaccine at Birth|Percentage of Participants Reporting Solicited Injection-site or Systemic Reaction After Each Vaccination With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Following a Documented Dose of Oral Poliovirus and Recombinant Hep B Vaccine at Birth","https://ClinicalTrials.gov/show/NCT01948193"
599,"NCT01439373","Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects","Completed","No Results Available","Hepatitis C, Chronic","Drug: GSK2336805|Drug: Pegylated interferon alfa-2a|Drug: Ribavirin|Drug: GSK2336805 Matching Placebo","GlaxoSmithKline|PPD","Both","Adult|Senior","Phase 2","17","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","115519","July 7, 2011","July 2011","December 2011","November 15, 2012","June 2012","No Study Results Posted","null","December 2011","Safety/tolerability of GSK2336805 in comparison with placebo.|HCV viral load reduction from baseline|Composite of pharmacokinetics, Day 1|Composite of pharmacokinetics, Days 7, 14, 21|Composite of pharmacokinetics, Day 28","https://ClinicalTrials.gov/show/NCT01439373"
600,"NCT00117676","A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B","Active, not recruiting","Has Results","Chronic Hepatitis B","Drug: TDF|Drug: ADV|Drug: TDF placebo|Drug: ADV placebo|Drug: FTC/TDF","Gilead Sciences","Both","Adult|Senior","Phase 3","375","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","GS-US-174-0102","June 30, 2005","June 2005","January 2016","August 21, 2015","August 2015","February 11, 2010","null","May 2007","Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48|Percentage of Participants With HBV DNA < 400 Copies/mL at Week 48|Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 96|Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 144, 192, 240, 288, 336, and 384|Change From Baseline in HBV DNA at Weeks 48, 96, 144, 192, 240, 288, 336, and 384|Change From Week 48 in HBV DNA at Weeks 96, 144, 192, 240, 288, 336, and 384|Percentage of Participants With Histological Response at Week 48|Percentage of Participants With Histological Response at Week 240|Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 48|Change From Baseline in Knodell and Ishak Necroinflammatory Scores at Week 240|Ranked Assessment of Necroinflammation and Fibrosis at Week 48|Ranked Assessment of Necroinflammation and Fibrosis at Week 240|Percentage of Participants With ALT Normalization at Week 48|Percentage of Participants With ALT Normalization at Weeks 96|Percentage of Participants With ALT Normalization at Weeks 144, 192, 240, 288, 336, and 384|Change From Baseline in ALT at Weeks 48, 96, 144, 192, 240, 288, 336, and 384|Change From Week 48 in ALT at Weeks 96, 144, 192, 240, 288, 336, and 384|Percentage of Participants With Hepatitis B S-Antigen (HBsAg) Loss or Seroconversion Antibody to HBs (Anti-HBs) at Week 48|Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Week 96|Percentage of Participants With HBsAg Loss and/or Seroconversion to Anti-HBs at Weeks 144, 192, 240, 288, 336, and 384|Number of Participants With HBV Genotypic Changes From Baseline at Week 48 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 96 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 144 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 192 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 240 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 288 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 336 (Resistance Surveillance)|Number of Participants With HBV Genotypic Changes From Baseline at Week 384 (Resistance Surveillance)","https://ClinicalTrials.gov/show/NCT00117676"
601,"NCT02362490","Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues","Active, not recruiting","No Results Available","Chronic Hepatitis B","Drug: peginterferon alpha 2a","Beijing Ditan Hospital","Both","Adult","Phase 4","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","DTXY004","February 9, 2015","January 2013","December 2016","March 1, 2015","January 2015","No Study Results Posted","null","December 2016","rate of HBsAg loss|decline of HBsAg level","https://ClinicalTrials.gov/show/NCT02362490"
602,"NCT01887275","A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Device: medical ozone therapy with humares|Drug: conventional interferon-Œ±","Nanfang Hospital of Southern Medical University","Both","Child|Adult","Phase 4","439","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","gyb61641947","June 23, 2013","March 2010","February 2013","June 25, 2013","October 2012","No Study Results Posted","null","February 2013","HBV DNA|HBeAg","https://ClinicalTrials.gov/show/NCT01887275"
603,"NCT01847430","Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix‚Ñ¢-B Kinder","Completed","No Results Available","Hepatitis B","Biological: Engerix‚Ñ¢-B Kinder","GlaxoSmithKline","Both","Child","Phase 4","303","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","116722|2012-003950-10","May 2, 2013","July 2013","February 2014","October 30, 2014","October 2014","No Study Results Posted","null","February 2014","Evaluation of anti-HBs immune status in terms of antibody concentrations|Occurrence of solicited local and general symptoms|Occurrence of unsolicited adverse events|Occurrence of serious adverse events (SAEs)","https://ClinicalTrials.gov/show/NCT01847430"
604,"NCT00044135","A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.","Active, not recruiting","No Results Available","Hepatitis B","Drug: clevudine (drug)","Triangle Pharmaceuticals","Both","Adult","Phase 2","30","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","L-FMAU-102 B","August 20, 2002","August 2002","null","June 23, 2005","November 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00044135"
605,"NCT00441974","Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients","Completed","Has Results","Chronic Hepatitis B","Drug: adefovir dipivoxil","GlaxoSmithKline","Both","Child|Adult","Phase 4","1470","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ADF108356","February 28, 2007","December 2006","September 2008","October 15, 2009","October 2009","August 26, 2009","null","September 2008","Number of Participants Achieving HBV DNA (Hepatitis B Virus Deoxyribonucleic Acid) <1000 Copies/Milliliter at Week 48|Number of HBeAg Positive Participants Achieving Histological Improvement at Week 48|Ranked Assessment of Liver Histology in HBeAg Positive Participants From Baseline to Week 48|Change From Screening in Median Serum HBV DNA at Weeks 24 and 48|Number of Participants Achieving ALT (Alanine Aminotransferase) Normalization at Week 48|Number of HBeAg Positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Week 48|Number of Participants With ADV-associated Resistance at Week 48","https://ClinicalTrials.gov/show/NCT00441974"
606,"NCT01265511","Study of SCY-635, Pegasys and Copegus in Hepatitis C","Completed","No Results Available","Hepatitis C Infection","Drug: Placebo|Drug: SCY-635|Drug: peginterferon alfa 2a|Drug: Ribavirin","Scynexis, Inc.","Both","Adult","Phase 2","11","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","SCY-635-201","November 23, 2010","November 2010","October 2011","May 29, 2012","May 2012","No Study Results Posted","null","October 2011","Undetectable HCV RNA|Partial early virologic response|Incidence and severity of treatment emergent adverse events and changes in laboratory values as measures of Safety and tolerability|Pharmacokinetic assessment of SCY-635|Pharmacokinetics of peginterferon alfa 2a and Ribavirin (trough concentrations)","https://ClinicalTrials.gov/show/NCT01265511"
607,"NCT01592006","Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients","Terminated","Has Results","Hepatitis C","Drug: Peginterferon alfa-2a|Drug: Ribavirin|Drug: telaprevir","University of Chicago","Both","Adult|Senior","Phase 4","3","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","12-0156","April 27, 2012","April 2012","September 2014","January 5, 2015","January 2015","January 5, 2015","null","September 2014","The Efficacy of Triple Antiviral Therapy|Safety of Triple Antiviral Therapy in HCV Infected OLT Recipients","https://ClinicalTrials.gov/show/NCT01592006"
608,"NCT01487876","Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients","Recruiting","No Results Available","Chronic Hepatitis B","Biological: HBV DNA vaccine|Other: Placebo","Fuqiang Yang|The 458 Hospital of Chinese PLA","Both","Adult","Phase 2","240","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","2011005SW0101","September 22, 2011","September 2011","December 2012","December 7, 2011","September 2011","No Study Results Posted","null","August 2012","HBV DNA suppression|Loss of HBeAg|Appearance of Anti-HBe|HBeAg seroconversion rate|The occurrence of YMDD mutants|Viral breakthrough rate|HBV Ag specific T cell immunity","https://ClinicalTrials.gov/show/NCT01487876"
609,"NCT01441609","Expression of Th9 Cells and Poor/Non-responsiveness to Hepatitis B Vaccination","Recruiting","No Results Available","Hepatitis B","","Beijing Municipal Science & Technology Commission","Both","Child|Adult","","94","Other","Observational","Observational Model: Case Control","BJCDCWJ201103","September 26, 2011","August 2011","May 2012","September 27, 2011","September 2011","No Study Results Posted","null","April 2012","Th9 cells","https://ClinicalTrials.gov/show/NCT01441609"
610,"NCT00630084","Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma","Completed","No Results Available","Chronic Hepatitis C|Neoplasms","Drug: pegylated interferon alpha 2a and plus ribavirin|Drug: pegylated interferon alpha 2a and plus ribavirin","Kaohsiung Medical University Chung-Ho Memorial Hospital","Both","Adult|Senior","Phase 4","120","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","KMUH-IRB-960044","February 26, 2008","August 2006","October 2008","September 3, 2015","September 2015","No Study Results Posted","null","October 2008","Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.|Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.|Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.|Safety - adverse event rate and profile","https://ClinicalTrials.gov/show/NCT00630084"
611,"NCT02118012","Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C","Recruiting","No Results Available","Chronic Hepatitis C","Drug: Chlorcyclizine HCL plus Ribavirin|Drug: Chlorcyclizine HCL Only","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 1","50","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","140084|14-DK-0084","April 16, 2014","March 2014","March 2017","January 28, 2015","December 2014","No Study Results Posted","null","March 2017","Decline in serum HCV RNA viral titer during therapy as compared to baseline measured by PCR. The ability to tolerate the drug at the prescribed dose for the duration of therapy.|1. A significant change in alanine aminotransferase (ALT) levels compared to baseline.2. Quantification of chlorcyclizine HCL and its metabolites in serum during therapy.3. Changes in symptom scale measurements during and after therapy.","https://ClinicalTrials.gov/show/NCT02118012"
612,"NCT00892697","Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)","Completed","Has Results","Hepatitis C","Drug: Telaprevir|Drug: Peginterferon alfa-2a|Drug: Ribavirin","Weill Medical College of Cornell University|Vertex Pharmaceuticals Incorporated","Both","Adult","Phase 2","15","Other|Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","0810010040","April 30, 2009","May 2009","December 2012","March 9, 2015","December 2014","December 18, 2014","null","December 2012","Intrahepatic and Plasma HCV Viral Kinetics|Intrahepatic and Peripheral Pharmacokinetic Assessment of Telaprevir","https://ClinicalTrials.gov/show/NCT00892697"
613,"NCT00907894","Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: LDT600 (Telbivudine)","Novartis Pharmaceuticals|Novartis","Both","Child|Adult","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","CLDT600A2104|EudraCT 2007-006218-40","May 22, 2009","February 2009","null","September 26, 2012","September 2012","No Study Results Posted","null","March 2012","LDT600 plasma concentration and pharmacokinetic (PK) parameters of exposure (Cmax and AUC)|Safety assessments will include vital signs, ECG and incidence of adverse events and serious adverse events.","https://ClinicalTrials.gov/show/NCT00907894"
614,"NCT00207311","Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus","Completed","No Results Available","Fatty Liver|Hepatitis C","Drug: Xenical, Pegasys, Copegus|Behavioral: Xenicare Program","Brooke Army Medical Center|Hoffmann-La Roche|The Geneva Foundation","Both","Adult|Senior","Phase 4","30","U.S. Fed|Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","C.2004.140","September 13, 2005","August 2005","May 2009","February 13, 2012","February 2012","No Study Results Posted","HCVNASH","May 2009","Sustained virological response (SVR) defined as the percentage of participants with undetectable HCV-RNA as measured by the Roche AMPLICORTM HCV Test, v 2.0 (detection limit 50 IU/mL) at 24 weeks post completion of the treatment period|Hepatic steatosis, necroinflammatory activity and fibrosis improvement at week 36 as determined by Dr. Elizabeth Brunt at Saint Louis University","https://ClinicalTrials.gov/show/NCT00207311"
615,"NCT00780416","Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Na√Øve Patients With Chronic Hepatitis C","Completed","Has Results","Hepatitis C","Drug: MP-424|Drug: Ribavirin|Drug: Peginterferon Alfa-2b|Drug: Ribavirin|Drug: Peginterferon Alfa-2b","Mitsubishi Tanabe Pharma Corporation|Vertex Pharmaceuticals Incorporated","Both","Adult","Phase 3","189","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","G060-A6","October 24, 2008","November 2008","August 2010","April 16, 2014","April 2014","June 5, 2012","null","August 2010","The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","https://ClinicalTrials.gov/show/NCT00780416"
616,"NCT01458535","A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Na√Øve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)","Completed","No Results Available","Hepatitis C Virus","Drug: ABT-450/r|Drug: ABT-267|Drug: ribavirin","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult","Phase 2","61","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M12-998","September 23, 2011","October 2011","May 2013","May 30, 2014","May 2014","No Study Results Posted","Navigator","May 2013","Assess the safety and antiviral activity (proportion of subjects with hepatitis C ribonucleic acid (HCV RNA) < lower limit of quantitation (LLOQ)|Assess the percentage of subjects with SVR12 (HCV RNA < LLOQ 12 Weeks post-treatment)|Assess the percentage of subjects with SVR24 (HCV RNA < LLOQ 24 Weeks post-treatment)|Assess the percentage of subjects with HCV RNA < 1000 IU/mL|Assess the percentage of subjects with HCV RNA < LLOQ|Assess the time to failure to suppress, rebound or relapse (confirmed increase of at least 1 log10 IU/mL above nadir or confirmed HCV RNA > LLOQ for subjects who previously achieved HCV RNA < LLOQ)","https://ClinicalTrials.gov/show/NCT01458535"
617,"NCT02224456","Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis","Recruiting","No Results Available","Hepatitis B, Chronic","Drug: Tenofovir disoproxil fumarate","GlaxoSmithKline","Both","Adult","Phase 4","240","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","201213","August 21, 2014","March 2015","November 2020","September 10, 2015","August 2015","No Study Results Posted","null","November 2020","Incidence of hepatocellular carcinoma at Week 240|Incidence of disease progression at Week 240|Incidence of HCC at Week 48, Week 96 Week 144, and Week 192|Cumulative incidence of HCC at Week 48, Week 96, Week 144, Week 192 and Week 240|Cumulative incidence of disease progression at Week 48, Week 96, Week 144, Week 192 and Week 240|The mean changes of liver stiffness measurement (LSM) at Week 48, Week 96, Week 144, Week 192 and Week 240|Proportion of subjects with serum HBV Deoxyribonucleic Acid (DNA) <20 International units per milliliter (IU/mL) at Week 48, Week 96, Week 144, Week 192 and Week 240|Mean log10 reduction in serum HBV DNA at Week 48, Week 96, Week 144, Week 192 and Week 240 compared with baseline|Proportion of subjects with alanine aminotransferase (ALT) normalization at Week 48, Week 96, Week 144, Week 192 and Week 240|Proportion of hepatitis B early antigen (HBeAg) positive subjects achieving HBeAg loss, HBeAg seroconversion or hepatitis B surface antigen (HBsAg) loss and HBsAg seroconversion at Week 24, Week 48, Week 96, Week 144, Week 192 and Week 240|Proportion of HBeAg negative subjects achieving HBsAg loss and HBsAg seroconversion at Week 48, Week 96, Week 144, Week 192 and Week 240|Incidence of virological breakthrough up to Week 48, Week 96, Week 144, Week 192 and Week 240|Proportion of subjects with histological improvement at Week 216 in the subset of subjects with paired baseline and Week 216 liver biopsies|Proportion of subjects with cirrhosis reversal at Week 216 in the subset of subjects with paired baseline and Week 216 liver biopsies and with a baseline Ishak score higher than or equal to five|Safety as determined by adverse events (AEs) and laboratory assessments","https://ClinicalTrials.gov/show/NCT02224456"
618,"NCT01243281","Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B","Recruiting","No Results Available","Chronic Hepatitis B","Drug: PEG-IFN and entecavir","Chulalongkorn University","Both","Adult","","126","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Investigator)","Biochem2010/01","November 17, 2010","March 2011","December 2013","June 26, 2011","June 2011","No Study Results Posted","null","May 2013","To determine whether a combination of PEG-IFN and entecavir improves the rate of sustained response and HBsAg clearance in patients with HBeAg-negative chronic hepatitis B|To determine host factors and viral factors associated with response to PEG-IFN alone or PEG-IFN plus entecavir treatment","https://ClinicalTrials.gov/show/NCT01243281"
619,"NCT00495391","Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C","Completed","Has Results","Chronic Hepatitis C","Drug: Nitazoxanide|Drug: Placebo|Biological: Peginterferon alfa-2a|Drug: Ribavirin","Romark Laboratories L.C.","Both","Adult|Senior","Phase 2","64","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","RM01-2025","July 2, 2007","July 2007","February 2010","April 8, 2014","April 2014","November 18, 2013","STEALTHC-2","February 2010","Sustained Virologic Response (HCV RNA Below Lower Limit of Detection)|End of Treatment Response (HCV RNA Below Lower Limit of Detection)|Early Virologic Response (HCV RNA Below Lower Limit of Detection)|Rapid Virologic Response (HCV RNA Below Lower Limit of Detection)|Changes in ALT","https://ClinicalTrials.gov/show/NCT00495391"
620,"NCT00962936","Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection","Terminated","No Results Available","Chronic Hepatitis C","Drug: CT-011","CureTech Ltd|Teva Pharmaceutical Industries","Both","Adult","Phase 1|Phase 2","13","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CT-2009-01","August 19, 2009","September 2009","January 2013","August 28, 2014","August 2014","No Study Results Posted","null","October 2011","To assess the safety and tolerability of CT-011 in patients with Chronic Hepatitis C due to HCV Genotype I infection","https://ClinicalTrials.gov/show/NCT00962936"
621,"NCT01105611","Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-na√Øve, HIV/Hepatitis C Drug Users","Recruiting","No Results Available","HIV Infections|Hepatitis C","Drug: Raltegravir|Drug: Atazanavir/Ritonavir","St. James's Hospital, Ireland","Both","Adult|Senior","Phase 4","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CB-2010-01|2010-018326-39","April 14, 2010","August 2010","December 2012","July 20, 2011","March 2010","No Study Results Posted","null","December 2012","Incidence of grade 3-4 liver function test (LFT) elevations|Viral suppression|Immunologic response|Overall safety in patients with mild to moderate hepatic impairment|Outpatient retention rates|QTc interval changes","https://ClinicalTrials.gov/show/NCT01105611"
622,"NCT01453075","Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)","Recruiting","No Results Available","Chronic Hepatitis C Infection","Drug: Valacyclovir|Drug: Placebo","VA Office of Research and Development|GlaxoSmithKline","Both","Adult|Senior","Phase 1","125","U.S. Fed|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","CLIN-001A-10F|1lK2CX00536|VAL115610","October 7, 2011","November 2011","March 2016","May 12, 2015","May 2015","No Study Results Posted","null","December 2015","Effect of HSV-2 suppression on HCV viral load.|Effect of 3 grams daily valacyclovir on liver tests in hepatitis C infection","https://ClinicalTrials.gov/show/NCT01453075"
623,"NCT01018615","Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C|Oxidative Stress","Drug: silymarin|Dietary Supplement: green tea extract (EGCG)","University of North Carolina, Chapel Hill|National Center for Complementary and Integrative Health (NCCIH)|National Institutes of Health (NIH)","Both","Adult|Senior","Phase 1|Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","08-1631|R21AT003892-01A2|CTRC-2779","November 20, 2009","November 2009","July 2013","November 5, 2013","November 2013","No Study Results Posted","null","April 2013","To assess the safety and tolerability of coadministered silymarin and green tea extract at different doses in patients with chronic hepatitis C.|To characterize the antioxidant effects of silymarin and EGCG administered alone or in combination.","https://ClinicalTrials.gov/show/NCT01018615"
624,"NCT01435044","Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection","Completed","No Results Available","Hepatitis C, Chronic","Drug: Sofosbuvir|Drug: GS-0938|Drug: RBV|Drug: Placebo to match sofosbuvir|Drug: Placebo to match GS-0938","Gilead Sciences|Quintiles","Both","Adult|Senior","Phase 2","239","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","P2938-0721","September 9, 2011","September 2011","May 2013","January 7, 2014","January 2014","No Study Results Posted","QUANTUM","April 2013","Percentage of participants with sustained virologic response (SVR) 12 weeks after discontinuation of study drug (SVR12)|Percentage of Participants Who Experienced Adverse Events|Change from baseline in HCV RNA|Percentage of Participants With HCV RNA < LLOQ during treatment|Percentage of Participants With ALT Normalization|Percentage of participants with SVR at 4 and 24 weeks after discontinuation of study drug (SVR4; SVR24)|Percentage of Participants Who Developed Resistance to Sofosbuvir","https://ClinicalTrials.gov/show/NCT01435044"
625,"NCT02455167","Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis","Recruiting","No Results Available","Hepatitis C","Drug: Simeprivir (SMV)|Drug: Sofosbuvir (SOF)|Drug: Ribavirin (RBV)","University of Colorado, Denver|Janssen Scientific Affairs, LLC","Both","Adult|Senior","Phase 3","25","Other|Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label","14-0919|UL1TR001082","April 21, 2015","May 2015","August 2016","October 2, 2015","October 2015","No Study Results Posted","null","August 2016","The sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation|Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) treatment using a new test of liver function, HepQuant-SHUNT.","https://ClinicalTrials.gov/show/NCT02455167"
626,"NCT01649245","Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C","Recruiting","No Results Available","Chronic Hepatitis C","Drug: Reiferon retard","MinaPharm Pharmaceuticals","Both","Adult","Phase 4","5000","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","HAPIC Trial","July 20, 2012","August 2012","August 2014","January 12, 2013","January 2013","No Study Results Posted","HAPIC","August 2014","Sustained Virologic Response (SVR)|Complete Early Virologic Response (cEVR)|End of Treatment Response (ETR)|Safety","https://ClinicalTrials.gov/show/NCT01649245"
627,"NCT01595633","Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy","Recruiting","No Results Available","Chronic Hepatitis B","Drug: Switching from adefovir (10mg/day) to tenofovir (300mg/day)","Yonsei University","Both","Adult|Senior","Phase 4","124","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","4-2011-0937","March 11, 2012","March 2012","February 2014","May 9, 2012","May 2012","No Study Results Posted","null","February 2014","number of patients with complete virologic response (HBV DNA < 60 IU/mL, approximately 300 copies/mL) at 48 weeks treatment|number of patients with antiviral response at 48 weeks therapy|number of patients with biochemical response at 48 weeks therapy|number of patients with serologic response at 48 weeks therapy|number of patients with appearance of resistant mutant strain at 48 weeks|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT01595633"
628,"NCT00006643","Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus","Completed","No Results Available","HIV Infections|Hepatitis C","","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Child|Adult|Senior","","44","NIH","Observational","","ACTG A5096|AACTG A5096","December 6, 2000","null","null","July 29, 2008","June 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006643"
629,"NCT00240500","Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers","Completed","Has Results","Hepatitis B","Biological: Engerix‚Ñ¢-B","GlaxoSmithKline","Both","Child|Adult","Phase 4","109","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","100448","October 13, 2005","October 2003","November 2007","May 28, 2009","May 2009","October 30, 2008","null","November 2007","Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations|Prevalence of Serological Markers for Hepatitis B Infection|Clinical Review for Hepatitis B Infection Status","https://ClinicalTrials.gov/show/NCT00240500"
630,"NCT00778843","Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Dietary Supplement: Viusid|Other: Placebo","Catalysis SL","Both","Adult","Phase 3","60","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","VIU-CHC-08","October 21, 2008","October 2008","May 2009","May 2, 2012","May 2012","No Study Results Posted","null","May 2009","The improvement of serum parameters related to oxidative stress (SOD, AT, MDA, MDA/HNE, GPx, GR, AOP, MPO, PAOP, GSH) at 24 weeks (end of the treatment).|The improvement of serum parameters related to immune response (IFN alpha, IFN gamma, IL-1 alpha, IL-2, IL-6, IL-10, IL-12, TNF alpha, Anti TNF alpha, Cathepsin L) at 24 weeks (end of the treatment).|Improvement of aminotransferase levels (ALAT and ASAT) at 24 weeks (end of the treatment).|Improvement of clinical symptoms and signs at 24 weeks (end of the treatment).","https://ClinicalTrials.gov/show/NCT00778843"
631,"NCT00502086","Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.","Completed","No Results Available","Cirrhosis|Chronic Hepatitis C","Dietary Supplement: Viusid (nutritional supplement)|Other: Placebo","Catalysis SL","Both","Adult|Senior","Phase 3","100","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","VIUHCV-07","July 13, 2007","May 2005","July 2009","February 10, 2011","February 2010","No Study Results Posted","null","July 2009","The mortality secondary to liver failure at 96 weeks.|The complication rates during the treatment. The hepatitis-related quality of live during the treatment. Clinical Activity Index during the treatment. The hepatocellular carcinoma incidence during the treatment.","https://ClinicalTrials.gov/show/NCT00502086"
632,"NCT00324961","Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B","Completed","Has Results","Chronic Hepatitis B","Drug: adefovir dipivoxil tablets","GlaxoSmithKline","Both","Adult","Phase 4","533","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ADF106632","May 9, 2006","January 2006","January 2009","October 26, 2009","October 2009","August 27, 2009","null","January 2009","Number of Participants Achieving HBV DNA ‚â§300 Copies/mL at Week 104|Number of Participants Achieving Histological Improvement After the 104-week Treatment|Liver Histology Scores in HBeAg Negative Participants With Two Sequential Liver Biopsies During the Period of 104 Weeks|Change From Baseline in Median Serum HBV DNA Over Time|Number of Participants Achieving ALT Normalization at Week 104|Number of Participants Achieving HBsAg Loss and HBsAg Seroconversion at Week 104|Number of Participants With ADV-associated Resistance at Week 104|Number of Participants Achieving HBV DNA ‚â§300 Copies/mL Over Time|Number of Participants Achieving Complete Response at Week 104|Time to Protocol-defined Complete Response Over a 104-week Treatment Period","https://ClinicalTrials.gov/show/NCT00324961"
633,"NCT00217139","A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection","Completed","No Results Available","Hepatitis C, Chronic","Drug: Celgosivir","BioWest Therapeutics Inc","Both","Adult","Phase 2","60","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HCV-05-002","September 13, 2005","September 2005","September 2006","September 27, 2006","September 2006","No Study Results Posted","null","null","Safety analysis|HCV viral load","https://ClinicalTrials.gov/show/NCT00217139"
634,"NCT00503347","Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus","Completed","No Results Available","Hepatitis C Virus|Hiv Infections","Drug: bavituximab","Peregrine Pharmaceuticals","Both","Adult|Senior","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","PPHM 0603","July 16, 2007","July 2007","June 2011","June 7, 2011","June 2011","No Study Results Posted","null","March 2011","‚Ä¢ Adverse events ‚Ä¢ Laboratory evaluations ‚Ä¢ Human anti-chimeric antibody ‚Ä¢ Pharmacokinetic analysis|Blood levels of HCV RNA and HIV RNA (PCR)","https://ClinicalTrials.gov/show/NCT00503347"
635,"NCT00277576","Safety Study of HBV DNA Vaccine to Treat Patients With Chronic Hepatitis B Infection","Completed","No Results Available","Chronic Hepatitis B","Biological: ppdpSC18 administered by PMED","PowderMed","Both","Adult","Phase 1","48","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double-Blind","PM HBV-001","January 13, 2006","January 2006","December 2007","November 20, 2008","November 2008","No Study Results Posted","null","null","Adverse Events at all visits, vaccine site evaluations, laboratory parameters pre and post vaccination|The secondary endpoints will assess the effect of the Investigational Product on:|immunological response to vaccine at each visit|clinical response to vaccine at each visit","https://ClinicalTrials.gov/show/NCT00277576"
636,"NCT01362517","Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B","Completed","Has Results","Diphtheria|Pertussis|Tetanus|Hepatitis B|Haemophilus Influenzae Infections","Biological: Quinvaxem","Crucell Holland BV","Both","Child","Phase 3","131","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","QVX-V-C001","May 26, 2011","April 2010","April 2011","August 29, 2013","August 2013","March 27, 2013","null","July 2010","Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component|Safety: Adverse and Serious Adverse Events","https://ClinicalTrials.gov/show/NCT01362517"
637,"NCT01532843","Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: peginterferon alpha-2b","Foundation for Liver Research","Both","Adult|Senior","Phase 4","82","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HBV 11-02","February 10, 2012","June 2012","August 2015","August 13, 2015","August 2015","No Study Results Posted","PEGON","August 2015","Sustained response","https://ClinicalTrials.gov/show/NCT01532843"
638,"NCT00015652","Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection","Completed","No Results Available","HIV Infections|Hepatitis C","Drug: Ribavirin|Drug: Aldesleukin|Drug: Peginterferon alfa-2b","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult","","24","NIH","Interventional","Endpoint Classification: Safety Study|Primary Purpose: Treatment","A5088|AACTG A5088|10676|ACTG A5088","April 26, 2001","null","March 2005","May 21, 2012","May 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00015652"
639,"NCT01732367","TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA","Enrolling by invitation","No Results Available","Chronic Hepatitis B","Drug: Lamivudine plus adefovir|Drug: Tenofovir","Keimyung University Dongsan Medical Center|Kyungpook National University|Daegu Catholic University Medical Center|DongGuk University|Pusan National University Hospital|Yeungnam University","Both","Adult|Senior","Phase 4","171","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","TDF0001","November 19, 2012","November 2012","February 2016","February 23, 2014","February 2014","No Study Results Posted","null","February 2016","Percentage number of patients with virus reactivation|Virologic response|Antiviral resistance|Biochemical response|Serologic response|Safety assessment","https://ClinicalTrials.gov/show/NCT01732367"
640,"NCT00491244","Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Na√Øve Hemodialysis Patients With Chronic Hepatitis C","Completed","Has Results","Chronic Hepatitis C","Drug: Peginterferon alfa-2a and ribavirin|Drug: Peginterferon alfa-2a","National Taiwan University Hospital|National Science Council, Taiwan|Department of Health, Executive Yuan, R.O.C. (Taiwan)","Both","Adult","Phase 4","377","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","200703010M","June 23, 2007","June 2007","September 2013","January 13, 2014","January 2014","September 29, 2013","null","September 2013","Sustained Virologic Response (SVR)Rate|Adverse Event (AE)-Related Withdrawal Rate","https://ClinicalTrials.gov/show/NCT00491244"
641,"NCT00656006","A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3","Completed","No Results Available","Chronic Hepatitis C","Drug: Albuferon|Drug: Ribavirin","Human Genome Sciences Inc.","Both","Adult","Phase 2","43","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HGS1008-C1052 (ALFR-HC-06)","December 20, 2005","November 2005","April 2007","August 1, 2013","August 2013","No Study Results Posted","null","April 2007","Primary safety endpoints are the common side effects of IFNa therapy including flu-like symptoms, depression, and hematologic abnormalities.|Primary efficacy end point is sustained virologic response (SVR), defined as undetectable HCV RNA at 24 weeks after the end of therapy.","https://ClinicalTrials.gov/show/NCT00656006"
642,"NCT00769730","Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication","Completed","No Results Available","Hepatocellular Carcinoma|Hepatitis B Virus","","Kaohsiung Medical University Chung-Ho Memorial Hospital","Both","Child|Adult|Senior","","25","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","KMUH-IRB-960331","September 29, 2008","January 2008","February 2009","August 2, 2009","July 2009","No Study Results Posted","null","February 2009","HBV viral load","https://ClinicalTrials.gov/show/NCT00769730"
643,"NCT01492426","Study Comparing BMS-790052 (Daclatasvir) to Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Untreated Hepatitis C Patients","Completed","No Results Available","Hepatitis C","Drug: BMS-790052 (Daclatasvir)|Drug: Telaprevir|Drug: Peginterferon alfa-2a|Drug: Ribavirin","Bristol-Myers Squibb","Both","Adult|Senior","Phase 3","605","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","AI444-052|2011-004237-14","December 13, 2011","January 2012","March 2014","May 5, 2014","May 2014","No Study Results Posted","COMMAND-3","December 2013","Proportion of genotype 1b patients with SVR12, defined as HCV RNA less than limit of quantitation at follow-up Week 12 in each group|Proportion of genotype 1b patients with hemoglobin value less than 10 g/dL|Proportion of genotype 1b patients with rash events|Proportion of genotype1b patients with HCV RNA undetectable Week 12|Proportion of genotype 1b patients with HCV RNA undetectable Week 4|Proportion of genotype 1b patients with HCV RNA undetectable Weeks 4 and 12|Proportion of genotype 1b patients with SVR24, defined as HCV RNA < Limit of Quantification (LOQ) at follow-up Week 24 for each cohort|Proportion of genotype 1b patients with SVR12 based on IL28B rs12979860 Single nucleotide polymorphism (SNP) genotype (CC or non-CC)|Proportion of genotype 1a patients with SVR12 defined as HCV RNA < LOQ at follow-up Week 12 for each cohort","https://ClinicalTrials.gov/show/NCT01492426"
644,"NCT00221286","Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients","Terminated","No Results Available","Chronic Hepatitis B|HIV Infections","Drug: pegylated interferon alfa-2a|Drug: tenofovir DF / emtricitabine combination therapy|Drug: pegIFN / TDF / FTC combination therapy","University Hospital, Bonn|Hoffmann-La Roche","Both","Adult","Phase 3","2","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Open Label","ML-18150","September 14, 2005","September 2004","January 2007","February 17, 2009","February 2009","No Study Results Posted","null","January 2007","Efficacy: HBeAg seroconversion (HBeAg loss and presence of anti HBe) ; intent to treat analysis.|Safety: study discontinuation due to adverse events; intent to treat analysis.|Efficacy: loss of HBe-Ag,HBV-DNA < 5x10¬≥ copies/ml(COBAS TaqMan HBV Test),decrease of HBV-DNA > 2xlog10 compared to baseline|normalization of ALT,intent to treat and as treated analysis; Viral kinetics of HBV-DNA; Paired liver biopsy comparison according to METAVIR-activity and fibrosis score.|for Arm B (B1 and B2): HIV-RNA < 50 copies/ml and CD4-cell increase intent to treat and as treated analysis|Safety: number of adverse events, according to type and severity.","https://ClinicalTrials.gov/show/NCT00221286"
645,"NCT00001035","The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections","Completed","No Results Available","HIV Infections|Hepatitis C","Drug: Interferon alfa-2b|Drug: Zidovudine|Drug: Zalcitabine|Drug: Didanosine","National Institute of Allergy and Infectious Diseases (NIAID)|Schering-Plough","Both","Child|Adult|Senior","Phase 1","10","NIH|Industry","Interventional","Primary Purpose: Treatment","ACTG 203P|11180","November 2, 1999","null","September 1996","April 27, 2012","April 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001035"
646,"NCT00323804","Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.","Completed","No Results Available","Hepatitis C, Chronic|Liver Fibrosis","Biological: Peginterferon alfa-2b|Drug: Ribavirin|Drug: Ribavirin-Placebo","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Merck Sharp & Dohme Corp.|Rennes University Hospital","Both","Adult|Senior","Phase 2|Phase 3","372","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","ANRS HC15 NRfi|2005-002937-11","May 9, 2006","May 2006","March 2013","September 3, 2014","August 2014","No Study Results Posted","null","February 2013","Rate of patients with at least a one point improvement in Metavir fibrosis score between the inclusion and the end-of-study liver biopsies.|Distribution of the Metavir scoring on the end-of-study biopsy|Distribution of the Chevallier fibrosis score|Evolution of the area of fibrosis between the inclusion and the end-of -study biopsies|Fibrosis serum markers|Liver elasticity before and after treatment|Safety of treatment and quality of life|Frequency of occurrence of hepatic complications and/or liver transplantations|Evolution of the hepatitis C viral load|Rate of patients with loss of detectable hepatitis C virus RNA","https://ClinicalTrials.gov/show/NCT00323804"
647,"NCT01531166","A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon","Recruiting","No Results Available","Chronic Hepatitis B","Drug: pegylated Interferon-alpha 2a","Yonsei University","Both","Adult","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","4-2011-0461","January 31, 2012","January 2012","January 2015","February 22, 2012","February 2012","No Study Results Posted","null","January 2015","HBsAg loss or appearance of anti-HBs antibody in treatment-na√Øve Korean CHB patients treated with Pegasys|Sustained suppression of HBV DNA|HBeAg loss and seroconversion in HBeAg-positive CHB|ALT normalization","https://ClinicalTrials.gov/show/NCT01531166"
648,"NCT01289782","An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients","Completed","Has Results","Hepatitis C","Drug: Placebo|Drug: TMC435|Drug: Peginterferon alpha-2a (PegIFN alpha-2a)|Drug: Ribavirin (RBV)","Janssen R&D Ireland","Both","Adult|Senior","Phase 3","395","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","CR017386|TMC435-TiDP16-C208","January 7, 2011","February 2011","January 2013","May 20, 2014","May 2014","January 27, 2014","QUEST-1","January 2013","The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)|The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)|The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)|The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)|Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)|Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)|Percentage of Participants With On-treatment Virologic Response at All Time Points|The Percentage of Participants Achieving a Rapid Virologic Response (RVR)|The Percentage of Participants Achieving a Early Virologic Response (EVR)|The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)|The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)|The Percentage of Participants With <1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4|Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels >1000 IU/mL at Week 4|Percentage of Participants With Null Response|Percentage of Participants With Partial Response|Percentage of Participants With Viral Breakthrough|Percentage of Participants With Viral Relapse|Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule|Percentage of Participants With On-treatment Failure|Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable or Detectable|Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable|Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <100 IU/mL|Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <1000 IU/mL|The Percentage of Participants With Viral Breakthrough at Different Time Points|Time From End-of-treatment to Viral Relapse|The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)|Median Time to Normalization of Alanine Aminotransferase (ALT) Levels|Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)|Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)|Plasma Concentration of TMC435: Systemic Clearance (CL)|Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for the Fatigue Severity Scale (FSS) Total Scores|Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Overall Work Productivity Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment|Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Daily Activity Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment|Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) in Work Productivity and Activity (WPAI) Absenteeism Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment","https://ClinicalTrials.gov/show/NCT01289782"
649,"NCT01488526","Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus","Active, not recruiting","No Results Available","Hepatitis B Infection|Chronic Infection|Viremia","Drug: TDF treatment","New Discovery LLC|Gilead Sciences","Female","Adult","Phase 4","200","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","IN-US 174-0174","November 30, 2011","December 2011","null","June 7, 2015","June 2015","No Study Results Posted","null","February 2015","Measure the number of infants who have HBV infection at the age of 28 weeks|Assessment of the safety and tolerability of TDF, measure the number of participants and paired infants with adverse events|Measure maternal HBV DNA reduction during the study period when compared to the baseline|percentage of mothers with sero-negativity or sero-conversion of HBsAg and/or HBeAg in each group for comparison","https://ClinicalTrials.gov/show/NCT01488526"
650,"NCT00646503","Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B","Completed","No Results Available","Hepatitis B, Chronic","Drug: Telbivudine","Novartis","Both","Adult|Senior","Phase 4","150","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CLDT600ACN04","March 26, 2008","March 2008","September 2009","June 16, 2011","June 2011","No Study Results Posted","null","September 2009","Proportion of patients experiencing serious adverse events (for all SAEs, and SAEs attributed to study drug). Proportion of patients experiencing adverse events, coded by body system ( all AEs, and AEs attributed to study drug).|For HBeAg-positive patients, Maintained Virologic Response, here defined as HBeAg loss and serum HBV DNA PCR negative (COBAS Amplicor PCR < 300 copies/ml) during the whole study period.","https://ClinicalTrials.gov/show/NCT00646503"
651,"NCT01726946","A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Na√Øve Subjects With Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: VX-135|Drug: ribavirin","Vertex Pharmaceuticals Incorporated","Both","Adult","Phase 2","10","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","VX12-135-101","November 7, 2012","November 2012","February 2014","March 27, 2015","March 2015","No Study Results Posted","null","February 2014","The safety and tolerability as assessed by adverse events, vital signs, 12-lead electrocardiograms, echocardiograms (Cohorts 1 and 2 only), and laboratory assessments|The proportion of subjects who have an SVR at 4 weeks after the last planned dose of treatment (SVR4)|The proportion of subjects who have an SVR at 12 weeks after the last planned dose of treatment (SVR12)|The proportion of subjects who have an SVR at 24 weeks after the last planned dose of treatment (SVR24)|The proportion of subjects who have virologic relapse|Viral kinetics, as determined at different time points by the proportion of subjects who achieve: -Undetectable HCV RNA -<LLOQ HCV RNA|The proportion of subjects who have virologic breakthrough|The proportion of subjects who achieve SVR12 by IL-28B genotype (CC versus non-CC)|The amino acid sequence of the nonstructural (NS)5B protein in subjects who fail treatment","https://ClinicalTrials.gov/show/NCT01726946"
652,"NCT02195518","Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study","Recruiting","No Results Available","Hepatitis B, Chronic","Drug: Tenofovir disoproxil fumarate","GlaxoSmithKline","Both","Adult","Phase 4","200","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","201215","July 17, 2014","March 2015","August 2018","October 29, 2015","July 2015","No Study Results Posted","null","August 2018","Proportion of subjects with serum HBV DNA <20 IU/mL at Week 144|Proportion of subjects with serum HBV DNA <20 IU/mL at Week 48 and 96|Log 10 reduction in serum HBV DNA at Week 48, 96 and144|Proportion of HBeAg positive subjects achieving HBeAg loss, HBeAg seroconversion or HBsAg loss and HBsAg seroconversion at Week 48, 96, and 144.|Proportion of HBeAg negative subjects achieving HBsAg loss and HBsAg seroconversion at Week 48, 96, and 144|Proportion of subjects achieving with ALT normalization at Week 48, 96, and 144 in subjects who have abnormal ALT at baseline|Incidences of subjects who experience viral breakthrough up to week 144|Proportion of subjects in the subgroup with confirmed multi-drug resistance mutations at baseline with serum HBV DNA <20 IU/ml at week 48, 96 and 144|Safety as assessed by adverse events|Safety as assessed by clinical laboratory tests","https://ClinicalTrials.gov/show/NCT02195518"
653,"NCT00877760","Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: pegylated interferon a-2a|Drug: Entecavir","Foundation for Liver Research","Both","Adult|Senior","Phase 4","184","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HBV 09-01","April 7, 2009","August 2009","July 2013","March 27, 2014","March 2014","No Study Results Posted","ARES","July 2013","The combined presence of HBV DNA level < 200 IU/mL and HBeAg loss|ALT normalization|Undetectable HBV DNA <60 IU/mL|HBsAg and HBeAg loss from serum|The emergence of HBV polymerase mutations associated with reduced susceptibility to entecavir|Sustained response defined as the combined presence of HBV DNA level < 200 IU/mL and HBeAg loss","https://ClinicalTrials.gov/show/NCT00877760"
654,"NCT02581189","Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir, ¬± Ribavirin in Patients With Chronic Hepatitis C in Canada","Enrolling by invitation","No Results Available","Chronic Hepatitis C","","AbbVie|Cato Research|IST GmbH Germany","Both","Adult|Senior","","600","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-651","October 19, 2015","October 2015","March 2018","October 27, 2015","October 2015","No Study Results Posted","AMBER","March 2018","Percentage of participants achieving sustained virological response at week 12 (SVR12)|Percentage of the direct-acting antiviral (DAA) dose taken in relation to the target dose of DAA|Percentage of the ribavirin (RBV) dose taken in relation to the target dose of RBV|Percentage of missed ribavirin (RBV) treatment days in relation to the target number of RBV treatment days","https://ClinicalTrials.gov/show/NCT02581189"
655,"NCT00895596","Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: LB80380","LG Life Sciences","Both","Adult","Phase 1|Phase 2","65","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment|Masking: Open Label","BVCL004","May 7, 2009","March 2004","December 2007","May 7, 2009","May 2009","No Study Results Posted","null","August 2006","Mean serum HBV DNA level (log10) reduction from the baseline at Week 12|Proportion of patients with HBeAg seroconversion at 12 weeks Proportion of patients with HBsAg seroconversion at 12 weeks Proportion of patients with ALT normalization at 12 weeks Safety assessment during the whole study period","https://ClinicalTrials.gov/show/NCT00895596"
656,"NCT00680342","Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment","Completed","No Results Available","Chronic Hepatitis C","Drug: Silymarin|Drug: Silymarin|Other: Placebo","National Center for Complementary and Integrative Health (NCCIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pennsylvania|University of North Carolina, Chapel Hill|Thomas Jefferson University|Beth Israel Deaconess Medical Center|University of Pittsburgh","Both","Adult|Senior","Phase 2","154","NIH|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","U01 AT003566|IND 74,887","May 15, 2008","April 2008","January 2011","March 11, 2013","March 2013","No Study Results Posted","SyNCH","January 2011","Efficacy - whether or not serum ALT (mg/dl) is less than or equal to 45 IU/L (approximate normal range) or achieves at least 50% decline to less than 65 IU/L (approximately 1.5 times the upper limit of normal)|Safety - occurence of a dose-limiting toxicity|Adherence - summary of missed dose information obtained from patient diaries and dose counts|Biomarkers - the following relationships will be explored: dose and change in biomarkers, changes in biomarkers and rate of treatment success, change in biomarkers and rate of toxicity","https://ClinicalTrials.gov/show/NCT00680342"
657,"NCT00042393","An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options","Approved for marketing","No Results Available","Chronic Hepatitis B","Drug: Adefovir Dipivoxil","Gilead Sciences","Both","Child|Adult|Senior","Phase 3","null","Industry","Expanded Access","","GS-01-550","July 27, 2002","null","null","January 3, 2014","January 2014","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00042393"
658,"NCT00532701","Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR","Completed","No Results Available","Chronic Hepatitis C","Drug: Peg-IFN + WB RBV for 16 weeks|Drug: Peg-IFN + LD RBV for 16 weeks|Drug: Peg-IFN + WB RBV for 24 weeks|Drug: Peg-IFN + WB RBV for 48 weeks|Drug: Peg-IFN + LD RBV for 24 weeks","National Taiwan University Hospital|National Science Council, Taiwan|Department of Health, Executive Yuan, R.O.C. (Taiwan)","Both","Adult|Senior","Phase 4","880","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","200709014M","September 18, 2007","November 2007","March 2014","June 3, 2014","June 2014","No Study Results Posted","null","March 2014","Sustained virologic response (SVR)|Histologic response (HR)|Biochemical response (BR)","https://ClinicalTrials.gov/show/NCT00532701"
659,"NCT00048724","Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)","Completed","Has Results","Chronic Hepatitis C|Cirrhosis","Biological: peginterferon alfa-2b (SCH 54031)","Merck Sharp & Dohme Corp.","Both","Adult","Phase 3","631","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P02569","November 6, 2002","June 2002","April 2008","March 26, 2015","March 2015","April 23, 2009","null","April 2008","Time to Observation of the First Clinical Event Experienced by a Subject|Time to Observation of the Disease Progression Experienced by a Subject","https://ClinicalTrials.gov/show/NCT00048724"
660,"NCT00491179","Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin","Completed","Has Results","Chronic Hepatitis C|Hemodialysis","Drug: Pegylated interferon alfa-2a and ribavirin|Drug: Pegylated interferon alfa-2a and ribavirin","National Taiwan University Hospital|National Science Council, Taiwan|Department of Health, Executive Yuan, R.O.C. (Taiwan)","Both","Adult","Phase 4","35","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","200703032M","June 23, 2007","June 2006","July 2008","October 7, 2009","October 2009","December 21, 2008","null","June 2008","1.Number of Participants With Sustained Virologic Response (SVR) 2.Number of Participants Who Droppoed Out of the Study Prematurely Due to Adverse Events (AEs)|Number of Participants With Histologic Response(HR)","https://ClinicalTrials.gov/show/NCT00491179"
661,"NCT00084279","CIFN and IFN Œ≥-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)","Completed","No Results Available","Chronic Hepatitis C","Drug: Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin","InterMune","Both","Adult|Senior","Phase 2","81","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","AGHC-002","June 9, 2004","April 2004","April 2006","July 1, 2009","July 2009","No Study Results Posted","null","null","Virologic response defined as >2 log (base 10) reduction in HCV RNA","https://ClinicalTrials.gov/show/NCT00084279"
662,"NCT00812331","A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)","Completed","Has Results","Hepatitis C","Drug: TMC435","Tibotec Pharmaceuticals, Ireland","Both","Adult|Senior","Phase 2","37","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CR012604|TMC435350-TiDP16-C202","December 18, 2008","March 2009","November 2009","July 1, 2014","July 2014","December 24, 2013","null","November 2009","Change From Baseline in log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels|Number of Participants With a Decrease From Baseline of Greater Than or Equal to 2 log10 IU/mL in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During the TMC435 Treatment Period|Number of Participants With Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Below the Limit of Quantification (Less Than 25 IU/mL) and Limit of Detection (Less Than 25 IU/mL Undetectable) During the TMC435 Treatment Period|Number of Participants Who Experienced Viral Breakthrough During TMC435 Treatment Period|Predose Plasma Concentration (C0h) of TMC435|Minimum Plasma Concentration (Cmin) of TMC435|Maximum Plasma Concentration (Cmax) of TMC435|Time to Reach the Maximum Plasma Concentration (Tmax) of TMC435|Average Steady-State Plasma Concentration (Css,av) of TMC435|Fluctuation Index (FI) of TMC435|Area Under the Plasma Concentration-time Curve From the Time of Administration up to 24 Hours After Dosing (AUC24h) of TMC435|Area Under the Plasma Concentration-time Curve From Time of Administration up to the Last Time Point With a Measurable Concentration After Dosing (AUClast) of TMC435|Elimination Rate Constant of TMC435|Terminal Elimination Half-life (t1/2,Term) of TMC435","https://ClinicalTrials.gov/show/NCT00812331"
663,"NCT01684787","Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients","Completed","No Results Available","Chronic Hepatitis C","Drug: Peginterferon alfa-2a + ribavirin in normal ALT|Drug: Peginterferon alfa-2a + ribavirin in elevated ALT","Miguel Santin|Hospital Universitari de Bellvitge","Both","Adult|Senior","Phase 4","80","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","Miguel Sant√≠n","June 11, 2010","September 2006","June 2011","September 12, 2012","September 2012","No Study Results Posted","CONTRA","May 2011","% patients with RNA-HCV negative","https://ClinicalTrials.gov/show/NCT01684787"
664,"NCT01833845","Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C","Terminated","Has Results","Hepatitis C","Drug: Ribavirin|Drug: Hydroxychloroquine","BioLineRx, Ltd.","Both","Adult|Senior","Phase 1|Phase 2","4","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","BL-8020.01","April 15, 2013","April 2013","April 2014","August 27, 2014","August 2014","July 30, 2014","null","April 2014","Efficacy|Safety: Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT01833845"
665,"NCT01667731","Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults","Completed","Has Results","Hepatitis C|Human Immunodeficiency Virus","Drug: SOF|Drug: RBV","Gilead Sciences","Both","Adult|Senior","Phase 3","224","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","GS-US-334-0123","August 9, 2012","July 2012","February 2014","November 14, 2014","November 2014","November 14, 2014","null","November 2013","Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)|Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)|Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)|Change From Baseline in HCV RNA at Week 1|Change From Baseline in HCV RNA at Week 2|Change From Baseline in HCV RNA at Week 4|Change From Baseline in HCV RNA at Week 6|Change From Baseline in HCV RNA at Week 8|Percentage of Participants Experiencing On-treatment Virologic Failure|Percentage of Participants Experiencing Viral Relapse","https://ClinicalTrials.gov/show/NCT01667731"
666,"NCT01491295","Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients","Recruiting","No Results Available","Chronic Hepatitis B","Drug: Tenofovir disoproxil fumarate|Drug: Lamivudine plus adefovir","Taipei Veterans General Hospital, Taiwan","Both","Adult|Senior","Phase 4","160","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","IN-US-174-0194","October 27, 2011","September 2012","December 2016","November 2, 2012","December 2011","No Study Results Posted","null","December 2016","Incidence of virological breakthrough (defined as HBV DNA > 100 IU/ml)|HBeAg seroconversion (for HBeAg-positive patients)|Incidence of HBsAg loss","https://ClinicalTrials.gov/show/NCT01491295"
667,"NCT02292706","A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","Enrolling by invitation","No Results Available","Hepatitis C Virus Infection","Drug: Sofosbuvir","Gilead Sciences","Both","Adult|Senior","","2000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GS-US-337-1431|2014-001249-26","November 13, 2014","December 2014","March 2021","October 1, 2015","October 2015","No Study Results Posted","null","March 2021","Proportion of participants maintaining sustained virologic response (SVR) at Week 240|Proportion of participants who develop liver disease progression or regression, as assessed by clinical and laboratory parameters|Proportion of participants who develop hepatocellular carcinoma (HCC) through Week 240|Proportion of participants with detectable HCV RNA due to re-emergence of pre-existing virus through Week 240|Proportion of participants with detectable HCV resistance mutations through Week 240|Proportion of participants with detectable HCV RNA due to re-infection through Week 240","https://ClinicalTrials.gov/show/NCT02292706"
668,"NCT01497834","A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients","Completed","No Results Available","Hepatitis C","Drug: BMS-790052 (Daclatasvir)|Drug: BMS-650032 (Asunaprevir)","Bristol-Myers Squibb","Both","Adult|Senior","Phase 3","224","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","AI447-026","December 2, 2011","January 2012","June 2013","September 23, 2015","September 2015","No Study Results Posted","null","April 2013","Antiviral activity, as determined by the proportion of subjects with SVR24|Antiviral activity, as determined by the proportion of subjects who achieve Hepatitis C virus (HCV) ribonucleic acid (RNA) below lower limit of quantitation (LLOQ) target detected or not detected|Antiviral activity, as determined by the proportion of subjects who achieve HCV RNA below LLOQ, target not detected|Safety, as measured by the frequency of serious adverse events (SAEs), discontinuations due to adverse events (AEs), AEs by intensity and laboratory abnormalities by toxicity grade|Proportion of subjects with SVR24 by IL28B status [CC, CT, or TT genotype at the IL28B rs12979860 single nucleotide polymorphisms (SNP)]","https://ClinicalTrials.gov/show/NCT01497834"
669,"NCT00768157","Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma","Recruiting","No Results Available","Hepatocellular Carcinoma|Hepatitis B Virus|Recurrence","Drug: antiviral treatment (lamivudine or entecavir)|Procedure: radical resection of HBV-related HCC","Sun Yat-sen University","Both","Adult|Senior","Phase 4","200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","SYSUCC-HCC004","October 6, 2008","April 2007","August 2010","February 6, 2009","February 2009","No Study Results Posted","null","August 2009","Overall survivals|Recurrence rate","https://ClinicalTrials.gov/show/NCT00768157"
670,"NCT02582658","Paritaprevir/r - Ombitasvir, ¬± Dasabuvir, ¬± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)","Recruiting","No Results Available","Chronic Hepatitis C","","AbbVie","Both","Adult|Senior","","170","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-695","October 20, 2015","October 2015","July 2017","October 20, 2015","October 2015","No Study Results Posted","REAL","July 2017","Percentage of participants achieving sustained virological response 12 Weeks Post-treatment (SVR12)|Usage pattern of treatment regimen in Austria|Percentage of the direct-acting antiviral (DAA) dose taken in relation to the target dose of DAA|Percentage of the Ribavirin (RBV) dose taken in relation to the target dose of RBV|Percentage of missed Ribavirin (RBV) treatment days in relation to the target number of RBV treatment days|Number of participants with concomitant medications|Number of participants with co-morbidities|Change in participants workability measured with the Work Productivity and Activity Impairment (WPAI):Hepatitis C questionnaire|Change in participants quality of life measured with the EuroQol 5 dimension 5 level (EQ-5D-5L) questionnaire|Change of participant activation with the Patient activation Measure (PAM-13) questionnaire.|Patient support program (PSP) utilization and satisfaction assessment","https://ClinicalTrials.gov/show/NCT02582658"
671,"NCT01968382","Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis","Recruiting","No Results Available","Hepatitis, Alcoholic","Drug: IMM 124-E (Hyperimmune Bovine Colostrum)|Drug: Placebo (High protein milk powder)","Virginia Commonwealth University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Immuron Ltd.","Both","Adult|Senior","Phase 2","66","Other|NIH|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","IMM 124-E|U01AA021891","August 30, 2013","December 2014","January 2018","April 20, 2015","April 2015","No Study Results Posted","TREAT","July 2017","Greater decrease in mean circulating endotoxin levels in those receiving Steroids+ Imm 124-E compared to steroids + placebo|Microbiome-metagenomic-immunologic data|Efficacy related outcomes|Safety Related endpoints","https://ClinicalTrials.gov/show/NCT01968382"
672,"NCT01475851","Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs","Completed","Has Results","Hepatitis B, Chronic","Drug: GSK548470 300 mg tablet","GlaxoSmithKline","Both","Child|Adult|Senior","Phase 3","34","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","115912","November 17, 2011","December 2011","October 2014","June 18, 2015","May 2015","August 22, 2013","null","June 2013","Number of Participants With HBV DNA Level < 2.1 log10 Copies/mL at Week 24|Mean Change From Baseline in Serum HBV DNA Level at Week 24, Week 48 and Week 96|Number of Participants With Serum HBV DNA < 2.1 log10 Copies/mL at Week 48 and Week 96|Number of Participants With Alanine Aminotransferase (ALT) Normalization at Week 24, Week 48 and Week 96|Number of Participants With HBeAg Loss at Week 24, Week 48 and Week 96|Number of Participants With HBeAg/HBeAb Seroconversion at Week 24, Week 48 and Week 96|Number of Participants Achieving HBsAg Loss at Week 24, Week 48 and Week 96|Number of Participants Achieving HBsAg/HBsAb Seroconversion at Week 24, Week 48 and Week 96|Number of Participants With Virological Breakthrough and Resistance-related Mutations|Number of Participants Achieving Each Indicated HBsAg Category at Baseline, Week 24, Week 48 and Week 96|Number of Participants Achieving Each Indicated HBcrAg Category at Baseline,Week 24, Week 48 and Week 96","https://ClinicalTrials.gov/show/NCT01475851"
673,"NCT00507507","A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)","Completed","Has Results","Chronic Hepatitis B","Drug: Tenofovir DF|Drug: FTC|Drug: Placebo","Gilead Sciences","Both","Adult|Senior","Phase 2","126","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","GS-US-203-0101","July 25, 2007","September 2007","August 2012","July 7, 2015","July 2015","May 23, 2013","null","February 2012","Percentage of Participants With HBV DNA < 400 Copies/mL at Week 192|Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 96, and 144|Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 96, 144, and 192|Change From Baseline in HBV DNA at Week 48|Change From Baseline in HBV DNA at Week 96|Change From Baseline in HBV DNA at Week 144|Change From Baseline in HBV DNA at Week 192|Number of Participants With Normal Alanine Aminotransferase (ALT) at Weeks 48, 96, 144, and 192|Number of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 48, 96, 144, and 192|Number of Participants With Seroconversion to Antibody Against HBeAg (Anti-HBe) at Weeks 48, 96, 144, and 192|Number of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 96, 144, and 192|Number of Participants With Seroconversion to Antibody to HBsAg (Anti-HBs) at Weeks 48, 96, 144, and 192|Occurrence of HBV Resistance Mutations","https://ClinicalTrials.gov/show/NCT00507507"
674,"NCT00199719","Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM","Completed","No Results Available","Chronic Hepatitis C","Drug: Ribavirine","University Hospital, Limoges|Hoffmann-La Roche","Both","Adult","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","I02022","September 14, 2005","June 2003","September 2006","October 30, 2007","June 2007","No Study Results Posted","CINAM","null","-Study of the complete pharmacokinetics of ribavirin at day 1, and day 84 (week 12).|-Study of the complete pharmacokinetics of amantadin and ribavirin at week 12 + one day and at week 24","https://ClinicalTrials.gov/show/NCT00199719"
675,"NCT00246363","A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C","Completed","No Results Available","HIV Infections|Hepatitis C","Drug: Silymarin|Drug: Placebo","Henry Sacks|National Institute of Nursing Research (NINR)|Icahn School of Medicine at Mount Sinai","Male","Adult|Senior","Phase 1|Phase 2","40","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","GCO 02-1185|R21NR008860","October 27, 2005","January 2005","December 2007","September 14, 2011","September 2011","No Study Results Posted","null","December 2007","progression of liver damage","https://ClinicalTrials.gov/show/NCT00246363"
676,"NCT02428491","Study of Sanofi Pasteur's DTaP-IPV Hep B-PRP-T Combined Vaccine in Infants Who Previously Received Hepatitis B Vaccine","Recruiting","No Results Available","Diphtheria|Tetanus|Pertussis|Poliomyelitis|Hepatitis B|Haemophilus Influenzae Type b","Biological: DTaP-IPV-Hep B-PRP-T combined vaccine (Hexaxim‚Ñ¢)|Biological: DTaP-IPV-Hep B-PRP-T combined vaccine (Hexaxim‚Ñ¢)","Sanofi Pasteur, a Sanofi Company|Sanofi","Both","Child","Phase 3","354","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","A3L35|U1111-1143-8177","April 23, 2015","April 2015","March 2017","July 10, 2015","July 2015","No Study Results Posted","null","September 2016","Number of Participants Reporting Solicited Injection-site Reactions, Solicited Systemic Reactions, Unsolicited Systemic Reactions, and Serious Adverse Events Occurring Throughout the Trial|Number of participants with anti Pertussis toxoid and anti Filamentous Hemagglutinin antibody concentrations ‚â• Lower Limit of Quantitation (LLOQ) and ‚â• 4 x LLOQ at baseline|Number of participants with ‚â• 4-fold and ‚â• 2-fold increase in anti-Pertussis toxoid and anti-Filamentous Hemagglutinin antibody concentrations (EU/mL) from pre-dose 1 to one month post-dose 3|Number of participants with vaccine response for pertussis toxoid and Filamentous Hemagglutinin antigens|Number of participants with anti-Diphtheria antibody concentrations ‚â• 0.01 and ‚â• 0.1 IU/mL International Units (IU)/mL post-third dose vaccination","https://ClinicalTrials.gov/show/NCT02428491"
677,"NCT00800007","Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus","Terminated","No Results Available","Chronic Hepatitis C","Drug: ANZ-521|Drug: Placebo","Anza Therapeutics, Inc.","Both","Adult","Phase 1|Phase 2","5","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","ANZ-521-101","November 26, 2008","November 2008","February 2009","February 19, 2009","February 2009","No Study Results Posted","null","February 2009","Subject incidence of AEs, clinically relevant changes in lab values, ECGs, and vital signs|Plasma HCV RNA titers relative to baseline|Serum transaminase levels relative to baseline|Innate and adaptive immune responses induced by ANZ-521|Blood, stool, and urine cultures of ANZ-521","https://ClinicalTrials.gov/show/NCT00800007"
678,"NCT01260610","Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients","Withdrawn","No Results Available","Chronic Hepatitis B","Drug: Tenofovir|Drug: Telbivudine|Drug: Tenofovir plus Telbivudine","Institute of Liver and Biliary Sciences, India","Both","Adult","","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CLDT600AIN05T","December 14, 2010","June 2011","June 2011","June 15, 2015","June 2011","No Study Results Posted","null","June 2011","Efficacy of combination of telbivudine plus tenofovir vs monotherapy with either drug alone|Percentage change in serum HBV DNA levels|Percentage of patients with ALT normalization|Percentage of patients with reduction in HBsAg concentration by >50%|Percentage of patients with virological breakthrough|Percentage of patients with primary treatment failure|Occurrence of adverse events","https://ClinicalTrials.gov/show/NCT01260610"
679,"NCT01804387","Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study","Recruiting","No Results Available","Chronic Hepatitis B","Drug: telbivudine plus adefovir|Drug: lamivudine plus adefovir","Korea University","Both","Adult|Senior","Phase 4","60","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","TeSLA study","December 23, 2011","May 2011","May 2014","March 3, 2013","March 2013","No Study Results Posted","TeSLA","December 2013","The mean reduction of serum HBV DNA from the baseline at week 52.|HBV DNA undetectability(<20 IU/mL)|mean serum HBV DNA level|rate of ALT normalization|rates of HBeAg loss|rate of HBeAg seroconversion at week 52.","https://ClinicalTrials.gov/show/NCT01804387"
680,"NCT00882193","Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers","Terminated","No Results Available","Chronic Hepatitis C|Genotype 1|Relapse","Drug: Betaine|Drug: Peginterferon alpha 2a|Drug: Ribavirin","University of Nebraska","Both","Adult|Senior","Phase 0","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","133-09","April 15, 2009","May 2009","May 2011","August 8, 2011","August 2011","No Study Results Posted","null","May 2011","To examine the safety and efficacy of betaine when combined with standard antiviral therapy in previously teated subjects with chronic hepatitis c genotype 1|The effect on interferon gene signaling in peripheral blood mononuclear cells in the first 12 weeks of treatment and 6 months following the end of therapy.","https://ClinicalTrials.gov/show/NCT00882193"
681,"NCT00759200","Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients","Completed","No Results Available","Chronic Hepatitis C","Drug: alb-interferon alfa 2b|Drug: alb-interferon alfa 2b|Drug: alb-interferon alfa 2b|Drug: alb-interferon alfa 2b|Drug: peg-interferon","Novartis|Human Genome Sciences Inc.","Both","Adult|Senior","Phase 2","525","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CABF656B2202","September 23, 2008","October 2008","December 2010","April 18, 2011","April 2011","No Study Results Posted","null","December 2010","Adverse events|Viral load","https://ClinicalTrials.gov/show/NCT00759200"
682,"NCT01215643","Efficacy and Safety of DEB025 Alone or Combined With Either Ribavirin or Peg-IFN Œ±2a in Chronic Hepatitis C Genotype 2 and 3 na√Øve Patients","Completed","No Results Available","Hepatitis C|Chronic Pain","Drug: DEB025 1000 mg QD|Drug: DEB025 600 mg QD + RBV 400 mg BID|Drug: DEB025 800 mg QD + RBV 400 mg BID|Drug: DEB025 600 mg QD + peg-IFNŒ±2a once weekly|Drug: SOC (peg-IFNŒ±2a once weekly + RBV 400 mg BID)","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 2","340","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CDEB025A2211|2010-020034-26","October 5, 2010","October 2010","null","June 5, 2014","June 2014","No Study Results Posted","null","May 2012","Measure: RVR : Rapid Viral Response : defined as serum HCV RNA undetectable (by LOQ) after 4 weeks of treatment.|Measure: SVR24 : Sustained Viral Response Week 24 : defined as serum HCV RNA undetectable (by LOD) after 24 weeks of treatment.","https://ClinicalTrials.gov/show/NCT01215643"
683,"NCT01056172","PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)","Recruiting","No Results Available","Chronic Hepatitis C","Drug: Peginterferon alfa-2a and Ribavirin|Drug: Peginterferon alfa-2a and Ribavirin","Pusan National University Yangsan Hospital|Severance Hospital|Pusan National University Hospital|Incheon St.Mary's Hospital|Soon Chun Hyang University|Inje University","Both","Adult|Senior","Phase 4","164","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","PNUYH-CHC001","January 25, 2010","January 2010","December 2012","April 18, 2012","April 2012","No Study Results Posted","null","June 2012","Sustained virologic response (SVR)|AEs|laboratory parameters|vital signs","https://ClinicalTrials.gov/show/NCT01056172"
684,"NCT02099604","Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C","Withdrawn","No Results Available","Chronic Hepatitis C","Drug: Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Institut Pasteur","Both","Adult","Phase 3","0","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ANRS 12226 ViZIR","March 24, 2014","April 2014","null","July 22, 2014","March 2014","No Study Results Posted","ViZIR","March 2017","Proportion of patients with Sustained Virological Response (SVR).|Rapid Virological Response (RVR)|Early Virological Response (EVR)|End of Treatment Response (ETR)|Normalization of ALT during treatment and 12 weeks after the end of treatment|Incidence of serious adverse events (SAE) grade 3 and 4 (ANRS scale)|Evolution of FibroScan values between pre-inclusion and week 60","https://ClinicalTrials.gov/show/NCT02099604"
685,"NCT00328549","A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)","Completed","No Results Available","Hepatitis C|Anemia","Drug: Pegylated Interferon and Ribavirin","Ortho Biotech Products, L.P.","Both","Adult|Senior","Phase 2","105","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CR005116","May 19, 2006","October 2001","December 2002","May 17, 2011","April 2010","No Study Results Posted","null","null","Primary endpoints were change in Hb and sEPO from baseline to week 8 (or early withdrawal)|Other endpoints measured were changes in reticulocytes, platelets, total bilirubin, and RBV dose from baseline to week 8.","https://ClinicalTrials.gov/show/NCT00328549"
686,"NCT01769833","HBsAg Decline After Pegylated-interferon-Œ± in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance","Active, not recruiting","No Results Available","Chronic Hepatitis B","Drug: PEG-interferon-Alfa-2A|Drug: Nucleosides","Pusan National University Hospital","Both","Adult|Senior","Phase 3","144","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ML25659","January 15, 2013","May 2013","May 2016","November 3, 2014","November 2014","No Study Results Posted","null","May 2015","Change in log10 HBsAg titer during antiviral therapy|HBV DNA undetectability and below 400 IU/mL during antiviral therapy and follow-up|HBeAg seroconversion and loss during antiviral therapy and at end of treatment and 1 and 2 years following end of treatment|HBsAg loss and HBsAg seroconversion at end of treatment and 1 and 2 years following end of treatment|Change in log10 HBsAg titer during follow-up|Mean change in log10 HBsAg titre over time, as estimated from the area between the baseline value and the curve of log10 HBsAg titre divided by the duration of treatment","https://ClinicalTrials.gov/show/NCT01769833"
687,"NCT00142103","CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects","Completed","No Results Available","Hepatitis, Chronic Active","Drug: CPG10101|Drug: CPG10101|Drug: CPG10101|Drug: CPG10101|Drug: Control|Drug: CPG10101","Pfizer","Both","Adult|Senior","Phase 1","91","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","B1211001|CPG10101-003","August 31, 2005","September 2005","February 2007","May 13, 2011","May 2011","No Study Results Posted","null","February 2007","Adverse events, vital signs, clinical and laboratory parameters, physical exam, ECG|Serum HCV RNA concentrations: Serum HCV concentrations over time to baseline","https://ClinicalTrials.gov/show/NCT00142103"
688,"NCT01323452","Entecavir for Chronic Hepatitis B","Completed","No Results Available","Entecavir for Chronic Hepatitis B Patients","Drug: Entecavir","Foundation for Liver Research","Both","Adult|Senior","","418","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","VIRGIL","March 21, 2011","November 2010","March 2011","March 24, 2011","March 2011","No Study Results Posted","null","January 2011","Virological response","https://ClinicalTrials.gov/show/NCT01323452"
689,"NCT01242787","Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B","Active, not recruiting","No Results Available","Chronic Hepatitis B","Drug: LB80380|Drug: Entecavir 0.5 mg","LG Life Sciences","Both","Adult|Senior","Phase 2","115","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","BVCL008","November 12, 2010","August 2010","September 2012","April 13, 2012","April 2012","No Study Results Posted","LB80380","September 2012","Percentage of patients showing HBV DNA mutation|Change of HBV DNA from Baseline of LG-BVCL007 study","https://ClinicalTrials.gov/show/NCT01242787"
690,"NCT01281839","An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy","Completed","Has Results","Hepatitis C","Drug: TMC435|Drug: Placebo|Drug: Peginterferon alpha-2a (PegIFN alpha-2a)|Drug: Ribavirin (RBV)","Janssen R&D Ireland","Both","Adult|Senior","Phase 3","394","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","CR017371|TMC435HPC3007|2010-021113-23","January 7, 2011","February 2011","February 2013","March 26, 2014","March 2014","February 3, 2014","PROMISE","February 2013","The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)|The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)|The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)|The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)|Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)|Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)|The Percentage of Participants With On-treatment Virologic Response at All Time Points|The Percentage of Participants Achieving a Rapid Virologic Response (RVR)|The Percentage of Participants Achieving a Early Virologic Response (EVR)|The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)|The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)|The Percentage of Participants With <1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4|Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels >1000 IU/mL at Week 4|The Percentage of Participants With Null Response|The Percentage of Participants With Partial Response|The Percentage of Participants With Viral Breakthrough|The Percentage of Participants With Viral Relapse|The Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule|The Percentage of Participants With On-treatment Failure|Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable|Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable or Detectable|Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <100 IU/mL|Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <1000 IU/mL|The Percentage of Participants With Viral Breakthrough at Different Time Points|Time From End-of-treatment to Viral Relapse|The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)|Median Time to Normalization of Alanine Aminotransferase (ALT) Levels|Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)|Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)|Plasma Concentration of TMC435: Systemic Clearance (CL)","https://ClinicalTrials.gov/show/NCT01281839"
691,"NCT00606099","Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B","Withdrawn","No Results Available","Chronic Hepatitis B","Drug: telbivudine|Drug: adefovir dipivoxil","Novartis","Both","Adult|Senior","Phase 4","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CLDT600AUS03","January 21, 2008","November 2007","null","May 1, 2012","May 2012","No Study Results Posted","null","November 2009","Efficacy at 24 weeks of treatment.|To compare biochemical response at week 24 of treatment. To compare changes in viral load at week 24 of treatment. To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.","https://ClinicalTrials.gov/show/NCT00606099"
692,"NCT00828269","Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123)","Completed","No Results Available","Chronic Hepatitis C","Procedure: Comparator: Fine needle aspiration biopsy","Merck Sharp & Dohme Corp.","Both","Adult","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic|Masking: Single Blind (Subject)","0000-123|123|2009_518","January 21, 2009","April 2009","March 2010","April 21, 2015","April 2015","No Study Results Posted","null","February 2010","To evaluate the probability that fine needle aspiration of the liver results in RNA suitable to conduct gene expression tests.|Comparison of qPCR and microarray signature from patients with no or minimal fibrosis to that from patients with moderate to advanced fibrosis.","https://ClinicalTrials.gov/show/NCT00828269"
693,"NCT02112890","Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico","Recruiting","No Results Available","Hepatitis A","Other: Data collection","GlaxoSmithKline","Both","Child|Adult","","2000","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","201076","April 10, 2014","December 2014","November 2015","October 29, 2015","October 2015","No Study Results Posted","null","November 2015","Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for anti-HAV|Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for anti-HBV (Hepatitis B core antibody [anti-HBc], Hepatitis B surface antigen [HBsAg]) and Hepatitis B surface antibody (anti-HBs)|Assessment of seropositivity status (defined as the percentage of subjects with antibody titres positive) for Pertussis antibodies|Assesment of the difference in HAV, HBV and B. pertussis seropositivity rates among - Socioeconomic strata, - Regions, - Age groups, - Genders, - Risk groups, - Vaccination status for B. pertussis (if available)","https://ClinicalTrials.gov/show/NCT02112890"
694,"NCT01026610","Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: LB80380 90 mg|Drug: LB80380 150 mg|Drug: entecavir 0.5 mg","LG Life Sciences","Both","Adult","Phase 2","115","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","BVCL007","December 3, 2009","August 2009","May 2011","October 4, 2012","October 2012","No Study Results Posted","null","November 2010","Changes in HBV DNA level (log10) from baseline|Proportion of patients with undetectable serum HBV DNA|Proportion of patients with HBeAg seroconversion|Proportion of patients with ALT normalization|Safety assessment during the whole study period","https://ClinicalTrials.gov/show/NCT01026610"
695,"NCT01634919","Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon Alpha-2a and Ribavirin","Recruiting","No Results Available","Chronic Hepatitis C","Device: chronic hepatitis C","Seoul National University Boramae Hospital|Roche Pharma AG","Both","Adult|Senior","Phase 4","55","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","06-2012-74","July 3, 2012","July 2012","December 2016","May 18, 2015","May 2015","No Study Results Posted","null","June 2016","Anti-fibrotic response|Histologic and noninvasive fibrosis assessments","https://ClinicalTrials.gov/show/NCT01634919"
696,"NCT01290679","An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants","Completed","Has Results","Hepatitis C","Drug: Placebo|Drug: TMC435|Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNŒ±-2a/b)|Drug: Ribavirin (RBV)","Janssen R&D Ireland","Both","Adult|Senior","Phase 3","393","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","CR017380|TMC435-TiDP16-C216|2010-021174-11","January 7, 2011","March 2011","February 2013","June 10, 2014","June 2014","February 3, 2014","QUEST-2","February 2013","The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)|The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)|The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)|The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)|Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)|Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)|Percentage of Participants With On-treatment Virologic Response at All Time Points|The Percentage of Participants Achieving a Rapid Virologic Response (RVR)|The Percentage of Participants Achieving a Early Virologic Response (EVR)|The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)|The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)|The Percentage of Participants With <1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4|Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels >1000 IU/mL at Week 4|Percentage of Participants With Null Response|Percentage of Participants With Partial Response|Percentage of Participants With Viral Breakthrough|Percentage of Participants With Viral Relapse|Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule|Percentage of Participants With On-treatment Failure|Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable or Detectable|Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable|Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <100 IU/mL|Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <1000 IU/mL|The Percentage of Participants With Viral Breakthrough at Different Time Points|Time From End-of-treatment to Viral Relapse|The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)|Median Time to Normalization of Alanine Aminotransferase (ALT) Levels|Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)|Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)|Plasma Concentration of TMC435: Systemic Clearance (CL)|Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for the Fatigue Severity Scale (FSS) Total Scores|Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Overall Work Productivity Due to Hepatitis C Virus (HCV) Infection and Its Treatment|Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Daily Activities Due to Hepatitis C Virus (HCV) Infection and Its Treatment|Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Time Missed From Work Due to Hepatitis C Virus (HCV) Infection and Its Treatment","https://ClinicalTrials.gov/show/NCT01290679"
697,"NCT00987337","Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects","Completed","Has Results","Hepatitis|Hepatitis C","Drug: Filibuvir|Drug: Filibuvir|Drug: Placebo","Pfizer","Both","Adult|Senior","Phase 2","288","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","A8121014","September 29, 2009","November 2009","January 2012","December 10, 2013","December 2013","December 10, 2013","FITNESS","January 2012","Percentage of Participants With Sustained Viral Response (SVR) at Week 72|Percentage of Participants With Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4, 12, 24 and 48|Percentage of Participants With Sustained Viral Response at 12 Weeks Following Completion of Therapy (SVR12)|Percentage of Participants With Sustained Viral Response at 24 Weeks Following Completion of Therapy (SVR24)|Percentage of Participants With Breakthrough Viremia|Percentage of Participants With Relapsed Response|Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4, 12 and 24|Number of Adverse Events (AEs) by Severity (All Causality)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Relationship to Study Drug (Any Therapy)|Number of Participants Who Discontinued Study Due to Adverse Events (AEs)|Number of Participants With Dose Reduction or Temporary Discontinuation Due to Adverse Events (AEs)|Number of Participants With Laboratory Test Abnormalities by Severity|Plasma Concentration of Filibuvir, Pegylated Interferon and Ribavirin","https://ClinicalTrials.gov/show/NCT00987337"
698,"NCT00240539","Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg)","Completed","Has Results","Hepatitis B","Procedure: Blood sampling","GlaxoSmithKline","Both","Child|Adult","Phase 4","36","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","100449","October 13, 2005","October 2003","July 2008","December 10, 2009","December 2009","July 16, 2009","null","July 2008","Number of Subjects Seropositive for Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies|Number of Subjects Who Tested Positive for Markers of Infection With Hepatitis B Virus|Number of Subjects With Chronic and With Clinical HBV Infection","https://ClinicalTrials.gov/show/NCT00240539"
699,"NCT00682591","Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy","Withdrawn","No Results Available","Chronic Hepatitis C Infection","","University of Wuerzburg","Both","Adult","","190","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P05595","May 20, 2008","July 2008","December 2011","February 3, 2009","February 2009","No Study Results Posted","null","December 2011","Time course of neurocognitive performance (as assessed by the TAP - Test Battery for Attentional Performance)","https://ClinicalTrials.gov/show/NCT00682591"
700,"NCT01500265","Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus","Active, not recruiting","No Results Available","Hepatitis B|Renal Failure With Tubular Necrosis","Biological: plasma and urine samples, sample with ADN","University Hospital, Limoges","Both","Adult|Senior","","216","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","I10006 HBVSECURE","December 22, 2011","December 2011","December 2015","February 17, 2014","February 2014","No Study Results Posted","HBVSECURE","December 2013","the prevalence of ""subclinical"" proximal tubular abnormalities|the prevalence at baseline of ""subclinical"" proximal tubular abnormalities","https://ClinicalTrials.gov/show/NCT01500265"
701,"NCT00724776","Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients","Completed","No Results Available","Chronic Hepatitis C","Biological: Albinterferon alfa 2b","Novartis","Both","Adult|Senior","Phase 1","30","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CABF656A1202","July 28, 2008","July 2008","null","August 10, 2010","August 2010","No Study Results Posted","null","July 2009","Safety and tolerability after single dose|Pharmacokinetics of albinterferon alfa 2b HCV RNA and ALT as pharmacodynamics evaluation","https://ClinicalTrials.gov/show/NCT00724776"
702,"NCT00807001","Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Na√Øve Subjects","Completed","Has Results","Chronic Hepatitis C (HCV)","Drug: IDX184","Merck Sharp & Dohme Corp.","Both","Adult","Phase 1|Phase 2","41","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","2355-003|IDX-08C-003","December 10, 2008","December 2008","July 2009","April 22, 2015","April 2015","October 8, 2010","null","July 2009","Number of Subjects With Any Adverse Event (Side Effect) and the Severity of Those Adverse Events|Antiviral Activity at Day 4. Change in Plasma HCV RNA (Hepatitis C Virus Ribonucleic Acid)","https://ClinicalTrials.gov/show/NCT00807001"
703,"NCT01010646","Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4","Active, not recruiting","No Results Available","Chronic Hepatitis C","Drug: IFN alfa-2b XL 27 MUI + Ribavirin|Drug: IFN alfa-2b XL 36 MUI + Ribavirin|Drug: IFN peg alfa-2b 1.5 ¬µg/kg + Ribavirin","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Flamel Technologies","Both","Adult","Phase 2","84","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","2009-015121-37|ANRS HC 23 COAT-IFN","November 9, 2009","March 2010","November 2013","September 19, 2013","September 2013","No Study Results Posted","COAT IFN","September 2012","Viral load decrease at Week 4 and Week 12 of treatment with IFN alfa-2b XL 27 MIU, IFN alfa-2b XL 36 MIU and the marketed reference product (PEG IFN alfa-2b 1.5Œºg/kg) in combination with ribavirin|Percentage of patients with early virologic response (EVR) (reduction of at least 2 log viral load) at the end of week 12|Percentage of patients with complete early virologic response (EVR) (viral load <15 IU) at the end of the week 12","https://ClinicalTrials.gov/show/NCT01010646"
704,"NCT02405013","Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir and Ribavirin for the Treatment of Genotype 1, 2 and 4 Hepatitis C Virus-infected Patients in West and Central Africa","Not yet recruiting","No Results Available","Hepatitis C|HIV Infection","Drug: Sofosbuvir|Drug: Ribavirin","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)","Both","Adult|Senior","Phase 2","120","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ANRS 12311 TAC","February 20, 2015","May 2015","November 2016","March 27, 2015","March 2015","No Study Results Posted","TAC","November 2016","Sustained Viral Load Response (SVR)|Tolerance|Viral kinetics as measured by SVR 24 and HCV-RNA|HIV treatment clinical parameters|Liver fibrosis|Adherence measured by number of remaining tablets at each visit based on the number of tablets should have been taken as a percentage of the total dose|Quality of life|Performance of an unit of nanotechnology|Setting up the network:|Integration Access initiatives evaluated by the number of patients off protocol that will have access to new anti-HCV treatment due to ""ACCESS"" programs of pharmaceutical companies conducting such programs in Sub-Saharan Africa|Biological events","https://ClinicalTrials.gov/show/NCT02405013"
705,"NCT02262728","An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease","Active, not recruiting","No Results Available","Hepatitis C, Chronic","Drug: Simeprevir|Drug: Daclatasvir|Drug: Sofosbuvir","Janssen Research & Development, LLC","Both","Adult|Senior","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CR105028|TMC435HPC2010","October 6, 2014","September 2014","January 2020","October 16, 2015","October 2015","No Study Results Posted","null","August 2015","Percentage of Participants With Sustained Virologic Response 12 Weeks After end of Study Drug Treatment (SVR12)|Percentage of Participants with On-treatment Virologic Response|Percentage of Participants with SVR 4 Weeks After end of Study Drug Treatment (SVR4) and SVR 24 Weeks After end of Study Drug Treatment (SVR24)|Percentage of Participants with On-treatment Failure|Percentage of Participants with Viral Relapse|Change From Baseline in HCV NS3/4A Sequence, NS5A and NS5B at Day 3, Week 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, and Year 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 After end of Treatment in Participants not Achieving SVR|Percentage of Participants with Normalized Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels|Time to Reach Maximum Plasma Concentration (Tmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)|Area Under the Plasma Concentration-Time Curve from Time 0 to 24 hours After Dosing (AUC[0-24]) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)|Maximum Plasma Concentration (Cmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)|Minimum Plasma Concentration (Cmin) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)|Pre-dose (trough) Concentration (C0h) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)|Percentage of Participants with SVR12 who Maintain to have HCV RNA <LLOQ Until the end of 5 years Follow up","https://ClinicalTrials.gov/show/NCT02262728"
706,"NCT00291616","Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: Pegylated Interferon-alpha2a|Drug: Thymosin alpha1 & Pegylated Interferon-alpha2a","Seoul National University Hospital|Roche Pharma AG|SciClone Pharmaceuticals","Both","Adult|Senior","Phase 4","52","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","12-05-008","February 13, 2006","December 2005","August 2008","July 20, 2011","July 2011","No Study Results Posted","null","August 2008","HBeAg seroconversion, HBV DNA titer<20,000 IU/mL|Normalization of serum ALT, loss of HBeAg and HBsAg, production of anti-HBs","https://ClinicalTrials.gov/show/NCT00291616"
707,"NCT02364336","Mechanisms Associated With Favorable Responses to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B","Recruiting","No Results Available","Chronic Hepatitis B","Drug: Peginterferon alfa-2a","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","60","NIH","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","150082|15-DK-0082","February 14, 2015","February 2015","September 2017","October 28, 2015","September 2015","No Study Results Posted","null","September 2016","Change in interferon-stimulated-genes|HBeAg and HBsAg seroconversion","https://ClinicalTrials.gov/show/NCT02364336"
708,"NCT01332552","A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects","Terminated","No Results Available","Hepatitis C","Drug: GSK2485852 70 mg|Drug: GSK2485852 420 mg|Drug: placebo|Drug: placebo|Drug: GSK2485852 420 mg|Drug: GSK2485852 420 mg|Drug: GSK2485852 630 mg|Drug: GSK2485852 70 mg + Ritonavir 100mg|Drug: GSK2485852 210 mg + Ritonavir 100mg|Drug: GSK2485852 210 mg +Ritonavir 100mg","GlaxoSmithKline","Both","Adult","Phase 1","27","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","115040","April 7, 2011","January 2011","April 2011","December 1, 2011","December 2011","No Study Results Posted","null","April 2011","Safety parameters: adverse events; telemetry; absolute values and changes over time of hematology, clinical chemistry, urinalysis, vital signs (blood pressure, heart rate), and electrocardiogram (ECG) parameters|GSK2485852 PK parameters following single dose administration: AUC(0-inf), AUC(0-t), AUC(0-24), Cmax, tmax, C24, t1/2, tlag, and CL/F|GSK2485852 PK parameters following repeat dose administration: AUC(0-œÑ), CœÑ, Cmax, tmax, t1/2, and CL/F|HCV RNA viral load reduction from baseline|HCV RNA change from baseline to nadir|Time course of HCV viral load at baseline, during dosing with GSK2485852, and > or = 14 days after GSK2485852 dosing|GSK2485852 PK parameters: AUC(0-24), Cmax, tmax and tlag following a single dose with and without moderate fat/calorie meal.|GSK2485852 accumulation ratio (R)|GSK2485852 time invariance in non-food cohorts|GSK2485852 dose proportionality after single or repeat dosing in non-food cohorts","https://ClinicalTrials.gov/show/NCT01332552"
709,"NCT00882908","A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment","Completed","Has Results","Hepatitis C","Drug: TMC435|Drug: Ribavirin (R)|Drug: PegIFNŒ±-2a (P)|Drug: Placebo","Tibotec Pharmaceuticals, Ireland","Both","Adult|Senior","Phase 2","386","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","CR015799|TMC435-TiDP16-C205|2008-007147-13","April 16, 2009","June 2009","April 2011","May 19, 2014","May 2014","December 18, 2013","PILLAR","April 2010","The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)|The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Undetectable During Treatment and Follow-up|The Percentage of Participants Who Achieved Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Detectable or Undetectable During Treatment and Follow-up|The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Greater Than or Equal to 2 log10 Drop During Treatment|The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)|The Percentage of Participants Achieving a Rapid Virologic Response (RVR)|The Percentage of Participants Achieving an Early Virologic Response (EVR)|The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)|The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)|Number of Participants With Viral Breakthrough|The Number of Participants With Viral Relapse|The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normalized ALT Levels at the End of Treatment (EOT)|Plasma Concentrations of TMC435|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435","https://ClinicalTrials.gov/show/NCT00882908"
710,"NCT01777295","Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System","Recruiting","No Results Available","Hepatitis B","Biological: Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.|Biological: EngerixTM-B","GlaxoSmithKline|Public Private Partnership with Institute for Medical Immunology (Universite Libre de Bruxelles)|Region Wallonne","Both","Adult","Phase 2","90","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Subject)","116640|2012-001344-22","January 24, 2013","February 2013","July 2016","April 20, 2015","April 2015","No Study Results Posted","null","May 2016","Innate/early immune response: Soluble mediators from the innate/early immune response in all subjects (Steps 1 and 2).|Adaptive response: Classical cellular and humoral immune response to components of the study vaccine.|Occurrence of solicited and non-serious unsolicited adverse events (AEs) (Steps 1 and 2).|Occurrence of any serious adverse event (SAE) (Steps 1 and 2).|Occurrence of any Potential Immune-Mediated Disease (pIMD) (Steps 1 and 2).|Occurrence of any new medical condition requiring medical attention (Steps 1 and 2).|Safety laboratory parameters (Steps 1 and 2).|Vital signs at protocol defined time-points (Steps 1 and 2).","https://ClinicalTrials.gov/show/NCT01777295"
711,"NCT00199732","Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a","Completed","No Results Available","Chronic Hepatitis B","","University Hospital, Limoges|Hoffmann-La Roche","Both","Adult|Senior","","19","Other|Industry","Observational","Time Perspective: Prospective","I04002","September 14, 2005","December 2004","July 2009","April 16, 2013","September 2005","No Study Results Posted","DNA-EVAL","July 2009","Kinetic cccDNA","https://ClinicalTrials.gov/show/NCT00199732"
712,"NCT02468648","Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816","Recruiting","No Results Available","Chronic Hepatitis C","Drug: Sofosbuvir|Drug: GS-5816","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","140","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","150143|15-DK-0143","June 9, 2015","June 2015","July 2017","September 12, 2015","March 2015","No Study Results Posted","null","July 2017","The primary endpoints will be changes in interferon stimulated gene and protein expression in the liver and changes in HCV RNA levels in liver and serum between baseline and 4 weeks.|Proportion who achieve SVR12 stratified by viral genotype|Secondary endpoints will be safety and rates of sustained virologic response 24 weeks off therapy","https://ClinicalTrials.gov/show/NCT02468648"
713,"NCT00854087","Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis","Completed","Has Results","Chronic Hepatitis C Infection","Drug: Fuzheng Huayu|Drug: Placebo","Tarek Hassanein|Shanghai Sundise Traditional Chinese Medicine Co., Ltd.|SCTI Research Foundation","Both","Adult|Senior","Phase 2","118","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","Fuzheng Huayu S-USIIT-01 Study","February 26, 2009","August 2010","August 2013","June 18, 2014","June 2014","May 19, 2014","null","April 2013","Safety of Fuzheng Huayu Treatment in Chronic Hepatitis C Subjects Who Have Failed Prior Anti-HCV Therapy or Cannot Receive or Refused Interferon Based Therapy.|Efficacy of Fuzheng Huayu Treatment in Chronic Hepatitis C Subjects Who Have Failed Prior Anti-HCV Therapy or Cannot Receive or Refused Interferon Based Therapy.","https://ClinicalTrials.gov/show/NCT00854087"
714,"NCT01148576","Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients","Recruiting","No Results Available","Chronic Hepatitis B|Hepatic Steatosis","Drug: entecavir|Drug: entecavir|Drug: essentiale + entecavir|Drug: Vitamin E + entecavir","Zhejiang University","Both","Adult|Senior","Phase 4","1200","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","NCTZJU201001","June 17, 2010","June 2010","February 2012","June 21, 2010","June 2010","No Study Results Posted","null","December 2011","Differences in the anti-viral effect of entecavir among CHB patients and CHB + hepatic steatosis patients who received different drugs|Differences in the sustained response rate to entecavir among CHB patients and CHB + hepatic steatosis patients who received different drugs and obtained anti-virus effect after 1 year treatment.|Differences in the anti-viral effect of entecavir among CHB patients and CHB + hepatic steatosis patients who received different drugs in a short term.","https://ClinicalTrials.gov/show/NCT01148576"
715,"NCT02116556","Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis","Recruiting","No Results Available","Alcoholic Hepatitis","Drug: Prednisone|Drug: Rifaximin","Hospital Universitari Vall d'Hebron Research Institute|Germans Trias i Pujol Hospital|Hospital del Mar|Hospital Clinic of Barcelona|Hospital de Sant Pau","Both","Adult|Senior","Phase 2","66","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","RIFA-AAH.","April 15, 2014","April 2013","December 2014","April 15, 2014","April 2014","No Study Results Posted","RIFA-AAH","December 2014","Rate of bacterial infections|Rate of Decompensations of Liver Cirrhosis","https://ClinicalTrials.gov/show/NCT02116556"
716,"NCT00332176","A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Na√Øve Patients With Chronic Hepatitis C","Recruiting","No Results Available","Chronic Hepatitis C","Drug: Celgosivir|Drug: Celgosivir|Drug: Peginterferon alfa 2b + ribavirin","BioWest Therapeutics Inc","Both","Adult","Phase 2","50","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HCV-06-001","May 30, 2006","June 2006","December 2008","April 3, 2008","April 2008","No Study Results Posted","null","December 2008","Safety analysis|HCV viral load|Pharmacokinetics of celgosivir/castanospermine","https://ClinicalTrials.gov/show/NCT00332176"
717,"NCT00954993","Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)","Terminated","Has Results","Chronic Hepatitis C Infection","Drug: Vaniprevir","Merck Sharp & Dohme Corp.","Both","Adult","Phase 1","3","Industry","Interventional","Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","7009-029|2009-013076-41","August 6, 2009","January 2010","March 2011","September 1, 2015","September 2015","September 26, 2014","null","March 2011","Area Under the Curve (AUC) (0-12 Hrs) of Vaniprevir in the Liver|Concentration of Vaniprevir in the Liver|Apparent Terminal Half-life (t-1/2) of Vaniprevir in the Liver","https://ClinicalTrials.gov/show/NCT00954993"
718,"NCT00608192","HIV and Hepatitis Care Coordination in Methadone Treatment","Completed","No Results Available","Hepatitis, Viral, Human|HIV Infections","Behavioral: Testing, Education, & Counseling (TEC)|Behavioral: Hepatitis Care Coordination (HCC)","University of California, San Francisco|National Institute on Drug Abuse (NIDA)","Both","Adult|Senior","","489","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Open Label","R01 DA020781|R01DA020781","January 18, 2008","January 2008","June 2011","January 15, 2013","January 2013","No Study Results Posted","null","June 2011","Vaccination adherence visits|Health Care Utilization Survey|Intervention Costs & Hepatitis Care Utilization: DATCAP, public and private health care system administrative databases|Hepatitis A Knowledge Test|Hepatitis B Knowledge Test|Hepatitis C Knowledge Test|HIV Knowledge Test|Risk Behavior Survey|Addiction Severity Index","https://ClinicalTrials.gov/show/NCT00608192"
719,"NCT00196664","Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin","Completed","No Results Available","Chronic Hepatitis C","Drug: Paroxetine","French National Agency for Research on AIDS and Viral Hepatitis","Both","Adult|Senior","Phase 3","144","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","2004-004102-24|ANRS HC18 PAROPEG","September 13, 2005","October 2005","February 2009","May 12, 2009","May 2009","No Study Results Posted","null","null","Incidence of depression based on MINI International Neuropsychiatric Interview (MINI, DSM IV)from D0 to W74|Evolution of depression score (MADRS and BDI scales) to W74,Quality of life (HQL questionnaire), Fatigue, Compliance to PEG-interferon and ribavirin, Virological response at W74 ,Safety","https://ClinicalTrials.gov/show/NCT00196664"
720,"NCT00192647","Induction Dosing With Pegylated Interferon Alfa 2a and Ribavirin in Patients With Chronic Hepatitis C Genotype 1","Completed","No Results Available","Chronic Hepatitis C","Drug: high dose peg-ifn plus rbv|Drug: standard peg-ifn plus ribavirin","Kirby Institute|Hoffmann-La Roche|The University of New South Wales","Both","Adult|Senior","Phase 4","896","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ML17908","September 13, 2005","August 2004","August 2008","June 1, 2011","June 2011","No Study Results Posted","null","July 2008","To evaluate the effect of peginterferon alfa-2a (Pegasys) plus ribavirin combination therapy induction dosing versus no induction dosing on the clearance of HCV viremia 24 weeks after completion of a 48 week treatment period.","https://ClinicalTrials.gov/show/NCT00192647"
721,"NCT02579382","A Study of the Safety, Tolerability, and Efficacy of GS-9620 in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated","Not yet recruiting","No Results Available","Chronic Hepatitis B","Drug: TDF|Drug: GS-9620|Drug: GS-9620 Placebo","Gilead Sciences","Both","Adult","Phase 2","175","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","GS-US-283-1062|2015-002017-30","October 15, 2015","October 2015","August 2019","October 16, 2015","October 2015","No Study Results Posted","null","November 2016","Mean change (measured in log10 IU/mL) in serum hepatitis B surface antigen (HBsAg) from baseline|Proportions of participants with hepatitis B e antigen (HBeAg) loss and seroconversion|Proportions of participants with HBsAg loss and seroconversion|Mean change (measured in log10 IU/mL) in HBsAg from baseline|Proportions of participants with a ‚â• 0.5 log10 IU/mL decline in serum HBsAg titers from baseline|Proportions of participants with hepatitis B virus (HBV) DNA < lower limit of quantitation (LLOQ) at Weeks 24 and 48|Proportion of subject experiencing virologic breakthrough|Proportion of participant with drug resistance mutations|Pharmacokinetic (PK) Parameter: AUClast of GS-9620|PK Parameter: AUCinf of GS-9620|PK Parameter: %AUCexp of GS-9620|PK Parameter: Cmax of GS-9620|PK Parameter: Clast of GS-9620|PK Parameter: Tmax of GS-9620|PK Parameter: Tlast of GS-9620|PK Parameter: T1/2 of GS-9620|PK Parameter: CL/F of GS-9620","https://ClinicalTrials.gov/show/NCT02579382"
722,"NCT00307242","Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: Adefovir Dipivoxil","Thomas Jefferson University","Both","Adult|Senior","Phase 4","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","05U.164","March 24, 2006","May 2005","null","December 8, 2014","December 2014","No Study Results Posted","null","null","Observe the proportion of patients with ALT elevations (> 10 x ULN) at any time over the course of the switch|Study serum HBV DNA levels over time|Study serum ALT levels over time|Study the proportion of patients with YMDD variants at entry|Study the safety during the switching period","https://ClinicalTrials.gov/show/NCT00307242"
723,"NCT02278419","An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection","Active, not recruiting","No Results Available","Hepatitis C","Drug: Simeprevir|Drug: Sofosbuvir","Janssen-Cilag International NV","Both","Adult|Senior","Phase 2","63","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CR104970|TMC435HPC2014","October 28, 2014","December 2014","October 2015","September 25, 2015","September 2015","No Study Results Posted","null","October 2015","Percentage of Participants With Sustained Virologic Response at Week 12 After End of Treatment (SVR12)|Percentage of Participants With Sustained Virologic Response at Week 4 After End of Treatment (SVR4)|Percentage of Participants With Sustained Virologic Response at Week 24 After End of Treatment (SVR24)|Percentage of Participants With on-treatment Failure|Percentage of Participants With Viral Relapse|Percentage of Participants With On-treatment Response|Percentage of Participants With Viral Breakthrough","https://ClinicalTrials.gov/show/NCT02278419"
724,"NCT00507689","Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant","Completed","Has Results","Chronic Hepatitis B","Drug: FTC/TDF|Drug: Hepatitis B Immunoglobulin (HBIg)","Gilead Sciences","Both","Adult|Senior","Phase 2","40","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","GS-US-203-0107","July 25, 2007","September 2007","May 2011","February 12, 2014","February 2014","July 15, 2013","null","May 2011","Percentage of Participants With HBV Recurrence Prior to or at Week 72|Percentage of Participants With HBV Recurrence at Week 96|Percentage of Subjects With HBV DNA < 169 Copies/mL at Week 72|Percentage of Participants With HBV DNA < 169 Copies/mL at Week 96|Percentage of Participants With Normal ALT at Week 72|Percentage of Participants With Normal ALT at Week 96","https://ClinicalTrials.gov/show/NCT00507689"
725,"NCT01203319","The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines","Completed","Has Results","Hepatitis b","Biological: 60mcg/1.0ml recombinant hepatitis B vaccine|Biological: 30mcg/1.0ml recombinant hepatitis B vaccine|Biological: 10mcg/1.0ml recombinant hepatitis B vaccine","Jiangsu Province Centers for Disease Control and Prevention|Shenzhen Kangtai Biological Products Co., LTD","Both","Child|Adult|Senior","Phase 2|Phase 3","1091","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator)","KT0003","September 15, 2010","November 2006","March 2011","April 21, 2012","April 2012","March 29, 2012","null","December 2010","Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders|the Safety of Recombinant Hepatitis B Vaccines in Nonresponders","https://ClinicalTrials.gov/show/NCT01203319"
726,"NCT01524679","Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen","Recruiting","No Results Available","Chronic Hepatitis B","Drug: Pegylated interferon alfa-2a plus nucleos(t)ide(s)","Johannes Gutenberg University Mainz|Roche Pharma AG","Both","Adult|Senior","Phase 2","170","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ML 27787","January 31, 2012","August 2012","November 2015","November 13, 2014","November 2014","No Study Results Posted","PADD-ON","November 2015","Difference in percentage of patients between treatment and comparator arm reaching a ‚â• 1log10 decline of quantitative HBsAg after 48 weeks|Decline of quantitative HBs antigen at week 12 and 24","https://ClinicalTrials.gov/show/NCT01524679"
727,"NCT00040144","Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B","Terminated","No Results Available","Chronic Hepatitis B","Drug: ACH126, 433 (b-L-Fd4C)","Achillion Pharmaceuticals","Both","Adult|Senior","Phase 2","85","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","ACH443-005","June 21, 2002","July 2002","May 2003","August 18, 2009","August 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00040144"
728,"NCT00670839","Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)","Completed","No Results Available","Hepatitis B|HIV Infection","Biological: GenHevac-B|Biological: GenHevac-B","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Sanofi Pasteur MSD","Both","Adult|Senior","Phase 3","178","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","2007-005023-15|ANRS HB04 B-BOOST","April 29, 2008","May 2008","February 2013","August 8, 2013","August 2013","No Study Results Posted","B-BOOST","December 2011","rate of HIV-infected patients who seroconvert one month after the last vaccination. Seroconversion is defined as anti-HBs titers equal or above 10 mUI per ml|According to the vaccine strategy (single-dose or double-dose), comparison of AbHBs titers, permanence of humoral response, intensity of clinical and biological events, and predicting factors related to seroconversion|immunological substudy: to understand genetic link between some alleles of HLA-DR and non-response to immunization","https://ClinicalTrials.gov/show/NCT00670839"
729,"NCT00356564","Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib","Completed","No Results Available","Hepatitis B","Biological: hepatitis B vaccine","GlaxoSmithKline","Both","Child","Phase 4","350","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","106744","July 25, 2006","July 2006","null","November 10, 2011","November 2011","No Study Results Posted","null","null","Anti-HBs antibody concentration|Persistence of antibodies to the other DTPa-HBV-IPV/Hib vaccine antigens.|Sol & unsol symptoms after HBV vaccination, SAEs","https://ClinicalTrials.gov/show/NCT00356564"
730,"NCT00335881","Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib","Completed","No Results Available","Hepatitis B","Biological: hepatitis B vaccine","GlaxoSmithKline","Both","Child","Phase 4","300","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","106745","June 9, 2006","June 2006","null","November 21, 2012","April 2012","No Study Results Posted","null","null","Anti-HBs antibody concentration|Persistence of antibodies to the other DTPa-HBV-IPV/Hib vaccine antigens.|Sol & unsol symptoms after HBV vaccination, SAEs","https://ClinicalTrials.gov/show/NCT00335881"
731,"NCT02326103","Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis","Recruiting","No Results Available","Alcoholic Hepatitis|Alcoholic Cirrhosis","Drug: Ciprofloxacin|Drug: Placebo","Helsinki University","Both","Adult","Phase 0","150","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HELSINKIU","December 22, 2014","April 2015","December 2017","August 17, 2015","August 2015","No Study Results Posted","null","December 2017","Death at 28 days|Death at 3 months|Death at 6 months|Early reduction in serum bilirubin level|Surrogate markers of liver function","https://ClinicalTrials.gov/show/NCT02326103"
732,"NCT00118768","A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: valopicitabine|Drug: Pegylated Interferon Alfa","Merck Sharp & Dohme Corp.","Both","Adult","Phase 2","175","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","NV-08A-006","June 30, 2005","August 2005","null","February 27, 2009","February 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00118768"
733,"NCT01829347","Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure","Terminated","No Results Available","Severe Acute Alcoholic Hepatitis","Biological: ELAD|Other: Standard of Care treatment","Vital Therapies, Inc.","Both","Adult|Senior","Phase 3","18","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","VTI-210","April 8, 2013","April 2014","October 2015","October 20, 2015","October 2015","No Study Results Posted","null","October 2015","Overall survival of sAAH subjects|To evaluate the proportion of survivors at End of Study Days 28 and 91.","https://ClinicalTrials.gov/show/NCT01829347"
734,"NCT00008463","A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)","Completed","No Results Available","HIV Infections|Hepatitis C","Drug: Ribavirin|Drug: Interferon alfa-2a|Drug: Peginterferon alfa-2a","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult","Phase 2","132","NIH","Interventional","Endpoint Classification: Safety Study|Primary Purpose: Treatment","A5071|10675|Substudy AACTG A5091s|ACTG A5071|AACTG A5071","January 9, 2001","November 2000","August 2006","June 7, 2013","June 2013","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00008463"
735,"NCT00296972","Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication","Terminated","No Results Available","Chronic Hepatitis C|HIV Infections","Drug: peg interferon plus ribavirin","University Health Network, Toronto|Hoffmann-La Roche","Both","Adult|Senior","Phase 3","100","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ML 18562A","February 23, 2006","July 2005","April 2007","April 19, 2007","April 2007","No Study Results Posted","null","null","To compare the safety and tolerability of PEG-IFN with ribavirin in HIV/HCV co-infected patients who continue HAART therapy compared to those who discontinue HAART therapy in the first 12 weeks|To compare the sustained virological response.","https://ClinicalTrials.gov/show/NCT00296972"
736,"NCT02377856","Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection","Recruiting","No Results Available","Acute Hepatitis C","Drug: pegylated interferon alpha 2a, ribavirin","Kaohsiung Medical University Chung-Ho Memorial Hospital","Both","Adult|Senior","Phase 4","80","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","KMUH-IRB-960056|KMUH","September 9, 2014","June 2007","December 2020","March 5, 2015","February 2015","No Study Results Posted","null","December 2020","treatment efficacy in terms of SVR rate|safety issues regarding adverse events","https://ClinicalTrials.gov/show/NCT02377856"
737,"NCT01274208","Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C","Recruiting","No Results Available","Gaucher Disease|Hepatitis C","","Shaare Zedek Medical Center","Both","Adult|Senior","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SZMC- 89/10","January 10, 2011","January 2011","April 2016","November 18, 2014","November 2014","No Study Results Posted","null","March 2016","Gaucher patients' immune system provide enhanced immunity against hepatitis c virus|the role Glucocerebroside level have by enhanced immunity in patients with Gaucher disease","https://ClinicalTrials.gov/show/NCT01274208"
738,"NCT00968357","Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed","Completed","No Results Available","Chronic Hepatitis C","Drug: SCV-07","SciClone Pharmaceuticals","Both","Adult|Senior","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Health Services Research|Masking: Open Label","SCI-SCV-HCV-P2-001","August 27, 2009","September 2009","January 2011","June 6, 2012","June 2012","No Study Results Posted","null","January 2011","To assess the safety of SCV-07 at 2 dose levels given as a monotherapy and to assess the immunomodulatory effects of SCV-07 given at 2 dose levels for 4 weeks and in combination with ribavirin for 4 weeks after monotherapy, respectively.|To assess the pharmacodynamic effects of SCV 07 and the pharmacokinetics as a monotherapy and in combination with ribavirin","https://ClinicalTrials.gov/show/NCT00968357"
739,"NCT00143000","Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3","Completed","No Results Available","Hepatitis C Virus","Drug: Peginterferon alfa-2a 40KD and Ribavirin","NORDynamIC Study Group","Both","Adult|Senior","Phase 4","392","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","Swedish MPA nr. 151:2004/3458|Ethical Committee nr. √ñ 763/03","September 1, 2005","April 2004","October 2006","April 4, 2008","April 2008","No Study Results Posted","null","null","Sustained Viral Response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA as measured by COBAS TaqMan 48‚Ñ¢ (<50 IU/mL) at 24 weeks post completion of the 12 or 24 week treatment period.|ALT measurements at 24 weeks post completion of the 12 or 24 week treatment period.","https://ClinicalTrials.gov/show/NCT00143000"
740,"NCT00467545","An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B","Completed","No Results Available","Chronic Hepatitis B","Drug: telbivudine","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 4","44","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CLDT600AKR02","April 27, 2007","April 2007","September 2009","May 7, 2012","May 2012","No Study Results Posted","null","September 2009","Safety of telbivudine (LDT600) up to 21 additional months of open-label treatment in patients with chronic hepatitis B who have completed study CLDT600A2407 assessed by Adverse Events, data of vital signs and other tests|Safety of patients switched from entecavir to telbivudine compared with patients continuing telbivudine assessed by Adverse Events, data of vital signs and other tests","https://ClinicalTrials.gov/show/NCT00467545"
741,"NCT02281929","Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone","Not yet recruiting","No Results Available","Alcoholic Hepatitis|Alcoholic Liver Disease","Drug: Amoxicillin|Drug: Placebo|Drug: Prednisolone","University Hospital, Lille|Ministry of Health, France","Both","Adult|Senior","Phase 3","280","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","2014_05|2014-002536-13|PHRC-2013-0552","October 28, 2014","May 2015","March 2018","April 9, 2015","April 2015","No Study Results Posted","AntibioCor","May 2017","Patient alive|Infection|Hepatorenal syndrome|MELD score <17|Lille Model","https://ClinicalTrials.gov/show/NCT02281929"
742,"NCT01204827","Follow Up of Patients Chronic Hepatitis B (CHB) Treated With Sebivo Using the 13C Methacetin Breath Test","Withdrawn","No Results Available","Chronic Hepatitis B","Device: 13C Methacetin Breath Test (BreathID)","Hadassah Medical Organization","Both","Adult|Senior","Phase 2|Phase 3","0","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Diagnostic","CLDT600AIL02T","September 16, 2010","null","null","August 27, 2012","June 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01204827"
743,"NCT00516945","A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers","Completed","No Results Available","Hepatitis B|Neoplasms","Drug: Lamivudine","Hospital Authority, Hong Kong","Both","Adult|Senior","","110","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","KC/KE04-0046/FR-2|HARECCTR0500016","August 15, 2007","September 2004","June 2008","September 3, 2013","July 2013","No Study Results Posted","null","null","incidence of chemotherapy interruptions|incidence of and survival free from hepatitis B reactivation|HBeAg positive seroconversion and YMDD mutant development rates|chemotherapy dose intensity reduction due to hepatitis B reactivation","https://ClinicalTrials.gov/show/NCT00516945"
744,"NCT00147784","HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.","Completed","No Results Available","Opiate Dependence|Hepatitis","Drug: Ribavirin|Drug: Pegylated Interferon","Sorlandet Hospital HF","Both","Adult","Phase 3","10","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","SSHF-70332|Protocol no 9772387|EudraCT no 2005-002869-37","September 6, 2005","March 2006","January 2008","March 26, 2008","March 2008","No Study Results Posted","null","June 2007","- Percent of patients with sustained virological response, defined as undetectable HCV RNA 24 weeks after end of treatment|Retention in treatment, compliance, psychological distress, measures of quality of life, perceived drug use control and urine toxicology","https://ClinicalTrials.gov/show/NCT00147784"
745,"NCT01277601","Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon Œ±-2a (PEG) Versus TDF or PEG Monotherapy in Chronic Hepatitis B","Completed","Has Results","Chronic Hepatitis B","Drug: TDF|Drug: PEG","Gilead Sciences","Both","Adult|Senior","Phase 4","751","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","GS-US-174-0149","January 13, 2011","April 2011","July 2015","September 9, 2015","September 2015","August 10, 2015","null","August 2014","Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus PEG Combination Versus PEG Alone for 48 Weeks or TDF Alone|Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With TDF (48 Weeks) Plus PEG (16 Weeks) Combination Versus PEG Alone for 48 Weeks or TDF Alone|Percentage of Participants With HBsAg Seroconversion at Week 72|Percentage of Participants With HBeAg Loss and Seroconversion at Week 72|Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 72|Percentage of Participants With Normal ALT at Week 72|Percentage of Participants Who Required Retreatment","https://ClinicalTrials.gov/show/NCT01277601"
746,"NCT01911845","An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine","Completed","Has Results","Chronic Hepatitis C Infection|Chronic Hepatitis C","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin (RBV)","AbbVie","Both","Adult|Senior","Phase 2","38","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-103","May 13, 2013","April 2013","September 2014","September 16, 2015","August 2015","December 23, 2014","null","December 2013","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants With Virologic Relapse Post-treatment|Area Under the Plasma Concentration-time Curve (AUC) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin|Maximum Plasma Concentration (Cmax) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin|Time to Maximum Plasma Concentration (Tmax) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin|Plasma Trough Concentration (Ctrough) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin","https://ClinicalTrials.gov/show/NCT01911845"
747,"NCT00992888","Inflammation, Immune Activation and Portal Hypertension in Alcoholic Hepatitis","Completed","No Results Available","Alcoholic Hepatitis","Device: Prometheus Liver Dialysis system (Fresenius Medical Care)","University of Aarhus","Both","Adult|Senior","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label","Heliac-01","October 8, 2009","August 2009","September 2011","September 14, 2011","September 2011","No Study Results Posted","Heliac","September 2011","Serum endotoxin levels|Endotoxin activation pathway proteins","https://ClinicalTrials.gov/show/NCT00992888"
748,"NCT00291941","A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.","Completed","No Results Available","Hepatitis B","Biological: Henogen HBV vaccine|Biological: FENDRIX","Henogen|GlaxoSmithKline","Both","Child|Adult|Senior","Phase 3","300","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","HN014/HBV-001 (105757)","February 14, 2006","February 2006","March 2007","August 27, 2008","August 2008","No Study Results Posted","null","March 2007","Anti-HBs seroprotection rate at Month 2.|Anti-HBs antibody concentrations|Anti-HBs seroprotection rates for all subjects.|Anti-HBs seropositivity rates for all subjects|Percentage of subjects with anti-HBs antibody concentrations equal or greater than 100 mIU/ml for all subjects.|Anti-HBs geometric mean concentrations calculated for all subjects.|Anti-RF-1 seropositivity rates (defined as the percentage of subjects with anti-RF-1 like antibody concentrations superior or equal to 33 EU/ml, the assay cut-off) in a random subset of 50 subjects per group.|Anti-RF-1 like antibody geometric mean concentration in a random subset of 50 subjects per group.|Occurrence and intensity of solicited local signs and symptoms, as well as occurrence, intensity and relationship to vaccination of solicited general signs and symptoms during a 4-day follow-up (i.e. Day 0 to Day 3) after each vaccination and overall.|Occurrence, intensity and relationship to vaccination of unsolicited symptoms reported during the 31-day (Day 0 to Day 30) follow-up period after each vaccination and overall.|Occurrence, intensity and relationship to vaccination of all serious adverse events (SAEs) up to Month 7.","https://ClinicalTrials.gov/show/NCT00291941"
749,"NCT00528528","An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants","Completed","Has Results","Chronic Hepatitis C","Drug: Telaprevir|Drug: Peg-IFN-alfa-2a|Drug: Peg-IFN-alfa-2b|Drug: Ribavirin (RBV) tablet|Drug: Ribavirin (RBV) capsule","Tibotec BVBA","Both","Adult","Phase 2","166","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CR013516|VX-950-TIDP24-C208|2007-001044-44","September 10, 2007","October 2007","August 2009","June 13, 2014","June 2014","March 18, 2013","null","July 2009","Percentage of Participants With Virologic Response at Week 12|Time to First Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level|Number of Participants With Viral Breakthrough at End of Treatment (EOT)|Percentage of Participants With Partial Response|Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at Week 12|Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at End of Treatment (EOT)|Percentage of Participants With Sustained Viral Response 24 Weeks After End of Treatment (SVR24)","https://ClinicalTrials.gov/show/NCT00528528"
750,"NCT01970904","Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment na√Øve Patients","Active, not recruiting","No Results Available","Hepatitis C, Liver Disease","Drug: DEB025 200mg|Drug: DEB025 300mg|Drug: DEB025 400mg","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 2","146","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CDEB025A2222|2012-004185-17","September 30, 2013","October 2013","March 2015","March 19, 2015","March 2015","No Study Results Posted","null","March 2015","Pharmacodynamics (PD)|Safety|SVR12","https://ClinicalTrials.gov/show/NCT01970904"
751,"NCT00668369","Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplantation","Completed","No Results Available","Hepatitis C Virus Infection|Liver Transplantation","Procedure: Gradual immunosuppression drug withdrawal.","Hospital Clinic of Barcelona","Both","Adult|Senior","Phase 2","34","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","Weaning_HCV","April 24, 2008","April 2008","September 2011","December 19, 2013","December 2013","No Study Results Posted","null","September 2011","Proportion of hepatitis C virus positive liver recipients successfully withdrawing immunosuppressive drugs.|Effects of immunosuppression withdrawal on hepatitis C virus induced liver damage.|Influence of HCV-induced immune responses on the feasibility of successfully withdrawing immunosuppressive drugs in liver transplant recipients.","https://ClinicalTrials.gov/show/NCT00668369"
752,"NCT01481649","Risk of Hepatitis B Reactivation After Bone Marrow Transplantation With Prior Hepatitis B Virus (HBV) Exposure","Enrolling by invitation","No Results Available","Exposure to Hepatitis B Virus","","The University of Hong Kong","Both","Adult|Senior","","70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HKCTR-1422","November 24, 2011","November 2011","February 2016","December 29, 2014","December 2014","No Study Results Posted","null","November 2015","HBV reactivation (defined as detectable HBV DNA >20 IU/mL)","https://ClinicalTrials.gov/show/NCT01481649"
753,"NCT00277238","CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","Completed","No Results Available","Hepatitis, Chronic Active","Drug: CPG10101|Drug: CPG10101|Drug: Control|Drug: CPG10101","Pfizer","Both","Adult|Senior","Phase 2","113","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","B1211002|CPG 10101-004","January 13, 2006","February 2006","July 2007","April 21, 2011","April 2011","No Study Results Posted","null","July 2007","Serum HCV RNA concentrations, over 12wks, relative to baseline, early virologic response (EVR)|Serum HCV RNA concentrations, 6months after treatment completed, relative to baseline, sustained virologic response (SVR)|Safety and Tolerability: adverse events, vital signs, clinical and laboratory parameters, depression score, physical exam, electrocardiogram (ECG), ophthalmologic exam (if required)|Dose exposure|Child-Pugh score|Serum Biomarkers: cytokines and chemokines, over time, relative to baseline|Immunophenotyping profile, over time, relative to baseline, HCV specific immune response, over time, relative to baseline, level of innate immune activation at baseline","https://ClinicalTrials.gov/show/NCT00277238"
754,"NCT00519649","Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.","Completed","Has Results","Hepatitis B Vaccine","Biological: Engerix‚Ñ¢-B Kinder","GlaxoSmithKline","Both","Child","Phase 4","301","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","110474","August 21, 2007","August 2007","December 2007","August 13, 2015","March 2013","December 17, 2008","null","December 2007","Number of Participants With Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-off Value|Number of Participants With Anti-HBs Antibody Concentrations Above the Cut-off Value|Number of Participants Reporting Solicited Local Symptoms|Number of Participants Reporting Solicited General Symptoms|Number of Participants Reporting Unsolicited Adverse Events|Number of Participants Reporting Serious Adverse Events (SAE)","https://ClinicalTrials.gov/show/NCT00519649"
755,"NCT01571583","An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation","Completed","No Results Available","Chronic Hepatitis C Virus (HCV) Infection","Drug: Telaprevir|Drug: Pegylated interferon alfa-2a|Drug: Ribavirin","Janssen-Cilag International NV","Both","Adult|Senior","Phase 3","74","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CR018721|VX-950HPC3006|2011-004724-35","December 16, 2011","December 2011","July 2014","July 14, 2015","July 2015","No Study Results Posted","REPLACE","April 2014","Number of patients achieving sustained virologic response (SVR) 12 planned|Number of patients achieving SVR12 planned(c)|Number of patients achieving SVR24 planned|Number of patients achieving SVR24 planned(c)|Number of patients having an undetectable HCV RNA level at Week 4 of treatment|Number of patients having an undetectable HCV RNA level at Week 12 of treatment|Number of patients having undetectable HCV RNA levels at Week 4 and Week 12 of treatment|Number of patients having an undetectable HCV RNA level at the actual end of treatment|Number of patients having an undetectable HCV RNA level at the planned end of treatment|Number of patients having less than 25 IU/mL at the planned end of treatment|Number of patients with on-treatment virologic failure|Number of patients with relapse after undetectable HCV RNA at actual end of treatment|Number of patients with relapse after undetectable HCV RNA at planned end of treatment|Number of patients with relapse after previous HCV RNA less than 25 IU/mL at planned end of treatment|Number of patients with viral breakthrough|Change from baseline in log HCV RNA values|Number of patients who have changes in liver graft biopsy histology|Number of patients with adverse events","https://ClinicalTrials.gov/show/NCT01571583"
756,"NCT00037622","Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.","Terminated","No Results Available","Chronic Hepatitis B","Drug: ACH-126, 443 (beta-L-Fd4C)","Achillion Pharmaceuticals","Both","Adult|Senior","","100","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ACH443-901","May 17, 2002","null","May 2003","August 18, 2009","August 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00037622"
757,"NCT00800787","Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation","Withdrawn","No Results Available","Chronic Hepatitis B Liver Disease|Orthostotic Liver Transplant","Biological: Hepatitis B immune globulin (Human)","Biotest Pharmaceuticals Corporation","Both","Adult","Phase 3","25","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","4210","November 26, 2008","April 2010","September 2010","June 29, 2010","June 2010","No Study Results Posted","Nabi-HB-SC","August 2010","To evaluate the efficacy of Nabi-HB administered subcutaneously weekly for a total of 14 weeks in patients who previously underwent a liver transplant. Levels will provide evidence if effective anti-HB levels >150 IU/ML can be maintained.|To evaluate the safety of Nabi-HB administered subcutaneously weekly for a total of 14 weeks.","https://ClinicalTrials.gov/show/NCT00800787"
758,"NCT02300792","The Effects of Honey, as a Dietary Supplement in Children With Hepatitis A","Completed","No Results Available","Hepatitis A","Dietary Supplement: honey|Dietary Supplement: molasses","Ain Shams University","Both","Child|Adult","Phase 2","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","11/013","November 19, 2014","November 2013","November 2014","November 24, 2014","November 2014","No Study Results Posted","null","May 2014","the recovery time defined as the number of days from the start of the intervention to subsidence of symptoms and signs of hepatitis and return of liver transaminases to their normal levels.","https://ClinicalTrials.gov/show/NCT02300792"
759,"NCT01479868","A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1","Completed","Has Results","Hepatitis C Virus Genotype-1","Drug: TMC435|Drug: Pegylated interferon alpha-2a|Drug: Ribavirin","Janssen R&D Ireland","Both","Adult|Senior","Phase 3","109","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CR018334|TMC435-TiDP16-C212","October 18, 2011","October 2011","August 2013","October 28, 2014","October 2014","August 26, 2014","null","August 2013","Percentage of Participants With Sustained Virologic Response at Week 12 (SVR 12)|Percentage of Participants With Sustained Virologic Response at Week 24 (SVR 24)|Percentage of Participants With Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Less Than (<) 25 International Units (IU/mL) Undetectable or Detectable/Undetectable|Percentage of Participants With On-treatment Failure|Percentage of Participants With Viral Breakthrough|Percentage of Participants With Viral Relapse|Percentage of Participants With Normalized Alanine Aminotransferase Levels|Percentage of Human Immunodeficiency Virus (HIV) Participants With Virologic Failure|Mean Change From Baseline in Log10 Plasma Human Immunodeficiency Virus (HIV) Viral Load|Mean Change From Baseline in CD4+ Cell Count|Change From Baseline in CD4+ Cell Count in Percentage|Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)","https://ClinicalTrials.gov/show/NCT01479868"
760,"NCT01922895","Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis","Recruiting","No Results Available","Acute Alcoholic Hepatitis","Dietary Supplement: Lactobacillus Rhamnosus GG|Drug: Placebo for Probiotic","University of Texas Southwestern Medical Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|The Cleveland Clinic|University of Massachusetts, Worcester|University of Louisville","Both","Adult|Senior","","130","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)","UTSW_092012-012|U01AA021893-01","August 12, 2013","October 2013","null","June 23, 2015","June 2015","No Study Results Posted","NTAH-Mod","August 2017","MELD score","https://ClinicalTrials.gov/show/NCT01922895"
761,"NCT02058108","Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection","Recruiting","No Results Available","Chronic Hepatitis B","Drug: Telbivudine|Drug: Placebo","Novartis Pharmaceuticals|Novartis","Both","Child|Adult","Phase 3","150","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","CLDT600A2306","February 5, 2014","October 2014","May 2018","October 13, 2015","October 2015","No Study Results Posted","null","May 2018","Antiviral efficacy of telbivudine compared to placebo in pediatric patients (2- < 18 years) (percentage of patients achieving serum HBV DNA level of <300 copies/mL (51 IU/mL)) at Week 24|Antiviral efficacy (proportion of patients achieving HBV DNA< 300 copies/mL (51 IU/mL)) at Week 52 and Week 104|Biochemical response (proportion of patients whose baseline ALTs were abnormal and subsequently normalized) at Week 24, 52 and 104|Serological response (proportion of patients with HBeAg loss, HBeAg seroconversion and HBsAg loss, HBsAg seroconversion) at Week 24, 52 and 104|Proportion of patients achieving a composite endpoints (HBV DNA < 300 copies/mL (51 IU/mL), ALT normalization and HBeAg seroconversion) at Week 52 and 104|The cumulative rate of virological breakthrough (VB) at Week 52 and 104|Presence of treatment emergent genotypic resistance associated with VB, or in patients with HBV DNA‚â•300 copies/mL (51 IU/mL) at Week 24 and discontinued from the study|Safety and tolerability of telbivudine at Week 52 and 104","https://ClinicalTrials.gov/show/NCT02058108"
762,"NCT02537379","Use-Results Surveillance Study of Sovaldi¬Æ Plus Copegus¬Æ in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection","Recruiting","No Results Available","Hepatitis C Virus Infection","Drug: SOF|Drug: COPE","Gilead Sciences|Chugai Pharmaceutical","Both","Child|Adult|Senior","","500","Industry","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","GS-US-334-1444 / COPE1501","August 28, 2015","September 2015","September 2018","October 14, 2015","October 2015","No Study Results Posted","null","September 2018","Incidence of adverse drug reaction (ADR) under real world settings|Proportion of participants with sustained virologic response (SVR) 12 and 24 weeks after discontinuation of therapy (SVR12 and SVR24)|Proportion of participants with HCV NS5B resistance associated variants among patients who do not achieve SVR at 12 weeks","https://ClinicalTrials.gov/show/NCT02537379"
763,"NCT00641654","Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin","Terminated","No Results Available","Chronic Hepatitis C","Drug: Pegylated interferon alfa-2a and ribavirin|Drug: Pegylated interferon alfa-2a and ribavirin|Drug: Pegylated interferon alfa-2a and ribavirin","G√∂teborg University|Hoffmann-La Roche","Both","Adult|Senior","Phase 4","75","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","EudractCT 2006-003409-18","March 17, 2008","January 2007","December 2009","August 29, 2012","March 2012","No Study Results Posted","RelapC","December 2009","Sustained viral response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA 24 weeks after completion of the 24 or 48 week treatment period.|Sustained viral response (SVR)rate and percentage of patients with normal serum ALT levels and its association with prespecified factors e.g. viral load","https://ClinicalTrials.gov/show/NCT00641654"
764,"NCT00260208","Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus","Terminated","Has Results","Liver Transplant|Hepatitis C","Drug: Cyclosporine A|Drug: Tacrolimus","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 4","361","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","COLO400A2426","November 30, 2005","January 2006","null","December 2, 2011","December 2011","September 14, 2011","null","September 2010","Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ‚â• 2] Within 1 Year Post-transplant|Number of Participants With Combined Endpoint of Death or Graft Loss or Fibrosis Score (FS) ‚â• 2|Number of Participants With Fibrosing Cholestatic Hepatitis|Number of Participants With Death, Graft Loss, Death or Graft Loss, Graft Loss With Re-transplantation|Number of Participants With Treated Acute Rejection, Biopsy Proven Acute Rejection (BPAR), and Sub-clinical Rejection|Number of Participants With Combined Endpoint of Death or Graft Loss or Biopsy Proven Acute Rejection (BPAR)|Number of Participants With Death or Re-transplantation Due to Recurrence of Hepatitis C Cirrhosis|Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ‚â• 2] Within 1 Year Post-transplant (Intent to Treat Population)|Mean Value of Liver Function Tests at 1 Year Post-transplantation|Log-transformed Hepatitis C Virus Ribonucleic Acid (HCV RNA) Values up to 1 Year Post Transplant|Percentage of Participants With an Increase of at Least 1 Stage in Fibrosis|Mean Fibrosis Score","https://ClinicalTrials.gov/show/NCT00260208"
765,"NCT01225380","A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys¬Æ and Copegus¬Æ in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C Infection","Drug: GS-9190|Drug: GS-9256|Biological: Pegasys¬Æ|Drug: Copegus¬Æ|Drug: GS-9190 placebo|Drug: GS-9256|Biological: Pegasys¬Æ|Drug: Copegus¬Æ|Drug: GS-9190 placebo|Drug: GS-9256 placebo|Biological: Pegasys¬Æ|Drug: Copegus¬Æ","Gilead Sciences","Both","Adult|Senior","Phase 2","324","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","GS-US-196-0123","October 18, 2010","October 2010","September 2013","December 20, 2013","December 2013","No Study Results Posted","null","January 2013","Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation|Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events|Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256|Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time|Long-term assessment of plasma HCV RNA in subjects who achieve SVR","https://ClinicalTrials.gov/show/NCT01225380"
766,"NCT00926419","Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery","Not yet recruiting","No Results Available","Varicella|Hepatitis A","Biological: Varicella Vaccine|Biological: Hepatitis A Vaccine","University of Sao Paulo General Hospital","Both","Child","Phase 2|Phase 3","600","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor)","CAPPesq 0911/08","June 19, 2009","June 2009","May 2010","June 22, 2009","May 2009","No Study Results Posted","InjHepAVar","November 2009","Immunogenicity: General seroconversion rate 45 days following immunization. Safety: General rate of local and systemic adverse events after immunization according to definition established by Brighton Collaboration Group|Degree and duration of local and systemic adverse events after immunization according to the Brighton Collaboration Group recommendations.|Seroconversion rates and number of local and systemic adverse events after immunization according to delivery system (needle-free injector or syringe with needle) for each dose tested|Actual volume administered intradermally according to the delivery system (needle-free injector or syringe with needle) for each fractional dose tested|Participants' parents or legal guardians acceptability according to the delivery system (needle-free injector or syringe with needle) for each dose tested|Distribution of vaccine jet evaluated through ultrasound for the needle-free injector group","https://ClinicalTrials.gov/show/NCT00926419"
767,"NCT01194037","A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon‚Ñ¢ in Combination With Ribavirin in Treatment-na√Øve Subjects With Genotype 1 Hepatitis C","Completed","No Results Available","Chronic Hepatitis C Infection|Genotype 1","Drug: recombinant variant of interferon-alpha 2b|Drug: Peginterferon alfa-2a","HanAll BioPharma Co., Ltd.","Both","Adult","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","HL-143IFN-SC-US-001","September 1, 2010","June 2011","June 2012","February 24, 2014","February 2014","No Study Results Posted","null","May 2012","HCV RNA level|Proportion of patients who reach RVR|PK & PD","https://ClinicalTrials.gov/show/NCT01194037"
768,"NCT00863785","Treatment of Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone","Completed","No Results Available","Alcoholic Hepatitis","Drug: Corticoids plus N Acetyl Cysteine","Centre Hospitalier Universitaire, Amiens","Both","Adult","Phase 3","174","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Subject)","PHRC R04 - Dr NGUYEN-KHAC|AFSSAPS 040276","March 17, 2009","April 2004","September 2009","October 19, 2009","October 2009","No Study Results Posted","HAA-NAC","August 2009","Survival at one, three and six months|bilirubin decrease at day seven survival at one and three months nac tolerance side effects","https://ClinicalTrials.gov/show/NCT00863785"
769,"NCT01572233","Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection","Recruiting","No Results Available","Hepatitis C Virus Infection, Response to Therapy of","Behavioral: Personalized Physical Activity and Psycho-Education (PPAPE) Program","National Taiwan University Hospital|National Health Research Institutes, Taiwan","Both","Adult|Senior","","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label","201103086RC","April 4, 2012","December 2011","June 2018","December 26, 2012","November 2012","No Study Results Posted","null","December 2017","Effects of Activity and Education Program on Patients with Chronic Hepatitis C Infection","https://ClinicalTrials.gov/show/NCT01572233"
770,"NCT00771446","Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency","Completed","No Results Available","Acute Hepatitis|Chronic Hepatitis","Biological: ELAD plus standard of care treatment|Other: Standard of care treatment","Vital Therapies, Inc.","Both","Adult|Senior","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","VTI-201","October 9, 2008","October 2008","April 2009","April 5, 2013","April 2013","No Study Results Posted","ELAD","April 2009","To provide evidence that (1) subjects treated with ELAD have a higher 30-day transplant-free survival in subjects with AOCH than those not treated with ELAD, and (2) it is safe when used for 3 to 10 days of treatment.","https://ClinicalTrials.gov/show/NCT00771446"
771,"NCT00804622","Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)","Completed","No Results Available","Chronic Hepatitis B","Drug: telbivudine|Drug: tenofovir disproxil fumarate|Drug: telbivudine plus tenofovir disproxil fumarate","The University of Hong Kong|Novartis Pharmaceuticals","Both","Adult|Senior","Phase 2","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CLDT600AHK01","December 8, 2008","December 2008","March 2010","July 10, 2012","July 2012","No Study Results Posted","null","June 2009","The primary variable is the reduction of HBV DNA level over 12 weeks of treatment|Reduction in HBV DNA level|Characterization of very early viral kinetics through estimation of various parameters|% patients who are PCR negative|% of patients who achieve HBeAg loss and HBeAg seroconversion","https://ClinicalTrials.gov/show/NCT00804622"
772,"NCT01756794","Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment","Recruiting","No Results Available","Alcoholic Hepatitis|Alcoholic Cirrhosis","Procedure: Liver transplantation","University Hospital, Lille|Ministry of Health, France","Both","Adult|Senior","","263","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","PROM 2010-26|2012-A00088-35","December 20, 2012","December 2012","January 2019","April 9, 2015","April 2015","No Study Results Posted","QuickTrans","January 2019","Non-inferiority of alcohol relapse in early liver transplantation for severe alcoholic hepatitis as compared to patients transplanted for alcoholic cirrhosis.|Validation of the survival benefit of transplanted patients as compared to non-transplanted patients with severe alcoholic hepatitis|Reproducibility of an algorithm of selection for candidates to liver transplantation|Incidence of alcohol relapse|Pattern of alcohol relapse in the two groups of transplanted patients","https://ClinicalTrials.gov/show/NCT01756794"
773,"NCT01949857","The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines","Active, not recruiting","No Results Available","Hepatitis A","Biological: Attenuated HAV Vaccine, H2 Strain|Biological: Attenuated HAV Vaccine, L-A-1 Strain|Biological: Inactivated HAV Vaccine, Lu8 Strain|Biological: Inactivated HAV Vaccine, TZ84 Strain","Chinese Academy of Medical Sciences|Jiangsu Province Centers for Disease Control and Prevention","Both","Child|Adult","Phase 4","6000","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Caregiver, Investigator)","qiangmingsun123456!","August 28, 2013","September 2013","June 2017","February 4, 2015","February 2015","No Study Results Posted","HAV","March 2017","changes of hepatitis A antibody concentration|The frequency of all the adverse events in vaccine group and placebo group","https://ClinicalTrials.gov/show/NCT01949857"
774,"NCT00959166","Study to Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection - A Positron Emission Tomography (PET) Study","Completed","No Results Available","Acute Hepatitis C|HIV|HIV Infections","","Imperial College London","Male","Adult|Senior","","24","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","09/H0712/17","August 13, 2009","June 2009","September 2011","June 3, 2015","May 2010","No Study Results Posted","null","June 2011","Association of 11C-labelled PK11195 uptake using PET with acute HCV and HIV infection|Association of CNS metabolite ratios and neurocognitive performance with acute HCV and HIV infection. Association between patient characteristics and 11C-labelled PK11195 uptake using PET, CNS metabolite ratios and neurocognitive performance.","https://ClinicalTrials.gov/show/NCT00959166"
775,"NCT01360970","Hepatitis A Vaccine in Patients With Immunomodulating Drugs","Completed","No Results Available","Response to Hepatitis A Vaccine","Biological: hepatitis A vaccine ( HAVRIX or EPAXAL)","Sormland County Council, Sweden","Both","Adult|Senior","Phase 2","68","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","EU 2009-016055-22","May 24, 2011","September 2009","May 2011","May 25, 2011","May 2011","No Study Results Posted","null","May 2011","seroconversion after a single dose of hepatitis A vaccine|seroconversion rates after a second dose of hepatitis A vaccine","https://ClinicalTrials.gov/show/NCT01360970"
776,"NCT00313950","Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine","Completed","No Results Available","Measles|Mumps|Rubella|Hepatitis A","Biological: Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|Biological: Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|Biological: Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella","Sanofi Pasteur, a Sanofi Company|Sanofi","Both","Child","Phase 4","470","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Single Blind (Outcomes Assessor)","HAF65","April 11, 2006","September 2006","April 2010","January 17, 2014","January 2014","No Study Results Posted","null","December 2009","To provide information concerning the immunogenicity of Hepatitis A Vaccine in subjects receiving Pediatric vaccines.","https://ClinicalTrials.gov/show/NCT00313950"
777,"NCT01277692","A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.","Completed","No Results Available","Hepatitis C","Drug: GSK2336805 10mg|Drug: GSK2336805 30mg|Drug: GSK2236805 100mg|Drug: GSK2236805 200mg|Drug: GSK2236805 10mg|Drug: GSK2236805 dose to be determined up to 100mg|Drug: GSK2236805 5mg|Drug: GSK2236805 30mg|Drug: GSK2236805 100mg","GlaxoSmithKline","Both","Adult","Phase 1","58","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)","114885","January 13, 2011","November 2010","May 2011","March 8, 2012","November 2011","No Study Results Posted","null","May 2011","GSK2336805 safety parameters : adverse events|GSK2336805 safety parameters: telemetry|GSK2336805 safety parameters: absolute values and changes over time of hematology, clinical chemistry, urinalysis|GSK2336805 safety parameters: vital signs (blood pressure, heart rate)|GSK2336805 safety parameters: electrocardiogram (ECG) parameters|GSK2336805 PK parameters following single dose administration: area under the plasma concentration curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)|GSK2336805 PK parameters following single dose administration: area under the plasma concentration curve over the dosing interval AUC(0-tau))|GSK2336805 PK parameters following single dose administration: maximum observed concentration (Cmax)|GSK2336805 PK parameters following single dose administration: time to maximum observed concentration (tmax)|GSK2336805 PK parameters following single dose administration: observed concentration at 24h post-dose (C24)|GSK2336805 PK parameters following single dose administration: terminal half-life (t1/2)|GSK2336805 PK parameters following single dose administration: lag time (tlag)|GSK2336805 PK parameters following single dose administration: apparent clearance (CL/F)|GSK2336805 PK parameters following repeat dose administration:AUC(0-tau)|GSK2336805 PK parameters following repeat dose administration: Pre-dose (trough) concentration at the end of the dosing interval Ctau|GSK2336805 PK parameters following repeat dose administration: Cmax|GSK2336805 PK parameters following repeat dose administration: tmax|GSK2336805 PK parameters following repeat dose administration: t1/2,|GSK2336805 PK parameters following repeat dose administration: CL/F|GSK2336805 PK parameters following single dose in HCV infected subjects: AUC(0-infinity) or AUC(0 - tau)|GSK2336805 PK parameters following single dose in HCV infected subjects: Cmax|GSK2336805 PK parameters following single dose in HCV infected subjects: C24|GSK2336805 PK parameters following single dose in HCV infected subjects: tmax|GSK2336805 PK parameters following single dose in HCV infected subjects: tlag|GSK2336805 PK parameters following single dose in HCV infected subjects: CL/F|HCV Ribonucleic acid (RNA) viral load reduction from baseline during the 24hr and post-dosing following a single dose of GSK2336805 in HCV subjects|HCV RNA change from baseline to nadir (maximum change) in HCV subjects|Time course of HCV viral load at baseline, after dosing with GSK2336805, and for greater than or equal to 2 weeks after GSK2336805 dosing (Part 3)|GSK2336805 PK parameters: AUC(0-infinity) or AUC (0 - tau) following single dose administration of a given dose of GSK2336805 with and without moderate fat/calorie meal (Part 1)|GSK2336805 PK parameters: Cmax following single dose administration of a given dose of GSK2336805 with and without moderate fat/calorie meal (Part 1)|GSK2336805 PK parameters: tmax following single dose administration of a given dose of GSK2336805 with and without moderate fat/calorie meal (Part 1)|GSK2336805 PK parameters: tlag following single dose administration of a given dose of GSK2336805 with and without moderate fat/calorie meal (Part 1)|GSK2336805 AUC(0-tau) on Day 7 compared to AUC(0-24) on Day 1 to estimate accumulation ratio (R) and GSK2336805 AUC(0-tau) on Day 7 compared to AUC(0-infinity) on Day 1|Pre-dose concentrations (Ctau) on Day 2 through 7 to assess the achievement of steady state of GSK2336805 following repeat administration (Part 2)|GSK2336805 PK parameters: AUC(0-infinity), AUC(0-t), Cmax, and C24 following single dose administration|GSK2336805 PK parameters: AUC(0-œÑ), CœÑ, and Cmax following repeat administration|Correlation between concentration and various safety parameters, if appropriate|Sequence analysis of the viral quasispecies as appropriate (Part 3).|GSK2336805 AUC(0-tau) on Day 14 compared to AUC(0-24) on Day 1 to estimate accumulation ratio (R) and GSK2336805 AUC(0-tau) on Day 14 compared to AUC(0-inf) on Day 1|Pre-dose concentrations (Ctau) on Day 2 through 14 to assess the achievement of steady state of GSK2336805 following repeat administration (Part 2 Cohort E)","https://ClinicalTrials.gov/show/NCT01277692"
778,"NCT02161653","Metadoxine as a Therapy for Severe Alcoholic Hepatitis","Completed","No Results Available","Severe Alcoholic Hepatitis","Drug: Prednisone plus Metadoxine|Drug: Pentoxifylline plus Metadoxine","Hospital General de Mexico","Both","Adult","Phase 4","135","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","DI/10/107/3/43","June 10, 2014","April 2010","September 2014","November 8, 2014","November 2014","No Study Results Posted","null","September 2014","30 day-survival|Malondialdehyde serum levels|3 month-survival|6 month-survival","https://ClinicalTrials.gov/show/NCT02161653"
779,"NCT02114151","Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis","Completed","No Results Available","Hepatitis C Virus Infection","Drug: Simeprevir|Drug: Sofosbuvir","Janssen Infectious Diseases BVBA","Both","Adult|Senior","Phase 3","103","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CR103431|TMC435HPC3018","April 2, 2014","April 2014","April 2015","June 4, 2015","June 2015","No Study Results Posted","null","January 2015","Number of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned end of Treatment (SVR12)|Number of Participants Achieving a Sustained Virologic Response 4 Weeks After the Planned end of Treatment (SVR4)|Number of Participants Achieving a Sustained Virologic Response 24 Weeks After the Planned end of Treatment (SVR24)|Number of Participants Achieving a On-treatment Virologic Response|Number of Participants with Viral Breakthrough|Number of Participants with Viral Relapse|Change from baseline in Hepatitis C Symptom and Impact Questionnaire (HCV-SIQ) scores|Change From Baseline in Fatigue Severity Scale (FSS) Scores|Change From Baseline in Center for Epidemiologic Studies Depression Scale (CES-D) Scores|Change From Baseline in EuroQol 5 Dimension (EQ-5D) Questionnaire Scores","https://ClinicalTrials.gov/show/NCT02114151"
780,"NCT02094443","Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Patients Who Have Previously Failed Interferon Therapy or Are Intolerant or Unable to Take Interferon","Active, not recruiting","No Results Available","Hepatitis C, Liver Disease","Drug: DEB025 and RBV|Drug: DEB025 and RBV","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior","Phase 2","52","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CDEB025A2233|2013-003751-38","March 18, 2014","March 2014","April 2015","April 22, 2015","April 2015","No Study Results Posted","ALtitude II","April 2015","Difference in the level of Heptatis C virus decrease|Difference in number of subjects with adverse events or with abnormal lab values|Pharmacokinetic|Sustained Virologic Response (SVR) 12","https://ClinicalTrials.gov/show/NCT02094443"
781,"NCT02114177","Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis","Completed","No Results Available","Hepatitis C Virus Infection","Drug: Simeprevir|Drug: Sofosbuvir","Janssen Infectious Diseases BVBA","Both","Adult|Senior","Phase 3","310","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CR103430|TMC435HPC3017","April 2, 2014","April 2014","April 2015","June 4, 2015","June 2015","No Study Results Posted","null","January 2015","Number of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned end of Treatment (SVR12)|Number of Participants Achieving a Sustained Virologic Response 4 Weeks After the Planned end of Treatment (SVR4)|Number of Participants Achieving a Sustained Virologic Response 24 Weeks After the Planned end of Treatment (SVR24)|Number of Participants Achieving a On-treatment Virologic Response|Number of Participants with Viral Breakthrough|Number of Participants with Viral Relapse|Change from Baseline in Hepatitis C Symptom and Impact Questionnaire (HCV-SIQ) scores|Change From Baseline in Fatigue Severity Scale (FSS) Scores|Change From Baseline in Center for Epidemiologic Studies Depression Scale (CES-D) Scores|Change From Baseline in EuroQol 5 Dimension (EQ-5D) Questionnaire Scores","https://ClinicalTrials.gov/show/NCT02114177"
782,"NCT01121731","A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C Virus Infection|Genotype 1|Treatment-Experienced Patients|Relapses","Drug: Interferon Œ±-5|Drug: Interferon-Œ±5 plus Interferon-Œ± 2b|Drug: Interferon Œ±-2b (INTRON¬Æ A)","Digna Biotech S.L.","Both","Adult|Senior","Phase 1|Phase 2","70","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","NAHE001-CHC-01|2009-012924-10","May 10, 2010","May 2010","January 2013","February 4, 2013","February 2013","No Study Results Posted","null","October 2012","Safe dose level|pharmacodynamic and pharmacokinetic parameters","https://ClinicalTrials.gov/show/NCT01121731"
783,"NCT01189656","A Clinical Study on Therapeutic Double-plasmid Hepatitis B Virus (HBV) DNA Vaccine in Patients With HBeAg-positive Chronic Hepatitis B","Active, not recruiting","No Results Available","Chronic Hepatitis B Patients With HBeAg-positive","Biological: HBV DNA Vaccine","The 458 Hospital of Chinese PLA|Guangzhou Baidi Biotechnology Co., Ltd|Guangzhou Pharmaceucal Company Limited","Both","Adult","Phase 2","33","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","71007.02","August 25, 2010","January 2009","December 2010","August 26, 2010","February 2009","No Study Results Posted","null","November 2010","The change of HBV DNA load at Week 72|The rate of subjects with HBV DNA titer reducing > 2 logarithms .|The change of HBeAg and HBsAg titer.|The change of ALT.|HBsAg/HBeAg serum conversion rate.|The INF-gamma expression level in peripheral blood mononuclear cells (PBMC).|The amount of HBV-specific CTL.|The change of expression level of peripheral cytokines (IL-4„ÄÅIL-10„ÄÅIL-12 and INF-gamma) against the baseline level.|The different occurence rates of HBV Drug Resistance Gene (YMDD) between the 2 arms.","https://ClinicalTrials.gov/show/NCT01189656"
784,"NCT01707849","The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation","Recruiting","No Results Available","Hepatitis C Recurrence After Liver Transplant","Drug: EVL arm|Drug: MMF arm","Hospital Vall d'Hebron","Both","Adult|Senior","Phase 3","40","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Basic Science|Masking: Open Label","EVL-VHC-HVH.12","October 13, 2012","October 2012","November 2016","March 17, 2015","March 2015","No Study Results Posted","null","November 2015","To compare the liver fibrosis progression (F‚â•2 under ISHAK score) in patients who receive everolimus vs mTOR free immunosuppression|To identify viral and recipient molecular predictors of fibrosis and anti-HCV treatment responses in liver transplant recipients under steroid-free immunosuppression","https://ClinicalTrials.gov/show/NCT01707849"
785,"NCT01349829","A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children","Completed","Has Results","Hepatitis A","Biological: HAVpur Junior|Biological: Havrix 720 Junior","Crucell Holland BV","Both","Child","Phase 4","251","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","EPA-V-A008","May 5, 2011","March 2010","April 2011","October 25, 2013","August 2013","October 25, 2013","null","April 2011","Seroprotection at Month 1|Seroprotection at Month 6|Seroprotection at Month 7|Geometric Mean Concentrations (GMCs)","https://ClinicalTrials.gov/show/NCT01349829"
786,"NCT01951677","Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine","Recruiting","No Results Available","Exposure to Hepatitis B Virus","Drug: HBsAg|Biological: PreS HBsAg|Biological: Advax-1(TM)|Biological: Advax-2(TM)|Biological: Advax-3(TM)|Biological: Alum","Vaxine Pty Ltd|Flinders Medical Centre","Both","Adult|Senior","Phase 1","240","Industry|Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Outcomes Assessor)","HBV002","September 16, 2013","July 2013","December 2016","January 4, 2015","January 2015","No Study Results Posted","null","December 2015","Safety|Hepatitis B surface antibody geometric mean titer|T cell responses|Efficacy","https://ClinicalTrials.gov/show/NCT01951677"
787,"NCT00973817","Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis","Completed","No Results Available","Acute On Chronic Hepatitis","Biological: ELAD plus standard of care treatment|Other: Standard of care","Vital Therapies, Inc.","Both","Adult|Senior","Phase 2|Phase 3","62","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","VTI-206","September 2, 2009","September 2009","May 2011","April 1, 2013","April 2013","No Study Results Posted","SILVER","April 2011","Time to progression at which a 5-point or greater Model for End stage Liver Disease (MELD) score is recorded relative to baseline|Time to progression at which a 5-point or greater MELD score is recorded relative to baseline","https://ClinicalTrials.gov/show/NCT00973817"
788,"NCT02124785","Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix¬Æ","Not yet recruiting","No Results Available","Hepatitis A","Procedure: Blood sampling","GlaxoSmithKline","Both","Child|Adult|Senior","Phase 4","120","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","116763|2013-001918-15","April 24, 2014","May 2015","July 2019","December 22, 2014","December 2014","No Study Results Posted","null","July 2019","Immunogenicity with respect to components of the study vaccine in terms of anti-HAV seropositivity status and GMCs.|Occurrence of serious adverse events (SAEs).","https://ClinicalTrials.gov/show/NCT02124785"
789,"NCT01809132","Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis","Recruiting","No Results Available","Acute Alcoholic Hepatitis","Drug: Anakinra|Drug: Pentoxifylline|Drug: Zinc Sulfate|Drug: Methylprednisolone","Mack Mitchell|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|The Cleveland Clinic|University of Massachusetts, Worcester|University of Louisville|University of Texas Southwestern Medical Center","Both","Adult|Senior","Phase 2|Phase 3","130","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","U01-AA021893-01|U01AA021893-01","March 8, 2013","September 2013","null","June 23, 2015","June 2015","No Study Results Posted","null","December 2015","Death|MELD score","https://ClinicalTrials.gov/show/NCT01809132"
790,"NCT02005146","Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs","Completed","No Results Available","Chronic Hepatitis B Treated With Nucleoside/Nucleotide Analogues","","Fundaci√≥n P√∫blica Andaluza Progreso y Salud|Andalusian Initiative for Advanced Therapies - Fundaci√≥n P√∫blica Andaluza Progreso y Salud","Both","Adult|Senior","","86","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ESG-HEP-2013-01","November 15, 2013","December 2013","December 2014","April 30, 2015","April 2015","No Study Results Posted","null","December 2014","Epidemiological characteristics from hepatitis B patients who lost HBsAg related to treatment with nucleoside/nucleotide analogues|Epidemiological characteristics in case of suspension of treatment.","https://ClinicalTrials.gov/show/NCT02005146"
791,"NCT00805675","Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB","Completed","Has Results","Hepatitis B Virus","Drug: Telbivudine|Drug: Tenofovir|Drug: Telbivudine plus tenofovir","Novartis Pharmaceuticals|Novartis","Both","Adult","Phase 3","83","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CLDT600AHK01","December 9, 2008","November 2008","null","January 26, 2012","January 2012","December 12, 2011","null","December 2010","Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Week 12.|Change in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Level From Baseline to Weeks 2, 4 and 8.|Percentage of Patients Who Are Polymerase Chain Reaction(PCR)Negative at Week 12|Percentage of Patients Who Achieve Hepatitis B ""e"" Antigen (HBeAg) Loss and HBeAg Seroconversion at Week 12|Characterization of Very Early Viral Kinetics Through Estimated Viral Load|Characterization of Very Early Viral Kinetics Through Viral Clearance|Characterization of Very Early Viral Kinetics Through Rate of Infected Cell Loss|Characterization of Very Early Viral Kinetics Through Efficiency Factor of Blocking Virus Production.|Characterization of Very Early Viral Kinetics Through Half-live of Free Virus","https://ClinicalTrials.gov/show/NCT00805675"
792,"NCT01312012","The Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test","Recruiting","No Results Available","Hepatitis B Virus Infection, Pregnancy","Drug: antiviral therapy","National Taiwan University Hospital","Female","Adult","Phase 4","120","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","201010078M, 201507025RINC","January 20, 2011","January 2011","December 2018","October 25, 2015","October 2015","No Study Results Posted","null","December 2017","Child-HBsAg|Child HBsAg|Children growth parameters|Children HBV status|Children serum biochemistry|Maternal HBeAg seroconversion rate|Maternal ALT elevation|Maternal HBV DNA|Children bone growth","https://ClinicalTrials.gov/show/NCT01312012"
793,"NCT00289757","Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule","Completed","Has Results","Hepatitis A","Biological: Havrix‚Ñ¢","GlaxoSmithKline","Both","Adult","Phase 4","78","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","100576 (Y11)|100577 (Y12)|100578 (Y13)|100579 (Y14)|100580 (Y15)|111028 (Y16)|111029 (Y17)|111030 (Y18)|111031 (Y19)|111032 (Y20)","February 9, 2006","January 2004","March 2013","July 24, 2014","May 2014","December 10, 2009","null","March 2013","Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration|Number of Seropositive Subjects for Anti-HAV Antibodies.|Number of Subjects Reporting Serious Adverse Events (SAE) Assessed by the Investigators as Related to Vaccination or to Study Procedures or Lack of Efficacy|Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms|Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms|Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AE)|Number of Subjects Reporting Serious Adverse Events (SAE)","https://ClinicalTrials.gov/show/NCT00289757"
794,"NCT00291876","Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule","Completed","Has Results","Hepatitis A","Biological: Havrix‚Ñ¢","GlaxoSmithKline","Both","Adult","Phase 4","135","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","100571 (M138)|100572 (M150)|100573 (M162)|100574 (M174)|100575 (M186)|110677 (M198)|110678 (M210)|110679|110680|110681","February 14, 2006","January 2004","March 2013","May 1, 2014","April 2014","December 10, 2009","null","March 2013","Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration|Number of Seropositive Subjects Against Hepatitis A Virus|Number of Subjects Reporting Solicited Local Symptoms|Number of Subjects Reporting Solicited General Symptoms|Number of Subjects Reporting Unsolicited Adverse Events (AE)|Number of Subjects Reporting Serious Adverse Events (SAE) Assessed by the Investigator as Related to Primary Study Vaccination, Procedures or Lack of Vaccine Efficacy|Number of Subjects Reporting Serious Adverse Events (SAE) After Additional Vaccination|Number of Subjects Reporting Pregnancies After Additional Vaccination","https://ClinicalTrials.gov/show/NCT00291876"
795,"NCT02412319","The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection","Active, not recruiting","No Results Available","HBeAg Positive Chronic Hepatitis B","Drug: Anti-HBV placenta transfer factor injection|Other: Placebo","Shineway Pharmaceutical Co.,Ltd","Both","Adult","Phase 4","288","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","SW002","March 10, 2015","October 2014","December 2017","April 5, 2015","April 2015","No Study Results Posted","null","December 2016","HBeAg serum conversion rate|HBeAg disappearance rate|HBV DNA titer|The proportion of subjects for the HBV DNA can not be detected|HBeAg and HBsAg titer|The quantitative changes of anti -HBc|The variation of ALT|The seroconversion rate of HBsAb and HBeAb|The resistance mutation rate of HBsAb and HBeAb|The cumulative incidence of virologic breakthroughrate of HBsAb and HBeAb|The changes of relative immune parameters of the transfer factor in peripheral blood(the number of T lymphocytes and the expression levels of cytokines)","https://ClinicalTrials.gov/show/NCT02412319"
796,"NCT00225537","4-Methylumbelliferone as a Treatment for Chronic HBV/HCV","Active, not recruiting","No Results Available","Chronic Hepatitis C|Chronic Hepatitis B","Drug: 4-Methylumbelliferone (Heparvit¬Æ)","MTmedical Institute of Health|The University of Texas Health Science Center at San Antonio|BioMonde Preparations Limited","Both","Adult","Phase 2","160","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double-Blind","UTHSCSA 045-900-246","June 30, 2005","September 2005","August 2007","September 7, 2006","April 2006","No Study Results Posted","null","null","Reduction of virus in blood to undetectable levels;|Normalization of serum ALT and AST.|Reduced viral loads; Improvement of serum ALT and AST;|Improvement in general health status;|Improvement in serum marker of hepatic fibrosis;|Loss of HBeAg/seroconversion to HBeAb (for HBV patients).","https://ClinicalTrials.gov/show/NCT00225537"
797,"NCT02219490","A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","Recruiting","No Results Available","Chronic Hepatitis C Virus (HCV) Infection Genotype 1","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin (RBV)","AbbVie","Both","Adult|Senior","Phase 3","1650","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M14-423|2014-001022-14","August 15, 2014","November 2014","June 2021","October 7, 2015","October 2015","No Study Results Posted","TOPAZ-I","September 2016","Incidence of pre-defined clinical outcomes observed during the study|Change in fibrosis|Percentage of subjects with sustained virologic response 12 weeks post-treatment (SVR12)","https://ClinicalTrials.gov/show/NCT02219490"
798,"NCT00473824","Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation","Terminated","Has Results","Sequelae of Viral Hepatitis|Transplantation Infection|Evidence of Liver Transplantation","Biological: Hepatitis C Immune Globulin Intravenous (Human) 5%","Biotest Pharmaceuticals Corporation","Both","Adult|Senior","Phase 2","7","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","Nabi-3104","May 14, 2007","May 2007","February 2009","May 7, 2012","May 2012","January 5, 2012","null","February 2009","Proportion of Subjects Who Achieve Reduction in Viral Load (as Measured Quantitatively by Hepatitis C Virus (HCV) Reverse Transcription-Polymerase Chain Reaction (HCV RT-PCR)) Post-transplant by ‚â• 2 log10 From the Baseline Pre-transplant Value.","https://ClinicalTrials.gov/show/NCT00473824"
799,"NCT01307436","Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines","Completed","No Results Available","Hepatitis A","Biological: Epaxal|Biological: Havrix 720","Crucell Holland BV","Both","Child","Phase 3","327","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","EPA 004 FU","February 28, 2011","March 2011","July 2013","July 28, 2014","August 2013","No Study Results Posted","null","July 2013","Anti-hepatitis A virus (HAV) antibody concentrations|Geometric mean concentrations (GMC)|Proportion of seroprotected subjects","https://ClinicalTrials.gov/show/NCT01307436"
800,"NCT00606086","Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection","Completed","Has Results","Genotype 1 Chronic Hepatitis C","Drug: GI-5005|Drug: Pegylated Interferon and Ribavirin","GlobeImmune","Both","Adult|Senior","Phase 2","140","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","GI-5005-02","January 18, 2008","December 2007","November 2012","June 17, 2014","May 2014","May 5, 2014","null","November 2012","EVR (Early Virologic Response)","https://ClinicalTrials.gov/show/NCT00606086"
801,"NCT00197184","Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared","Completed","Has Results","Hepatitis B|Hepatitis A","Biological: Twinrix‚Ñ¢ Adult|Biological: Twinrix‚Ñ¢ Junior","GlaxoSmithKline","Both","Child","Phase 3","276","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","208127/132 (EXT Y2)|208127/133 (EXT Y3)|208127/134 (EXT Y4)|208127/137 (EXT Y5)","September 15, 2005","November 2003","February 2008","October 2, 2014","November 2011","February 20, 2009","null","February 2008","Anti-hepatitis A (HAV) Antibody Concentrations|Anti-hepatitis B (HBs) Antibody Concentrations|Anti-HAV Antibody Concentrations in Subjects Receiving the Additional Vaccine Dose.|Anti-HBs Antibody Concentrations in Subjects Receiving the Additional Vaccine Dose.|Number of Subjects Reporting Serious Adverse Events (SAEs) Determined by the Investigator to Have a Causal Relationship to Primary Vaccination or Due to Lack of Vaccine Efficacy.|Number of Subjects Receiving an Additional Vaccine Dose and Reporting Solicited Local Symptoms|Number of Subjects Receiving an Additional Vaccine Dose and Reporting Solicited General Symptoms.|Number of Subjects Receiving an Additional Vaccine Dose and Reporting Unsolicited Adverse Events (AEs).|Number of Subjects Receiving an Additional Vaccine Dose and Reporting Any Serious Adverse Events","https://ClinicalTrials.gov/show/NCT00197184"
802,"NCT00564811","Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom)","Completed","No Results Available","Hepatitis C|Nutritional Status|Hepatitis, Viral, Human","Dietary Supplement: Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)","UPECLIN HC FM Botucatu Unesp","Both","Adult|Senior","","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","upeclin/HC/FMB-Unesp-03","November 27, 2007","March 2003","September 2004","May 27, 2015","May 2015","No Study Results Posted","null","null","Measure: influence of Agaricus blazei (Murrill) ss. Heinemann on the evolution of nutritional state and liver function in hepatitis C patients. Time Frame: six months","https://ClinicalTrials.gov/show/NCT00564811"
803,"NCT02392598","A Hepatitis B With Hepatic Steatosis Study","Not yet recruiting","No Results Available","Hepatitis B, Chronic|Hepatic Steatosis","","Fatty Liver and Alcoholic Liver Disease Study Group, China|Unimed Scientific Inc.","Both","Child|Adult|Senior","","3000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HBV2015","March 13, 2015","August 2015","December 2020","August 3, 2015","August 2015","No Study Results Posted","HBHS","December 2020","liver cirrhosis|liver cancer|liver failure|type 2 diabetes|cardiovascular and cerebrovascular events|death|response of hepatic steatosis to anti-virus treatment|effect of hepatic steatosis on HBeAg negativation among patients without anti-virus treatment|effect of hepatic steatosis on HBsAg negativation among patients without anti-virus treatment","https://ClinicalTrials.gov/show/NCT02392598"
804,"NCT00209898","Hepatitis C Treatment of Inmates","Terminated","No Results Available","Chronic Hepatitis C","Procedure: Fast initiation procedure","Haukeland University Hospital|Bergen Prison, Norwegian correctional service|Hoffmann-La Roche","Both","Adult|Senior","Phase 4","42","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","12952","September 13, 2005","August 2003","January 2009","March 19, 2015","June 2003","No Study Results Posted","PEGPRI","January 2009","- adherence|- Sustained virologic response rates defined as percentage of patients with non-detectable HCV-RNA as measured by Roche AMPLICOR HCV Test, v2.0 (>50 IU/mL).|Percentage of patients with non-detectable HCV-RNA at study week 12, 24 and 48 as measured by Roche AMPLICOR HCV Test v2.0 (<50 IU/mL).|- adverse event rate and profile|- Hemoglobin|- Other laboratory tests|- Medical Outcomes Study 36 Item Short Form health Survey (SF-36)","https://ClinicalTrials.gov/show/NCT00209898"
805,"NCT02265328","Efficacy of Combination Therapy of Glucocorticoids and Bovine Colostrum in Treatment of Severe Alcoholic Hepatitis.","Completed","No Results Available","Severe Alcoholic Hepatitis in 'Extremis'- Defined by mDF>54","Dietary Supplement: Bovine colostrum|Dietary Supplement: Enteral Nutrition|Other: prednisolone","Dayanand Medical College and Hospital","Both","Adult","Phase 2","25","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","COBS-2014","September 8, 2014","September 2014","June 2015","September 14, 2015","September 2015","No Study Results Posted","COBS","May 2015","Change in mDf Value from baseline to 8 weeks|Change in Endotoxin level from baseline to 8 weeks|Cytokines Levels (Œ±TNF, IL 6, IL 8) from baseline to 8 weeks.","https://ClinicalTrials.gov/show/NCT02265328"
806,"NCT01310062","The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer","Recruiting","No Results Available","Hepatitis B,Chronic|Carcinoma,Hepatocellular","","Ministry of Health, Malaysia|GeneNews Sdn Bhd","Both","Adult|Senior","","1600","Other","Observational","Time Perspective: Cross-Sectional","09-317-3991","March 4, 2011","August 2010","August 2012","March 4, 2011","March 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01310062"
807,"NCT00088140","A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients","Completed","No Results Available","Hepatitis C, Chronic","Drug: IDN-6556|Drug: Placebo","Conatus Pharmaceuticals Inc.|Idun Pharmaceuticals","Both","Adult|Senior","Phase 2","204","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","CL-000006556-PRO-0007","July 20, 2004","July 2004","October 2005","August 9, 2012","August 2012","No Study Results Posted","null","October 2005","Median absolute change in aspartate transaminase (AST) values measured from baseline to Week 10|Median absolute change in alanine aminotransferase (ALT) values measured from baseline to Week 10","https://ClinicalTrials.gov/show/NCT00088140"
808,"NCT01926860","PCV13 + Hepatitis A Vaccine for Adults","Not yet recruiting","No Results Available","Measurement of Immune Response to Prevenar13|Measurement of Immune Response to Hepatitis A","Biological: Prevenar13|Biological: Hepatitis A vaccine","Helsinki University Central Hospital","Both","Adult|Senior","Phase 4","300","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","PCV13 adults + Hep A","August 19, 2013","September 2013","September 2015","August 20, 2013","August 2013","No Study Results Posted","PCV13+HepA","September 2014","Immune response to PCV13|Immune response to Hep A vaccine","https://ClinicalTrials.gov/show/NCT01926860"
809,"NCT02267473","Hepatitis B Patients Under Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function","Recruiting","No Results Available","Hepatitis B, Chronic","","Johann Wolfgang Goethe University Hospitals","Both","Adult|Senior","","400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","JWGUHMED1-008","October 14, 2014","October 2014","December 2020","October 14, 2014","October 2014","No Study Results Posted","BONIKA","October 2020","Change in Kidney Function|Kidney relevant Comorbidities|Kidney relevant Comedication|HBV-DNS|quantitative HBs Antigen|Mitochondrial Toxicity","https://ClinicalTrials.gov/show/NCT02267473"
810,"NCT00932971","HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis","Active, not recruiting","No Results Available","Hepatitis D","Drug: PEG-IFN alfa-2a, Tenofovir|Drug: PEG-IFN alfa-2a, placebo","HepNet Study House, German Liverfoundation|Hannover Clinical Trial Center GmbH|Hoffmann-La Roche|Gilead Sciences","Both","Adult|Senior","Phase 2","70","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","Hep-Net-HIDIT-II|EudraCT-No.: 2008-005560-13","July 3, 2009","June 2009","May 2017","December 3, 2014","December 2014","No Study Results Posted","HIDIT-II","May 2017","Negativation of HDV-RNA at the end of therapy|Negativation of HDV-RNA at week 48 of treatment|Negativation of HDV-RNA 24 weeks after the end of treatment|Normalization of ALT levels at the end of treatment and at the end of follow-up|HDV-RNA-levels over time|Suppression of HBV-DNA below 6 IU/ml using the Cobas TaqMan assay at treatment weeks 48 and 96 and 24 weeks after treatment|Liver histology at end of treatment (Ishak score for inflammation and fibrosis)|Quantitative HBsAg levels over time. Loss of HBsAg and development of anti-HBs antibodies, intrahepatic cccDNA and HBV-DNA levels over time|HBV- and HDV-virus-specific T cell responses during therapy and after 24 weeks of follow up if virological and biochemical efficacy has been shown|Virological long-term outcome|Clinical long-term outcome|Quality of Life","https://ClinicalTrials.gov/show/NCT00932971"
811,"NCT01805882","Combination Therapy for Chronic Hepatitis C Infection","Completed","No Results Available","Hepatitis C, Chronic","Drug: Fixed Dose GS-7977/GS-5885|Drug: FDC with GS-9451|Drug: FDC with GS-9669","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Both","Adult|Senior","Phase 2","237","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","130066|13-I-0066","March 5, 2013","January 2013","August 2015","August 6, 2015","July 2015","No Study Results Posted","null","August 2015","The incidence and severity of adverse events (AEs) during and following treatment with GS-7977 in combination with GS-5885, GS-9669 or GS-9451 and the proportion of subjects who achieve SVR12.|Correlation and comparison of early viral kinetics with response to treatment; host and viral factors influencing response, comparison of HCV viral kinetics and pharmacodynamics in HCV treatment naive vs. null responders.","https://ClinicalTrials.gov/show/NCT01805882"
812,"NCT01907230","Entecavir for Biological Agents Associated HBV Reactivation in Rheumatoid Arthritis Patients","Not yet recruiting","No Results Available","Rheumatoid Arthritis|Hepatitis B Reactivation|Exposure to Hepatitis B Virus","Drug: Entecavir","Taipei Veterans General Hospital, Taiwan|Bristol-Myers Squibb","Both","Adult|Senior","Phase 4","220","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","AI463-962","July 14, 2013","July 2013","null","July 18, 2013","July 2013","No Study Results Posted","null","July 2016","HBV reactivation|HBsAg reverse seroconversion in occult HB patients.","https://ClinicalTrials.gov/show/NCT01907230"
813,"NCT01337479","A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials","Completed","No Results Available","Hepatitis B","","Bristol-Myers Squibb","Both","Child|Adult|Senior","","1097","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AI463-049","April 15, 2011","February 2003","September 2010","April 18, 2011","April 2011","No Study Results Posted","null","September 2010","The proportion of subjects who have newly reported hepatitis B-related complications during AI463049 (reported by Phase III treatment groups)|To determine the proportion of subjects who have a HBV Deoxyribonucleic acid (DNA) by Polymerase chain reaction (PCR) of < 300 copies/mL over the AI463049 follow-up period by the phase III treatment group|To determine the proportion of subjects who have Alanine transaminase (ALT) ‚â§ 1.0 x Upper limit of normal (ULN) over the AI463049 follow-up period by the phase III treatment group|To determine the proportion of subjects who were Hepatitis B e antigen (HBeAg) positive at the beginning of Phase III trials who have HBeAg loss or HBe seroconversion over the AI463049 follow-up period by the phase III treatment group|To determine the number of anti-HBV medications following enrollment in AI463049 by the phase III treatment group|To determine all cause mortality by the phase III treatment group|To determine HBV-related mortality by the phase III treatment group|To determine Non-hepatic malignancies by the phase III treatment group","https://ClinicalTrials.gov/show/NCT01337479"
814,"NCT01155427","Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)","Completed","No Results Available","Hepatitis B, Chronic","","Bristol-Myers Squibb","Both","Child|Adult|Senior","","100","Industry","Observational","Observational Model: Cohort","AI463-186","June 29, 2010","May 2009","April 2010","June 30, 2010","June 2010","No Study Results Posted","null","April 2010","Viral load|Histological improvement","https://ClinicalTrials.gov/show/NCT01155427"
815,"NCT00197249","Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity","Completed","No Results Available","Hepatitis B|Typhoid|Hepatitis A","Biological: Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix","GlaxoSmithKline","Both","Adult","Phase 3","1034","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","270362/006|270362/007 (Ext. Mth12)|270362/008 (Ext. Mth24)|270362/009 (Ext. Mth36)","September 15, 2005","May 2002","November 2005","November 17, 2011","November 2011","No Study Results Posted","null","June 2003","Anti-Vi seropositivity rates (i.e., percentage of subjects with anti-Vi antibody titres > or = 150 EL.U/ml) at Month 1 after administration of study vaccine (Comparison of Hepatyrix versus concomitant Havrix+Typherix and Hepatyrix versus Typhim Vi).|Anti-HAV seropositivity rates (i.e., percentage of subjects with anti-HAV antibody titres >or = 15 mIU/ml) at Month 1 after administration of study vaccine, (Comparison of Hepatyrix versus concomitant Havrix+Typherix and Hepatyrix versus Havrix).|Anti-Vi seropositivity rates at Day 14, Month 6 and Month 7 and GMTs at Day 14, Month 1, Month 6 and Month 7 after administration of study vaccine.|Anti-HAV seropositivity rates at Day 14, Month 6 and Month 7 and GMTs at Day 14, Month 1, Month 6 and Month 7 after administration of study vaccine.|Anti-Vi and anti-HAV seropositivity rates and GMTs at Months 12, 24, 36 after administration of study vaccine.|Occurrence and intensity of solicited local symptoms after vaccination (Day 0 to 4).|Occurrence, intensity and relationship of solicited general symptoms after vaccination (Day 0 to 4).|Occurrence, intensity and relationship to vaccination of unsolicited signs and symptoms after vaccination (Day 0 to 30).|Occurrence, intensity and relationship to vaccination of serious adverse events (SAEs) during the study period and during the follow-up period up to Months 12, 24 and 36 after administration of study vaccine.","https://ClinicalTrials.gov/show/NCT00197249"
816,"NCT00197236","Immunogenicity and Safety of Havrix‚Ñ¢ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months","Completed","Has Results","Hepatitis A Vaccine|Hepatitis A","Biological: Havrix‚Ñ¢|Biological: Infanrix‚Ñ¢|Biological: ActHIB‚Ñ¢","GlaxoSmithKline","Both","Child","Phase 3","468","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","208109/232","September 15, 2005","November 2003","December 2007","April 11, 2013","March 2011","December 2, 2008","null","December 2007","Number of Seropositive Subjects for Anti-hepatitis A Virus (HAV) Antibodies Following the Second Dose of Havrix|Number of Anti-diphtheria, Anti-tetanus and Anti-polyribosylribitol Phosphate (PRP) Seroprotected Subjects|Number of Vaccine Responders for Anti-pertussis Toxoid (PT), Anti-filamentous Hemagglutinin (FHA) and Anti-pertactin (PRN)|Anti-diphtheria and Anti-tetanus Antibody Geometric Mean Concentrations (GMC)|Anti-polyribosylribitol Phosphate (PRP) Antibody Geometric Mean Concentrations (GMC)|Number of Subjects Seropositive for Anti-pertussis Toxoid (PT), Anti-filamentous Hemagglutinin (FHA), Anti-pertactin (PRN) and Anti-polyribosylribitol Phosphate (PRP)|Number of Seropositive Subjects for Anti-hepatitis A Virus (HAV) Antibodies Following the First Dose of Havrix|Anti-hepatitis A Virus (HAV) Antibody Geometric Mean Concentrations (GMC) Following the First Dose of Havrix|Anti-hepatitis Virus A (HAV) Antibody Geometric Mean Concentrations (GMC) Following the Second Dose of Havrix|Number of Subjects With Vaccine Response to Havrix‚Ñ¢.|Number of Subjects Reporting Solicited Local Adverse Events (AEs)|Number of Subjects Reporting Solicited General Adverse Events (AEs)|Number of Subjects Reporting Unsolicited Adverse Events (AEs)|Number of Subjects Reporting Serious Adverse Events (SAEs), New Chronic Illnesses and Medically Significant Events","https://ClinicalTrials.gov/show/NCT00197236"
817,"NCT00727259","Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)","Completed","Has Results","Hepatitis C, Chronic","Biological: Peginterferon alfa-2b (SCH 54031)|Drug: Ribavirin (SCH 18908)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","1995","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P04067","July 30, 2008","October 2004","April 2008","April 7, 2015","April 2015","June 18, 2009","SATISFACTION","April 2008","Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months","https://ClinicalTrials.gov/show/NCT00727259"
818,"NCT01833611","Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT","Active, not recruiting","No Results Available","Chronic Hepatitis","Drug: Entecavir|Drug: placebo","National Cheng-Kung University Hospital","Both","Adult","Phase 4","130","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","ETV HR-96-23","April 27, 2012","September 2008","May 2015","April 14, 2013","April 2013","No Study Results Posted","null","November 2014","Improvement of liver histology in patients with chronic hepatitis B virus infection and persistently normal ALT receiving entecavir. Please refer to ""Description"" section for the definiton of improvement of liver histology|Undetectable HBV DNA|the reduction of HBV DNA from baseline","https://ClinicalTrials.gov/show/NCT01833611"
819,"NCT00723645","Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)","Completed","Has Results","Hepatitis C, Chronic","","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","279","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P05181","July 25, 2008","April 2008","February 2011","December 17, 2014","December 2014","March 23, 2012","FAST-4","April 2010","Percentage of Participants With Relapse At 24 Weeks After the End Of Treatment (EOT)|Percentage of Participants Who Relapsed After EOT at Week 72 (Late Relapser)","https://ClinicalTrials.gov/show/NCT00723645"
820,"NCT00705263","Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)","Completed","Has Results","Hepatitis C, Chronic|Hepacivirus","Biological: Peginterferon alfa-2b (SCH 54031)|Drug: Ribavirin (SCH 18908)","Schering-Plough","Both","Adult|Senior","","113","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P04244","June 23, 2008","October 2005","May 2008","August 20, 2009","August 2009","May 28, 2009","null","May 2008","Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.","https://ClinicalTrials.gov/show/NCT00705263"
821,"NCT00811967","Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)","Terminated","No Results Available","Hepatitis C, Chronic|Liver Cirrhosis","Biological: PegIntron (peginterferon alfa-2b; SCH 54031)|Drug: Rebetol (ribavirin; SCH 18908)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 3","50","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P03811|JPC-02-320-34","December 18, 2008","February 2003","May 2006","April 9, 2015","April 2015","No Study Results Posted","null","May 2006","Sustained virologic response rate, defined as the proportion of subjects with undetectable HCV-RNA at 24-week post-treatment follow-up|Rate of subject with undetectable HCV-RNA at the end of treatment (or at discontinuation of treatment)","https://ClinicalTrials.gov/show/NCT00811967"
822,"NCT01928147","A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients","Active, not recruiting","No Results Available","Hepatitis C, Chronic","Drug: PPI-383|Drug: Placebo","Presidio Pharmaceuticals, Inc.","Both","Adult","Phase 1","144","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","PPI-383-101","August 19, 2013","August 2013","November 2015","October 20, 2015","October 2015","No Study Results Posted","null","July 2015","Safety and tolerability, as measured by clinical adverse events and laboratory assessments|PPI-383 plasma levels|serum HCV RNA levels","https://ClinicalTrials.gov/show/NCT01928147"
823,"NCT00279565","Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)","Terminated","No Results Available","Hepatitis C, Chronic","Drug: buprenorphine|Drug: methadone|Drug: pegylated interferon alfa-2b plus ribavirin","Reckitt Benckiser Pharmaceuticals Inc.|AESCA Pharma GmbH","Both","Adult","Phase 4","128","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P04279","January 17, 2006","August 2005","February 2007","November 21, 2012","February 2007","No Study Results Posted","null","February 2007","","https://ClinicalTrials.gov/show/NCT00279565"
824,"NCT01770483","The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients","Completed","Has Results","Hepatitis C, Chronic|DIABETES MELLITUS Type 2","Drug: nitazoxanide|Drug: conventional interferon alfa|Drug: Ribavirin","Services Institute of Medical Sciences, Pakistan|Getz Pharma","Both","Adult","Phase 4","66","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","SIMS","January 8, 2013","July 2011","March 2013","September 15, 2013","September 2013","March 7, 2013","HEP-C-FM","March 2013","Sustained Viral Response,|Normalization of Alanine Transferase Test","https://ClinicalTrials.gov/show/NCT01770483"
825,"NCT02129829","PROLIFICA - West African Treatment Cohort for Hepatitis B","Recruiting","No Results Available","Hepatitis B, Chronic|Hepatocellular Carcinoma","Drug: Tenofovir disoproxil","Imperial College London|Medical Research Council Unit, The Gambia|Department of State for Health and Social Welfare, The Gambia|UFR Sante de Thies, Senegal|Cheikh Anta Diop University, Senegal|Institut National de la Sant√© Et de la Recherche M√©dicale, France|International Agency for Research on Cancer","Both","Adult|Senior","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","WMDH-P34114","April 30, 2014","October 2011","December 2016","June 1, 2015","June 2011","No Study Results Posted","WATCH","December 2016","Incidence of HCC or decompensated cirrhosis|Uptake of screening|Prevalence of HBV infection|Rate of linkage into care|Treatment rate","https://ClinicalTrials.gov/show/NCT02129829"
826,"NCT00529321","Immunotherapy With TG4040 in Treatment-na√Øve Patients Chronically Infected With Hepatitis C Virus","Completed","No Results Available","Hepatitis C, Chronic","Biological: MVA-HCV (Immunotherapy)","Transgene","Both","Adult","Phase 1","42","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","TG4040.01","September 7, 2007","December 2006","September 2010","September 2, 2010","September 2010","No Study Results Posted","null","September 2009","Safety (adverse events, vital signs, physical examination, standard laboratory tests)|Virology (quantification of HCV-RNA), immunology (cellular-mediated and humoral immune responses)","https://ClinicalTrials.gov/show/NCT00529321"
827,"NCT02499562","A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis","Recruiting","No Results Available","Hepatitis B, Chronic","Drug: Hydronidone|Drug: Placebo|Drug: Entecavir","Shanghai Genomics, Inc.","Both","Adult","Phase 2","240","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","GNI-F351-201402","June 26, 2015","July 2015","July 2017","July 13, 2015","May 2015","No Study Results Posted","HBV","July 2017","Changes in hepatic fibrosis in chronic viral hepatitis B","https://ClinicalTrials.gov/show/NCT02499562"
828,"NCT00695019","Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C","Completed","Has Results","Hepatitis C, Chronic","Drug: interferon-alpha lozenges|Drug: placebo lozenges","Amarillo Biosciences, Inc.|CytoPharm, Inc.","Both","Adult|Senior","Phase 2","169","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","07HWHC09","June 9, 2008","June 2009","February 2012","August 27, 2013","August 2013","February 5, 2013","null","November 2011","Relapse Rate|Sustained Virologic Response Rate|Normalization of ALT|Change in Serum HCV RNA Concentration|Change in Serum ALT|Change in Social Functioning|Change in Fibrotest Score","https://ClinicalTrials.gov/show/NCT00695019"
829,"NCT01554189","A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)","Terminated","No Results Available","Hepatitis C, Chronic","Drug: MK-8325|Drug: Placebo","Merck Sharp & Dohme Corp.","Male","Adult","Phase 1","37","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","8325-002|2011-006263-22","March 12, 2012","April 2012","April 2013","July 20, 2015","July 2015","No Study Results Posted","null","April 2013","Change from baseline to Day 5 in plasma HCV ribonucleic acid (RNA) in GT1 participants|Mean maximum reduction from baseline through Day 5 in HCV ribonucleic acid (RNA) in GT3 participants|Number of participants experiencing at least one adverse event|Number of participants discontinuing study drug due to an adverse event|Trough plasma concentration (C24hr) of MK-8325|Area under the concentration curve from Hour 0 to Hour 24 (AUC0-24hr) for MK-8325|Maximum plasma concentration (Cmax) of MK-8325","https://ClinicalTrials.gov/show/NCT01554189"
830,"NCT01221298","A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)","Completed","Has Results","Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1","Drug: ABT-450|Drug: ABT-072|Drug: Ribavirin|Drug: Ritonavir","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult","Phase 2","11","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","M12-267","October 13, 2010","October 2010","April 2012","December 29, 2014","December 2014","December 29, 2014","null","May 2011","Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Quantitation (LLOQ) From Week 4 Through Week 12|Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) < 1000 International Units Per Milliliter (IU/mL)|Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Below the Lower Limit of Quantitation (LLOQ) at Week 4|Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment|Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-Treatment|Time to Failure to Suppress or Rebound During Treatment|Time to Virologic Relapse Through 24 Weeks Post-treatment","https://ClinicalTrials.gov/show/NCT01221298"
831,"NCT01980290","Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C","Completed","No Results Available","Hepatitis, Chronic","","Janssen Pharmaceutica N.V., Belgium","Both","Adult|Senior","Phase 4","50","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR100966|VX-950HPC4017","November 4, 2013","May 2013","February 2015","March 6, 2015","March 2015","No Study Results Posted","INTEGRATE","February 2015","Sustained Virologic Response at 12 weeks (SVR12)|adherence to telaprevir until Week 12|adherence to PegIFN alfa and RBV|on-treatment virologic response undetectable|on treatment virologic response|health-related quality of life based on EQ-5D|Hospital Anxiety and Depression Scale (HADS)|alcohol use disorders identification test (AUDIT)","https://ClinicalTrials.gov/show/NCT01980290"
832,"NCT00723879","Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)","Terminated","No Results Available","Hepatitis C, Chronic|Hepacivirus","Biological: Peginterferon alfa-2b (SCH 54031)|Drug: Ribavirin (SCH 18908)|Behavioral: Patient assistance program","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","115","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P04206","July 25, 2008","October 2004","July 2008","October 19, 2015","October 2015","No Study Results Posted","null","July 2008","Proportion of patients who complete treatment with PegIntron plus Rebetol therapy for hepatitis C when administered with a patient assistance program.|Average length of treatment for patients receiving a patient assistance program as part of their treatment for hepatitis C with PegIntron plus Rebetol.","https://ClinicalTrials.gov/show/NCT00723879"
833,"NCT00704522","Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)","Completed","Has Results","Hepatitis C, Chronic|Hepacivirus","Biological: Peginterferon alfa-2b (SCH 54031)|Drug: Ribavirin (SCH 18908)|Behavioral: Patient assistance program","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","601","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P04281","June 23, 2008","March 2005","April 2009","October 5, 2015","October 2015","April 21, 2010","null","April 2009","Number of Participants Who Complete Treatment With PegIntron Pen/Rebetol Therapy for Hepatitis C When Administered With a Patient Assistance Program|Average Length of Treatment With PegIntron/Rebetol","https://ClinicalTrials.gov/show/NCT00704522"
834,"NCT02167113","Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay","Recruiting","No Results Available","Hepatitis B, Chronic","","Hologic, Inc.","Both","Adult|Senior","","300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","V10434-HBVQPS-CSP-01","June 12, 2014","April 2014","December 2015","September 10, 2015","September 2015","No Study Results Posted","HBVQuant","December 2015","Association between virologic response at Week 12 (assessed using the Aptima HBV Quant assay) and virologic response at Week 48 (assessed using an FDA-approved HBV quant assay).|Association between virologic response at Week 24 (assessed using the Aptima HBV Quant assay) and virologic response at Week 48 (assessed using an FDA-approved HBV quant assay).","https://ClinicalTrials.gov/show/NCT02167113"
835,"NCT00724451","Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)","Completed","Has Results","Hepatitis C|Hepatitis C, Chronic","Biological: Peginterferon alfa-2b|Drug: Ribavirin|Biological: Peginterferon alfa-2a","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","1128","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P05488","July 25, 2008","July 2008","October 2011","September 24, 2015","September 2015","October 5, 2012","null","October 2011","Number of Participants Not Eligible for Antiviral Treatment by Reason for Non-eligibility|Number of Participants Discontinued From Treatment by Reason for Discontinuation|Number of Participants With Treatment Failure by Reason for Failure","https://ClinicalTrials.gov/show/NCT00724451"
836,"NCT01088659","A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.","Active, not recruiting","No Results Available","Hepatitis D, Chronic","Drug: peginterferon alfa-2a [Pegasys]|Drug: placebo|Drug: tenofovir","Hoffmann-La Roche","Both","Adult|Senior","Phase 3","50","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","ML22364","March 16, 2010","February 2010","November 2017","October 1, 2015","October 2015","No Study Results Posted","null","November 2017","proportion of patients becoming HDV-RNA negative|HDV-RNA levels, HBsAg levels, HBV DNA, biochemical disease activity, liver histology|Safety and tolerability: adverse events, laboratory parameters, vital signs","https://ClinicalTrials.gov/show/NCT01088659"
837,"NCT00378599","Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)","Completed","Has Results","Liver Transplantation|Hepatitis C, Chronic|Liver Cirrhosis","Drug: Combination of (a) pegylated interferon alfa-2b and (b) rebetol","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 3","125","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","P04590","September 18, 2006","May 2006","July 2009","April 7, 2015","April 2015","June 17, 2010","null","July 2009","A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment","https://ClinicalTrials.gov/show/NCT00378599"
838,"NCT01074008","A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072","Completed","Has Results","Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1","Drug: ABT-450|Drug: ABT-072|Drug: ABT-333|Drug: Ritonavir|Drug: Peginterferon alpha-2a|Drug: Ribavirin|Other: Placebo","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult","Phase 2","74","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","M11-602","February 22, 2010","March 2010","January 2012","December 29, 2014","December 2014","December 29, 2014","Champion2","June 2011","Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-450/r, ABT-333, or ABT-072 Monotherapy Treatment|Maximum Plasma Concentration (Cmax) of ABT-450|Time to Maximum Plasma Concentration (Tmax) of ABT-450|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-450|Maximum Plasma Concentration (Cmax) of Ritonavir|Time to Maximum Plasma Concentration (Tmax) of Ritonavir|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of Ritonavir|Maximum Plasma Concentration (Cmax) of ABT-072|Time to Maximum Plasma Concentration (Tmax) of ABT-072|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-072|Maximum Plasma Concentration (Cmax) of ABT-333|Time to Maximum Plasma Concentration (Tmax) of ABT-333|Area Under the Plasma Concentration-time Curve From 0 to 12 Hours (AUC12) Post-dose of ABT-333|Percentage of Participants With Rapid Virologic Response (RVR) at Week 4|Percentage of Participants With Partial Early Virologic Response (EVR) at Week 12|Percentage of Participants With Complete Early Virologic Response (cEVR) at Week 12","https://ClinicalTrials.gov/show/NCT01074008"
839,"NCT00723892","Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)","Completed","Has Results","Hepatitis C, Chronic|Hepacivirus","Biological: Peginterferon alfa-2b (PegIntron)|Drug: Rebetol (Ribavirin)|Behavioral: Psychotherapy support program","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","614","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P04252|MK-4031-245","July 25, 2008","July 2005","May 2009","October 29, 2015","October 2015","August 25, 2010","null","May 2009","Number of Participants Who Complete Treatment With PegIntron/Rebetol Therapy for Hepatitis C When Administered With a Patient Psychotherapy Support Program as Compared to a Group Without a Psychotherapy Support Program.|the Average Length of Treatment for Participants on Treatment for Hepatitis C With PegIntron Pen/Rebetol","https://ClinicalTrials.gov/show/NCT00723892"
840,"NCT00087633","PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.","Completed","Has Results","Hepatitis C, Chronic","Drug: peginterferon alfa-2a [Pegasys]|Drug: Copegus","Hoffmann-La Roche","Both","Adult|Senior","Phase 4","115","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ML18124","July 12, 2004","October 2004","October 2008","December 22, 2010","December 2010","October 14, 2009","null","null","Percentage of Patients With Histologically-confirmed Recurrence of Hepatitis C Virus (HCV)|Summary of Virologic Response","https://ClinicalTrials.gov/show/NCT00087633"
841,"NCT02309086","Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic","Biological: Autologous dendritic cells transduced with Ad encoding NS3","Clinica Universidad de Navarra, Universidad de Navarra|Centro de Investigaci√≥n M√©dica Aplicada (CIMA)","Both","Adult","Phase 1|Phase 2","5","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","CD-AdNS3","November 18, 2014","May 2011","May 2014","July 16, 2015","May 2015","No Study Results Posted","null","May 2013","Safety and tolerability determined by the evaluation of the number of participants with the type adverse events. Liver safety will be assessed by blood analysis and Ultrasound.|Efficacy on viral load and immune response","https://ClinicalTrials.gov/show/NCT02309086"
842,"NCT01005238","Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine","Terminated","No Results Available","Hepatitis, Chronic","Drug: Lamivudine|Drug: Telbivudine","University Hospital, Basel, Switzerland","Both","Adult|Senior","Phase 4","27","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","SASL28","October 29, 2009","September 2009","null","March 9, 2015","March 2015","No Study Results Posted","SASL28","December 2014","The primary endpoint is the rate of viral breakthrough during treatment defined as an increase of the viral titer to > 200 IU/mL.","https://ClinicalTrials.gov/show/NCT01005238"
843,"NCT01671046","An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection","Active, not recruiting","No Results Available","Hepatitis C, Chronic","","Hoffmann-La Roche","Both","Adult|Senior","","123","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML27944","August 20, 2012","July 2012","October 2015","October 1, 2015","October 2015","No Study Results Posted","null","October 2015","Correlation of liver elasticity with liver biopsy performed no later than 3 months before study start|Correlation of liver elasticity evolution with viral kinetics|Safety: incidence of adverse events|Correlation of liver fibrosis stages with sustained virological response (SVR)|Correlation of patients characteristics with sustained virological response|Hepatic transient elastography (M-transducer)|Hepatic transient elastography (XL-transducer)|Correlation of hepatic steatosis score with sustained virological response|Correlation of liver steatosis measured by Controlled Attenuation Parameter (CAP) with that obtained by liver biopsy|Correlation of liver stiffness of HCV monoinfected patients with HCV/HIV co-infected patients","https://ClinicalTrials.gov/show/NCT01671046"
844,"NCT00127777","Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)","Active, not recruiting","No Results Available","Hepatitis C, Chronic","Drug: Amantadine sulphate (in addition to standard treatment)","University Hospital, Saarland|Hoffmann-La Roche","Both","Adult|Senior","Phase 4","700","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double-Blind","ML17002","August 4, 2005","July 2002","December 2006","August 24, 2005","August 2005","No Study Results Posted","null","null","Proof that peginterferon alfa-2a, ribavirin and amantadine sulphate over a period of 50 weeks improves the permanent virological efficacy by more than 10% compared to peginterferon alfa-2a and ribavirin|Verification of the initial virological efficacy up to week 12, defined as negative HCV-RNA test results by means of quantitative proof methods, e.g. Roche AmplicorTM HCV Monitor v.2.0 (sensitivity <600 IE/ml)|Biochemical efficacy, defined by the serum GPT values 24 weeks after the end of the therapy|Virological efficacy, measured on the basis of the HCV-RNA values at the end of the therapy|Biochemical efficacy defined by the serum GPT values at the end of the therapy","https://ClinicalTrials.gov/show/NCT00127777"
845,"NCT00724893","Efficacy of Pegetron¬Æ Redipen‚Ñ¢ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)","Completed","Has Results","Hepatitis C, Chronic|Hepatitis C","Biological: PegIFN-2b|Drug: Ribavirin","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","2430","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P04423|MK-4031-267","July 25, 2008","August 2005","August 2012","July 20, 2015","July 2015","July 29, 2013","null","August 2012","Number of Participants Achieving Viral Response at Any Evaluation Point (Stage 1)|Number of Participants Achieving Viral Response at 12 Weeks After EOT (Stage 1)|Number of Participants Achieving Sustained Viral Response (SVR) (Stage 1)|Number of Participants Achieving SVR (Stage 2)|Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2)|Number of Participants Achieving Viral Response at Any Evaluation Point, Excluding Participants Who Discontinued Treatment Prior to Early Virologic Response (EVR) Evaluation (Stage 1)|Number of Participants Achieving Viral Response at 12 Weeks After EOT, Excluding Participants Who Discontinued Prior to EVR Evaluation (Stage 1)|Number of Participants Achieving SVR, Excluding Participants Who Discontinued Prior to EVR Evaluation (Stage 1)|The Number of Participants Achieving Viral Response at 12 Weeks After EOT, Excluding Participants Who Discontinued Prior to EVR Evaluation and Participants With Missing Data (Stage 1)|The Number of Participants Achieving SVR Excluding Participants Who Discontinued Prior to EVR Evaluation and Participants With Missing Data (Stage 1)|The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Chronic HCV Genotype (Stage 1)|The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Liver Fibrosis Stage (Stage 1)|Number of Participants Achieving SVR by Liver Fibrosis Stage (Stage 1)|Number of Participants Achieving SVR by Chronic HCV Genotype (Stage 1)|Number of Participants Achieving SVR by Viral Load (Stage 1)|Number of Participants Achieving SVR by Weight (Stage 1)|Number of Participants Achieving SVR by Chronic HCV Genotype + Liver Fibrosis Stage (Stage 1)|Number of Participants Achieving SVR by Chronic HCV Genotype + Viral Load (Stage 1)|Number of Participants Achieving SVR by Weight + Chronic HCV Genotype (Stage 1)|Number of Participants Achieving EVR (Stage 1)|Number of Participants Achieving SVR by EVR Type (Stage 1)|Number of Participants Achieving SVR by Gender (Stage 1)|Number of Participants Achieving SVR by Race (Stage 1)|Number of Participants Achieving SVR by Human Immunodeficiency Virus (HIV) Status (Stage 1)|Number of Participants With End of Treatment (EOT) Response (Stage 1)|Number of Participants With EOT Response by Chronic HCV Genotype (Stage 1)|Number of Participants With EVR by Selected Chronic HCV Genotypes (Stage 1)|Relapse Rate by HCV Genotype (Stage 1)|Number of Participants Discontinued From Study Drug Due to Adverse Events by Chronic HCV Genotype (Stage 1)|Number of Participants Achieving Rapid Virologic Response (RVR) (Stage 2)|Number of Participants Achieving EVR (Stage 2)|Number of Participants Achieving RVR by Race (Stage 2)|Number of Participants Achieving EVR by Race (Stage 2)|Number of Participants Achieving SVR by Race (Stage 2)|Number of Participants Achieving RVR Who Achieved SVR (Stage 2)|Number of Participants Achieving EVR Who Achieved SVR (Stage 2)|Number of Participants Achieving RVR by Liver Fibrosis Stage (Stage 2)|Number of Participants Achieving EVR by Liver Fibrosis Stage (Stage 2)|Number of Participants Achieving SVR by Liver Fibrosis Score (Stage 2)|Number of Participants Achieving RVR by Weight (Stage 2)|Number of Participants Achieving EVR by Weight (Stage 2)|Number of Participants Achieving SVR by Weight (Stage 2)|Number of Participants Achieving RVR by Chronic HCV Genotype 1 Subtype (Stage 2)|Number of Participants Achieving EVR by Chronic HCV Genotype 1 Subtype (Stage 2)|Number of Participants Achieving SVR by Chronic HCV Genotype 1 Subtype (Stage 2)|Number of Participants Achieving RVR by Gender (Stage 2)|Number of Participants Achieving EVR by Gender (Stage 2)|Number of Participants Achieving SVR by Gender (Stage 2)|Number of Participants Achieving RVR by HIV Status (Stage 2)|Number of Participants Achieving EVR by HIV Status (Stage 2)|Number of Participants Achieving SVR by HIV Status (Stage 2)|Percentage of Compliance for Participants Achieving SVR Based on Medication Adherence Questionnaire (MAQ) (Stage 2)","https://ClinicalTrials.gov/show/NCT00724893"
846,"NCT00513461","S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate in Preventing Liver Cancer in Patients With Chronic Hepatitis C Infection","Active, not recruiting","No Results Available","Adult Primary Liver Cancer|Hepatitis C Infection","Drug: S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Other: placebo|Other: laboratory biomarker analysis|Other: immunoenzyme technique|Other: high performance liquid chromatography","National Cancer Institute (NCI)","Both","Adult|Senior","Phase 2","110","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator)","NCI-2009-00897|UCI 06-07|N01CN35160|CDR0000558657","August 6, 2007","October 2007","December 2013","February 15, 2013","February 2013","No Study Results Posted","null","August 2012","Change in serum AFP levels|Treatment-related changes in additional serum markers for hepatocellular carcinoma|Change in markers of liver disease|Changes in markers of oxidative stress|Change in SAMe metabolites|Safety and tolerability of SAMe|Changes in quality of life","https://ClinicalTrials.gov/show/NCT00513461"
847,"NCT00707603","Chronic Hepatitis C and Insulin Resistance","Completed","No Results Available","Hepatitis C|Insulin Resistance","","Garvan Institute of Medical Research","Male","Adult","","50","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","H04/126","June 29, 2008","May 2006","December 2008","July 13, 2015","July 2015","No Study Results Posted","null","December 2008","Insulin Resistance by euglycaemic hyperinsulinaemic clamp Liver fat, abdominal fat and muscle fat measures|insulin resistance post treatment of Hep C","https://ClinicalTrials.gov/show/NCT00707603"
848,"NCT00310336","Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine","Completed","No Results Available","Hepatitis C","Drug: S-adenosyl-L-methionine|Drug: betaine|Drug: pegylated interferon alpha2b|Drug: ribavirin","University Hospital, Basel, Switzerland","Both","Adult","Phase 2|Phase 3","30","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","EKBB 37/06","March 31, 2006","August 2006","September 2009","October 27, 2010","October 2010","No Study Results Posted","null","August 2009","Sustained response rate|Early virologic response after 12 weeks of therapy with PegIntron, Rebetol, AdoMet and betaine.","https://ClinicalTrials.gov/show/NCT00310336"
849,"NCT00423800","Efficacy and Safety of 24 vs 48 Weeks of Pegetron¬Æ (Peginterferon Alfa-2b + Ribavirin) in Na√Øve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)","Terminated","Has Results","Hepatitis C, Chronic","Drug: Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)","Merck Sharp & Dohme Corp.","Both","Adult","Phase 3","56","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P05016","January 17, 2007","December 2006","October 2009","October 8, 2015","October 2015","January 27, 2011","null","October 2009","Number of Participants With a Sustained Virologic Response|Number of Participants With a Virological Relapse","https://ClinicalTrials.gov/show/NCT00423800"
850,"NCT02545387","Hepatitis C Virus in Neutrophil Granulocyte Progenitor Cells","Active, not recruiting","No Results Available","Chronic Hepatitis C","","Medical University of Graz","Both","Adult|Senior","","45","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HCV-KM","July 29, 2015","January 2015","June 2016","October 2, 2015","October 2015","No Study Results Posted","null","October 2015","viral RNA|neutrophil phagocytic capacity|hepatitis C virus proteins","https://ClinicalTrials.gov/show/NCT02545387"
851,"NCT01353911","Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Na√Øve Patients With Chronic Hepatitis C (MK-5172-003)","Completed","No Results Available","Hepatitis C, Chronic","Drug: Grazoprevir|Drug: Boceprevir|Drug: Placebo for Grazoprevir|Drug: Placebo for Boceprevir|Drug: Peg-interferon alfa-2b|Drug: Ribavirin","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 2","368","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","5172-003","May 12, 2011","June 2011","March 2015","April 9, 2015","April 2015","No Study Results Posted","null","June 2012","Number of Participants Achieving complete Early Viral Response (cEVR) in the Grazoprevir Treatment Arms|Number of participants experiencing adverse events|Number of participants discontinued from study due to adverse events|Number of Participants Achieving Sustained Viral Response 24 weeks After the End of All Study Therapy (SVR24)","https://ClinicalTrials.gov/show/NCT01353911"
852,"NCT01440595","Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012 AM1)","Terminated","No Results Available","Hepatitis C, Chronic","Drug: Grazoprevir|Drug: Placebo to Grazoprevir|Drug: Peginterferon alfa-2b (Peg-IFN)|Drug: Ribavirin (RBV)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 2","5","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","5172-012","September 22, 2011","November 2011","May 2012","November 9, 2014","November 2014","No Study Results Posted","null","May 2012","Number of participants achieving complete early virologic response (cEVR) in the grazoprevir treatment arms|Time to first achievement of undetectable HCV ribonucleic acid (RNA)|Number of participants achieving rapid viral response (RVR)|Number of participants achieving sustained viral response 12 weeks after completion of therapy (SVR12)|Number of participants achieving sustained viral response 24 weeks after completion of therapy (SVR24)|Number of participants achieving undetectable HCV RNA at Week 12 in the Placebo arm|Number of participants achieving complete early virologic response (cEVR) at Week 24 in the Placebo arm","https://ClinicalTrials.gov/show/NCT01440595"
853,"NCT00704756","An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)","Withdrawn","No Results Available","Hepatitis C, Chronic|Hepatitis C","Biological: PegIntron (peginterferon alfa-2b; SCH 54031)|Drug: Rebetol (ribavirin; SCH 18908)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","0","Industry","Observational","Observational Model: Case-Only","P05494","June 23, 2008","January 2009","March 2010","August 8, 2014","August 2014","No Study Results Posted","PEGIMPACT","March 2010","Safety parameters: common adverse events [AEs], drug-to-drug interaction AEs, and dose modifications|Relapse rates and Sustained Virologic Response (SVR) rates and their association with demographic, virologic, histological, and safety parameters|Predictors of response at End-of-Treatment","https://ClinicalTrials.gov/show/NCT00704756"
854,"NCT00724464","Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-na√Øve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)","Completed","Has Results","Hepatitis C, Chronic|Hepatitis C","Biological: PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)|Drug: Rebetol (ribavirin)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","332","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","P05209","July 25, 2008","December 2007","October 2010","October 16, 2015","October 2015","October 4, 2011","null","October 2010","Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up|Number of Participants Who Demonstrated Virological Relapse as Assessed at 24-week Post-treatment Follow-up|Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on HCV Genotype at Baseline|Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Liver Fibrosis Stage at Baseline|Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on HCV-RNA Viral Load at Baseline|Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Alanine Aminotransferase (ALT) Levels at Baseline|Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Study Treatment Dosage Modification|Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Achievement of Rapid Virological Response|Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Compliance With the 80/80/80 Rule","https://ClinicalTrials.gov/show/NCT00724464"
855,"NCT00963885","A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection","Completed","No Results Available","Hepatitis C, Chronic","Drug: Copegus|Drug: Pegasys|Drug: Placebo|Drug: Placebo|Drug: danoprevir|Drug: danoprevir|Drug: danoprevir|Drug: danoprevir","Hoffmann-La Roche","Both","Adult|Senior","Phase 2","229","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","NV21075|2009-009608-38","August 18, 2009","August 2009","January 2012","October 1, 2015","October 2015","No Study Results Posted","null","January 2012","Sustained virological response|Virological response over time|Adverse events; laboratory parameters","https://ClinicalTrials.gov/show/NCT00963885"
856,"NCT01399619","Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)","Completed","Has Results","Hepatitis C, Chronic","Drug: PegIFN/RBV|Drug: PegIFN/RBV|Drug: BI201335|Drug: BI201335 24W|Drug: PegIFN/RBV|Drug: Bi 201335","Boehringer Ingelheim","Both","Adult|Senior","Phase 3","310","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","1220.19|2010-021734-59","July 20, 2011","September 2011","June 2014","August 6, 2015","August 2015","July 3, 2015","null","September 2013","Sustained Virological Response (SVR12)|Virological Response 24 Weeks Post Treatment (SVR24)|Early Treatment Success (ETS)|The Number of Participants With Alanine Aminotransferase (ALT) Normalisation at End of Treatment (EoT) When SVR12=Yes|The Number of Participants With Alanine Aminotransferase (ALT) Normalisation at End of Treatment When SVR12=no|The Number of Participants With Alanine Aminotransferase (ALT) Normalisation at Post Treatment When SVR12=Yes|The Number of Participants With Alanine Aminotransferase (ALT) Normalisation at Post Treatment When SVR12=no|The Number of Participants With Aspartate Aminotransferase (AST) Normalisation at End of Treatment When SVR12=Yes|The Number of Participants With Aspartate Aminotransferase (AST) Normalisation at End of Treatment When SVR12=no|The Number of Participants With Aspartate Aminotransferase (AST) Normalisation at Post Treatment When SVR12=Yes|The Number of Participants With Aspartate Aminotransferase (AST) Normalisation at Post Treatment When SVR12=no","https://ClinicalTrials.gov/show/NCT01399619"
857,"NCT01447420","A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Na√Øve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)","Completed","No Results Available","Hepatitis C, Chronic","Drug: peginterferon alfa-2a|Drug: ribavirin [Copegus]","Hoffmann-La Roche","Both","Adult|Senior","Phase 4","129","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ML25592","October 4, 2011","February 2011","November 2012","October 1, 2015","October 2015","No Study Results Posted","null","November 2012","Rate of sustained virological response (undetectable HCV RNA 24 weeks after end of treatment) in relation to Interleukin 28B (IL28-b) expression|Incidence of anemia|Response rate (rapid/early/end of treatment) in relation to IL28-b expression|Correlation between sustained virological response and anemia (Hb levels) during the first month of treatment|Correlation between sustained virological response and anemia (Hb levels) after the first month of treatment|Correlation between viral load (HCV RNA levels) 12 weeks after the end of treatment and sustained virological response","https://ClinicalTrials.gov/show/NCT01447420"
858,"NCT01358864","Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)","Completed","Has Results","Hepatitis C, Chronic","Drug: BI 201335|Drug: Pegylated Interferon-alpha (IFN)|Drug: Ribavirin (RBV)|Drug: Placebo","Boehringer Ingelheim","Both","Adult|Senior","Phase 3","678","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","1220.7|2010-021715-17","May 23, 2011","June 2011","May 2014","September 22, 2015","September 2015","July 3, 2015","null","February 2013","Sustained Virological Response 12 Weeks Post Treatment (SVR12)|Virological Response After 24 Weeks of Treatment Discontinuation (SVR24)|Early Treatment Success (ETS)|ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=NO|ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=YES|AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=NO|AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=YES|ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, When SVR12=NO|ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, SVR12=YES|AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, When SVR12=NO|AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, SVR12=YES","https://ClinicalTrials.gov/show/NCT01358864"
859,"NCT00328042","Hepatitis C Self-Management","Completed","Has Results","Hepatitis C|Chronic Disease","Behavioral: Self-Management Workshop|Behavioral: Information Only","VA Office of Research and Development","Both","Child|Adult|Senior","","134","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Single Blind (Investigator)","IAC 05-067","May 17, 2006","May 2007","August 2010","April 6, 2015","July 2014","August 26, 2014","null","August 2010","Quality of Well-being Scale - Self-Administered (QWB-SA)|Hepatitis C Knowledge Questionnaire","https://ClinicalTrials.gov/show/NCT00328042"
860,"NCT00596843","Chronic Hepatitis Intervention Project for Drug Users","Active, not recruiting","No Results Available","HIV|Hepatitis C","Behavioral: Motivational interviewing|Behavioral: Educational intervention","National Institute on Drug Abuse (NIDA)","Both","Adult|Senior","Phase 3","851","NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","DESPR DA013763|RO1 DA13763-01-A2","January 7, 2008","September 2003","February 2008","November 13, 2008","November 2008","No Study Results Posted","null","November 2006","Reduction/cessation of alcohol use|Reductions in direct and indirect needle and syringe sharing|Reductions in unprotected sexual behavior","https://ClinicalTrials.gov/show/NCT00596843"
861,"NCT01728324","Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2","Completed","No Results Available","Hepatitis C, Chronic","Drug: BI 207127-placebo: 8-week treatment|Drug: Ribavirin: 24-week treatment|Drug: BI 207127: 24-week treatment|Drug: Faldaprevir: 24-week treatment|Drug: Faldaprevir: 24-week treatment|Drug: Ribavirin-placebo: 8-week treatment|Drug: BI 207127: 24-week treatment|Drug: Faldaprevir-placebo: 8-week treatment|Drug: Faldaprevir: 16-week treatment|Drug: Ribavirin: 16-week treatment|Drug: RBV: 24-week treatment|Drug: BI 207127: 16-week treatment","Boehringer Ingelheim","Both","Adult|Senior","Phase 3","496","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","1241.36|2012-003535-27","November 2, 2012","November 2012","January 2015","February 4, 2015","February 2015","No Study Results Posted","null","January 2015","Sustained Virologic Response (SVR) at Week 12 post-treatment (SVR12)|SVR4|SVR24","https://ClinicalTrials.gov/show/NCT01728324"
862,"NCT02463331","Association of Chloroquine and Prednisone as an Alternative Treatment for Autoimmune Hepatitis","Active, not recruiting","No Results Available","Autoimmune Hepatitis","Drug: Chloroquine diphosphate|Drug: prednisone|Drug: azathioprine","University of Sao Paulo General Hospital","Both","Adult|Senior","Phase 4","57","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","0571/04","May 18, 2015","May 2003","July 2015","June 1, 2015","May 2015","No Study Results Posted","null","December 2014","Biochemical response to therapy|Histopathological response to therapy","https://ClinicalTrials.gov/show/NCT02463331"
863,"NCT00312858","Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)","Completed","Has Results","Hepatitis A Virus","Biological: Comparator: VAQTA‚Ñ¢ (Hepatitis A vaccine)|Biological: Comparator: ProQuad‚Ñ¢ (Measles, Mumps, Rubella and Varicella vaccine)|Biological: Comparator: Prevnar‚Ñ¢ (Pneumococcal 7-Valent Conjugate vaccine)","Merck Sharp & Dohme Corp.","Both","Child","Phase 4","653","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","V251-067|2005_075","April 7, 2006","April 2006","March 2008","October 29, 2015","October 2015","March 24, 2009","null","March 2008","Antibody Response to Hepatitis A - Participants With a Serological Response|Antibody Response to Varicella - Participants With a Serological Response|Antibody Response to Streptococcus Pneumoniae - Geometric Mean Titers|Participants With 1 or More Systemic Adverse Experience|Participants With 1 or More Systemic Adverse Experience.|Participants With 1 or More Injection-site Adverse Experience|Participants With Elevated Temperature (‚â•102.2F/ ‚â•39.0C)|Participants With 1 or More Serious Vaccine-related Adverse Experience","https://ClinicalTrials.gov/show/NCT00312858"
864,"NCT01462981","Cohort of Hepatitis B Research of Amsterdam","Recruiting","No Results Available","Hepatitis B","","Public Health Service of Amsterdam|UMC Utrecht","Female","Adult","","172","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","COBRA","October 28, 2011","September 2011","July 2012","November 1, 2011","November 2011","No Study Results Posted","COBRA","null","","https://ClinicalTrials.gov/show/NCT01462981"
865,"NCT01655121","Effect of High-protein High-fiber Diet in Patients With Autoimmune Hepatitis","Completed","No Results Available","Autoimmune Hepatitis|Cirrhosis","Dietary Supplement: High protein high fiber diet","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Both","Adult|Senior","","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care|Masking: Open Label","GAS-501-11/12-1","July 12, 2012","January 2012","July 2014","August 18, 2014","August 2014","No Study Results Posted","null","July 2014","Nutritional Status|Minimal hepatic encephalopathy|Quality of life","https://ClinicalTrials.gov/show/NCT01655121"
866,"NCT00412750","Efficacy and Safety of Telbivudine in Treatment na√Øve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)","Terminated","Has Results","Hepatitis B","Drug: Telbivudine (LdT)|Drug: peginterferon alpha-2a","Novartis","Both","Adult|Senior","Phase 3","159","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CLDT600A2406","December 15, 2006","December 2006","February 2009","June 14, 2011","June 2011","December 2, 2010","null","February 2009","Percentage of Participants Who Achieved HBV DNA Non-detectability With Peginterferon Alpha-2a Plus Telbivudine Combination Therapy Versus Peginterferon Alpha-2a Monotherapy|Percentage of Participants With HBV DNA Non-detectability and Alanine Aminotransferase (ALT) Normalization at Week 12 and Week 24 in Participants With HBeAg-positive Chronic Hepatitis B (CHB)|Change From Baseline in HBV DNA Concentration|Percentage of Participants Who Experienced Virologic Breakthrough at Weeks 48 and 52|Percentage of Participants With Hepatitis B 'e' Antigen (HBeAg) Loss and HBeAg Seroconversion|Percentage of Participants Who Achieved HBV DNA Non-detectability With Telbivudine Monotherapy Versus Peginterferon Alpha-2a Monotherapy|Percentage of Participants Who Achieved HBV DNA Non-detectability With Peginterferon Alpha-2a Plus Telbivudine Combination Therapy Versus Telbivudine Monotherapy","https://ClinicalTrials.gov/show/NCT00412750"
867,"NCT02402218","CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS","Enrolling by invitation","No Results Available","Hepatitis C|Human Immunodeficiency Virus","Other: Usual care plus peer-mentors|Other: Usual care plus incentives|Other: Usual Care","Johns Hopkins University|National Institute on Drug Abuse (NIDA)|National Institutes of Health (NIH)","Both","Adult|Senior","Phase 4","164","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","IRB00055591|5R01DA016065-12","March 18, 2015","March 2015","March 2018","March 24, 2015","March 2015","No Study Results Posted","CHAMPS","March 2018","Proportion of coinfected IDUs who initiate HCV therapy|To compare and evaluate adherence behavior|To compare and evaluate adverse events both related and unrelated to treatment|To compare and evaluate the antiviral efficacy of UC, IC, and PMC|Patient reported depression|Explore the interaction of liver stiffness and HCV treatment|Alcohol intake during HCV treatment|Assess for re-infection post-treatment in patients who achieve treatment-related sustained virologic response.|Patient reported fatigue|Patient reported quality of life|Patient reported provider-patient communication|Patient reported emotional support|Drug intake during HCV treatment|Patient reported alcohol use|Patient reported drug use","https://ClinicalTrials.gov/show/NCT02402218"
868,"NCT00838214","Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis","Completed","No Results Available","Autoimmune Hepatitis","Drug: budesonide|Drug: prednisone","Dr. Falk Pharma GmbH","Both","Child|Adult|Senior","Phase 2|Phase 3","208","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","BUC-38/AIH","February 5, 2009","March 2001","December 2008","February 5, 2009","February 2009","No Study Results Posted","null","December 2008","Biochemical remission (=serum levels of ASAT and ALAT within normal ranges) at the individual last visit of Segment A and lack of steroid specific side effects|incidence of biochemical remission","https://ClinicalTrials.gov/show/NCT00838214"
869,"NCT00059267","Prevention of Recurrent Hepatitis B After Liver Transplantation","Completed","No Results Available","Hepatitis B|Cirrhosis|Acute Liver Failure|Hepatocellular Carcinoma","Drug: HBIG, Epivir, Hepsera","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Both","Child|Adult|Senior","","500","NIH","Observational","","NIH HBV-OLT (completed)","April 22, 2003","June 2001","null","January 12, 2010","January 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00059267"
870,"NCT00674492","Hepatitis C Virus (HCV) Treatment Completion or Withdrawal","Completed","Has Results","Hepatitis C","","VA Office of Research and Development","Both","Adult|Senior","","21","U.S. Fed","Observational","Time Perspective: Retrospective","SHP 08-193","May 6, 2008","May 2008","August 2008","April 27, 2015","April 2015","February 5, 2015","null","August 2008","Attributes of Treatment Experience","https://ClinicalTrials.gov/show/NCT00674492"
871,"NCT00289913","Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)","Completed","Has Results","Hepatitis A Virus","Biological: Comparator: VAQTA‚Ñ¢|Biological: Comparator: Infanrix‚Ñ¢|Biological: Comparator: PedvaxHIB‚Ñ¢","Merck Sharp & Dohme Corp.","Both","Child","Phase 4","1274","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","V251-068|2005_076","February 8, 2006","April 2006","June 2010","September 7, 2015","September 2015","June 9, 2011","null","June 2010","Seropositivity Rate (SPR) to Hepatitis A|Antibody Response Rate to Haemophilus Influenzae Type b (Hib)|Number of Participants With Adverse Events (AE)|Geometric Mean Titers (GMTs) to Antibodies for the Pertussis Toxin (PT), Pertussis Filamentous Hemagglutinin Antibody (FHA), and Pertactin (PRN) Components of Infanrix‚Ñ¢","https://ClinicalTrials.gov/show/NCT00289913"
872,"NCT00030030","Evaluating Silymarin for Chronic Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic","Drug: Silymarin (milk thistle)","National Center for Complementary and Integrative Health (NCCIH)|Office of Dietary Supplements (ODS)","null","Child|Adult|Senior","Phase 2","null","NIH","Interventional","Allocation: Randomized|Primary Purpose: Prevention|Masking: Double-Blind","R21 AT000277-01","January 30, 2002","July 2000","June 2002","August 17, 2006","July 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00030030"
873,"NCT00843076","Impact of Hepatitis C Virus Variability on Steatosis","Terminated","No Results Available","Chronic Hepatitis C","","University Hospital, Tours","Both","Adult|Senior","","27","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AORT08-PR/VIRO-St√©atose","February 12, 2009","January 2009","April 2011","November 8, 2013","November 2013","No Study Results Posted","Viro-steatosis","April 2011","","https://ClinicalTrials.gov/show/NCT00843076"
874,"NCT00047814","Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection","Completed","No Results Available","Hepatitis C","Drug: FK788","Astellas Pharma Inc|Astellas Pharma US, Inc.","Both","Adult","Phase 2","48","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment|Masking: Double-Blind","FA-788-0004","October 18, 2002","October 2002","March 2006","December 8, 2011","December 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00047814"
875,"NCT01610115","HBV DNA Levels During Pregnancy in Chronic Hepatitis B","Recruiting","No Results Available","Hepatitis B|Pregnancy","","Chang Gung Memorial Hospital","Female","Adult","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HBV-P-01","May 30, 2012","January 2012","December 2014","May 30, 2012","May 2012","No Study Results Posted","null","December 2013","","https://ClinicalTrials.gov/show/NCT01610115"
876,"NCT00230061","Hepatitis B Vaccination in HIV-infected Persons","Completed","No Results Available","HIV Infections|Hepatitis B","Biological: HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml","Erasmus Medical Center|Stichting Nuts Ohra","Both","Adult|Senior","Phase 4","800","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","SNO-T-07-102","September 28, 2005","April 2004","February 2010","June 1, 2010","June 2010","No Study Results Posted","null","May 2008","Measurement of anti-Hbs titer after completing hepatitis B vaccination.|To compare response and compliance between two vaccination schedules: short and standard","https://ClinicalTrials.gov/show/NCT00230061"
877,"NCT01251276","Hepatitis B Challenge Dose in Adults","Completed","No Results Available","Hepatitis B","Biological: 1 dose at Day 1","Sanofi Pasteur MSD","Both","Adult|Senior","Phase 3","204","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","rHB01C","November 23, 2010","November 2010","June 2011","October 10, 2011","October 2011","No Study Results Posted","null","June 2011","Pre-challenge anti HBs seroprotection rate (percentage of subjects with titre >=10 mIU/mL)|Post-challenge anti HBs seroprotection rate (percentage of subjects with titre >=10 mIU/mL)|Injection-site reactions, systemic injection site reactions, adverse events and serious adverse events","https://ClinicalTrials.gov/show/NCT01251276"
878,"NCT02044055","Mother-to-child Hepatitis D Transmission","Recruiting","No Results Available","Hepatitis D|Transmission","","Hopital Lariboisi√®re","Both","Child","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Liver004","January 18, 2014","October 2014","July 2016","September 30, 2015","September 2015","No Study Results Posted","null","July 2016","Hepatitis D antibodies (Ab) in children|HDV RNA in children with positive HDV Ab","https://ClinicalTrials.gov/show/NCT02044055"
879,"NCT00633243","Effective Treatment of Hepatitis C in Substance Users","Completed","Has Results","Hepatitis C|Opiate Dependence","Procedure: Modified Directly Observed Therapy (mDOT)|Procedure: Self-Administered Therapy (SAT)","Yale University|National Institute on Drug Abuse (NIDA)","Both","Adult|Senior","","21","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Health Services Research|Masking: Open Label","0702002306|NIDA 022143","February 29, 2008","April 2007","September 2011","January 1, 2013","January 2013","October 19, 2012","null","September 2011","Number of Participants With a Sustained Virologic Response (SVR)","https://ClinicalTrials.gov/show/NCT00633243"
880,"NCT00155155","Studies of Immune Responses in Patients With Chronic Hepatitis B","Completed","No Results Available","Hepatitis B","","National Taiwan University Hospital","Both","Child|Adult|Senior","Phase 1","100","Other","Observational","Time Perspective: Prospective","9361701122|NSC 94-3112-B-002-030","September 9, 2005","May 2005","null","December 1, 2008","November 2008","No Study Results Posted","null","April 2008","","https://ClinicalTrials.gov/show/NCT00155155"
881,"NCT01766115","Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers","Withdrawn","No Results Available","Viral Hepatitis C","Drug: Telaprevir","Massachusetts General Hospital","Both","Adult|Senior","Phase 4","0","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","2012P000954","January 7, 2013","April 2013","May 2014","August 12, 2014","August 2014","No Study Results Posted","null","May 2014","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Election rate of study drug|Rate of HCV infection","https://ClinicalTrials.gov/show/NCT01766115"
882,"NCT01821547","New Methods to Measure the Immune Response to Hepatitis B Vaccine","Recruiting","No Results Available","Hepatitis B","Drug: Hepatitis B vaccine","University of Oxford","Both","Adult","Phase 4","16","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label","OVG 2012/09","March 18, 2013","March 2013","null","March 26, 2013","March 2013","No Study Results Posted","null","November 2013","Part 2- To assess B cell VH/L gene segment usage by HepB specific B cells during and following administration of a three dose course of HepB vaccine given at 0,1, 2 or 0, 1, 6 months.|Part 1- To validate B cell assays and assess the kinetics of HepB specific B cell subsets following administration of a booster dose of HepB vaccine given to previously immunised healthy adults.|Part 1 ‚Ä¢ To measure HepB surface antigen-specific antibody concentration following administration of a booster dose of HepB vaccine given to previously immunised healthy adults|Part 1 ‚Ä¢ To assess B-cell receptor VH/L gene sequences used in HepB specific and non-antigen specific B-cells prior to and following administration of a booster dose of HepB vaccine given to previously immunised healthy adults|Part 1 ‚Ä¢ Comparison of B cell receptor VH/L gene segment usage as determined by two different next-generation sequencing methods (RNA-sequencing and 454).|Part 1 ‚Ä¢ Collection of mRNA for subsequent gene expression analysis|Part 2 ‚Ä¢ To measure HepB specific plasma and memory B cell frequencies during and following administration of a three dose course of HepB vaccine given at 0, 1, 2 or 0, 1, 6 months.|Part 2 ‚Ä¢ To measure HepB surface antigen-specific antibody concentration during and following administration of a three dose course of HepB vaccine given at 0,1, 2 or 0, 1, 6 months.","https://ClinicalTrials.gov/show/NCT01821547"
883,"NCT02511743","Knowledge and Practice of Chinese Medical Specialists Regarding Chronic Hepatitis B Virus Infection","Recruiting","No Results Available","Hepatitis B","Other: physicians","Peking University First Hospital","Both","Adult|Senior","","3000","Other","Observational","Time Perspective: Prospective","2015[888]","May 4, 2015","April 2015","November 2015","July 29, 2015","July 2015","No Study Results Posted","null","August 2015","30-item self-administered questionnaire assessing physicians' knowledge and behavior regarding chronic Hepatitis B Virus infection.","https://ClinicalTrials.gov/show/NCT02511743"
884,"NCT02548325","Prevalence of Hepatitis B in Vall√©s Occidental. Observational Multicentric Study","Recruiting","No Results Available","Hepatitis B","Other: Not apply","Corporacion Parc Tauli|Hospital Mutua de Terrassa|Consorci Sanitari de Terrassa","Both","Adult|Senior","","450","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CorporacionPT","September 8, 2015","July 2015","December 2015","September 10, 2015","September 2015","No Study Results Posted","null","December 2015","prevalence hepatitis B|stage of the disease and if they are in treatment or not","https://ClinicalTrials.gov/show/NCT02548325"
885,"NCT00930995","Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C","Withdrawn","No Results Available","Hepatitis C","Drug: Candesartan|Drug: Placebo","Kaiser Permanente|University of California, Davis","Both","Adult","Phase 2","0","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","CN-05SBala-01-B","July 1, 2009","null","null","April 23, 2012","April 2012","No Study Results Posted","null","null","Primary: ‚Ä¢ Stellate cell activity by alpha SMA stain quantitated by morphometry|‚Ä¢ Hepatic fibrosis by morphometry|Surrogate markers for fibrosis (liver TGF-beta levels, serum procollagen-III peptide levels)|Functional status- Albumin, INR, T. Bilirubin, MELD score","https://ClinicalTrials.gov/show/NCT00930995"
886,"NCT00010816","Herbal Treatment of Hepatitis C in Methadone Maintained Patients","Completed","No Results Available","Hepatitis C","Drug: Herbal remedies","National Center for Complementary and Integrative Health (NCCIH)","Both","Adult|Senior","Phase 2","null","NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment|Masking: Double-Blind","P50 AT000009-02P3|P50 AT000009-02|P50 AT000009-03","February 2, 2001","September 1998","June 2003","August 17, 2006","August 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00010816"
887,"NCT00343525","Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: bavituximab","Peregrine Pharmaceuticals","Both","Adult|Senior","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","PPHM 0601","June 21, 2006","May 2006","null","April 28, 2008","April 2008","No Study Results Posted","null","January 2007","adverse events|laboratory evaluations|human anti-chimeric antibody|pharmacokinetic analysis|viral kinetic analysis|cytokine analysis","https://ClinicalTrials.gov/show/NCT00343525"
888,"NCT02344498","Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa","Recruiting","No Results Available","Hepatitis B","Drug: Tenofovir disoproxil","Oslo University Hospital|Addis Ababa University|The Research Council of Norway|University of Agder, Norway|South-Eastern Norway Regional Health Authority, Norway|St Paul Hospital Millennium Medical College, Ethiopia|Haramaya University,Ethiopia","Both","Adult|Senior","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2014/1146","January 16, 2015","January 2015","December 2017","October 14, 2015","October 2015","No Study Results Posted","null","December 2017","Death, HCC or decompensated cirrhosis|Viral suppression and genotypic resistance|Regression of liver inflammation/fibrosis|Adherence to therapy","https://ClinicalTrials.gov/show/NCT02344498"
889,"NCT01647191","Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China","Active, not recruiting","No Results Available","Hepatitis C","Behavioral: intervention group|Behavioral: control group","Shanghai Mental Health Center","Both","Adult|Senior","","340","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Open Label","JDu-001","April 17, 2012","July 2011","May 2015","July 18, 2012","July 2012","No Study Results Posted","null","May 2015","Knowledge„ÄÅRisk Behaviors and some other aspects related to HCV/HIV will be measured among IDUs in MMT|The barriers will be measured.|The ways will be measured.","https://ClinicalTrials.gov/show/NCT01647191"
890,"NCT00096811","Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program","No longer available","No Results Available","Hepatitis B|Chronic Disease","Drug: Entecavir","Bristol-Myers Squibb","Both","Child|Adult|Senior","","null","Industry","Expanded Access","","AI463-900","November 15, 2004","September 2003","August 2008","May 7, 2010","May 2010","No Study Results Posted","null","August 2008","","https://ClinicalTrials.gov/show/NCT00096811"
891,"NCT00164073","Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection","Recruiting","No Results Available","Hepatitis C","Procedure: Liver biopsy","Bayside Health|University of Adelaide","Both","Adult|Senior","","60","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Prospective","122/03","September 13, 2005","February 2004","February 2007","July 31, 2007","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00164073"
892,"NCT02558114","Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.","Not yet recruiting","No Results Available","Hepatitis E","Drug: Ribavirin","Hospital Universitari Vall d'Hebron Research Institute","Both","Adult|Senior","Phase 4","56","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","RACHE","September 18, 2015","December 2015","October 2018","September 22, 2015","September 2015","No Study Results Posted","null","June 2018","Sustained virological response measured by HEV RNA","https://ClinicalTrials.gov/show/NCT02558114"
893,"NCT01470651","Armodafinil for Patients Starting Hepatitis C Virus Treatment","Terminated","No Results Available","Hepatitis C","Drug: Armodafinil|Drug: Placebo Comparator","Research Foundation for Mental Hygiene, Inc.|Icahn School of Medicine at Mount Sinai|Weill Medical College of Cornell University","Both","Adult|Senior","Phase 4","26","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","C10953/6285","October 13, 2011","October 2011","June 2014","May 4, 2015","May 2015","No Study Results Posted","null","June 2014","Adherence to Medications Form|Fatigue Severity Scale (FSS)","https://ClinicalTrials.gov/show/NCT01470651"
894,"NCT02288208","Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B","Terminated","No Results Available","Hepatitis B","Drug: Antiviral Therapy (tenofovir or entecavir)|Drug: Birinapant|Drug: Placebo (for birinapant)","TetraLogic Pharmaceuticals","Both","Adult|Senior","Phase 1","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)","TL32711-POC-0095-PTL","November 3, 2014","November 2014","May 2015","October 8, 2015","October 2015","No Study Results Posted","null","May 2015","Number of participants with adverse events|Pharmacokinetics of birinapant (in plasma): maximum concentration (Cmax), time of maximum concentration (Tmax), area under the curve (AUC) extrapolated to time infinity, AUC from dosing to last quantifiable concentration|Pharmacokinetics of birinapant (in plasma): terminal elimination half-life (t1/2), clearance (CL), terminal disposition rate constant,volume of distribution (Vdss)|Pharmacokinetics of oral antiviral medication (tenofovir or entecavir): Cmax, Tmax, AUC from dosing to last quantifiable concentration, t1/2, CL, terminal disposition rate constant, Vdss|Hepatitis B markers (Determine levels of HBsAg, HBeAg, HBV DNA, and HBsAb)|Pharmacodynamic effect of birinapant on cIAP1 and cIAP2 levels in peripheral blood mononuclear cells (PBMC) and levels of cluster of differentiation 4 and 8 (CD4+, CD+8) lymphocytes","https://ClinicalTrials.gov/show/NCT02288208"
895,"NCT00251199","VX-950 and Peginterferon for Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: VX-950|Drug: peginterferon","Vertex Pharmaceuticals Incorporated","Both","Adult","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind","VX05-950-103","November 7, 2005","October 2005","March 2006","December 17, 2007","December 2007","No Study Results Posted","null","null","Viral kinetics|Assess the safety of VX-950 in combination with peginterferon","https://ClinicalTrials.gov/show/NCT00251199"
896,"NCT00925990","CTS-1027 in Interferon-Naive Hepatitis C Patients","Completed","Has Results","Hepatitis C","Drug: ribavirin|Drug: CTS-1027|Drug: Placebo for ribavirin","Conatus Pharmaceuticals Inc.","Both","Adult|Senior","Phase 2","70","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","CTS-1027-03","June 19, 2009","June 2009","July 2010","February 27, 2012","February 2012","February 9, 2012","null","May 2010","Mean Change in HCV-RNA (Hepatitis C Virus Ribonucleic Acid) Levels From Baseline Through 24 Weeks of Treatment|Mean Change in Aminotransferases From Baseline to 24 Weeks of Treatment","https://ClinicalTrials.gov/show/NCT00925990"
897,"NCT00277758","Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I","Terminated","No Results Available","Hepatitis C","Biological: Interleukin 2|Drug: Ribavirin|Biological: Pegylated Interferon Alpha|Biological: Inteleukin-2|Drug: Ribavirin + Pegylated interferon-alpha","Weill Medical College of Cornell University|National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult","Phase 1","18","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","00-092|UO1 AI48224","January 12, 2006","March 2004","August 2006","March 6, 2008","March 2008","No Study Results Posted","null","July 2006","Determination of the safety and tolerability of 12 weeks IL2 monotherapy followed by 48 weeks of IL2 combined with PEG-IFN/RBV|Determination of specific immunologic responses to HCV. Immunologic assessment will be performed as the sme time intervals as the assays for plasma virus.","https://ClinicalTrials.gov/show/NCT00277758"
898,"NCT01810835","Prevention of Hepatitis B Virus Mother-to-child Transmission by Serovaccination.","Completed","No Results Available","Hepatitis B","","Hopital Lariboisi√®re","Female","Adult","","28","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","URT-Liver-001","March 12, 2013","November 2011","November 2013","December 5, 2013","December 2013","No Study Results Posted","null","November 2013","Rate of HBsAg positivity in infants at 9 months, despite a correct immunization at birth","https://ClinicalTrials.gov/show/NCT01810835"
899,"NCT02496078","A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection","Recruiting","No Results Available","Hepatitis C","Drug: Daclatasvir|Drug: Asunaprevir","Bristol-Myers Squibb","Both","Adult|Senior","Phase 3","200","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","AI447-114","July 9, 2015","August 2015","March 2017","October 15, 2015","August 2015","No Study Results Posted","null","March 2017","Proportion of treated subjects randomized to Active Dual therapy with Sustained Virologic Response (SVR12)|Proportion of subjects with anemia on active Dual therapy|Proportion of subjects with neutropenia on active Dual therapy|Proportion of subjects with thrombocytopenia on active Dual therapy|On treatment safety, as measured by frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)|Differences in rates of selected Grade 3-4 laboratory abnormalities for hematology between treatments (DCV + Asunaprevir (ASV) vs PBO)|Differences in rates of selected Grade 3-4 laboratory abnormalities for liver function between treatments (DCV + Asunaprevir (ASV) vs PBO)|Proportion of subjects with SVR12 by the rs12979860 single nucleotide polymorphism (SNP) in the interleukin (IL) -28B gene for each cohort|Proportion of subjects with hepatitis C virus (HCV) RNA < LLOQ-TD/TND in each arm at various intervals after the initiation of active Dual therapy|Proportion of subjects who achieve HCV RNA < LLOQ-TND at each arm at various intervals after the initiation of active Dual therapy|Proportion of treated subjects with SVR12 for subjects randomized to placebo","https://ClinicalTrials.gov/show/NCT02496078"
900,"NCT02258581","Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection","Enrolling by invitation","No Results Available","Hepatitis B","Drug: GS-4774|Drug: GS-9620|Drug: Tenofovir disoproxil fumarate (TDF)","Gilead Sciences","Both","Adult|Senior","","500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GS-US-330-1508|2015-001050-16","October 3, 2014","December 2014","October 2019","October 9, 2015","October 2015","No Study Results Posted","null","October 2019","Proportion of participants with serum hepatitis B surface antigen (HBsAg) decline ‚â• 0.5 log10 IU/ml from baseline at Week 48|Proportion of participants who remain HBsAg negative at Week 48|Proportion of participants with serum HBsAg decline ‚â• 0.5 log10 IU/ml from baseline at Week 144|Proportion of participants who achieve HBsAg loss at Weeks 48 and 144|Proportion of participants who remain HBsAg negative at Week 144|Proportions of participants with hepatitis B envelope antigen (HBeAg) loss and seroconversion at Week 48|Proportions of participants with HBeAg loss and seroconversion at Week 144|Proportions of participants who remain HBeAg negative and hepatitis B envelope antibody (HBeAb) positive at Week 48|Proportions of participants who remain HBeAg negative and HBeAb positive at Week 144|Proportion of participants with HBV DNA < the lower limit of quantitation (LLOQ) at Weeks 48, 96 and 144|Change from Baseline in HBV DNA at Weeks 48, 96, and 144","https://ClinicalTrials.gov/show/NCT02258581"
901,"NCT00128544","Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B","Completed","No Results Available","Hepatitis B","Drug: telbivudine|Drug: valtorcitabine","Novartis|Novartis Pharmaceuticals","Both","Adult|Senior","Phase 2","130","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","NV-02C-004","August 8, 2005","May 2005","May 2007","May 8, 2015","May 2015","No Study Results Posted","null","May 2007","","https://ClinicalTrials.gov/show/NCT00128544"
902,"NCT00124241","An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B","Completed","No Results Available","Hepatitis B","Drug: telbivudine|Drug: lamivudine","Novartis|Novartis Pharmaceuticals","Both","Adult","Phase 2","null","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","NV-02B-010","July 25, 2005","null","November 2005","May 8, 2015","May 2015","No Study Results Posted","null","February 2003","","https://ClinicalTrials.gov/show/NCT00124241"
903,"NCT01369212","Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B","Recruiting","No Results Available","Hepatitis B","Drug: Tenofovir|Drug: Peginterferon-alfa 2a and tenofovir","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pittsburgh","Both","Adult|Senior","","376","NIH|Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","DK082864 HBRN Immune Active","June 6, 2011","November 2012","October 2020","October 28, 2015","October 2015","No Study Results Posted","HBRN","October 2019","Hepatitis B surface antigen (HBsAg) loss|Cumulative HBsAg loss|Serious Adverse Events|Adverse events|Hepatitis B e antigen (HBeAg) loss|HBeAg loss|HBsAg seroconversion|HBeAg seroconversion|Normalization of Alanine Transaminase(ALT) levels|HBV DNA <1000 IU/mL|HBV DNA <20 IU/mL(Lower limit of quantification [LLOQ]) of COBAS Ampliprep/COBAS TaqMan HBV v2.0 test)|Absence of detectable antiviral drug-resistance HBV mutations|Sustained HBV DNA <1000 IU/mL","https://ClinicalTrials.gov/show/NCT01369212"
904,"NCT01492478","Psychobiological Characterization of Depression in Hepatitis C","Not yet recruiting","No Results Available","Depression|Hepatitis c","","Centro Hospitalar Lisboa Norte","Both","Adult","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","39772","December 13, 2011","January 2012","December 2015","December 14, 2011","December 2011","No Study Results Posted","null","July 2015","","https://ClinicalTrials.gov/show/NCT01492478"
905,"NCT02528461","Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C","Recruiting","No Results Available","Hepatitis C","Drug: Galactose|Procedure: Gastroscopy|Procedure: Liver biopsy|Procedure: Fibroscan|Procedure: Liver vein catheterization|Drug: Sofosbuvir","University of Aarhus|Aarhus University Hospital","Both","Adult|Senior","Phase 4","80","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","HCV sCD163 Sofosbuvir","August 14, 2015","January 2015","January 2020","August 18, 2015","August 2015","No Study Results Posted","null","January 2020","Changes in the macrophage activation markers sCD163 and sCD206|Changes in liver fibrosis with fibroscan|Changes in histological liver fibrosis|Changes in clinical status|Changes in hepatic venous pressure|Changes in metabolic liver function determined by the galactose elimination capacity (GEC) test","https://ClinicalTrials.gov/show/NCT02528461"
906,"NCT00241618","Timing and Duration of Acute Hepatitis C Treatment","Completed","No Results Available","Hepatitis C","Drug: Pegylated interferon alpha 2|Drug: Ribavirin","Ain Shams University|University Hospital Freiburg|Beth Israel Deaconess Medical Center|Alexander von Humboldt Association|Fulbright|National Institute of Allergy and Infectious Diseases (NIAID)|TEMPUS|International Society for Infectious Diseases","Both","Adult","Phase 4","180","Other|NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","994058402|AI054887|AI41563|Fulbright|TEMPUS|ISID","October 18, 2005","January 2002","January 2006","September 7, 2006","September 2006","No Study Results Posted","null","null","Sustained viral response rate in treatment group versus control|End of treatment virologic response|Early virologic response at week 4|Quality of life","https://ClinicalTrials.gov/show/NCT00241618"
907,"NCT01329978","Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6","Completed","Has Results","Hepatitis C, Chronic","Drug: Sofosbuvir|Drug: RBV|Drug: PEG","Gilead Sciences","Both","Adult|Senior","Phase 2","332","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P7977-0724","March 30, 2011","March 2011","August 2012","April 24, 2014","April 2014","January 6, 2014","ATOMIC","August 2012","Percentage of Participants With Sustained Virologic Response 24 Weeks Following Completion of Treatment (SVR24)|Percentage of Participants Who Experienced Adverse Events|Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12)|Change in HCV RNA at Week 2|Change in HCV RNA at Week 4|Change in HCV RNA at Week 8|Change in HCV RNA at Week 12|Percentage of Participants With HCV RNA < LOD at Week 2|Percentage of Participants With HCV RNA Below < LOD at Week 4|Percentage of Participants With HCV RNA Below < LOD at Week 8|Percentage of Participants With HCV RNA Below < LOD at Week 12|Percentage of Participants With HCV RNA Below < LOD at Week 24|Percentage of Participants With ALT Normalization at Week 12|Percentage of Participants With ALT Normalization at Week 24|Percentage of Participants With ALT Normalization at Post-treatment Week 4|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants With Virologic Failure Following Treatment (Viral Relapse).","https://ClinicalTrials.gov/show/NCT01329978"
908,"NCT00527540","Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon¬Æ) Plus Ribavirin in the Patients With Chronic Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: Pegylated Interferon alpha 2a + Ribavirin","Tehran Hepatitis Center|Kermanshah University of Medical Sciences","Both","Adult|Senior","Phase 3","60","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","THC-10","September 8, 2007","February 2007","December 2008","January 18, 2009","January 2009","No Study Results Posted","null","June 2008","End of treatment response rate (HCV RNA:Neg)|Sustain response rate (HCV RNA:Neg) 6 month after end of treatment","https://ClinicalTrials.gov/show/NCT00527540"
909,"NCT02044042","Vertical Transmission of Hepatitis C Virus","Recruiting","No Results Available","Hepatitis C|Transmission","","Hopital Lariboisi√®re","Both","Child","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Liver005","January 19, 2014","October 2014","July 2016","September 30, 2015","September 2015","No Study Results Posted","null","July 2016","HCV status in children born from chronically HCV infected pregnant women|HCV RNA in children with positive HCV antibodies (Ab)","https://ClinicalTrials.gov/show/NCT02044042"
910,"NCT02505243","Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens","Recruiting","No Results Available","HCV Coinfection|Hepatitis C","","Radboud University|Erasmus Medical Center|University Medical Center Groningen|UMC Utrecht|Maastricht University Medical Center","Both","Adult|Senior","","150","Other","Observational","Observational Model: Cohort","UMCN-AKF-15.03","July 15, 2015","June 2015","February 2016","July 21, 2015","July 2015","No Study Results Posted","RIBACOP","January 2016","Ribavirin concentration|Sustained virological response (SVR12)|Hemoglobin concentrations","https://ClinicalTrials.gov/show/NCT02505243"
911,"NCT02526641","Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C","Recruiting","No Results Available","Hepatitis C","Procedure: Functional Hepatic Nitrogen Clearance (FHNC)|Procedure: Galactose Elimination Capacity (GEC)|Procedure: Liver vein catheterization","University of Aarhus|Aarhus University Hospital|AbbVie","Both","Adult|Senior","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","HCV sCD163 AbbVie","August 13, 2015","August 2015","September 2022","August 14, 2015","August 2015","No Study Results Posted","null","September 2017","Change in the hepatic venous pressure gradient determined by liver vein catheterization from baseline to 12 weeks|Change in the hepatic venous pressure gradient determined by liver vein catheterization from baseline to 1 year|Changes in the levels of the macrophage specific activation marker sCD163|Changes in metabolic liver function determined by the galactose elimination capacity (GEC) test|Changes in the functional hepatic nitrogen clearance (FHNC)","https://ClinicalTrials.gov/show/NCT02526641"
912,"NCT01718301","HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin","Completed","No Results Available","Hepatitis C|HIV Infections|COINFECTION","Drug: boceprevir|Drug: Ribavirin|Drug: Peginterferon alfa-2a|Drug: Peginterferon alfa-2b","Anna Cruceta|Fundacion Clinic per a la Recerca Biom√©dica","Both","Adult|Senior","Phase 3","128","Other","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","BOC-HIV|2012-003984-23","October 25, 2012","March 2013","June 2015","July 8, 2015","July 2015","No Study Results Posted","BOC-HIV","March 2015","Achievement of sustained virological response (SVR) at week 24|Achievement of sustained virological response at weeks 2,4,8,12.|The proportion of subjects with undetectable HCV-RNA at FW 12.|The proportion of subjects with undetectable HCV-RNA at 72 weeks after randomization.|Number of adverse events|Resistance of HCV after boceprevir (BOC) containing regimen","https://ClinicalTrials.gov/show/NCT01718301"
913,"NCT00275652","A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.","Completed","No Results Available","Hepatitis B|Cirrhosis","Drug: LdT (Telbivudine) and lamivudine","Mayo Clinic|Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 3","6","Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double-Blind","207-04","January 10, 2006","June 2004","August 2007","March 22, 2011","March 2011","No Study Results Posted","null","August 2007","A composite endpoint called ""clinical response"" which is defined as HBV DNA <10 4 copies/ml and normal ALT and improvement, or stabilization in CTP score.|Durability of clinical response|Proportion of patients achieving improvement, stabilization, and worsening in CTP score|Proportion of patients with normal ALT|Improvements in serum albumin levels, in patients with hypoalbuminemia pre-treatment|Time to clinical response|Duration of clinical response|Improvement, stabilization, and worsening in a modified CTP score.|ALT normalization.","https://ClinicalTrials.gov/show/NCT00275652"
914,"NCT01509391","Keyhole Limpet Hemocyanin in Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C|Liver Cirrhosis","Drug: keyhole-limpet hemocyanin","Medical University of Graz","Both","Adult|Senior","","14","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","HCVGRZ-IM1","January 9, 2012","January 2012","October 2012","October 16, 2012","October 2012","No Study Results Posted","IM1","October 2012","Hepatitis C viral load at week 24|Hepatitis c viral load at weeks 1,2,4,8,12,18,32","https://ClinicalTrials.gov/show/NCT01509391"
915,"NCT00753467","A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B","Not yet recruiting","No Results Available","Hepatitis B","Drug: IFN-Œ≥ 1b (Actimmune)|Drug: Adefovir dipivoxil|Drug: IFN-Œ≥ 1b and Adefovir dipivoxil combination","Huntington Medical Research Institutes|InterMune","Both","Adult|Senior","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","TONG-HBV-0801","September 15, 2008","September 2008","August 2009","October 20, 2010","September 2008","No Study Results Posted","null","August 2009","The primary objective is to evaluate the safety and tolerability of IFN-Œ≥ 1b either alone or in combination with Adefovir dipivoxil in patients with chronic Hepatitis B.|Evaluate the changes in serum HBV DNA concentrations following administration of Adefovir dipivoxil alone, IFN-Œ≥ 1b either alone or in combination with Adefovir dipivoxil in patients with chronic Hepatitis B.|Evaluate the changes in liver tests and hematology following administration of Adefovir dipivoxil alone, IFN-Œ≥ 1b either alone or in combination with Adefovir dipivoxil in patients with chronic Hepatitis B.","https://ClinicalTrials.gov/show/NCT00753467"
916,"NCT01257204","Study in Genotype 2/3 Subjects With Chronic Hepatitis C","Completed","No Results Available","Hepatitis C Virus","Drug: Placebo|Drug: BMS-790052|Drug: BMS-790052|Drug: Pegylated-interferon alfa 2a|Drug: Pegylated-interferon alfa 2a|Drug: Pegylated-interferon alfa 2a|Drug: Ribavirin|Drug: Ribavirin|Drug: Ribavirin","Bristol-Myers Squibb","Both","Adult|Senior","Phase 2","152","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator)","AI444-031|2010-022408-28","December 1, 2010","December 2010","September 2012","June 24, 2013","June 2013","No Study Results Posted","null","May 2012","To assess antiviral activity, as determined by the proportion of subjects who achieve SVR24 for each HCV genotype, defined as undetectable HCV RNA|To assess safety, as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)|To assess safety, as measured by the frequency of SAEs and discontinuations due to AEs|To assess the proportion of subjects with RVR for each HCV genotype, ie, undetectable HCV RNA|To assess the proportion of subjects with SVR12 for each HCV genotype ie, undetectable HCV RNA|Frequency of genotypic substitutions associated with virologic failure for each HCV genotype","https://ClinicalTrials.gov/show/NCT01257204"
917,"NCT00545558","Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV","Completed","No Results Available","Hepatitis C|HIV Infections","Drug: Efavirenz|Drug: Emtricitabine/Tenofovir disoproxil fumarate","University of Cincinnati|National Institute of Allergy and Infectious Diseases (NIAID)","Both","Adult|Senior","Phase 1","18","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","5R01AI065256-01|5R01AI065256","October 15, 2007","April 2006","March 2012","August 8, 2014","August 2014","No Study Results Posted","ART and HCV","March 2012","Underlying patterns of liver injury and hepatitis C virus (HCV) viral changes after antiretroviral therapy (ART) initiation","https://ClinicalTrials.gov/show/NCT00545558"
918,"NCT02068963","Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing","Active, not recruiting","No Results Available","Hepatitis C","","Hologic, Inc.","Both","Adult|Senior","","400","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P10433-HCVQPS-01","February 14, 2014","February 2014","December 2015","May 13, 2015","May 2015","No Study Results Posted","null","April 2015","Sustained viral response based on lower limit of quantitation","https://ClinicalTrials.gov/show/NCT02068963"
919,"NCT01327729","Y- Shaped Pegylated Interferon (YPEG-IFNŒ±-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C","Recruiting","No Results Available","Self Efficacy|Hepatitis C","Drug: pegylated interferon alpha 2a YPEG-IFN Œ±-2a 180mcg","BioGeneric Pharma|Xiamen Amoytop Biotech Co., Ltd.","Both","Adult","Phase 2|Phase 3","300","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CHT00234","March 31, 2011","November 2010","May 2013","April 1, 2011","March 2011","No Study Results Posted","null","April 2011","viral clearance at 72 weeks|interferon level","https://ClinicalTrials.gov/show/NCT01327729"
920,"NCT00536263","PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)","Completed","Has Results","Hepatitis B, Chronic","Drug: pegylated interferon alpha-2b|Drug: pegylated interferon alpha-2b|Drug: pegylated interferon alpha-2b","Merck Sharp & Dohme Corp.","Both","Adult","Phase 3","671","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P05170","September 26, 2007","September 2007","November 2009","February 25, 2015","February 2015","November 23, 2010","null","November 2009","Number of Participants With Hepatitis B Envelope Antigen (HBe or HBeAg) Loss|Number of Participants With HBeAg Loss|HBe Seroconversion|Number of Participants With Hepatitis B Virus - Deoxyriboncleic Acid (HBV-DNA) <20,000 IU/mL|Number of Participants With HBV-DNA < 200 IU/mL|Number of Participants With HBV-DNA Undetectable|Number of Participants With Biochemical Response|Number of Participants With Combined Response|Hepatitis B Surface Antigen (HBsAg) Loss|Hepatitis B Surface Antigen (HBs) Seroconversion|Change From Baseline in Liver Biopsy Score","https://ClinicalTrials.gov/show/NCT00536263"
921,"NCT02485262","Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience","Recruiting","No Results Available","Hepatitis C","Drug: Sofosbuvir and simeprevir","Arrowhead Regional Medical Center","Both","Adult|Senior","","340","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1234|14-25","June 19, 2015","November 2013","November 2016","June 29, 2015","June 2015","No Study Results Posted","null","November 2016","SVR 12|Safety and Tolerability as measured by the number of participants with AEs, Change in baseline laboratory results","https://ClinicalTrials.gov/show/NCT02485262"
922,"NCT01525810","Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial","Completed","No Results Available","Hepatitis C","Drug: Peginterferon Lambda-1a (BMS-914143)","Bristol-Myers Squibb","Both","Adult|Senior","","218","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AI452-016|2011-005293-31","January 11, 2012","March 2012","November 2014","March 25, 2015","March 2015","No Study Results Posted","null","November 2014","Durability of virologic response (time to loss of virologic response)|Long-term progression of liver disease|Duration of persistence of anti-Lambda antibodies in subjects who are positive for anti-Lambda antibodies at end of treatment in the parent study","https://ClinicalTrials.gov/show/NCT01525810"
923,"NCT02011932","Prospective Observational Study of Disease Progression in Chronic Hepatitis C","Active, not recruiting","No Results Available","Hepatitis C, Chronic|Disease Progression|Liver Cirrhosis","","Beijing YouAn Hospital","Both","Adult|Senior","","133","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BJYAH-2011-045","December 6, 2013","July 2010","July 2030","December 13, 2013","December 2013","No Study Results Posted","null","June 2011","Fibrosis progression rate|The incidence of cirrhosis|Risk factors for the occurrence of cirrhosis|The incidence of hepatocellular carcinoma|Number of participants with chronic hepatitis C-related complications","https://ClinicalTrials.gov/show/NCT02011932"
924,"NCT01090531","Patients With Chronic Hepatitis B and Low Viremia Not Receiving Antiviral Therapy","Recruiting","No Results Available","Hepatitis B, Chronic","","Johann Wolfgang Goethe University Hospitals","Both","Adult|Senior","","600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","JWGUHMED1-002","March 19, 2010","August 2009","null","May 21, 2012","May 2012","No Study Results Posted","null","August 2019","Indication for Antiviral Treatment|Development of hepatocellular carcinoma (HCC)|Progression of Liver Fibrosis|HBV-DNA|Quantitative HBsAg|Serum ALT|Serum AFP|FibroTest/ActiTest","https://ClinicalTrials.gov/show/NCT01090531"
925,"NCT00857311","MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)","Completed","Has Results","Hepatitis C","Biological: MRKAd5 HIV-1 gag vaccine (V520)|Biological: Comparator: Placebo|Biological: Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed|Biological: MRKAd5 HIV-1 gag vaccine (V520)","Merck Sharp & Dohme Corp.","Both","Adult","Phase 1","17","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","V520-022|2009_556","March 4, 2009","May 2004","May 2010","August 11, 2015","August 2015","June 9, 2011","null","January 2006","Number of Participants With Vaccine-related Clinical (Systemic and Injection-site), and Laboratory Adverse Events (AE)|Number of Participants With Systemic and Laboratory Adverse Events (AE)|Immune Response by Levels of Unfractionated Gag-specific IFN-gamma Following a 3-dose Vaccine Regimen","https://ClinicalTrials.gov/show/NCT00857311"
926,"NCT02545400","Quantification of Side Effects During Hepatitis C Therapy","Completed","No Results Available","Hepatitis C","","Medical University of Graz","Both","Adult|Senior","","108","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HCV-side effects","July 29, 2015","November 2013","June 2015","October 2, 2015","October 2015","No Study Results Posted","null","June 2014","frequency of adverse events|type of adverse events","https://ClinicalTrials.gov/show/NCT02545400"
927,"NCT01200420","Multiple Ascending Dose Study of Miravirsen in Treatment-Na√Øve Chronic Hepatitis C Subjects","Completed","No Results Available","Hepatitis C","Drug: miravirsen|Drug: saline","Santaris Pharma A/S","Both","Adult","Phase 2","38","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","SPC3649-203|2010-019057-17","September 9, 2010","September 2010","December 2011","January 26, 2012","January 2012","No Study Results Posted","null","December 2011","Safety and tolerability|Pharmacokinetics|Miravirsen treatment effect on viral titer","https://ClinicalTrials.gov/show/NCT01200420"
928,"NCT02431312","Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects","Recruiting","No Results Available","Hepatitis B","Biological: Group A: INO-1800 alone delivered by EP|Biological: Group B: INO-1800 + INO-9112 delivered by EP|Drug: Entecavir/Tenofovir","Inovio Pharmaceuticals|Hoffmann-La Roche","Both","Adult","Phase 1","126","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Factorial Assignment|Primary Purpose: Treatment|Masking: Open Label","HBV-001","April 21, 2015","January 2015","November 2017","October 17, 2015","October 2015","No Study Results Posted","null","November 2017","Safety Assessment (Composite of multiple measures: pain (VAS), adverse events, lab abnormalities, changes in vital signs)|Immunogenicity Assessment|Viral/Antiviral Assessment","https://ClinicalTrials.gov/show/NCT02431312"
929,"NCT00976781","Identifying the Gaps in the Diagnosis and Management of Hepatitis C","Active, not recruiting","No Results Available","Hepatitis C","","Henry Ford Health System","Both","Adult|Senior","","200","Other","Observational","Time Perspective: Retrospective","IRB no. 4775","September 10, 2009","August 2008","null","September 11, 2009","September 2009","No Study Results Posted","null","null","This is a retrospective observational study. The outcome measure would be the number of patients who are actually followed and treated for hepatitis C after they have been diagnosed","https://ClinicalTrials.gov/show/NCT00976781"
930,"NCT02336139","A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use","Not yet recruiting","No Results Available","Hepatitis C","Drug: Sofosbuvir (SOF)/GS-5816","Kirby Institute","Both","Adult|Senior","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","VHCRP1309","January 4, 2015","November 2015","December 2018","August 31, 2015","August 2015","No Study Results Posted","SIMPLIFY","December 2016","Sustained Virological Response (SVR12)|Treatment adherence|Impact of adherence on therapy (association between adherence and response to treatment )|Factors associated with on-treatment adherence|End of Treatment Response (ETR) (proportion of participants with undetectable HCV RNA at the end of treatment (ETR)|Safety and tolerability (number and type of adverse events and serious adverse events)|Change in drug use|Change in mental health|Change in health related quality of life|Impact of mixed infection on treatment response|Reinfection Rate|Immunovirological factors associated with treatment clearance|Utility of Dried Blood Spot (DBS) (method for monitoring HCV including treatment response)","https://ClinicalTrials.gov/show/NCT02336139"
931,"NCT01728935","Tenofovir in Asian Chronic Hepatitis B Patients","Completed","No Results Available","Chronic Hepatitis B","Drug: Tenofovir disoproxil","The University of Hong Kong|Gilead Sciences","Both","Adult|Senior","","141","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","TDF-HKU|UW 11-241","November 8, 2012","April 2008","March 2013","December 29, 2014","December 2014","No Study Results Posted","null","November 2012","Serum HBV DNA levels|Resistance Profile|HBsAg levels","https://ClinicalTrials.gov/show/NCT01728935"
932,"NCT00911963","Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection","Completed","No Results Available","Hepatitis C","Drug: VCH-222 or matching placebo|Drug: VCH-222 or matching placebo|Biological: peginterferon alfa-2a|Drug: ribavirin","Vertex Pharmaceuticals Incorporated|ViroChem Pharma","Both","Adult","Phase 1|Phase 2","49","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","VCH-222-102","May 29, 2009","April 2009","September 2012","February 6, 2014","February 2014","No Study Results Posted","null","September 2012","To assess the antiviral activity of VCH-222, in subjects with genotype 1 hepatitis C virus (HCV) infection after once (QD) or twice (b.i.d.) daily dosing for 3 days (Part A)|To assess the antiviral activity of VCH-222, in subjects with genotype 1 HCV infection after b.i.d. daily dosing for 12 weeks in combination with Peg-interferon-alfa-2a and ribavirin (Part B)|Assess the safety and tolerability of VCH-222 when administered in combination with Peg-IFN-alfa-2a/RBV for 12 weeks (Part B)|To assess the safety and tolerability of VCH-222 when administered for 3 days in monotherapy (Part A)|To evaluate the pharmacokinetic (PK) profile of VCH-222 in HCV infected subjects (Part B)","https://ClinicalTrials.gov/show/NCT00911963"
933,"NCT02175966","Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)","Active, not recruiting","No Results Available","Hepatitis C","Drug: DCV/ASV/BMS-791325|Drug: Ribavirin|Drug: Sofosbuvir|Drug: Peginterferon Œ±-2a","Bristol-Myers Squibb","Both","Adult|Senior","Phase 2","30","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","AI443-131","June 25, 2014","July 2014","December 2015","July 3, 2015","July 2015","No Study Results Posted","FOURward","January 2015","Proportion of treated subjects with SVR12, defined as HCV RNA < LLOQ target detected or target not detected (LLOQ TD/TND) for each treatment arm|On-treatment safety, as measured by frequency of deaths, SAEs, discontinuations due to AEs, and Grade 3/4 laboratory abnormalities (hematologic and liver function, based on DAIDs criteria) by each arm and overall|Proportion of subjects in each arm who achieve HCV RNA <LLOQ TD/TND|Proportion of subjects in each arm who achieve HCV RNA <LLOQ TND|Proportion of subjects in each arm achieving SVR12 associated with HCV geno subtype 1a vs 1b|Proportion of subjects in each arm achieving SVR12 associated with interleukin-28B (IL28B) rs12979860 SNP status (CC genotype or non-CC genotype)","https://ClinicalTrials.gov/show/NCT02175966"
934,"NCT02445547","Telbivudine and Tenofovir in Men of Childbearing Age With Immune-tolerant Chronic Hepatitis B","Active, not recruiting","No Results Available","Hepatitis B,Chronic","Drug: Telbivudine and Tenofovir","Fuzhou General Hospital","Male","Adult","Phase 1|Phase 2","90","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","TTIT-HBV-M","May 13, 2015","October 2014","null","May 14, 2015","May 2015","No Study Results Posted","null","October 2016","Percentage of Participants With HBV DNA < 500 Copies/mL at Week 4|Percentage of Participants With HBV DNA < 500 Copies/mL at Week 12, 24, and 48|Number of Participants With Normal Alanine Aminotransferase (ALT) at Week 4, 12, 24, and 48|Number of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 4, 12, 24, and 48|Number of Participants With Seroconversion to Antibody Against HBeAg (AntiHBe) at Week 4, 12, 24, and 48|Number of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 4, 12, 24, and 48|Number of Participants With Seroconversion to Antibody to HBsAg (AntiHBs) at Week 4, 12, 24, and 48|Occurrence of HBV Resistance Mutations|off-treatment recurrence of HBV","https://ClinicalTrials.gov/show/NCT02445547"
935,"NCT02172898","Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium","Recruiting","No Results Available","Alcoholic Hepatitis","","Indiana University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","Both","Adult|Senior","","1260","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","TREAT Observational|U01AA021840-01","June 9, 2014","June 2013","December 2018","August 24, 2015","August 2015","No Study Results Posted","null","December 2017","Developing a repository of biological samples from AH patients and heavy drinking controls.|Characterizing AH subjects and controls to serve as the foundation for novel mechanistic and therapeutic studies.","https://ClinicalTrials.gov/show/NCT02172898"
936,"NCT00446940","Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: rosuvastatin|Drug: atorvastatin","Bader, Ted, M.D.","Both","Adult|Senior","Phase 2","16","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","13133","March 11, 2007","December 2006","March 2007","September 8, 2008","September 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00446940"
937,"NCT02479880","Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection","Recruiting","No Results Available","Hepatitis B","Drug: Tenofovir DF|Radiation: DEXA Scan","Gilead Sciences","Both","Child","Phase 4","100","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label","GS-EU-174-1403|2014-004939-39","June 17, 2015","July 2015","June 2019","September 3, 2015","September 2015","No Study Results Posted","null","June 2019","Proportion of participants with bone-related adverse events and/or a ‚â• 4% reduction in BMD from baseline to Week 96.|Outcomes of renal and bone-related adverse events|Cumulative exposure time at bone or renal-related adverse event onset|Virological status from baseline to Week 96|Immunological status from baseline to Week 96|Provider recommendations for dietary supplements|Participant adherence to dietary supplement recommendations|Tenofovir DF discontinuation|Documentation of the medical management of detected renal laboratory abnormalities|Classification of detected renal laboratory abnormalities|Documentation of the medical management of detected bone laboratory abnormalities|Classification of detected bone laboratory abnormalities","https://ClinicalTrials.gov/show/NCT02479880"
938,"NCT00097435","A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: Albuferon|Drug: Ribavirin","Human Genome Sciences Inc.","Both","Adult","Phase 2","115","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","Clinical Protocol ALFR-HC-05","November 23, 2004","October 2004","August 2007","August 1, 2013","August 2013","No Study Results Posted","null","August 2007","The major safety endpoints are the common side effects of IFNa therapy including flu-like symptoms, depression, and hematologic abnormalities.|Sustained virologic response (SVR), defined as undetectable virus at 24 weeks after the end of therapy. The primary efficacy assessment is HCV RNA level.","https://ClinicalTrials.gov/show/NCT00097435"
939,"NCT00333710","Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD","Completed","Has Results","Chronic Disease|Hepatitis C|Stress Disorders, Post-Traumatic","Behavioral: Individual psychotherapy|Behavioral: Telehealth Intervention","VA Office of Research and Development","Both","Adult|Senior","","53","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label","F4120-V","June 2, 2006","September 2006","October 2009","December 9, 2014","December 2014","November 19, 2014","null","October 2009","Hepatitis C Virus Knowledge Questionnaire","https://ClinicalTrials.gov/show/NCT00333710"
940,"NCT01716156","A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039 AM1)","Completed","No Results Available","Hepatitis C","Drug: Grazoprevir|Drug: Ribavirin","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 2","26","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","5172-039","October 25, 2012","January 2013","March 2014","November 9, 2014","November 2014","No Study Results Posted","null","March 2014","Number of participants achieving Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12)|Number of participants experiencing at least one adverse event (AE) on study|Number of participants discontinuing study therapy due to an AE|Time to first achievement of undetectable hepatitis C virus ribonucleic acid (HCV RNA)|Number of participants achieving undetectable HCV RNA at Week 2|Number of participants achieving undetectable HCV RNA at Week 4|Number of participants achieving undetectable HCV RNA at Week 12|Number of participants achieving HCV RNA <25 IU/mL at Week 2|Number of participants achieving HCV RNA <25 IU/mL at Week 4|Number of participants achieving HCV RNA <25 IU/mL at Week 12|Number of participants achieving end-of-treatment response (EOTR)|Number of participants achieving sustained virologic response 4 weeks after the end of all study therapy (SVR 4)|Number of participants achieving sustained virologic response 24 weeks after the end of all study therapy (SVR 24)","https://ClinicalTrials.gov/show/NCT01716156"
941,"NCT01717326","A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ¬± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)","Completed","No Results Available","Hepatitis C","Drug: Grazoprevir|Drug: Elbasvir|Drug: Placebo|Drug: Ribavirin","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 2","573","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","5172-035|2012-003354-89","October 26, 2012","February 2013","May 2015","May 15, 2015","May 2015","No Study Results Posted","C-WORTHy","May 2015","Number of participants achieving Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12)|Number of participants experiencing at least one Adverse Event (AE) on study|Number of participants discontinuing study therapy due to an AE|Time to first achievement of undetectable hepatitis C virus ribonucleic acid (HCV RNA)|Number of participants achieving undetectable HCV RNA at Week 2|Number of participants achieving undetectable HCV RNA at Week 4|Number of participants achieving undetectable HCV RNA at Week 12|Number of participants achieving HCV RNA <25 IU/mL at Week 2|Number of participants achieving HCV RNA <25 IU/mL at Week 4|Number of participants achieving HCV RNA <25 IU/mL at Week 12|Number of participants achieving End-Of-Treatment Response (EOTR)|Number of participants achieving Sustained Virologic Response 4 weeks after the end of all therapy (SVR4)|Number of participants achieving Sustained Virologic Response 24 weeks after the end of all study therapy (SVR24)","https://ClinicalTrials.gov/show/NCT01717326"
942,"NCT01707030","Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C","Recruiting","No Results Available","Hepatitis C|Alcohol Abuse","Other: Web-Based Brief Alcohol Intervention|Other: Usual Care","VA Office of Research and Development","Both","Adult|Senior","Phase 2|Phase 3","340","U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CRE 12-009","October 3, 2012","March 2015","December 2017","October 20, 2015","October 2015","No Study Results Posted","null","August 2017","Days of Unhealthy Alcohol Consumption|Drinks Per Drinking Day","https://ClinicalTrials.gov/show/NCT01707030"
943,"NCT01333813","Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children","Completed","Has Results","Hepatitis B","Biological: Engerix-B‚Ñ¢ Kinder","GlaxoSmithKline","Both","Child","Phase 4","300","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Prevention|Masking: Open Label","112688","April 7, 2011","April 2011","September 2011","July 6, 2015","July 2015","July 19, 2012","null","September 2011","Number of Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentration Equal to or Above (‚â•) 100 Milli-International Units Per Milliliter (mIU/mL)|Anti-HBs Antibody Concentrations After Previous Vaccination With Infanrix Hexa Vaccine.|Number of Subjects With Anti-HBs Antibody Concentrations Equal to or Above the Protocol Specified Cut-off Values After Previous Vaccination With Infanrix Hexa Vaccine|Number of Subjects With Anti-HBs Antibody Concentrations Equal to or Above Protocol Specified Cut-off Values|Anti-HBs Antibody Concentrations|Number of Subjects Demonstrating an Anamnestic Response to the Engerix-B Kinder Challenge Dose|Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)|Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs|Number of Subjects Reporting Any Unsolicited AEs|Number of Subjects Reporting Any Serious Adverse Events (SAEs)","https://ClinicalTrials.gov/show/NCT01333813"
944,"NCT00322361","Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)(COMPLETED)","Completed","No Results Available","Hepatitis B|Hepatocellular Carcinoma","Biological: Comparator: RECOMBIVAX HB‚Ñ¢|Biological: Comparator: Modified process Hepatitis B Vaccine","Merck Sharp & Dohme Corp.","Both","Child","Phase 2","566","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Prevention|Masking: Double Blind (Subject, Investigator)","V232-056|2006_007","May 2, 2006","May 2006","July 2007","June 1, 2015","June 2015","No Study Results Posted","null","July 2007","Geometric mean titer to hepatitis B surface antigen at Month 7|Safety and tolerability including use of Vaccination Report Card","https://ClinicalTrials.gov/show/NCT00322361"
945,"NCT02338674","Telbivudine and Tenofovir in Women of Childbearing Age With Immune-tolerant Chronic Hepatitis B","Active, not recruiting","No Results Available","Hepatitis B, Chronic","Drug: Telbivudine and Tenofovir","Fuzhou General Hospital","Female","Adult","Phase 1|Phase 2","90","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","TTIT-HBV","January 11, 2015","October 2014","null","June 10, 2015","June 2015","No Study Results Posted","null","October 2016","Percentage of Participants With HBV DNA < 500 Copies/mL at Week 4|Percentage of Participants With HBV DNA < 500 Copies/mL at Week 12, 24, and 48|Number of Participants With Normal Alanine Aminotransferase (ALT) at Week 4, 12, 24, and 48|Number of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 4, 12, 24, and 48|Number of Participants With Seroconversion to Antibody Against HBeAg (AntiHBe) at Week 4, 12, 24, and 48|Number of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 4, 12, 24, and 48|Number of Participants With Seroconversion to Antibody to HBsAg (AntiHBs) at Week 4, 12, 24, and 48|Occurrence of HBV Resistance Mutations|off-treatment recurrence of HBV|Down syndrome Occurrence|Fetal Malformations Occurrence","https://ClinicalTrials.gov/show/NCT02338674"
946,"NCT02566148","Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France","Completed","No Results Available","HIV Infection|Chronic Hepatitis B","","French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Ministry of Health, France|Institut de Recherche pour le Developpement|Institut National de la Sant√© Et de la Recherche M√©dicale, France|Institut national de prevention et d'education pour la sante","Both","Adult","","2468","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","ANRS PARCOURS","June 19, 2015","February 2012","May 2013","September 30, 2015","September 2015","No Study Results Posted","PARCOURS","February 2012","Lapse of time from arrival in France to HIV testing|Lapse of time from arrival in France to hepatitis B testing|Lapse of time from HIV diagnostic to access to care|Lapse of time from hepatitis B diagnostic to access to care|Condom use|Evolution in concurrent sexual partnerships after migration in France|Evolution in occasional sexual partnerships after migration in France|Evolution in transactional sexual partnerships after migration in France","https://ClinicalTrials.gov/show/NCT02566148"
947,"NCT00000583","Hepatitis B Vaccine Clinical Trial","Completed","No Results Available","Hepatitis B|Hepatitis, Viral, Human|Liver Diseases","Biological: hepatitis B vaccines","National Heart, Lung, and Blood Institute (NHLBI)","Male","Adult","Phase 3","null","NIH","Interventional","Allocation: Randomized|Primary Purpose: Prevention|Masking: Double-Blind","303|P01HL009011-18A1","October 27, 1999","November 1978","June 1980","November 25, 2013","April 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00000583"
948,"NCT02168361","The SIM-SOF Trial for Hepatitis C","Active, not recruiting","No Results Available","Chronic Hepatitis C","Drug: Pegylated Interferon alfa-2b|Drug: Simeprevir|Drug: Ribavirin|Drug: Sofosbuvir","Center For Hepatitis C, Atlanta, GA","Both","Adult|Senior","Phase 4","82","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","CHC-21","June 17, 2014","December 2013","November 2014","June 19, 2014","June 2014","No Study Results Posted","null","August 2014","Sustained Virologic Response 12 (SVR-12)|Virologic Relapse|Virologic Breakthrough|Adverse events","https://ClinicalTrials.gov/show/NCT02168361"
949,"NCT00810875","Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy","Terminated","No Results Available","Hepatitis C","","University of California, San Francisco","Both","Child|Adult|Senior","","6","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","HCVP-1","December 16, 2008","April 2009","August 2010","August 21, 2014","August 2014","No Study Results Posted","null","August 2010","Detection and characterization of cord blood immune responses against hepatitis C virus and influenza virus vaccine|Characterization of immune responses in infants against hepatitis C virus and influenza virus vaccine|Detection and characterization of immune responses against hepatitis C virus and influenza virus vaccine in mothers","https://ClinicalTrials.gov/show/NCT00810875"
950,"NCT00970216","Study of Telbivudine in Chronic Hepatitis B","Recruiting","No Results Available","Chronic Hepatitis B","","Chang Gung Memorial Hospital","Both","Adult|Senior","","200","Other","Observational","Time Perspective: Prospective","PMST-Y-1","September 1, 2009","February 2009","January 2012","July 10, 2011","March 2010","No Study Results Posted","null","January 2012","","https://ClinicalTrials.gov/show/NCT00970216"
951,"NCT02053519","Can Vitamin D Supplementation Improve Hepatitis C Cure Rates","Not yet recruiting","No Results Available","Hepatitis C","Drug: Active Comparator: Vigantol Oil (Vitamin D3)|Drug: Mygliol Oil","Jim Flood|University of Dundee","Both","Adult|Senior","Phase 3","160","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","2012GA03|2013-003573-10","January 16, 2014","February 2014","April 2015","April 22, 2014","April 2014","No Study Results Posted","ViaDUCT","April 2015","The primary outcome measure is the number of patients with sustained virologic responses, (SVR), at 12 weeks post standard therapy on Vitamin D3 as compared to placebo|Secondary Objectives","https://ClinicalTrials.gov/show/NCT02053519"
952,"NCT00487747","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.","Completed","No Results Available","Hepatitis B, Chronic","Drug: peginterferon alfa-2a [Pegasys]","Hoffmann-La Roche","Both","Adult|Senior","Phase 4","19","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ML20003","June 18, 2007","null","October 2009","February 15, 2010","February 2010","No Study Results Posted","null","null","HBV DNA <100,000 copies/mL (HBeAg positive patients)|HBV DNA <20,000 copies/mL (HBeAg negative patients)|HBV DNA <400 copies/mL, HbsAg seroconversion, ALT normalization, sustained HBe seroconversion in HBeAg positive patients.|AEs and laboratory parameters","https://ClinicalTrials.gov/show/NCT00487747"
953,"NCT00705666","Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)","Completed","Has Results","Hepatitis C, Chronic|Hepacivirus","Biological: Peginterferon alfa-2b (SCH 54031)|Drug: Ribavirin (SCH 18908)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","789","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P04437","June 23, 2008","February 2006","July 2008","October 1, 2015","October 2015","March 30, 2010","ADEQUATION","July 2008","The Number of Participants Receiving the Recommended Treatment Duration (24 Weeks for Genotypes 2 and 3 and 48 Weeks for Genotype 1 According to the French 2002 Consensus Meeting).","https://ClinicalTrials.gov/show/NCT00705666"
954,"NCT02126137","Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection","Recruiting","No Results Available","Chronic Hepatitis C","Drug: Ezetimibe","Pontificia Universidad Catolica de Chile","Both","Adult|Senior","Phase 1","20","Other","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Basic Science|Masking: Open Label","12-199|1130357","April 27, 2014","October 2013","March 2016","October 29, 2014","October 2014","No Study Results Posted","EZE-1","January 2016","HCV plasma viral load|HCV biliary viral load","https://ClinicalTrials.gov/show/NCT02126137"
955,"NCT01574521","Seroepidemiologic Study of Spermatozoal Transmission of Hepatitis B Virus (HBV)","Completed","No Results Available","Hepatitis B","","YiYang Zhu|Taizhou Hospital","Female","Child|Adult","","407","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","tz2008032","April 8, 2012","January 2008","December 2011","April 9, 2012","April 2012","No Study Results Posted","null","December 2010","positive rate of HBV in uterus|response rate of postnatal vaccination","https://ClinicalTrials.gov/show/NCT01574521"
956,"NCT00860626","Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B","Recruiting","No Results Available","Hepatitis B, Chronic","Drug: interferon Œ± plus nucleoside analogue|Drug: interferon Œ±|Drug: interferon Œ±","Sun Yat-sen University","Both","Adult","","50","Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","interferonshorttermnucleoside","March 11, 2009","January 2008","February 2010","March 11, 2009","March 2009","No Study Results Posted","null","December 2009","HBeAg seroconversion rate|HBV DNA loss rate|HBsAg loss rate","https://ClinicalTrials.gov/show/NCT00860626"
957,"NCT01492504","Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial","Active, not recruiting","No Results Available","Hepatitis C","Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)","Bristol-Myers Squibb","Both","Adult|Senior","","1850","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AI444-046|2011-005287-21","November 30, 2011","February 2012","February 2021","October 15, 2015","August 2015","No Study Results Posted","null","February 2021","Durability of Sustained viral response [SVR] (time to loss of virologic response)|Frequency of viral genotypic substitutions in subjects previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) who did not achieve or did not maintain SVR12|Long-term progression of liver disease, as measured by the frequency of hepatic disease progression, all cause mortality, and liver-related mortality","https://ClinicalTrials.gov/show/NCT01492504"
958,"NCT00725751","Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)","Completed","Has Results","Hepatitis C, Chronic","Biological: Pegylated interferon alfa-2b (PegIFN-2b)|Drug: Ribavirin","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","353","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P05255","July 25, 2008","September 2007","March 2011","October 1, 2015","October 2015","March 23, 2012","null","March 2011","Number of Participants Who Completed Treatment With PegIFN-2b/Ribavirin|Number of Participants Who Achieved Sustained Virologic Response (SVR)|Number of Participants Who Received Antiviral Treatment Who Were Also on Substitution Therapy","https://ClinicalTrials.gov/show/NCT00725751"
959,"NCT00168194","Cellular Immune Responses to Hepatitis B Virus (HBV)- Longitudinal Follow up and Natural History","Completed","No Results Available","Hepatitis B|HIV Infections","","The Alfred|National Institutes of Health (NIH)","Both","Adult|Senior","","104","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","235/04","September 9, 2005","December 2004","December 2009","January 19, 2012","January 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00168194"
960,"NCT00136214","Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects","Recruiting","No Results Available","Hepatitis C","","Beth Israel Deaconess Medical Center|Schering-Plough","Both","Adult|Senior","","26","Other|Industry","Observational","Time Perspective: Prospective","2003P-000341","August 25, 2005","March 2004","December 2006","December 19, 2007","August 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00136214"
961,"NCT00863109","Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)","Completed","Has Results","Hepatitis C, Chronic|Genotype 1|HCV-1","Biological: Peginterferon alfa-2b (PEG)|Drug: Ribavirin (RBV)","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","133","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P05278|MK-4031-336","March 12, 2009","April 2009","May 2013","April 15, 2015","April 2015","May 14, 2014","VIDA","May 2013","Change From Baseline (BL) to Week 72 (WK72) in 36-Item Short-Form Health Survey (SF-36) Scores|Change From Baseline (BL) to Week 72 (WK72) in Chronic Liver Disease Questionnaire-Hepatitis C Virus (CLDQ-HCV)|Change From Baseline to Week 72 (WK72) in SF-36 Scores Among Participants Who Completed Treatment and Participants Who Had Early End of Treatment (Subset Analysis)|Change From Baseline to Week 72 (WK72) in CLDQ-HCV Scores Among Participants Who Completed Treatment and Participants Who Had Early End of Treatment (Subset Analysis)|Minimal Clinically Important Difference (MCID) in SF-36 Scores|MCID in CLDQ-HCV Scores|Percentage of Participants Who Were Compliant With Treatment According To Medication Count (Subset Analysis)","https://ClinicalTrials.gov/show/NCT00863109"
962,"NCT00055341","Treatment of Hepatitis C in Hemophilic Patients With HIV","Completed","No Results Available","HIV Infections|Hepatitis C|Hemophilia","Drug: Peginterferon alfa-2a|Drug: Ribavirin","National Institute of Allergy and Infectious Diseases (NIAID)","Both","Child|Adult|Senior","Phase 2","22","NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","1R01AI49508-01|5R01AI049508-02","February 25, 2003","March 2002","June 2005","July 29, 2008","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00055341"
963,"NCT01356901","Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients","Completed","No Results Available","Hepatitis B, Chronic","","Bristol-Myers Squibb","Both","Adult|Senior","","230","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AI463-232","April 15, 2011","January 2011","January 2015","July 3, 2015","June 2015","No Study Results Posted","null","January 2015","Percentage of Chronic hepatitis B (CHB) patients treated with Entecavir (ETV) and any switch or add-on therapy who are persistent over a time period of two years in a real-life setting.|Adherence rates using administrative measures (continuous multiple-interval medication gaps, continuous single interval medication availability), and self-report measures, 8-item self-report Morisky Medication Adherence Scale (MMAS)|Reasons for therapy non-persistence (therapy discontinuation) and low therapy adherence (qualitative questionnaire for causal assessment of non-persistence/non-adherence)|Proportion of patients with HBV DNA below the limit of detection (according to local lab standard), mean log reduction of HBV DNA from baseline, proportion of subjects with normal ALT and with e antigen (eAg)/Surface antigen (sAg) seroconversion/loss|Frequency of Serious adverse drug reaction ((S)ADR)s and study discontinuations due to (S)ADRs|Number of participants with occuring resistances based on results from resistance tests|Assessment of Health Status (SF-12¬Æ Health Survey)","https://ClinicalTrials.gov/show/NCT01356901"
964,"NCT00502788","Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)","Completed","No Results Available","Hepatitis C|Thalassemia","Drug: Peginterferon Alfa-2a and Ribavirin|Drug: Ribavirin","New England Research Institutes|National Heart, Lung, and Blood Institute (NHLBI)","Both","Adult","Phase 2","21","Other|NIH","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","503|U01HL065238|U01 HL065238-07","July 16, 2007","May 2003","August 2006","March 3, 2014","March 2014","No Study Results Posted","HepC","June 2006","Safety of peginterferon alfa-2a and ribavirin in individuals with thalassemia (measured by changes in liver iron stores and development of iron overload-related complications)|Mean change in hepatic iron concentration from baseline biopsy to follow-up biopsy; relationship of change to baseline level|Transfusion frequency and volume required to maintain trough Hb 9.0-10.5 g/dL during treatment, as compared to that required in the 6 months prior to hepatitis C treatment|Cumulate change in deferoxamine dose; evidence for deferoxamine toxicity during hepatitis C treatment|Response rate (undetectable hepatitis C virus RNA)|Sustained virologic response rate (undetectable hepatitis C virus RNA 24 weeks after the end of treatment) and its association with baseline hepatic iron concentration|Rate of viral clearance from serum in the first 4 weeks of treatment, rate of early virologic response at week 12, and each rate's association with sustained virologic response|Change in liver inflammation and fibrosis scores from baseline to 48 weeks|Adverse events|Cardiac adverse events, defined as either symptomatic left ventricular dysfunction requiring medication or pathologic arrhythmia requiring medication|Quality of life","https://ClinicalTrials.gov/show/NCT00502788"
965,"NCT00709228","Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)","Completed","Has Results","Hepatitis C","Drug: PegIntron|Drug: Rebetol","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","496","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P04793","June 23, 2008","May 2006","November 2008","January 14, 2015","January 2015","November 9, 2009","null","November 2008","Number of HCV LVL G1 Participants Who Relapsed","https://ClinicalTrials.gov/show/NCT00709228"
966,"NCT01205165","An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB)","Completed","No Results Available","Hepatitis B, Chronic","Drug: Adefor dipivoxil","GlaxoSmithKline","Both","Adult|Senior","Phase 4","104","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","103814","September 17, 2010","December 2004","April 2006","January 22, 2011","November 2010","No Study Results Posted","null","April 2006","Mean log 10 reduction in serum HBV DNA level from baseline to Week 12|Proportion of patients achieving ALT normalization at Week 52|‚Ä¢ Proportion of patients achieving virological response (HBV DNA level no less than 300 copies/mL) at Week 52|‚Ä¢ HBV DNA levels at each collection timepoint through Week 52|‚Ä¢ Proportion of patients with HBeAg loss, HBeAg seroconversion, HBsAg loss and HBsAg seroconversion at Week 52|‚Ä¢ Proportion of patients achieving ALT normalization at Week 12|‚Ä¢ Safety assessment with adverse events as well as incidence of laboratory abnormalities","https://ClinicalTrials.gov/show/NCT01205165"
967,"NCT01144936","Study of VX-985 in Subjects With Chronic Hepatitis C","Completed","No Results Available","Chronic Hepatitis C","Drug: VX-985 or matching placebo|Drug: VX-985 or matching placebo|Drug: VX-985 or matching placebo","Vertex Pharmaceuticals Incorporated","Both","Adult","Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","VX09-985-101","June 14, 2010","June 2010","October 2010","March 8, 2011","March 2011","No Study Results Posted","null","October 2010","Safety and tolerability (vital signs, 12-lead electrocardiograms, physical examinations, laboratory assessments, and adverse events)|Plasma pharmacokinetic parameters of VX-985|HCV RNA levels","https://ClinicalTrials.gov/show/NCT01144936"
968,"NCT02170727","A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1","Completed","No Results Available","Hepatitis C Virus","Drug: DCV/ASV/BMS-791325","Bristol-Myers Squibb","Both","Adult|Senior","Phase 3","169","Industry","Interventional","Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","AI443-123","June 20, 2014","June 2014","September 2015","October 15, 2015","April 2015","No Study Results Posted","UNITY 4","June 2015","Proportion of treated subjects with SVR12 in the naive cohort|Proportion of treated subjects with SVR12 in the IFNŒ± experienced cohort|Proportion of subjects in each cohort who achieve HCV RNA < LOQ TD/TND|Proportion of subjects in each cohort who achieve HCV RNA < LOQ TND|Safety in each cohort, as measured by frequency of serious adverse events(SAEs), discontinuations due to AEs, and selected Grade 3-4 laboratory abnormalities (including hematologic and liver function, based on DAIDS criteria)|Proportion of subjects with anemia defined as Hb < 10 g/dL on-treatment who have Hb ‚â•10 g/dL at baseline in each cohort|Proportion of subjects in each cohort achieving SVR12 associated with hepatitis C virus (HCV) genotype subtype 1a vs 1b|Proportion of subjects in each cohort achieving SVR12 associated with IL28B rs12979860 Single Nucleotide Polymorphisms (SNP) status (CC genotype or non CC genotype)|Proportion of cirrhotic and non cirrhotic subjects who achieve SVR12|Safety of non-cirrhotic vs cirrhotic subjects, as measured by the frequency of SAEs, discontinuations due to adverse events (AEs), and selected Grade 3 4 laboratory abnormalities (including hematologic and liver function, based on DAIDS criteria)","https://ClinicalTrials.gov/show/NCT02170727"
969,"NCT01425190","Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)","Terminated","Has Results","Hepatitis C, Chronic","Drug: Boceprevir","Merck Sharp & Dohme Corp.","Both","Child","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","P07614|2010-023498-20|MK-3034-063","August 26, 2011","January 2012","March 2013","September 4, 2015","September 2015","October 3, 2014","null","March 2013","Area Under the Plasma Concentration Time Curve (AUC) From 0-Infinity of Single Dose Boceprevir|Maximum Plasma Concentration (Cmax) of Single Dose Boceprevir|Time of Maximum Plasma Concentration (Tmax) of Single Dose Boceprevir|Final Dose of Boceprevir By Age Group","https://ClinicalTrials.gov/show/NCT01425190"
970,"NCT01401400","Genetic Study of Peginterferon Treatment in Hepatitis B Patients: The GIANT-B Study","Completed","No Results Available","Chronic Hepatitis B","","Foundation for Liver Research","Both","Adult|Senior","","1350","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HBV10-03","July 22, 2011","May 2010","June 2015","August 13, 2015","August 2015","No Study Results Posted","GIANT-B","June 2015","Response to (PEG)IFN in relation to single-nucleotide polymorphisms identified by a GWAS|Response","https://ClinicalTrials.gov/show/NCT01401400"
971,"NCT01787279","An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B","Completed","No Results Available","Hepatitis B, Chronic","Drug: peginterferon alfa-2a [Pegasys]","Hoffmann-La Roche","Both","Adult|Senior","Phase 4","59","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ML19522","February 6, 2013","January 2006","April 2012","October 1, 2015","October 2015","No Study Results Posted","null","April 2012","Percentage of patients achieving HCV DNA <10'000 copies/ml (Roche PCR or Taqman tests)|Percentage of patients achieving normalization of alanine aminotransferase (ALT)|Safety: Incidence of adverse events|Percentage of patients achieving HBV DNA < 400 copies/ml (Roche PCR or Taqman tests)|Percentage of patients achieving HBsAg seroconversion (HBsAg-negative, anti-HBs positive)|Percentage of patients achieving combined response (HBV DNA < 10'000 copies/ml and normal ALT)","https://ClinicalTrials.gov/show/NCT01787279"
972,"NCT02531269","Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period","Active, not recruiting","No Results Available","Hepatitis C","","Bristol-Myers Squibb|Basel Institute of Clinical Epidemiology (BICE)","Both","Adult|Senior","","300","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","AI444-319","August 11, 2015","December 2012","January 2016","October 27, 2015","October 2015","No Study Results Posted","null","December 2015","SVR12|SVR4|SVR24|On-treatment Virological response at week 4 assessed by measuring viral load|Virological response at the end of treatment (EOT) assessed by measuring viral load|The occurrence of virological failure (on-treatment and relapse) assessed by measuring viral load","https://ClinicalTrials.gov/show/NCT02531269"
973,"NCT00570336","Study of CTS-1027 in Hepatitis C Patients","Completed","No Results Available","Chronic Hepatitis C Virus Infection","Drug: CTS-1027|Other: Placebo","Conatus Pharmaceuticals Inc.|FGK Clinical Research GmbH","Both","Adult|Senior","Phase 2","87","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","CTS-1027-01","December 6, 2007","December 2007","July 2009","September 14, 2010","September 2010","No Study Results Posted","null","July 2009","Number of adverse events at each dose level|Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) levels at each dose|Peak and trough levels of CTS-1027 in plasma","https://ClinicalTrials.gov/show/NCT00570336"
974,"NCT00441584","The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)","Terminated","Has Results","Hepatitis C, Chronic","Biological: PegIntron (peginterferon alfa-2b)|Drug: Rebetol (ribavirin)","Merck Sharp & Dohme Corp.|Integrated Therapeutics Group","Both","Adult|Senior","Phase 3","117","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","P03833|ESPECIAL","February 28, 2007","July 2005","June 2008","October 7, 2015","October 2015","June 18, 2009","null","June 2008","Number of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment","https://ClinicalTrials.gov/show/NCT00441584"
975,"NCT00593151","Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C","Completed","No Results Available","Hepatitis C","Other: Locteron (controlled-release interferon alpha 2b)|Biological: pegylated IFNa2b","Biolex Therapeutics, Inc.","Both","Adult|Senior","Phase 1|Phase 2","32","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","S07-200-02-003","January 2, 2008","January 2008","March 2009","February 1, 2012","February 2012","No Study Results Posted","PLUS","December 2008","To assess in subjects with chronic hepatitis C the safety and tolerability of Locteron in comparison with PEG-Intron.|To assess in subjects with chronic hepatitis C receiving a weight-based oral daily dose of ribavirin: ‚Ä¢ The PK profile of Locteron (IFNa2b) ‚Ä¢ The preliminary efficacy of Locteron assessed by serial quantitation of HCV RNA levels","https://ClinicalTrials.gov/show/NCT00593151"
976,"NCT01628692","Study of Daclatasvir and TMC435 for Subjects With Genotype 1 Chronic Hepatitis C","Completed","No Results Available","Hepatitis C Virus","Drug: Daclatasvir (DCV)|Drug: Daclatasvir (DCV)|Drug: Daclatasvir (DCV)|Drug: TMC435|Drug: TMC435|Drug: TMC435|Drug: Ribavirin|Drug: Ribavirin|Drug: Ribavirin|Biological: pegIFNŒ±-2a","Bristol-Myers Squibb|Janssen Research & Development, LLC","Both","Adult|Senior","Phase 2","168","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","AI444-062|2012-000070-28","June 25, 2012","July 2012","November 2013","May 5, 2014","May 2014","No Study Results Posted","null","August 2013","Antiviral activity, as determined by the proportion of subjects with SVR12, defined as HCV RNA < LOQ at post-treatment Week 12, for each cohort defined by the previous response status, HCV genotype, initial treatment regimen and treatment duration|On-treatment safety, as measured by the frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs)|Proportion of subjects with Sustained virologic response12 (SVR12) (HCV RNA < LOQ at post-treatment Week 12) by the rs12979860 single nucleotide polymorphisms (SNP) in the IL28B gene for each treatment arm|Proportion of subjects with Hepatitis C virus (HCV) Ribonucleic acid (RNA) < Limit of quantitation (LOQ)|Proportion of subjects with HCV RNA undetectable","https://ClinicalTrials.gov/show/NCT01628692"
977,"NCT01926288","Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B","Active, not recruiting","No Results Available","Chronic Hepatitis B","Drug: Entecavir maleate tablets|Drug: blank Baraclude tablets|Drug: Blank maleate entecavir tablets|Drug: Baraclude tablets","Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd","Both","Adult","Phase 4","287","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","CTTQ805-4","August 13, 2013","October 2008","March 2014","August 19, 2013","August 2013","No Study Results Posted","null","March 2014","Compared with baseline, decline of serum HBV-DNA in the value","https://ClinicalTrials.gov/show/NCT01926288"
978,"NCT01705717","A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C","Completed","Has Results","Hepatitis C, Chronic","","Hoffmann-La Roche","Both","Adult|Senior","","49","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ML25436","October 10, 2012","June 2011","May 2012","January 5, 2015","January 2015","January 5, 2015","null","May 2012","Sustained Virological Response (SVR): Percentage of Participants Who Were HCV Seronegative at 6 Months After Completing Therapy|Percentage of Participants Who Were HCV Seronegative at the End of Treatment|Percentage of Participants With HCV Relapse (Biochemical or Virological) After Treatment Completion|Percentage of Participants Who Progressed From CHC to Cirrhosis|Percentage of Participants Who Progressed From CHC to Hepatocellular Carcinoma (HCC)|Percentage of Participants Who Died","https://ClinicalTrials.gov/show/NCT01705717"
979,"NCT01544582","Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)","Completed","No Results Available","Hepatitis C Chronic","","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","719","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P08518|EP08043.001|SCH 503034 P08518","February 2, 2012","May 2012","June 2015","June 30, 2015","June 2015","No Study Results Posted","null","June 2015","Boceprevir utilization versus other therapies|Clinical management of health outcomes of interest ([HOI], anemia, neutropenia, thrombocytopenia, or serious rash)|Incidence of anemia, neutropenia, thrombocytopenia, and serious skin rash","https://ClinicalTrials.gov/show/NCT01544582"
980,"NCT00316719","Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients","Completed","Has Results","Chronic Hepatitis B","Drug: LAM group|Drug: ADV group","GlaxoSmithKline","Both","Child|Adult","Phase 3","105","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)","ADF105220","April 19, 2006","January 2006","January 2008","October 1, 2009","October 2009","June 15, 2009","null","January 2008","Mean Change From Baseline in Hepatitis B Virus (HBV) DNA at Week 52|Percentage of Participants With HBV DNA Loss (<400 Copies/mL) at Week 52|Time to Onset of HBV DNA Loss (< 400 Copies/mL)|Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 52|Percentage of Participants With Hepatitis B e Antigen/Antibody (HBeAg/Ab) Seroconversion at Week 52|Time to Onset of HBeAg Loss|Time to Onset of HBeAg/Ab Seroconversion|Percentage of Participants With Hepatitis B s Antigen (HBsAg) Loss at Week 52|Percentage of Participants With Hepatitis B s Antigen/ Antibody (HBsAg/Ab) Seroconversion at Week 52|Mean Alanine Aminotransferase (ALT) Level at Week 52|Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 52|Time to Onset of ALT Normalization|Rate of Emergence of Resistant Virus at Week 52","https://ClinicalTrials.gov/show/NCT00316719"
981,"NCT02556086","A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)","Not yet recruiting","No Results Available","Hepatitis C","Drug: Daclatasvir|Drug: Sofosbuvir","Bristol-Myers Squibb","Both","Adult|Senior","Phase 2","70","Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","AI444-378|2015-003467-12","September 15, 2015","December 2015","July 2017","October 15, 2015","October 2015","No Study Results Posted","null","July 2017","Proportion of subjects with SVR12|Sustained virologic response (SVR12) rate|Treatment safety measured by the number of incidence of serious adverse event (SAEs), discontinuations due to adverse event (AEs), Grade 3/4 AEs and Grade 3/4 clinical laboratory abnormalities through the end of treatment|Proportion of subjects who achieve HCV RNA < LLOQ-TD/TND at each of the following Weeks: 1, 2, 4, 6, 8, EOT, post-treatment Week 4 in subjects on the 8-week regimen of DCV/SOF|Proportion of subjects who achieve HCV RNA < LLOQ TND at each of the following Weeks: 1, 2, 4, 6, 8, end of treatment (EOT), in subjects on the 8-week regimen of DCV/SOF|Proportion of subjects receiving cART who maintain HIV virologic suppression|Proportion of subjects receiving cART who experience HIV virologic failure","https://ClinicalTrials.gov/show/NCT02556086"
982,"NCT00262483","Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C","Completed","No Results Available","Hepatitis C","Drug: VX-950|Drug: ribavirin|Drug: peginterferon alfa-2a","Vertex Pharmaceuticals Incorporated","Both","Adult","Phase 2","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","VX05-950-102","December 2, 2005","December 2005","April 2006","December 17, 2007","December 2007","No Study Results Posted","null","null","Safety of triple combination therapy.|Pharmacokinetics of VX-950, peginterferon alfa-2a and ribavirin.|Plasma HCV RNA levels","https://ClinicalTrials.gov/show/NCT00262483"
983,"NCT00553930","Low Dose Peginterferon-Œ± 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients","Completed","No Results Available","Hepatitis C, Chronic|HIV Infections","Drug: Pegylated interferon alfa-2a and Ribavirin|Drug: Pegylated interferon alfa 2a and Ribavirin","Sociedad Andaluza de Enfermedades Infecciosas","Both","Adult|Senior","Phase 4","71","Other","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","SAEI_IFN_1","November 3, 2007","November 2007","May 2010","May 16, 2010","May 2010","No Study Results Posted","SAEI_IFN_1","May 2010","Sustained viral response(undetectable serum HCV-RNA)|Relationships between the plasma interferon an ribavirin concentrations and efficacy. The safety and tolerability of the studied medications will be evaluated by means of clinical adverse events, physical examination and laboratory results.","https://ClinicalTrials.gov/show/NCT00553930"
984,"NCT01667081","Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)","Enrolling by invitation","No Results Available","Hepatitis C","Drug: Grazoprevir","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","3250","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","5172-017|2012-002232-85","August 14, 2012","October 2012","September 2020","October 21, 2015","October 2015","No Study Results Posted","null","September 2020","Time to Viral Relapse|Number of Participants With Antiviral Resistance","https://ClinicalTrials.gov/show/NCT01667081"
985,"NCT00104052","Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)","Completed","Has Results","Hepatitis C, Chronic","Biological: peginterferon alfa-2b (PEG2b) (SCH 54031)|Drug: ribavirin (SCH 18908)","Merck Sharp & Dohme Corp.","Both","Child","Phase 3","107","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","P02538: Part 1","February 22, 2005","February 2005","November 2007","March 26, 2015","March 2015","November 14, 2008","null","November 2007","Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment","https://ClinicalTrials.gov/show/NCT00104052"
986,"NCT01276756","Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)","Completed","Has Results","Chronic Hepatitis c","Drug: Pegylated interferon alfa-2a|Drug: Nitazoxanide|Drug: Ribavirin","Cairo University|Egyptian Railway Hospital","Both","Adult","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Single Blind (Outcomes Assessor)","RAIL001","January 12, 2011","December 2010","November 2012","March 19, 2013","March 2013","January 30, 2013","null","November 2012","Sustained Virologic Response|Rapid Virological Response|Early Virological Response|End-of-treatment Response|Safety of Nitazoxanide (Number of Participants Experiencing Adverse Events)","https://ClinicalTrials.gov/show/NCT01276756"
987,"NCT02545335","Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C","Recruiting","No Results Available","Chronic Hepatitis C","","Medical University of Graz","Both","Adult|Senior","","150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HCV-neutrophil","July 29, 2015","November 2014","December 2016","September 7, 2015","September 2015","No Study Results Posted","null","December 2015","neutrophil phagocytosis|number of infections","https://ClinicalTrials.gov/show/NCT02545335"
988,"NCT00701272","FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation","Enrolling by invitation","No Results Available","Liver Transplantation|Hepatitis C","","University Health Network, Toronto","Both","Adult|Senior","","70","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","08-0385-T","June 18, 2008","June 2008","December 2014","July 24, 2013","July 2013","No Study Results Posted","null","December 2014","serum FGL2 levels","https://ClinicalTrials.gov/show/NCT00701272"
989,"NCT00880763","A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)","Completed","Has Results","Hepatitis C","Drug: Vaniprevir|Drug: Pegylated Interferon (peg-IFN)|Drug: Ribavirin|Drug: Comparator: Placebo","Merck Sharp & Dohme Corp.","Both","Adult","Phase 2","90","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","7009-016|2009_576","April 10, 2009","April 2009","February 2012","September 1, 2015","September 2015","September 26, 2014","null","June 2010","Percentage of Participants Achieving Rapid Viral Response|Percentage of Participants Achieving a > or = 2-log10 Decrease in HCV RNA From Baseline to Week 4|Percentage of Participants Achieving a > or = 3-log10 Decrease in HCV RNA From Baseline to Week 4|Change From Baseline in HCV RNA in log10 at Week 4|Number of Participants Who Experienced at Least One Adverse Event|Number of Participants Who Discontinued Study Drug Due to an Adverse Event","https://ClinicalTrials.gov/show/NCT00880763"
990,"NCT02250001","Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C","Recruiting","No Results Available","Chronic Hepatitis C","","Bristol-Myers Squibb","Both","Adult|Senior","","3000","Industry","Observational","Observational Model: Case-Only","AI444-244","September 24, 2014","September 2014","February 2017","July 3, 2015","July 2015","No Study Results Posted","null","February 2017","The real-world safety, specifically the incidence rates of hepatic toxicity, pyrexia, and resistance, of Daclatasvir/Asunaprevir (DCV/ASV) dual therapy in Japanese patients chronically infected with Hepatitis C virus Genotype 1 (HCV GT-1)|Antiviral activity as determined by the proportion of patients with sustained virologic response at 24 weeks post-treatment Sustained virologic response at 24 weeks post-treatment (SVR24)","https://ClinicalTrials.gov/show/NCT02250001"
991,"NCT00922779","A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic","Drug: peginterferon alfa-2a [Pegasys]|Drug: ribavirin","Hoffmann-La Roche","Both","Adult|Senior","Phase 4","7755","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ML16709","June 16, 2009","June 2002","June 2012","September 1, 2015","September 2015","No Study Results Posted","null","June 2012","Adverse events; laboratory parameters|Sustained viral response","https://ClinicalTrials.gov/show/NCT00922779"
992,"NCT00423891","A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection","Active, not recruiting","Has Results","Hepatitis B, Chronic","Drug: Entecavir","Bristol-Myers Squibb","Both","Child|Adult","Phase 1|Phase 2","64","Industry","Interventional","Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","AI463-028","January 16, 2007","June 2007","October 2017","October 7, 2015","October 2015","July 15, 2014","null","August 2013","Mean Maximum Observed Plasma Concentration (Cmax) and Mean Trough Observed Plasma Concentration (Cmin) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort|Median Time of Maximum Observed Plasma Concentration (Tmax) in LVD-naive and LVD-experienced Participants, by Age Cohort|Mean Area Under the Concentration-Time Curve in One Dosing Interval [AUC(TAU)] of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort|Mean Apparent Total Body Clearance (CLT/F) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort|Number of Participants With Serious Adverse Events (SAE) and Discontinuations Due to Adverse Events (AEs) - On Treatment|Number of Participants With HBV DNA Less Than 50 IU/mL Through Week 48 (Non-Completer=Failure) in Treated Participants|Number of Participants With Hepatitis B e Antigen (HBeAg) Loss Through Week 48 (Non-Completer=Failure) in Treated Participants|Number of Participants With Hepatitis B s Antigen (HBsAg) Loss Through Week 48 (Non-Completer=Failure) in Treated Participants|Number of Participants With Hepatitis B e Antigen Seroconversion Through Week 48 (Non-Completer=Failure) in Treated Participants|Number of Participants With HBV DNA Less Than Lower Limit of Detection (LLD) for the Roche COBAS TaqMan - HPS Assay (Non-Completer=Failure) at Week 48 in Treated Participants|Number of Participants With HBV DNA Less Than Lower Limit of Quantification (LLQ) for the Roche COBAS TaqMan - HPS Assay (Non-Completer=Failure) Through Week 48 in Treated Participants|Number of Participants With HB s Antigen (HBsAg) Seroconversion Through Week 48 (Non-Completer=Failure) in Treated Participants|Number of Participants Who Had a Protocol Defined Response (PDR) Through Week 48 (Non-Completer=Failure) in Treated Participants|Mean Log10 Change From Baseline in HBV DNA Using Roche COBAS TaqMan - HPS Through Week 48 in Treated Participants|Alanine Aminotransferase (ALT) Normalization From Baseline Through Week 48 (Non-Completer=Failure) in Treated Participants|Number of Participants With HBV DNA by PCR Categories (Non-Completer=Failure) at Week 48 in Treated Participants|Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL Through Week 48 (Non-Completer=Failure) in Treated Participants|Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Plus HBeAg Seroconversion Through Week 48 (Non-Completer=Failure) in Treated Participants|Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Without HBeAg Seroconversion, Through Week 48 (Non-Completer=Failure) in Treated Participants|Number of Participants With Hematology Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants|Number of Participants With Chemistry Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants|Number of Participants With Electrolyte Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants","https://ClinicalTrials.gov/show/NCT00423891"
993,"NCT02203149","Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)","Active, not recruiting","No Results Available","Hepatitis C","Drug: Grazoprevir|Drug: Elbasvir|Drug: Placebo","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 2|Phase 3","399","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","5172-058|142638","July 25, 2014","August 2014","April 2016","August 6, 2015","August 2015","No Study Results Posted","null","February 2016","Proportion of Participants Achieving SVR12|Number of Participants Experiencing an Adverse Events (AE)|Number of Participants Withdrawing from Study Therapy due to AEs","https://ClinicalTrials.gov/show/NCT02203149"
994,"NCT00474955","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.","Completed","No Results Available","Hepatitis C, Chronic","Drug: peginterferon alfa-2a [Pegasys]","Hoffmann-La Roche","Both","Adult","Phase 4","27","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ML20434","May 16, 2007","July 2007","June 2011","October 1, 2015","October 2015","No Study Results Posted","null","June 2011","Percentage of patients with SVR|Percentage of patients with undetectable HCV-RNA|Percentage of patients with a 2log10 drop in HCV-RNA|SAEs, premature withdrawals, AEs and laboratory parameters.","https://ClinicalTrials.gov/show/NCT00474955"
995,"NCT00940420","A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C","Completed","No Results Available","Hepatitis C, Chronic","Drug: Copegus (ribavirin)|Drug: Copegus (ribavirin)|Drug: peginterferon alfa-2a [Pegasys]|Drug: peginterferon alfa-2a [Pegasys]","Hoffmann-La Roche","Both","Adult|Senior","Phase 4","2695","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Open Label","ML16837","July 6, 2009","October 2002","November 2009","October 1, 2015","October 2015","No Study Results Posted","null","November 2009","safety and tolerability with regard to clinical AEs and laboratory parameters|safety with regard to hematological parameters","https://ClinicalTrials.gov/show/NCT00940420"
996,"NCT00705432","Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)","Completed","Has Results","Hepatitis C, Chronic","Biological: Peginterferon alfa-2b (PEG)|Drug: Ribavirin (RBV)|Drug: Placebo|Drug: Boceprevir","Merck Sharp & Dohme Corp.","Both","Adult|Senior","Phase 3","1472","Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment|Masking: Double Blind (Subject, Investigator)","P05216|EUDRACT # 2007-005508-42","June 24, 2008","August 2008","May 2010","October 16, 2015","October 2015","May 13, 2011","SPRINT-2","May 2010","Sustained Virologic Response (SVR) Rate|Sustained Virologic Response (SVR) Rate in Participants Treated With Study Drug (Boceprevir or Placebo)|Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.|Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 2, 4, 8, 12, 16, or 20)|Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 4, 8, 12, 16, or 20) Who Achieved SVR","https://ClinicalTrials.gov/show/NCT00705432"
997,"NCT01519921","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.","Completed","No Results Available","Hepatitis B, Chronic","Drug: peginterferon alfa-2a [Pegasys]","Hoffmann-La Roche","Both","Adult","Phase 4","150","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ML18495","January 5, 2012","October 2005","October 2008","October 1, 2015","October 2015","No Study Results Posted","null","October 2008","Percentage of patients with hepatitis B virus DNA <100,000 copies/mL|Percentage of patients with hepatitis B virus HBeAg loss rate|Percentage of patients with alanine aminotransferase (ALT) normalization|Percentage of patients with hepatitis B virus (HBV) DNA below limit of detection|Percentage of patients with a combined response of HBeAg seroconversion, loss of HBeAg, and alanine aminotransferase normalization|Percentage of patients with HBeAg seroconversion|Percentage of patients with loss of HBsAg|Percentage of patients with loss of HBsAg and presence of anti-HBs|Safety: Incidence of adverse events","https://ClinicalTrials.gov/show/NCT01519921"
998,"NCT01438424","Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials","Completed","Has Results","Hepatitis B Virus|HBV","Drug: Entecavir|Drug: Lamivudine","Bristol-Myers Squibb","Both","Child|Adult|Senior","Phase 2","1053","Industry","Interventional","Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","AI463-901","September 16, 2011","January 2001","April 2011","July 19, 2012","July 2012","June 12, 2012","null","December 2009","Overall Study: Number of Participants With Death As Outcome, Any Adverse Event (AE), Grade 3-4 AEs, Serious Adverse Events (SAEs), and Discontinuations Due to AEs|Overall Study: Number of Participants With Normal Hematology Values at Baseline and Abnormalities in Hematology Laboratory Test Results Through Week 240|Overall Study: Number of Participants With Normal Pancreatic Enzyme and Renal Function Values at Baseline and Abnormalities in Pancreatic Enzyme and Renal Function Laboratory Test Results at End of Dosing|Overall Study: Number of Participants With Normal Electrolyte and Fasting Glucose Values at Baseline and Abnormalities in Electrolyte and Fasting Glucose Laboratory Test Results at End of Dosing|Week 144: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results|Week 192: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results|Off-treatment Follow-up: Percentage of Participants With Sustained Hepatitis B Virus (HBV) DNA <10,000 Copies by Polymerase Chain Reaction (PCR) Assay (Amendment 11 Cohort)|Overall Study: Percentage of Participants With Sustained HBV DNA Level <300 Copies/mL by PCR Assay|Overall Study: Percentage of Participants With Sustained HBV DNA <10^4 Copies/mL by PCR Assay|Overall Study: Percentage of Participants by HBV DNA Category by PCR Assay|Overall Study: Mean HBV DNA Level by PCR Assay|Overall Study: Percentage of Participants Who Achieved a Loss of Hepatitis B e Antigen (HBeAg)|Overall Study: Percentage of Participants With HBeAg Seroconversion|Overall Study: Mean Alanine Transaminase (ALT) Levels|Overall Study: Percentage of Participants Who Achieved ALT Normalization|Week 192: Percentage of Participants With Histologic Improvement (Efficacy Evaluable Cohort)|Week 192: Percentage of Participants With Improvement in Fibrosis (Efficacy Evaluable Cohort)|Overall Study: Percentage of Participants With a Confirmed ‚â•1 log10 Increase From Nadir in HBV DNA by PCR Assay|Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAG, Seroconversion, and ALT ‚â§1.0*Upper Limit of Normal (ULN) (Entecavir Continuous Treatment Cohort)|Percentage of Participants Who Achieved HBV DNA <300 and <10^4 Copies/mL by PCR Assay and ALT ‚â§1.0*Upper Limit of Normal (ULN) (Entecavir Retreatment Cohort)|Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAg, HBeAg Seroconversion, and ALT ‚â§1.0*ULN (Lamivudine Continuous Switch Cohort)|Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ‚â§1.0*ULN (Lamivudine Continuous Switch Cohort)|Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ‚â§1.0*ULN (Lamivudine Retreatment Switch Cohort)|Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ‚â§1.0*ULN (Lamivudine Retreatment Switch Cohort)|Off-treatment Follow-up: Percentage of Participants With Sustained HBV DNA <1,000, <300, and <10,000 Copies/mL by PCR Assay and With ALT ‚â§1*ULN (Amendment 11 Cohort)|Off-treatment Follow-up: Mean Change in HBV DNA (Amendment 11 Cohort)","https://ClinicalTrials.gov/show/NCT01438424"
999,"NCT00436163","A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).","Completed","No Results Available","Hepatitis B, Chronic","Drug: peginterferon alfa-2a [Pegasys]","Hoffmann-La Roche","Both","Adult|Senior","Phase 4","38","Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label","ML20601","February 15, 2007","March 2007","May 2010","October 1, 2015","October 2015","No Study Results Posted","null","May 2010","Number of patients with HBV DNA <100,000 copies/mL|HBV DNA <400 copies/mL, HBsAg seroconversion, ALT normalization, sustained HBe seroconversion.|AEs, laboratory parameters.","https://ClinicalTrials.gov/show/NCT00436163"
1000,"NCT01098097","Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)","Completed","Has Results","Hepatitis C, Chronic","Biological: Peginterferon alpha|Drug: Ribavirin","Merck Sharp & Dohme Corp.","Both","Adult|Senior","","963","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P06011","April 1, 2010","June 2009","October 2011","November 14, 2014","November 2014","October 17, 2012","POMOSCH","October 2011","Incidence of Serious Adverse Events (SAEs) and/or Clinically Significant Adverse Events (AEs)|Incidence of Thrombocytopenia|Incidence of Treatment Discontinuations Due to Adverse Events|Incidence of Particular Adverse Events Resulting in Treatment Discontinuation|Incidence of Dose Modifications Due to Adverse Events|Proportion of Participants Who Achieve Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA)","https://ClinicalTrials.gov/show/NCT01098097"
